                              ANTI-CD22 ANTIBODIES
ABSTRACT
       Anti-CD22 antibodies, including isolated nucleic acids that encode at least one
such anti-CD22 antibody, vectors, host cells, transgenic animals or plants, and methods of
making and using thereof, including therapeutic compositions, methods and devices.

                                       AUSTRALIA
                                      Patents Act 1990
                        ORIGINAL COMPLETE SPECIFICATION
                                   STANDARD PATENT
Invention title:       ANTI-CD22 ANTIBODIES
This application is a divisional of Australian Patent Application No 2013251482 which is
the Australian national phase entry of PCT/US2013/038370, which claims priority to US
patent application No 61/638,834 filed 26 April 2012. Each of these applications is
herein incorporated by reference in their entireties.
The following statement is a full description of this invention, including the best method
of performing it known to us:

                                 ANTI-CD22 ANTIBODIES
                          BACKGROUND OF THE INVENTION
[0001]       1.  FIELD OF THE INVENTION
[0002]      The present invention relates to antibodies, including specified portions or
variants, specific for at least one CD22 protein or fragment thereof, as well as nucleic
acids encoding such anti-CD22 antibodies, complementary nucleic acids, vectors, host
cells, and methods of making and using thereof, including therapeutic formulations,
administration and devices.
[0003]      2. RELATED ART
[0004]       CD22 is a member of the Siglec, sialic acid binding receptor protein
superfamily, and is produced by developing B cells. In vivo, B cells represent the main
sources of CD22. Other cells such as lymphoma, leukemic and lymphocytic B cells also
produce CD22. CD22 has been implicated as a prognostic factor for non-Hodkin's
lymphoma and both acute and chronic lymphocytic leukemias cancer progression. CD22
production can be regulated by B-cell differentiation processes in the germinal centers of
lymph nodes.
[0005]       CD22 ligands, sialic-acid containing extracellular surface molecules, can bind
to the CD22 receptor expressed on developing B cells during the humoral immune
responses. The CD22 receptor has immunoglobuline-like repeat sequences that are
responsible for CD22-ligand binding.
[0006]      There are at least two major biological functions of CD22: CD22 can interact
with the B cell receptor complex (BCR) to stimulate cellular signaling to promote B cell
differentiation and production of immunoglobulins, and can also interact with the BCR to
inhibit cellular signaling and cell growth and differentiation. Binding of the murine
monoclonal anti-CD22 antibody stimulates CD22 tyrosine phosphorylation and
negatively regulates mitogenic signal transduction (Carnahan et al., Cancer Res
September 1, 2003 9; 3982s)
[0007]      There is a need to provide high affinity, neutralizing chimeric or human
antibodies to CD22 or fragments thereof for use in preventing, treating, ameliorating, or
                                              2

diagnosing conditions related to lymphoma, acute and chronic leukemias and other B-cell
dysplasias and B-cell dependent autoimmune diseases.
[0008]
                            SUMMARY OF THE INVENTION
[0009]      In a first aspect there is provided an expression vector comprising a nucleotide
sequence encoding an antibody or antibody fragment that binds to human CD22, wherein
the antibody or antibody fragment comprises:
        a heavy chain variable region having three complementarity determining regions
(CDR1, CDR2, and CDR3), wherein the complementarity determining region 1 (CDR1)
has at least 90% sequence identity with a complementarity determining region 1 (CDR1)
of a heavy chain variable region of VM1000 (SEQ ID NO: 49), the complementarity
determining region 2 (CDR2) has at least 90% sequence identity with a complementarity
determining region 2 (CDR2) of the heavy chain variable region of VM1000 (SEQ ID
NO: 49), the complementarity determining region 3 (CDR3) has at least 90% sequence
identity with a complementarity determining region 3 (CDR3) of the heavy chain variable
region of VM1000 (SEQ ID NO: 49);
        a light chain variable region having three complementarity determining regions
(CDR4, CDR5, and CDR6), wherein the complementarity determining region 4 (CDR4)
has at least 90% sequence identity with a complementarity determining region 4 (CDR4)
of a light chain variable region of VM1000 or VM1015 (SEQ ID NO: 17 or 32), the
complementarity determining region 5 (CDR5) has at least 90% sequence identity with a
complementarity determining region 5 (CDR5) of the light chain variable region of
VM1000 (SEQ ID NO: 17), the complementarity determining region 6 (CDR6) has at
                                                3

least 90% sequence identity with a complementarity determining region 6 (CDR6) of the
light chain variable region of VM1000 (SEQ ID NO: 17); and
        a heavy chain constant region and a light chain constant region derived from one
or more human antibodies, wherein the heavy chain constant region is associated with the
heavy chain variable region and the light chain constant region is associated with the light
chain variable region.
[0010]      In a second aspect there is provided a host cell comprising the expression
vector of the first aspect.
[0011]      In a third aspect there is provided a method for producing an antibody or
antibody fragment, comprising a step of translating the nucleotide sequence in the
expression vector of the first aspect.
[0012]      In a fourth aspect there is provided an antibody or antibody fragment produced
by the method of the third aspect.
[0013]      In a fifth aspect there is provided a composition comprising the antibody or
antibody fragment of the fourth aspect and a carrier or diluent.
[0014]      The present invention provides isolated humanized, anti-CD22 antibodies,
having at least one antigen binding region derived from the high affinity VM1000,
VM1001, VM1002, VM1003, VM1004, VM1005, VM1006, VM1007, VM1008,
VM1009, VM1010, VM101 1, VM1012, VM1013, VM1014, or VM1015 anti-CD22
antibodies, as well as anti-CD22 antibody compositions, conjugated version of these anti
CD22 antibodies, encoding or complementary nucleic acids, vectors, host cells,
compositions, formulations, devices, transgenic animals, transgenic plants related thereto,
and methods of making and using thereof, as described and enabled herein, in
combination with what is known in the art. The antibodies of the invention specifically
neutralize human CD22 with high affinity.
[0015]      The present invention provides at least one isolated anti-CD22 antibody as
described herein. The antibody according to the present invention includes any one of
VM1000, VM1001, VM1002, VM1003, VM1004, VM1005, VM1006, VM1007,
                                               4

VM1008, VM1009, VM1010, VM1O11, VM1012, VM1013, VM1014, or VM1015, or
any protein or peptide molecule that comprises at least one complementarity determining
region (CDR) (e.g., CDR1, CDR2 or CDR3) of a heavy or light chain or a ligand binding
portion thereof, derived from one of VM1000, VM1001, VM1002, VM1003, VM1004,
VM1005, VM1006, VM1007, VM1008, VM1009, VM1010, VM101 1, VM1012,
VM1013, VM1014, or VM1015, in combination with a heavy chain or light chain
constant region, a framework region, or any portion thereof, that can be incorporated into
an antibody of the present invention. In one embodiment the invention is directed to an
anti-CD22 antibody comprising a light chain and a heavy chain, each of the chains
comprising at least part of a human constant region and at least part of a variable region
(v) derived from one or more of VM1000, VM1001, VM1002, VM1003, VM1004,
VM1005, VM1006, VM1007, VM1008, VM1009, VM1010, VM101 1, VM1012,
VM1013, VM1014, or VM1015 each of which has specificity to human CD22, said
antibody binding with high affinity to an inhibiting and/or neutralizing epitope of human
CD22. The invention also includes fragments or a derivative of such an antibody, such as
one or more portions of the antibody chain, such as the heavy chain constant, joining,
diversity or variable regions, or the light chain constant, joining or variable regions.
[0016]      The antibody can comprise at least one specified portion of at least one
complementarily determining region (CDR) (e.g., CDR1, CDR2 or CDR3 of the heavy or
light chain variable region) derived from an anti-CD22 antibody (as such term is defined
herein), and/or at least one constant or variable framework region or any portion thereof.
The antibody amino acid sequence can further optionally comprise at least one specified
substitution, insertion or deletion as described herein or as known in the art.
[0017]      Preferred antibodies of the present invention include VM1000, VM1001,
VM1002, VM1003, VM1004, VM1005, VM1006, VM1007, VM1008, VM1009,
VM1010, VM1011, VM1012, VM1013, VM1014, and VM1015, as well as fragments
and regions thereof.
[0018]      In one embodiment, the disclosure provides an isolated antibody or antibody
fragment that binds to human CD22, comprising a heavy chain variable region having the
amino acid sequence of SEQ ID NO: 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62,
63, or 64; a light chain variable region having the amino acid sequence of SEQ ID NO:
                                               5

17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31 or 32; and a constant region
derived from one or more human antibodies. In one aspect, the disclosure provides an
isolated antibody or antibody fragment that binds to human CD22, comprising a heavy
chain and light chain complementarity determining regions (CDRs) derived from the
variable regions from one or more of VM1000, VM1001, VM1002, VM1003, VM1004,
VM1005, VM1006, VM1007, VM1008, VM1009, VM1010, VM101 1, VM1012,
VM1013, VM1014, and VM1015, and a constant region derived from one or more human
antibodies. In another aspect, the disclosure provides an antibody or fragment according
to claim 1 or 2, wherein said antibody or fragment competitively inhibits in vivo the
binding to human CD22 of an anti CD22 murine antibody.
[0019]      Preferred antibodies of the present invention are those that bind human CD22
and induce CD22 tyrosine phosphorylation and internalization and negatively regulate B
cell growth and differentiation. Preferred methods for determining monoclonal antibody
specificity and affinity by competitive inhibition can be found in Harlow, et al,
Antibodies: A Laboratory Manual, Cold Spring Harbor Laboratory Press, Cold Spring
Harbor, N.Y., 1988), hereby incorporated by reference into the present application. At
least one antibody of the invention binds at least one specified epitope specific to human
CD22 protein, subunit, fragment, portion or any combination thereof, for example as
described by (Stein R, Belisle E, Hansen HJ, Goldenberg DM: Epitope specificityof the
anti-(B cell lymphoma) monoclonal antibody, LL2.CancerImmunol Immunother 1993,
37:293-298.) The monoclonal antibody LL2 binds to the third immunoglobulin (Ig) repeat
sequence in the extracellular domain of CD22 and is important for its modulatory effects
on CD22 expressing B cell populations and lymphoma and leukemia cells. The epitope
can comprise at least one antibody binding region, which epitope is preferably comprised
of at least 1-5 amino acids of at least one portion thereof, such as but not limited to, at
least one functional, extracellular, soluble, hydrophillic, external or cytoplasmic domain
of human CD22 protein, or any portion thereof.
[0020]      In one aspect, the present invention provides at least one isolated mammalian
anti-CD22 antibody, comprising at least one variable region from one of VM1000,
VM1001, VM1002, VM1003, VM1004, VM1005, VM1006, VM1007, VM1008,
                                                6

VM1009, VM1O1O, VM101 1, VM1012, VM1013, VM1014, and VM1015 and the
nucleic acid sequences encoding them.
[0021]       In another aspect, the present invention provides at least one isolated
mammalian anti-CD22 antibody, comprising either (i) all of the heavy chain
complementarity determining regions (CDR) amino acid sequences derived from
VM1000, VM1001, VM1002, VM1003, VM1004, VM1005, VM1006, VM1007,
VM1008, VM1009, VM1O1O, VM1O11, VM1012, VM1013, VM1014, or VM1015 and
the nucleic acid sequences encoding them; or (ii) all of the light chain CDR amino acids
sequences from one of VM1OOO, VM1001, VM1002, VM1003, VM1004, VM1005,
VM1006, VM1007, VM1008, VM1009, VM1O1O, VM101 1, VM1012, VM1013,
VM1014, or VM1015 and the nucleic acid sequences encoding them.
[0022]       In another aspect, the present invention provides at least one isolated
mammalian anti-CD22 antibody, comprising at least one heavy chain or light chain CDR
having the amino acid sequence derived from VM1000, VM1001, VM1002, VM1003,
VM1004, VM1005, VM1006, VM1007, VM1008, VM1009, VM1O1O, VM1O11,
VM1012, VM1013, VM1014, and VM1015 and the nucleic acid sequences encoding
them.
[0023]       In other aspect the present invention provides at least one isolated mammalian
chimeric, humanized or CDR-grafted anti-CD22 antibody, comprising at least one human
CDR, or no human CDRs, wherein the antibody specifically binds at least one epitope
comprising at least 1-3 amino acids of an epitope of human CD22.
[0024]       At least one antibody can optionally further bind CD22 with an affinity (KDof
at least 10-9 M, preferably at least 10-10 M, and/or substantially neutralize at least one
activity of at least one CD22 protein. In a preferred embodiment, the antibody binds
CD22 with an affinity (KDs) of at least 5 x 10-10 M, preferably 5 x 10-1, more preferably 5
x 10-12 and neutralizes human CD22.
[0025]       The present invention provides, in one aspect, isolated nucleic acid molecules
comprising, complementary, or hybridizing to, a polynucleotide encoding the
aforementioned specific anti-CD22 antibodies, comprising at least one specified
sequence, domain, portion or variant thereof The present invention further provides
                                               7

recombinant vectors comprising said anti-CD22 antibody nucleic acid molecules, host
cells containing such nucleic acids and/or recombinant vectors, as well as methods of
making and/or using such antibody nucleic acids, vectors and/or host cells. Thus, the
invention comprises isolated nucleic acid encoding at least one isolated mammalian anti
CD22 antibody; an isolated nucleic acid vector comprising the isolated nucleic acid,
and/or a prokaryotic or eukaryotic host cell comprising the isolated nucleic acid. The
host cell can optionally be at least one selected from COS-1, COS-7, HEK293, BHK21,
CHO, BSC-1, Hep G2, 653, SP2/0, 293, HeLa, myeloma, or lymphoma cells, or any
derivative, immortalized or transformed cell thereof. Also provided is a method for
producing at least one anti-CD22 antibody, comprising translating the antibody encoding
nucleic acid under conditions in vitro, in vivo or in situ, such that the CD22 antibody is
expressed in detectable or recoverable amounts.
[0026]      The present invention also provides at least one method for expressing at least
one aforementioned anti-CD22 antibody, in a host cell, comprising culturing a host cell as
described herein under conditions wherein at least one anti-CD22 antibody is expressed in
detectable and/or recoverable amounts.
[0027]      The present invention also provides at least one composition comprising (a) an
isolated anti-CD22 antibody encoding nucleic acid and/or antibody as described herein;
and (b) a suitable carrier or diluent. The carrier or diluent can optionally be
pharmaceutically acceptable, according to known carriers or diluents. The composition
can optionally further comprise at least one further compound, protein or composition.
[0028]      The present invention further provides at least one anti-CD22 antibody method
or composition, for administering a therapeutically effective amount to modulate or treat
at least one CD22 related condition in a cell, tissue, organ, animal or patient and/or, prior
to, subsequent to, or during a related condition, as known in the art and/or as described
herein. Thus, the invention provides a method for diagnosing or treating a CD22 related
condition in a cell, tissue, organ or animal, comprising contacting or administering a
composition comprising an effective amount of at least one isolated anti-CD22 antibody
of the invention with, or to, the cell, tissue, organ or animal. The method can optionally
further comprise using an effective amount of 0.001-50 mg/kilogram of an anti-CD22
antibody of the invention to the cells, tissue, organ or animal. The method can optionally
                                                 8

further comprise using the contacting or the administrating by at least one mode selected
from parenteral, subcutaneous, intramuscular, intravenous, intrarticular, intrabronchial,
intraabdominal, intracapsular, intracartilaginous, intracavitary, intracelial, intracelebellar,
intracerebroventricular, intracolic, intracervical, intragastric, intrahepatic,
intramyocardial, intraosteal, intrapelvic, intrapericardiac, intraperitoneal, intrapleural,
intraprostatic, intrapulmonary, intrarectal, intrarenal, intraretinal, intraspinal,
intrasynovial, intrathoracic, intrauterine, intravesical, bolus, vaginal, rectal, buccal,
sublingual, intranasal, or transdermal. The method can optionally further comprise
administering, prior, concurrently, or after the antibody contacting or administering at
least one composition comprising an effective amount of at least one compound or
protein selected from at least one of a detectable label or reporter, a TNF antagonist, an
antirheumatic, a muscle relaxant, a narcotic, a non-steroid anti-inflammatory drug
(NSAID), an analgesic, an anesthetic, a sedative, a local anesthetic, a neuromsucula-r
blocker, an antimicrobial, an antipsoriatic, a corticosteriod, an anabolic steroid, an
erythropoietin, an immunization, an immunoglobulin, an immunosuppressive, a growth
hormone, a hormone replacement drug, a radiopharmaceutical, an antidepressant, an
antipsychotic, a stimulant, an asthma medication, a beta agonist, an inhaled steroid, an
epinephrine or analog thereof, a cytotoxic or other anti-cancer agent, an anti-metabolite
such as methotrexate, an anti-proliferative agent, a cytokine, a cytokine antagonist, and an
anti-TNFa or other monoclonal antibody or bifunctional antibody.
[0029]      The present invention further provides at least one anti-CD22 antibody method
for diagnosing at least one CD22 related condition in a cell, tissue, organ, animal or
patient and/or, prior to, subsequent to, or during a related condition, as known in the art
and/or as described herein.
[0030]      The present invention also provides at least one composition, device and/or
method of delivery for diagnosing of at least one anti-CD22 antibody, according to the
present invention.
[0031]      Also provided is a medical device, comprising at least one isolated
mammalian anti-CD22 antibody of the invention, wherein the device is suitable to
contacting or administering the at least one anti-CD22 antibody by at least one mode
selected from parenteral, subcutaneous, intramuscular, intravenous, intrarticular,
                                                9

intrabronchial, intraabdominal, intracapsular, intracartilaginous, intracavitary, intracelial,
intracelebellar, intracerebroventricular, intracolic, intracervical, intragastric, intrahepatic,
intramyocardial, intraosteal, intrapelvic, intrapericardiac, intraperitoneal, intrapleural,
intraprostatic, intrapulmonary, intrarectal, intrarenal, intraretinal, intraspinal,
intrasynovial, intrathoracic, intrauterine, intravesical, bolus, vaginal, rectal, buccal,
sublingual, intranasal, or transdermal.
[0032]      In a further aspect, the disclosure provides a kit comprising at least one anti
CD22 antibody or fragment of the disclosure in lyophilized form in a first container, and
an optional second container comprising sterile water, sterile buffered water, or at least
one preservative selected from the group consisting of phenol, m-cresol, p-cresol, o
cresol, chlorocresol, benzyl alcohol, phenylmercuric nitrite, phenoxyethanol,
formaldehyde, chlorobutanol, magnesium chloride, alkylparaben, benzalkonium chloride,
benzethonium chloride, sodium dehydroacetate and thimerosal, or mixtures thereof in an
aqueous diluent. In one aspect, in the kit, the concentration of anti-CD22 antibody or
specified portion or variant in the first container is reconstituted to a concentration of
about 0.1 mg/ml to about 500 mg/ml with the contents of the second container. In
another aspect, the second container further comprises an isotonicity agent. In another
aspect, the second container further comprises a physiologically acceptable buffer. In one
aspect, the disclosure provides a method of treating at least one anti-CD22 mediated
condition, comprising administering to a patient in need thereof a formulation provided in
a kit and reconstituted prior to administration.
[0033]      Also provided is an article of manufacture for human pharmaceutical or
diagnostic use, comprising packaging material and a container comprising a solution or a
lyophilized form of at least one isolated mammalian anti-CD22 antibody of the present
invention. The article of manufacture can optionally comprise having the container as a
component of a parenteral, subcutaneous, intramuscular, intravenous, intrarticular,
intrabronchial, intraabdominal, intracapsular, intracartilaginous, intracavitary, intracelial,
intracelebellar, intracerebroventricular, intracolic, intracervical, intragastric, intrahepatic,
intramyocardial, intraosteal, intrapelvic, intrapericardiac, intraperitoneal, intrapleural,
intraprostatic, intrapulmonary, intrarectal, intrarenal, intraretinal, intraspinal,
                                                10

intrasynovial, intrathoracic, intrauterine, intravesical, bolus, vaginal, rectal, buccal,
sublingual, intranasal, or transdermal delivery device or system.
 [0034]      The present invention further provides any invention described herein.
 [0035]      It is to be noted that, throughout the description and claims of this
specification, the word 'comprise' and variations of the word, such as 'comprising' and
'comprises', is not intended to exclude other variants or additional components, integers or
steps. Modifications and improvements to the invention will be readily apparent to those
skilled in the art. Such modifications and improvements are intended to be within the
scope of this invention.
 [0036]      Any reference to or discussion of any document, act or item of knowledge in
this specification is included solely for the purpose of providing a context for the present
invention. It is not suggested or represented that any of these matters or any combination
thereof formed at the priority date part of the common general knowledge, or was known
to be relevant to an attempt to solve any problem with which this specification is
concerned.
                             DESCRIPTION OF THE FIGURES
 [0037]      Figure 1 shows the nucleic acid sequences and amino acid sequences,
respectively, for the light chain (SEQ ID NOs: 1, 17) and heavy chain (SEQ ID NOs: 33,
49) variable region of VM1000.
 [0038]      Figure 2 shows the nucleic acid sequences and amino acid sequences,
respectively, for the light chain (SEQ ID NOs: 2, 18) and heavy chain (SEQ ID NOs:
34,50) variable region of VM1001.
 [0039]      Figure 3 shows the nucleic acid sequences and amino acid sequences,
respectively, for the light chain (SEQ ID NOs: 3, 19) and heavy chain (SEQ ID NOs: 35,
51) variable region of VM1002.
 [0040]      Figure 4 shows the nucleic acid sequences and amino acid sequences,
respectively, for the light chain (SEQ ID NOs: 4, 20) and heavy chain (SEQ ID NOs: 36,
52) variable region of VM1003.
                                                11

[0041]      Figure 5 shows the nucleic acid sequences and amino acid sequences,
respectively, for the light chain (SEQ ID NOs: 5, 21) and heavy chain (SEQ ID NOs: 37,
53) variable region of VM1004.
[0042]      Figure 6 shows the nucleic acid sequences and amino acid sequences,
respectively, for the light chain (SEQ ID NOs: 6, 22) and heavy chain (SEQ ID NOs: 38,
54) variable region of VM1005.
[0043]      Figure 7 shows the nucleic acid sequences and amino acid sequences,
respectively, for the light chain (SEQ ID NOs: 7, 23) and heavy chain (SEQ ID NOs: 39,
55) variable region of VM1006.
[0044]      Figure 8 shows the nucleic acid sequences and amino acid sequences,
respectively, for the light chain (SEQ ID NOs: 8, 24) and heavy chain (SEQ ID NOs: 40,
56) variable region of VM1007.
[0045]      Figure 9 shows the nucleic acid sequences and amino acid sequences,
respectively, for the light chain (SEQ ID NOs: 9, 25) and heavy chain (SEQ ID NOs: 41,
57) variable region of Anti-CD22 Ab VM1008.
[0046]      Figure 10 shows the nucleic acid sequences and amino acid sequences,
respectively, for the light chain (SEQ ID NOs: 10, 26) and heavy chain (SEQ ID NOs: 42,
58) variable region of VM1009.
[0047]      Figure 11 shows the nucleic acid sequences and amino acid sequences,
respectively, for the light chain (SEQ ID NOs: 11, 27) and heavy chain (SEQ ID NOs: 43,
59) variable region of VM1010.
[0048]      Figure 12 shows the nucleic acid sequences and amino acid sequences,
respectively, for the light chain (SEQ ID NOs: 12, 28) and heavy chain (SEQ ID NOs: 44,
60) variable region of VM 1011.
[0049]      Figure 13 shows the nucleic acid sequences and amino acid sequences,
respectively, for the light chain (SEQ ID NOs: 13, 29) and heavy chain (SEQ ID NOs: 45,
61) variable region of VM1012.
                                             12

[0050]      Figure 14 shows the nucleic acid sequences and amino acid sequences,
respectively, for the light chain (SEQ ID NOs: 14, 30) and heavy chain (SEQ ID NOs: 46,
62) variable region of VM1013.
[0051]      Figure 15 shows the nucleic acid sequences and amino acid sequences,
respectively, for the light chain (SEQ ID NOs: 15, 31) and heavy chain (SEQ ID NOs: 47,
63) variable region of VM1014.
[0052]      Figure 16 shows the nucleic acid sequences and amino acid sequences,
respectively, for the light chain (SEQ ID NOs: 16, 32) and heavy chain (SEQ ID NOs: 48,
64) variable region of VM1015.
[0053]      Figure 17 shows data for the affinity ELISA analysis of selected clones of
VM1000, VM1001, VM1002, VM1003, VM1004, VM1005, VM1006, VM1007,
VM1008, VM1009, VM1010, VM1011, VM1012, VM1013, VM1014, and VM1015 of
the invention.
[0054]      Figure 18 shows data for the Surface Plasmon Resonance (SPR) determination
of the affinity constants (KD) for recombinant CD22 extracellular domain of VM1000,
VM1001, VM1002, VM1003, VM1004, VM1005, VM1006, VM1007, VM1008,
VM1009, VM1010, VM101 1, VM1012, VM1013, VM1014, and VM1015 of the
invention and controls (VM006G and VM006H).
[0055]      Figures 19 shows data for the surface binding and internalization analysis on
CD22 expressing human lymphoma cells, such as Daudi, RAMOS and RAJI B cell lines
by fluorescent activated cell sorting (FACS) of selected clones from VM1000, VM1001,
VM1002, VM1003, VM1004, VM1005, VM1006, VM1007, VM1008, VM1009,
VM1010, VM1011, VM1012, VM1013, VM1014, and VM1015 as well as controls. All
peaks on the right in each Box represent the control (no antibody); all peaks on the left in
each Box show data with antibody, whereby shifts to lower fluorescent signal indicate
receptor/antibody internalization. Box 1 shows a positive control antibody, Box 2 shows
VM1000, Box 3 shows VM1001, Box 4 shows VM1002, Box 5 shows VM1004, Box 6
shows VM1005, Box 7 shows VM1006, and Box 8 shows VM1011.
[0056]      Figure 20 shows a table with data from surface binding and internalization
analysis using FACS of VM1000, VM1001, VM1002, VM1003, VM1004, VM1005,
                                             13

 VM1006, VM1007, VM1008, VM1009, VM1O1O, VM101 1, VM1012, VM1013,
 VM10 14, and VM1015 and a control (BA006G).
 [0057]      Figures 21 shows data for the rapid surface binding and intracellular
 internalization using quantitative confocal immunofluorescent microscopy of antibodies
 VM1000, VM1001, VM1002, VM1003, VM1004, VM1005, VM1006, VM1007,
 VM1008, VM1009, VM1O1O, VM1011, VM1012, VM1013, VM1014, and VM1015 of
 the invention.
 [0058]      Figures 22A and 22B show induction of CD22 tyrosine phosphorylation of
 CD22 present on the surface of the human lymphoma cell line Daudi upon exposure to
 selected antibodies from VM1000, VM1001, VM1002, VM1003, VM1004, VM1005,
 VM1006, VM1007, VM1008, VM1009, VM1O1O, VM101 1, VM1012, VM1013,
 VM1014, and VM1015 of the invention.
 [0059]      Figure 23 shows data demonstrating cross reactivity of anti-CD22 antibodies
 to CD22 expressed on cells of the primate species, cynomologus macaques (Macaca
fascicularis). The cells for each test condition were washed in PBS, and then fixed with
 4% formaldehyde in PBS for 10 min at room temperature. The cells were then
 resuspended in 0.5 ml of PBS containing 2% FBS then analyzed for CD22 and CD20
 surface staining by fluorescent activated cell sorting (FACS) analysis (1). Cells treated
 with no antibody did not have an appreciable shift in fluorescent intensity in either the
 FITC or PE channels (lA), whereas cell stained with VM101-PE contained a CD22
 positive population (1B). Similarly, cells stained with anti-CD20-FIT contained a CD20
 positive population (IC). Cells stained with both VM101-PE and CD20-FITC antibodies
 have a double labeled population as one would expect based on the expression patterns of
 both antigen in PBMC's (ID). VM101 specifically recognizes the cynomologus CD22
 protein.
 [0060]      Figure 24 shows high level expression data in mammalian cells of anti-CD22
 antibodies of the present invention.
                                               14

                   DETAILED DESCRIPTION OF THE INVENTION
[0061]       Citations
[0062]      All publications or patents cited herein are entirely incorporated herein by
reference as they show the state of the art at the time of the present invention and/or to
provide description and enablement of the present invention. Publications refer to any
scientific or patent publications, or any other information available in any media format,
including all recorded, electronic or printed formats. The following references are entirely
incorporated herein by reference: Ausubel, et al., ed., Current Protocols in Molecular
Biology, John Wiley & Sons, Inc., NY, N.Y. (1987-2001); Sambrook, et al., Molecular
Cloning: A Laboratory Manual, 2.sup.nd Edition, Cold Spring Harbor, N.Y. (1989);
Harlow and Lane, Antibodies, a Laboratory Manual, Cold Spring Harbor, N.Y. (1989);
Colligan, et al., eds., Current Protocols in Immunology, John Wiley & Sons, Inc., NY
(1994-200 1); Colligan et al., Current Protocols in Protein Science, John Wiley & Sons,
NY, N.Y., (1997-2001).
[0063]      Amino Acid Codes
[0064]      The amino acids that make up anti-CD22 antibodies of the present invention
are often abbreviated. The amino acid designations can be indicated by designating the
amino acid by its single letter code, its three letter code, name, or three nucleotide
codon(s) as is well understood in the art (see Alberts, B., et al., Molecular Biology of The
Cell, Third Ed., Garland Publishing, Inc., New York, 1994).
[0065]      Definitions
[0066]      As used herein, an "Anti-CD22 antibody," "Anti-CD22 antibody," "Anti
CD22 antibody portion," or "Anti-CD22 antibody fragment" and/or "Anti-CD22 antibody
variant" and the like include any protein or peptide containing molecule that comprises at
least a portion of an immunoglobulin molecule, containing at least one complementarity
determining region (CDR) of a heavy or light chain or a ligand binding portion thereof
derived from at least one of VM1000, VM1001, VM1002, VM1003, VM1004, VM1005,
VM1006, VM1007, VM1008, VM1009, VM1010, VM101 1, VM1012, VM1013,
VM1014, or VM1015 , in combination with a heavy chain or light chain variable region,
a heavy chain or light chain constant region, a framework region, or any portion thereof,
                                               15

of non-murine origin, preferably of human origin, which can be incorporated into an
antibody of the present invention. Alternatively, the term "Anti-CD22 antibody" shall
refer collectively or individually to the humanized monoclonal antibodies VM1000,
VM1001, VM1002, VM1003, VM1004, VM1005, VM1006, VM1007, VM1008,
VM1009, VM1O1O, VM1011, VM1012, VM1013, VM1014, and VM1015. Such
antibody is capable of modulating, decreasing, antagonizes, mitigates, alleviates, blocks,
inhibits, abrogates and/or interferes with at least one CD22 activity or binding, or with
CD22 receptor activity or binding, in vitro, in situ and/or in vivo. As a non-limiting
example, a suitable Anti-CD22 antibody, specified portion or variant of the present
invention can bind with high affinity to an inhibiting and/or neutralizing epitope of
human CD22 recognized by at least one of VM1000, VM1001, VM1002, VM1003,
VM1004, VM1005, VM1006, VM1007, VM1008, VM1009, VM1O1O, VM1O11,
VM1012, VM1013, VM1014, orVM1015 monoclonal antibody. A suitable Anti-CD22
antibody, specified portion, or variant can also optionally affect at least one of CD22
activity or function, such as but not limited to, RNA, DNA or protein synthesis, CD22
release, CD22 receptor signaling, membrane CD22 cleavage, CD22 activity, CD22
production and/or synthesis.
[0067]       The term "antibody" is further intended to encompass antibodies, digestion
fragments, specified portions and variants thereof, including antibody mimetics or
comprising portions of antibodies that mimic the structure and/or function of an antibody
or specified fragment or portion thereof, including single chain antibodies and fragments
thereof, each containing at least one CDR derived from an Anti-CD22. Functional
fragments include antigen-binding fragments that bind to a mammalian CD22. For
example, antibody fragments capable of binding to CD22 or portions thereof, including,
but not limited to Fab (e.g., by papain digestion), Fab' (e.g., by pepsin digestion and
partial reduction) and F(ab') 2 (e.g., by pepsin digestion), facb (e.g., by plasmin digestion),
pFc' (e.g., by pepsin or plasmin digestion), Fd (e.g., by pepsin digestion, partial reduction
and reaggregation), Fv or scFv (e.g., by molecular biology techniques) fragments, are
encompassed by the invention (see, e.g., Colligan, Immunology, supra).
[0068]       Antibody fragments can be produced by enzymatic cleavage, synthetic or
recombinant techniques, as known in the art and/or as described herein. Antibodies can
                                                16

also be produced in a variety of truncated forms using antibody genes in which one or
more stop codons have been introduced upstream of the natural stop site. For example, a
combination gene encoding a F(ab') 2 heavy chain portion can be designed to include
DNA sequences encoding the CHi domain and/or hinge region of the heavy chain. The
various portions of antibodies can be joined together chemically by conventional
techniques, or can be prepared as a contiguous protein using genetic engineering
techniques.
[0069]       As used herein "chimeric" antibodies or "humanized" antibodies or "CDR
grafted" include any combination of the herein described Anti-CD22 Abs, or any CDR
derived therefrom combined with one or more proteins or peptides derived from a non
murine, preferably, human antibody. In accordance with the invention, chimeric or
humanized antibodies include those wherein the CDR's are derived from one or more of
the Anti-CD22 Abs described herein and at least a portion, or the remainder of the
antibody is derived from one or more human antibodies. Thus, the human part of the
antibody may include the framework, CL, CH domains (e.g., CH1, CH2, CH3), hinge, (VL,
VH))   regions which are substantially non-immunogenic in humans. The regions of the
antibody that are derived from human antibodies need not have 100% identity with
human antibodies. In a preferred embodiment, as many of the human amino acid residues
as possible are retained in order for the immunogenicity to be negligible, but the human
residues may be modified as necessary to support the antigen binding site formed by the
CDR's while simultaneously maximizing the humanization of the antibody. Such
changes or variations optionally and preferably retain or reduce the immunogenicity in
humans or other species relative to non-modified antibodies. It is pointed out that a
humanized antibody can be produced by a non-human animal or prokaryotic or
eukaryotic cell that is capable of expressing functionally rearranged human
immunoglobulin (e.g., heavy chain and/or light chain) genes. Further, when the antibody
is a single chain antibody, it can comprise a linker peptide that is not found in native
human antibodies. For example, an Fv can comprise a linker peptide, such as two to
about eight glycine or other amino acid residues, which connects the variable region of
the heavy chain and the variable region of the light chain. Such linker peptides are
considered to be of human origin.
                                              17

[0070]       Antibody humanization can be performed by, for example, synthesizing a
combinatorial library comprising the six CDRs of a non-human target monoclonal
antibody fused in frame to a pool of individual human frameworks. A human framework
library that contains genes representative of all known heavy and light chain human
germline genes can be utilized. The resulting combinatorial libraries can then be screened
for binding to antigens of interest. This approach can allow for the selection of the most
favorable combinations of fully human frameworks in terms of maintaining the binding
activity to the parental antibody. Humanized antibodies can then be further optimized by
a variety of techniques.
[0071]       For full-length antibody molecules, the immunoglobulin genes can be obtained
from genomic DNA or mRNA of hybridoma cell lines. Antibody heavy and light chains
are cloned in a mammalian vector system. Assembly is documented with double strand
sequence analysis. The antibody construct can be expressed in other human or
mammalian host cell lines. The construct can then be validated by transient transfection
assays and Western blot analysis of the expressed antibody of interest. Stable cell lines
with the highest productivity can be isolated and screened using rapid assay methods.
[0072]       Several publications describe in detail uses, applications and methods of use
and application of anti-CD22 antibodies, including anti-CD22 antibodies of the present
invention, for example U.S. Patent Application Number US20110182887 entitled
"Humanized Anti-CD22 Antibodies and Their Use", U.S. Patent Application Number
US20110020344 entitled "Human Monoclonal Antibodies Specific for CD22", and U.S.
Patent Application Number US20100143368 entitled "Human Antibodies That Bind
CD22 and Uses Thereof' all of which are incorporated herein by reference.
[0073]       Antibodies of the Present Invention
[0074]       In accordance with the present invention, the Anti-CD22 antibodies comprise
any one of VM1OOO, VM1001, VM1002, VM1003, VM1004, VM1005, VM1006,
VM1007, VM1008, VM1009, VM1O1O, VM101 1, VM1012, VM1013, VM1014, or
VM1015 antibodies or an antibody in which the variable region or CDRs are derived
from any one of VM1OOO, VM1001, VM1002, VM1003, VM1004, VM1005, VM1006,
VM1007, VM1008, VM1009, VM1O1O, VM101 1, VM1012, VM1013, VM1014, or
                                              18

VM1015 antibody and the framework and constant regions of the antibody are derived
from one or more human antibodies. The variable region or CDRs derived from the
antibody preferably have from about 90% to about 100% identity with the variable region
or CDRs of any one of VM1000, VM1001, VM1002, VM1003, VM1004, VM1005,
VM1006, VM1007, VM1008, VM1009, VM1010, VM101 1, VM1012, VM1013,
VM10 14, or VM1015 antibody, although any and all modifications, including
substitutions, insertions and deletions, are contemplated so long as the chimeric antibody
maintains the ability to bind to and inhibit CD22. The regions of the chimeric,
humanized or CDR-grafted antibodies that are derived from human antibodies need not
have 100% identity with the human antibodies. In a preferred embodiment, as many of
the human amino acid residues as possible are retained in order that immunogenicity is
negligible, but the human residues, in particular residues of the framework region, are
substituted as required and as taught herein below in accordance with the present
invention. Such modifications as disclosed herein are necessary to support the antigen
binding site formed by the CDRs while simultaneously maximizing the humanization of
the antibody.
[0075]      In accordance with the present invention, the nucleic acid sequences and the
deduced amino acid sequences of the variable regions (light and heavy chain) of the Anti
CD22 antibodies are set forth in Figures 1-15. Each of the heavy and light chain variable
regions contain three CDRs that combine to form the antigen binding site. The three
CDRs are surrounded by four framework regions that primarily function to support the
CDRs. The sequences of the CDRs within the sequences of the variable regions of the
heavy and light chains can be identified by computer-assisted alignment according to
Kabat et al. (1987) in Sequences of Proteins of Immunological Interest, 4th ed., United
States Department of Health and Human Services, U.S. Government Printing Office,
Washington, D.C., or by molecular modeling of the variable regions, for example
utilizing the ENCAD program as described by Levitt (1983) J. Mol. Biol. 168:595.
[0076]      In a preferred embodiment the CDRs are derived from any one of VM1000,
VM1001, VM1002, VM1003, VM1004, VM1005, VM1006, VM1007, VM1008,
VM1009, VM1O1O, VM101 1, VM1012, VM1013, VM1014, or VM1015. Determination
                                               19

of the heavy chain CDRs and light chain CDRs is well within the skill of one in the art.
See, for example, http://www.bioinforg.uk/abs/.
[0077]      The sequences of the CDRs of the Anti-CD22 antibody may be modified by
insertions, substitutions and deletions to the extent that the CDR-grafted antibody
maintains the ability to bind to and inhibit human CD22. The ordinarily skilled artisan
can ascertain the maintenance of this activity by performing the functional assays
described herein below.
[0078]      Alternatively, the entire heavy chain variable region and light chain variable
region of any one of VM1000, VM1001, VM1002, VM1003, VM1004, VM1005,
VM1006, VM1007, VM1008, VM1009, VM1010, VM101 1, VM1012, VM1013,
VM1014, or VM1015 may be combined with the human constant and framework regions
to form the chimeric antibody of the present invention. Clone VM1000 comprises light
chain VM1000LC (SEQ ID NO: 1) and heavy chain VM1000HC (SEQ ID NO: 33).
Clone VM1001 comprises light chain VM1001LC (SEQ ID NO: 2) and heavy chain
VM1001HC (SEQ ID NO: 34). Clone VM1002 comprises light chain VM1002LC (SEQ
ID NO: 3) and heavy chain VM1002HC (SEQ ID NO: 35). Clone VM1003 comprises
light chain VM1003LC (SEQ ID NO: 4) and heavy chain VM1003HC (SEQ ID NO: 36).
Clone VM1004 comprises light chain VM1004LC (SEQ ID NO: 5) and heavy chain
VM1004HC (SEQ ID NO: 37). Clone VM1005 comprises light chain VM1005LC (SEQ
ID NO: 6) and heavy chain VM1005HC (SEQ ID NO: 38). Clone VM1006 comprises
light chain VM1006LC (SEQ ID NO: 7) and heavy chain VM1006HC (SEQ ID NO: 39).
Clone VM1007 comprises light chain VM1007LC (SEQ ID NO: 8) and heavy chain
VM1007HC (SEQ ID NO: 40). Clone VM1008 comprises light chain VM1008LC (SEQ
ID NO: 9) and heavy chain VM1008HC (SEQ ID NO: 41). Clone VM1009 comprises
light chain VM1009LC (SEQ ID NO: 10) and heavy chain VM1009HC (SEQ ID NO:
42). Clone VM1010 comprises light chain VM101OLC (SEQ ID NO: 11) and heavy
chain VM101OHC (SEQ ID NO: 43). Clone VM10 11 comprises light chain VM1011LC
(SEQ ID NO: 12) and heavy chain VM1011HC (SEQ ID NO: 44). Clone VM1012
comprises light chain VM1012LC (SEQ ID NO: 13) and heavy chain VM1012HC (SEQ
ID NO: 45). Clone VM1013 comprises light chain VM1013LC (SEQ ID NO: 14) and
heavy chain VM1013HC (SEQ ID NO: 46). Clone VM1014 comprises light chain
                                               20

VM1014LC (SEQ ID NO: 15) and heavy chain VM1014HC (SEQ ID NO: 47). Clone
VM1015 comprises light chain VM1015LC (SEQ ID NO: 16) and heavy chain
VM1015HC (SEQ ID NO: 48).
[0079]       Human genes which encode the constant (C) regions of the humanized
antibodies, fragments and regions of the present invention can be derived from a human
fetal liver library, by known methods. Human C region genes can be derived from any
human cell including those which express and produce human immunoglobulins. The
human CH region can be derived from any of the known classes or isotypes of human H
chains, including y, , a, 6, z, and subtypes thereof, such as GI, G2, G3 and G4. Since
the H chain isotype is responsible for the various effector functions of an antibody, the
choice of CH region will be guided by the desired effector functions, such as complement
fixation, or activity in antibody-dependent cellular cytotoxicity (ADCC). Preferably, the
CH  region is derived from gamma 1 (IgG1).
[0080]       The human CL region can be derived from either human L chain isotype,
kappa or lambda, preferably kappa.
[0081]        Genes encoding human immunoglobulin C regions are obtained from human
cells by standard cloning techniques (Sambrook, et al. (Molecular Cloning: A Laboratory
Manual, 2"n Edition, Cold Spring Harbor Press, Cold Spring Harbor, N.Y. (1989) and
Ausubel et al., eds. Current Protocols in Molecular Biology (1987-1993)). Human C
region genes are readily available from known clones containing genes representing the
two classes of L chains, the five classes of H chains and subclasses thereof. Chimeric
antibody fragments, such as F(ab )2 and Fab, can be prepared by designing a chimeric H
chain gene which is appropriately truncated. For example, a chimeric gene encoding an
H chain portion of an F(ab)    2 fragment would include DNA sequences encoding the CHI
domain and hinge region of the H chain, followed by a translational stop codon to yield
the truncated molecule.
[0082]        Generally, in one example, humanized antibodies, fragments and regions of
the present invention are produced by cloning DNA segments encoding the H and L chain
antigen-binding regions of the Anti CD22 specific antibody, and joining these DNA
                                              21

segments to DNA segments including CH and CL regions, respectively, to produce full
length immunoglobulin-encoding genes.
[0083]       The sequences of the variable regions of the antibody may be modified by
insertions, substitutions and deletions to the extent that the chimeric antibody maintains
the ability to bind to and inhibit human CD22. The ordinarily skilled artisan can ascertain
the maintenance of this activity by performing the functional assays described
hereinbelow. The variable regions can have, for example, from about 50% to about 100%
homology to the variable regions of SEQ ID NOS: 1-64. In a preferred embodiment, the
variable regions of the antibody have from about 80% to about 100% homology to the
variable regions of SEQ ID NOS: 1-64. In a more preferred embodiment the variable
regions have from about 90% to about 100% homology to the variable regions of SEQ ID
NOS: 1-64.
[0084]       In one specific aspect, preferred anti-CD22 Mabs of the disclosure comprise
variable light chain regions having 95%, 96%, 97%, 98% or 99% amino acid sequence
homology to SEQ ID NO: 17-32 and further comprise variable heavy chain regions
having 95%, 96%, 97%, 98% or 99% amino acid sequence homology to SEQ ID NO: 49
64.
[0085]       In one specific aspect, preferred anti-CD22 Mabs of the disclosure comprise a
variable light chain region selected from one of SEQ ID NO: 1-16. In another specific
aspect, preferred anti-CD22 Mabs of the disclosure comprise a variable heavy chain
region selected from one of SEQ ID NO: 33-48.
[0086]       Methods for engineering or humanizing non-human or human antibodies can
be used and are well known in the art. Generally, a humanized or engineered antibody
has one or more amino acid residues from a source which is non-human, e.g., but not
limited to mouse, rat, rabbit, non-human primate or other mammal. These human amino
acid residues are often referred to as "import" residues, which are typically taken from an
"import" variable, constant or other domain of a known human sequence. Known human
Ig sequences are disclosed, e.g., www.ncbi.nlm.nih.gov/entrez/query.fcgi;
www.atcc.org/phage/hdb.html; www.sciquest.com/; www.abcam.com/;
www.antibodyresource.com/onlinecomp.html;
                                               22

www.public.iastate.edu/.about.pedro/researchtools.html; www. mgen.uni
heidelberg.de/SD/IT/IT.html; www.whfreeman.com/immunology/CHO5/kubyO5.htm;
www.library.thinkquest.org/12429/Immune/Antibody.html;
www.hhmi.org/grants/lectures/1996/vlab/;
www.path.cam.ac.uk/.about.mrc7/mikeimages.html; www.antibodyresource.com/;
mcb.harvard.edu/BioLinks/Immunology.html. www.immunologylink.com/;
pathbox.wustl.edu/.about.hcenter/index.html; www.biotech.ufl.edu/.about.hcl/;
www.pebio.com/pa/340913/340913.html; www.nal.usda.gov/awic/pubs/antibody/;
www.m.ehime-u.ac.jp/.about.yasuhito/Elisa.html; www.biodesign.com/table.asp;
www.icnet.uk/axp/facs/davies/links.html; www.biotech.ufl.edu/.about.fccl/protocol.html;
www. isac-net. org/sites geo.html; aximt l. imt.uni-marburg.de/. about.rek/AEPStart.html;
baserv.uci.kun.nl/.about.jraats/linksl.html; www.recab.uni
hd.de/immuno.bme.nwvu.edu/; www.mrc-cpe. cam.ac.uk/imt-doc/public/INTRO.html;
www.ibt.unam.mx/vir/V_mice.html; imgt.cnusc.fr:8104/;
www.biochem.ucl.ac.uk/.about.martin/abs/index.html; antibody.bath.ac.uk/;
abgen.cvm.tamu.edu/lab/wwwabgen.html;
www.unizh.ch/.about.honegger/AHOseminar/SlideO1.html;
www.cryst.bbk.ac.uk/.about.ubcg07s/; www.nimr.mrc.ac.uk/CC/ccaewg/ccaewg.htm;
www.path.cam.ac.uk/.about.mrc7/humanisation/TAHHP.html;
www.ibt.unam.mx/vir/structure/stataim.html;
www.biosci.missouri.edu/smithgp/index.html;
www.cryst.bioc.cam.ac.uk/.about.fmolina/Web-pages/Pept/spottech.html;
www.jerini.de/frproducts.htm; www. patents. ibm. con/ibm.html. Kabat et al. Sequences
of Proteins of Immunological Interest, U.S. Dept. Health (1983), each entirely
incorporated herein by reference.
[0087]      Such imported sequences can be used to reduce immunogenicity or reduce,
enhance or modify binding, affinity, on-rate, off-rate, avidity, specificity, half-life, or any
other suitable characteristic, as known in the art. Generally part or all of the non-human
or human CDR sequences are maintained while the non-human sequences of the variable
and constant regions are replaced with human or other amino acids. Antibodies can also
optionally be humanized with retention of high affinity for the antigen and other
                                              23

favorable biological properties. To achieve this goal, humanized antibodies can be
optionally prepared by a process of analysis of the parental sequences and various
conceptual humanized products using three-dimensional models of the parental and
humanized sequences. Three-dimensional immunoglobulin models are commonly
available and are familiar to those skilled in the art. Computer programs are available
which illustrate and display probable three-dimensional conformational structures of
selected candidate immunoglobulin sequences. Inspection of these displays permits
analysis of the likely role of the residues in the functioning of the candidate
immunoglobulin sequence, i.e., the analysis of residues that influence the ability of the
candidate immunoglobulin to bind its antigen. In this way, FR residues can be selected
and combined from the consensus and import sequences so that the desired antibody
characteristic, such as increased affinity for the target antigen(s), is achieved. In general,
the CDR residues are directly and most substantially involved in influencing antigen
binding. Humanization or engineering of antibodies of the present invention can be
performed using any known method, such as but not limited to those described in, Winter
(Jones et al., Nature 321:522 (1986); Riechmann et al., Nature 332:323 (1988);
Verhoeyen et al., Science 239:1534 (1988)), Sims et al., J. Immunol. 151: 2296 (1993);
Chothia and Lesk, J. Mol. Biol. 196:901 (1987), Carter et al., Proc. Natl. Acad. Sci.
U.S.A. 89:4285 (1992); Presta et al., J. Immunol. 151:2623 (1993), U.S. Pat. Nos.
5,723,323, 5,976,862, 5,824,514, 5,817,483, 5,814,476, 5,763,192, 5,723,323, 5,766,886,
5,714,352, 6,204,023, 6,180,370, 5,693,762, 5,530,101, 5,585,089, 5,225,539; 4,816,567,
PCT/: US98/16280, US96/18978, US91/09630, US91/05939, US94/01234, GB89/01334,
GB91/01134, GB92/01755; W090/14443, W090/14424, W090/14430, EP 229246, each
entirely incorporated herein by reference, included references cited therein.
[0088]      The human constant region of the humanized antibody of the invention can be
of any class (IgG, IgA, IgM, IgE, IgD, etc.) or isotype and can comprise a kappa or
lambda light chain. In one embodiment, the human constant region comprises an IgG
heavy chain or defined fragment, for example, at least one of isotypes, IgGI, IgG2, IgG3
or IgG4. In another embodiment, the anti-human CD22 human antibody comprises an
IgGI heavy chain and a IgGI K light chain. The isolated anti-CD22 antibodies of the
present invention comprise antibody amino acid sequences disclosed herein encoded by
                                               24

any suitable polynucleotide as well as. Preferably, the antibody or antigen-binding
fragment binds human CD22 and, thereby partially or substantially neutralizes at least
one biological activity of the protein. The antibody, or specified portion or variant
thereof, partially or preferably substantially neutralizes at least one biological activity of
at least one CD22 protein or fragment and thereby inhibit activities mediated through the
binding of CD22 to the CD22 receptor or through other CD22-dependent or mediated
mechanisms. As used herein, the term "neutralizing antibody" refers to an antibody that
can inhibit an CD22-dependent activity by about 20-120%, preferably by at least about
10, 20, 30, 40, 50, 55, 60, 65, 70, 75, 80, 85, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 10000
or more depending on the assay. The capacity of an Anti-CD22 antibody to inhibit a
CD22-dependent activity is preferably assessed by at least one suitable CD22 protein or
receptor assay, as described herein and/or as known in the art.
[0089]      At least one antibody of the invention binds at least one specified epitope
specific to at least one CD22 protein, subunit, fragment, portion or any combination
thereof. The at least one epitope can comprise at least one antibody binding region that
comprises at least one portion of the protein, which epitope is preferably comprised of at
least one extracellular, soluble, hydrophillic, external or cytoplasmic portion of the
protein. Generally, the human antibody or antigen-binding fragment of the present
invention will comprise an antigen-binding region that comprises at least one human
complementarity determining region (CDR1, CDR2 and CDR3) or variant of at least one
heavy chain variable region and at least one human complementarity determining region
(CDR4, CDR5 and CDR6) or variant of at least one light chain variable region, derived
from an anti-CD22 Ab described herein. In a particular embodiment, the antibody or
antigen-binding fragment can have an antigen-binding region that comprises at least a
portion of at least one heavy chain CDR (i.e., CDR1, CDR2 and/or CDR3) having the
amino acid sequence of the corresponding CDRs 1, 2 and/or 3. In another particular
embodiment, the antibody or antigen-binding portion or variant can have an antigen
binding region that comprises at least a portion of at least one light chain CDR (i.e.,
CDR4, CDR5 and/or CDR6) having the amino acid sequence of the corresponding CDRs
4, 5 and/or 6. In a preferred embodiment the three heavy chain CDRs and the three light
chain CDRs of the antibody or antigen-binding fragment have the amino acid sequence of
                                               25

the corresponding CDR of at least one of VM1000, VM1001, VM1002, VM1003,
VM1004, VM1005, VM1006, VM1007, VM1008, VM1009, VM1010, VM1011,
VM1012, VM1013, VM1014, or VM1015. Such antibodies can be prepared by
chemically joining together the various portions (e.g., CDRs, framework) of the antibody
using conventional techniques, by preparing and expressing a (i.e., one or more) nucleic
acid molecule that encodes the antibody using conventional techniques of recombinant
DNA technology or by using any other suitable method and using any of the possible
redundant codons that will result in expression of a polypeptide of the invention.
[0090]       Liquid phase synthesis of combinatorial variable domain humanized libraries
for the light chain and the heavy chain can be employed. The assembly of a humanized
light chain (LC) variable domain library, for example, contains human light chain
frameworks (FW) and non-human complementarity determining regions (CDR). The
library is assembled by, for example, by using stepwise liquid phase ligation of FW and
CDR DNA fragments. The libraries are assembled by using stepwise liquid phase
ligation of FW and CDR DNA fragments in the order of FW1-CDR1-FW2-CDR2-FW3
CDR3 by techniques known to one of skill in the art. For example, by the techniques of
one or more of the following references, each of which is incorporated herein by
reference. Lo, B.K., 2003, Antibody humanization by CDR grafting. Antibody
Engineering, Methods and protocols. Edit by Benny K. C. Lo, Methods in Molecular
Biology, 248, 135-159; Kashmiri et al., 2003, Developing a minimally immunogenic
humanized antibody by CDR grafting. Antibody Engineering, Methods and protocols.
Edit by Benny K. C. Lo, Methods in Molecular Biology, 248, 361-376; Bassette, P. H., et
al., 2003, Construction of Designed Protein Libraries Using Gene Assembly Mutagenesis.
Directed Evolution Library Creation, Methods and protocols. Edit. Arnold and Georgiou,
Methods in Molecular Biology, 231, 29-37; Chames, P., et al., 2001, Selections on
Biotinylated antigens. Antibody Engineering, Edit by R. Kontermann and S. Dubel,
Springer Lab Manual, 149-166; O'Brien S., and Jones, T., 2001, Humanising antibodies
by CDR grafting. Antibody Engineering, Edit by R. Kontermann and S. Dubel, Springer
Lab Manual, 567-590.
[0091]       Antibodies that bind to human CD22 and that comprise the defined heavy or
light chain variable region or CDR regions can be prepared using suitable methods, such
                                             26

as phage display (Katsube, Y., et al., Int J. Mol. Med, 1(5):863-868 (1998)) or methods
that employ transgenic animals, as known in the art and/or as described herein. For
example, the antibody, specified portion or variant can be expressed using the encoding
nucleic acid or portion thereof in a suitable host cell.
[0092]      As stated, the invention also relates to antibodies, antigen-binding fragments,
immunoglobulin chains and CDRs comprising amino acids in a sequence that is
substantially the same as an amino acid sequence described herein. Such Anti-CD22
antibodies can include one or more amino acid substitutions, delations or additions, either
from natural mutations or human manipulation, as specified herein. Preferably, such
antibodies or antigen-binding fragments and antibodies comprising such chains or CDRs
can bind human CD22 with high affinity (e.g., KD less than or equal to about 10-9 M).
Amino acid sequences that are substantially the same as the sequences described herein
include sequences comprising conservative amino acid substitutions, as well as amino
acid deletions and/or insertions. A conservative amino acid substitution refers to the
replacement of a first amino acid by a second amino acid that has chemical and/or
physical properties (e.g., charge, structure, polarity, hydrophobicity/hydrophilicity) that
are similar to those of the first amino acid. Conservative substitutions include
replacement of one amino acid by another within the following groups: lysine (K),
arginine (R) and histidine (H); aspartate (D) and glutamate (E); asparagine (N), glutamine
(Q), serine (S), threonine (T), tyrosine (Y), K, R, H, D and E; alanine (A), valine (V),
leucine (L), isoleucine (I), proline (P), phenylalanine (F), tryptophan (W), methionine
(M), cysteine (C) and glycine (G); F, W and Y; C, S and T.
[0093]      Of course, the number of amino acid substitutions a skilled artisan would
make depends on many factors, including those described above. Generally speaking, the
number of amino acid substitutions, insertions or deletions for any given Anti-CD22
antibody, fragment or variant will not be more than 40, 30, 20, 19, 18, 17, 16, 15, 14, 13,
12, 11, 10, 9, 8, 7, 6, 5, 4, 3, 2, 1, such as 1-30 or any range or value therein, as specified
herein.
[0094]      Amino acids in an Anti-CD22 antibody of the present invention that are
essential for function can be identified by methods known in the art, such as site-directed
mutagenesis or alanine-scanning mutagenesis (e.g., Ausubel, supra, Chapters 8, 15;
                                                 27

Cunningham and Wells, Science 244:1081-1085 (1989)). The latter procedure introduces
single alanine mutations at every residue in the molecule. The resulting mutant molecules
are then tested for biological activity, such as, but not limited to at least one CD22
neutralizing activity. Sites that are critical for antibody binding can also be identified by
structural analysis such as crystallization, nuclear magnetic resonance or photoaffinity
labeling (Smith, et al., J. Mol. Biol. 224:899-904 (1992) and de Vos, et al., Science
255:306-312 (1992)).
[0095]       Anti-CD22 antibodies of the present invention can include, but are not limited
to, at least one portion, sequence or combination selected from 5 to all of the contiguous
amino acids of at least one of CDRs derived from SEQ ID NOS: 17-32 and 49-64.
[0096]       An Anti-CD22 antibody can further optionally comprise a polypeptide of at
least one of 70-100% of the contiguous amino acids of the CDRs derived from at least
one of SEQ ID NOS: 17-32 and 49-64. In one specific aspect, the anti-CD22 antibody
comprises a polypeptide of 95-99% sequence homology to SEQ ID NO: 1-16. In another
specific aspect, the anti-CD22 antibody comprises a polypeptide of 95-99% sequence
homology to SEQ ID NO: 33-48.
[0097]       In one embodiment, the amino acid sequence of an immunoglobulin chain, or
portion thereof (e.g., variable region, CDR) has about 70-100% identity (e.g., 70, 71, 72,
73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96,
97, 98, 99, 100 or any range or value therein) to the amino acid sequence of at least one of
SEQ ID NOS: 17-32 or 49-64. Preferably, 70-100% amino acid identity (i.e., 90, 91, 92,
93, 94, 95, 96, 97, 98, 99, 100 or any range or value therein) is determined using a
suitable computer algorithm, as known in the art. In one specific aspect, the anti-CD22
antibody comprises a polypeptide of 95-99% sequence homology to SEQ ID NO: 17-32
or 49-64.
[0098]       Exemplary heavy chain and light chain variable regions sequences are
provided in SEQ ID NOS: 1-64. The antibodies of the present invention, or specified
variants thereof, can comprise any number of contiguous amino acid residues from an
antibody of the present invention, wherein that number is selected from the group of
integers consisting of from 10-100% of the number of contiguous residues in an Anti
                                                28

CD22 antibody. Optionally, this subsequence of contiguous amino acids is at least about
10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 110, 120, 130, 140, 150, 160, 170, 180, 190, 200,
210, 220, 230, 240, 250 or more amino acids in length, or any range or value therein.
Further, the number of such subsequences can be any integer selected from the group
consisting of from I to 20, such as at least 2, 3, 4, or 5.
[0099]      As those of skill will appreciate, the present invention includes at least one
biologically active antibody of the present invention. Biologically active antibodies have
a specific activity at least 20%, 30%, or 40%, and preferably at least 50%, 60%, or 70%,
and most preferably at least 80%, 90%, or 95%-100% of that of the native (non
synthetic), endogenous or related and known antibody. Methods of assaying and
quantifying measures of enzymatic activity and substrate specificity, are well known to
those of skill in the art.
[00100]     In another aspect, the invention relates to human antibodies and antigen
binding fragments, as described herein, which are modified by the covalent attachment of
an organic moiety. Such modification can produce an antibody or antigen-binding
fragment with improved pharmacokinetic properties (e.g., increased in vivo serum half
life). The organic moiety can be a linear or branched hydrophilic polymeric group, fatty
acid group, or fatty acid ester group. In particular embodiments, the hydrophilic
polymeric group can have a molecular weight of about 800 to about 120,000 Daltons and
can be a polyalkane glycol (e.g., polyethylene glycol (PEG), polypropylene glycol
(PPG)), carbohydrate polymer, amino acid polymer or polyvinyl pyrolidone, and the fatty
acid or fatty acid ester group can comprise from about eight to about forty carbon atoms.
[00101]     The modified antibodies and antigen-binding fragments of the invention can
comprise one or more organic moieties that are covalently bonded, directly or indirectly,
to the antibody. Each organic moiety that is bonded to an antibody or antigen-binding
fragment of the invention can independently be a hydrophilic polymeric group, a fatty
acid group or a fatty acid ester group. As used herein, the term "fatty acid" encompasses
mono-carboxylic acids and di-carboxylic acids. A "hydrophilic polymeric group," as the
term is used herein, refers to an organic polymer that is more soluble in water than in
octane. For example, polylysine is more soluble in water than in octane. Thus, an
antibody modified by the covalent attachment of polylysine is encompassed by the
                                               29

invention. Hydrophilic polymers suitable for modifying antibodies of the invention can
be linear or branched and include, for example, polyalkane glycols (e.g., PEG,
monomethoxy-polyethylene glycol (mPEG), PPG and the like), carbohydrates (e.g.,
dextran, cellulose, oligosaccharides, polysaccharides and the like), polymers of
hydrophilic amino acids (e.g., polylysine, polyarginine, polyaspartate and the like),
polyalkane oxides (e.g., polyethylene oxide, polypropylene oxide and the like) and
polyvinyl pyrolidone. Preferably, the hydrophilic polymer that modifies the antibody of
the invention has a molecular weight of about 800 to about 150,000 Daltons as a separate
molecular entity. For example PEG 5ooo and PEG 2 0 0, 00 , wherein the subscript is the
average molecular weight of the polymer in Daltons, can be used. The hydrophilic
polymeric group can be substituted with one to about six alkyl, fatty acid or fatty acid
ester groups. Hydrophilic polymers that are substituted with a fatty acid or fatty acid
ester group can be prepared by employing suitable methods. For example, a polymer
comprising an amine group can be coupled to a carboxylate of the fatty acid or fatty acid
ester, and an activated carboxylate (e.g., activated with N,N-carbonyl diimidazole) on a
fatty acid or fatty acid ester can be coupled to a hydroxyl group on a polymer.
[00102]        Fatty acids and fatty acid esters suitable for modifying antibodies of the
invention can be saturated or can contain one or more units of unsaturation. Fatty acids
that are suitable for modifying antibodies of the invention include, for example, n
dodecanoate (C12, laurate), n-tetradecanoate (C14, myristate), n-octadecanoate (Cis,
stearate), n-eicosanoate (C 20 , arachidate), n-docosanoate (C 2 2 , behenate), n-triacontanoate
(C 3 o), n-tetracontanoate (C4 0 ), cis-6 9-octadecanoate (Cis, oleate), all cis-6 5,8,11,14
eicosatetraenoate (C 20 , arachidonate), octanedioic acid, tetradecanedioic acid,
octadecanedioic acid, docosanedioic acid, and the like. Suitable fatty acid esters include
mono-esters of dicarboxylic acids that comprise a linear or branched lower alkyl group.
The lower alkyl group can comprise from one to about twelve, preferably one to about
six, carbon atoms.
[00103]        The modified human antibodies and antigen-binding fragments can be
prepared using suitable methods, such as by reaction with one or more modifying agents.
A "modifying agent" as the term is used herein, refers to a suitable organic group (e.g.,
hydrophilic polymer, a fatty acid, a fatty acid ester) that comprises an activating group.
                                                  30

An "activating group" is a chemical moiety or functional group that can, under
appropriate conditions, react with a second chemical group thereby forming a covalent
bond between the modifying agent and the second chemical group. For example, amine
reactive activating groups include electrophilic groups such as tosylate, mesylate, halo
(chloro, bromo, fluoro, iodo), N-hydroxysuccinimidyl esters (NHS), and the like.
Activating groups that can react with thiols include, for example, maleimide, iodoacetyl,
acrylolyl, pyridyl disulfides, 5-thiol-2-nitrobenzoic acid thiol (TNB-thiol), and the like.
An aldehyde functional group can be coupled to amine- or hydrazide-containing
molecules, and an azide group can react with a trivalent phosphorous group to form
phosphoramidate or phosphorimide linkages. Suitable methods to introduce activating
groups into molecules are known in the art (see for example, Hernanson, G. T.,
Bioconjugate Techniques, Academic Press: San Diego, Calif (1996)). An activating
group can be bonded directly to the organic group (e.g., hydrophilic polymer, fatty acid,
fatty acid ester), or through a linker moiety, for example a divalent C1-C 12 group wherein
one or more carbon atoms can be replaced by a heteroatom such as oxygen, nitrogen or
sulfur. Suitable linker moieties include, for example, tetraethylene glycol, --(CH 2 ) 3 --, -
NH--(CH 2)6 --NH--, --(CH 2) 2--NH-- and --CH 2--O--CH 2 --CH 2--O--CH 2--CH 2--O--CH-
NH--. Modifying agents that comprise a linker moiety can be produced, for example, by
reacting a mono-Boc-alkyldiamine (e.g., mono-Boc-ethylenediamine, mono-Boc
diaminohexane) with a fatty acid in the presence of 1-ethyl-3-(3-dimethylaminopropyl)
carbodiimide (EDC) to form an amide bond between the free amine and the fatty acid
carboxylate. The Boc protecting group can be removed from the product by treatment
with trifluoroacetic acid (TFA) to expose a primary amine that can be coupled to another
carboxylate as described, or can be reacted with maleic anhydride and the resulting
product cyclized to produce an activated maleimido derivative of the fatty acid. (See, for
example, Thompson, et al., WO 92/16221 the entire teachings of which are incorporated
herein by reference.)
[00104]     The modified antibodies of the invention can be produced by reacting a human
antibody or antigen-binding fragment with a modifying agent. For example, the organic
moieties can be bonded to the antibody in a non-site specific manner by employing an
amine-reactive modifying agent, for example, an NHS ester of PEG. Modified human
                                               31

antibodies or antigen-binding fragments can also be prepared by reducing disulfide bonds
(e.g., intra-chain disulfide bonds) of an antibody or antigen-binding fragment. The
reduced antibody or antigen-binding fragment can then be reacted with a thiol-reactive
modifying agent to produce the modified antibody of the invention. Modified human
antibodies and antigen-binding fragments comprising an organic moiety that is bonded to
specific sites of an antibody of the present invention can be prepared using suitable
methods, such as reverse proteolysis (Fisch et al., Bioconjugate Chem., 3:147-153 (1992);
Werlen et al., Bioconjugate Chem., 5:411-417 (1994); Kumaran et al., Protein Sci.
6(10):2233-2241 (1997); Itoh et al., Bioorg. Chem., 24(1): 59-68 (1996); Capellas et al.,
Biotechnol. Bioeng., 56(4):456-463 (1997)), and the methods described in Hermanson, G.
T., Bioconjugate Techniques, Academic Press: San Diego, Calif. (1996).
[00105]      The antibodies of the invention can bind human CD22 with a wide range of
affinities (KD). In a preferred embodiment at least one human mAb of the present
invention can optionally bind human CD22 with high affinity. For example, a mAb can
bind human CD22 with a KD equal to or less than about 10-7 M, such as but not limited to,
0.1-9.9 (or any range or value therein) X 10-7, 10-1, 10-9,10-10, 10-11, 10-2, 10-13 or any
range or value therein.
[00106]      The affinity or avidity of an antibody for an antigen can be determined
experimentally using any suitable method. (See, for example, Berzofsky, et al.,
"Antibody-Antigen Interactions," In Fundamental Immunology, Paul, W. E., Ed., Raven
Press: New York, N.Y. (1984); Kuby, Janis Immunology, W. H. Freeman and Company:
New York, N.Y. (1992); and methods described herein). The measured affinity of a
particular antibody-antigen interaction can vary if measured under different conditions
(e.g., salt concentration, pH). Thus, measurements of affinity and other antigen-binding
parameters (e.g., KD, Ka, Kd) are preferably made with standardized solutions of antibody
and antigen, and a standardized buffer, such as the buffer described herein.
[00107]      Anti-CD22 antibodies useful in the methods and compositions of the present
invention are characterized by high affinity binding to CD22 and optionally and
preferably having low toxicity. In particular, an antibody, specified fragment or variant
of the invention, where the individual components, such as the variable region, constant
region and framework, individually and/or collectively, optionally and preferably possess
                                                32

low immunogenicity, is useful in the present invention. The antibodies that can be used
in the invention are optionally characterized by their ability to treat patients for extended
periods with measurable alleviation of symptoms and low and/or acceptable toxicity.
Low or acceptable immunogenicity and/or high affinity, as well as other suitable
properties, can contribute to the therapeutic results achieved. "Low immunogenicity" is
defined herein as raising significant HAHA, HACA or HAMA responses in less than
about 75%, or preferably less than about 50% of the patients treated and/or raising low
titres in the patient treated (less than about 300, preferably less than about 100 measured
with a double antigen enzyme immunoassay) (Elliott et al., Lancet 344:1125-1127 (1994),
entirely incorporated herein by reference).
[00108]      Bispecific, heterospecific, heteroconjugate or similar antibodies can also be
used that are monoclonal, humanized, antibodies that have binding specificities for at
least two different antigens. In the present case, one of the binding specificities is for at
least one CD22 protein, the other one is for any other antigen. Methods for making
bispecific antibodies are known in the art. Traditionally, the recombinant production of
bispecific antibodies is based on the co-expression of two immunoglobulin heavy chain
light chain pairs, where the two heavy chains have different specificities (Milstein and
Cuello, Nature 305:537 (1983)). Because of the random assortment of immunoglobulin
heavy and light chains, these hybridomas (quadromas) produce a potential mixture of 10
different antibody molecules, of which only one has the correct bispecific structure. The
purification of the correct molecule, which is usually done by affinity chromatography
steps, is rather cumbersome, and the product yields are low. Similar procedures are
disclosed, e.g., in WO 93/08829, U.S. Pat. Nos. 6,210,668, 6,193,967, 6,132,992,
6,106,833, 6,060,285, 6,037,453, 6,010,902, 5,989,530, 5,959,084, 5,959,083, 5,932,448,
5,833,985, 5,821,333, 5,807,706, 5,643,759, 5,601,819, 5,582,996, 5,496,549, 4,676,980,
WO 91/00360, WO 92/00373, EP 03089, Traunecker et al., EMBO J. 10:3655 (1991),
Suresh et al., Methods in Enzymology 121:210 (1986), each entirely incorporated herein
by reference.
[00109]      Nucleic Acid Molecules
[00110]      Using the information provided herein, such as the nucleotide sequences
encoding at least 70-100% of the contiguous amino acids of at least one of SEQ ID NOS:
                                                33

17-32 or 49-64, variants or consensus sequences thereof, or a deposited vector comprising
at least one of these sequences, a nucleic acid molecule of the present invention encoding
at least one Anti-CD22 antibody can be obtained using methods described herein or as
known in the art.
[00111]     Nucleic acid molecules of the present invention can be in the form of RNA,
such as mRNA, hnRNA, tRNA or any other form, or in the form of DNA, including, but
not limited to, cDNA and genomic DNA obtained by cloning or produced synthetically,
or any combinations thereof. The DNA can be triple-stranded, double-stranded or single
stranded, or any combination thereof. Any portion of at least one strand of the DNA or
RNA can be the coding strand, also known as the sense strand, or it can be the non-coding
strand, also referred to as the anti-sense strand.
[00112]     Isolated nucleic acid molecules of the present invention can include nucleic
acid molecules comprising an open reading frame (ORF), optionally with one or more
introns, e.g., but not limited to, at least one specified portion of at least one CDR, as
CDR1, CDR2 and/or CDR3 of at least one heavy chain (e.g., SEQ ID NOS: 33-48) or
light chain (e.g., SEQ ID NOS: 1-16); nucleic acid molecules comprising the coding
sequence for an anti-CD22 antibody or variable region; and nucleic acid molecules which
comprise a nucleotide sequence substantially different from those described above but
which, due to the degeneracy of the genetic code, still encode at least one Anti-CD22
antibody as described herein and/or as known in the art. Of course, the genetic code is
well known in the art. Thus, it would be routine for one skilled in the art to generate such
degenerate nucleic acid variants that code for specific Anti-CD22 antibodies of the
present invention. See, e.g., Ausubel, et al., supra, and such nucleic acid variants are
included in the present invention. Non-limiting examples of isolated nucleic acid
molecules of the present invention include SEQ ID NOS: 1-16 and 33-48; corresponding
to non-limiting examples of a nucleic acid encoding, respectively, HC CDR1, HC CDR2,
HC CDR3, LC CDR1, LC CDR2, LC CDR3, HC variable region and LC variable region.
[00113]     As indicated herein, nucleic acid molecules of the present invention which
comprise a nucleic acid encoding an Anti-CD22 antibody can include, but are not limited
to, those encoding the amino acid sequence of an antibody fragment, by itself, the coding
sequence for the entire antibody or a portion thereof, the coding sequence for an antibody,
                                                34

fragment or portion, as well as additional sequences, such as the coding sequence of at
least one signal leader or fusion peptide, with or without the aforementioned additional
coding sequences, such as at least one intron, together with additional, non-coding
sequences, including but not limited to, non-coding 5' and 3' sequences, such as the
transcribed, non-translated sequences that play a role in transcription, mRNA processing,
including splicing and polyadenylation signals (for example--ribosome binding and
stability of mRNA); an additional coding sequence that codes for additional amino acids,
such as those that provide additional functionalities. Thus, the sequence encoding an
antibody can be fused to a marker sequence, such as a sequence encoding a peptide that
facilitates purification of the fused antibody comprising an antibody fragment or portion.
[00114]      Polynucleotides which Selectively Hybridize to a Polynucleotide as
Described Herein
[00115]      The present invention provides isolated nucleic acids that hybridize under
selective hybridization conditions to a polynucleotide disclosed herein. Thus, the
polynucleotides of this embodiment can be used for isolating, detecting, and/or
quantifying nucleic acids comprising such polynucleotides. For example, polynucleotides
of the present invention can be used to identify, isolate, or amplify partial or full-length
clones in a deposited library. In some embodiments, the polynucleotides are genomic or
cDNA sequences isolated, or otherwise complementary to, a cDNA from a human or
mammalian nucleic acid library.
[00116]      Preferably, the cDNA library comprises at least 80% full-length sequences,
preferably at least 85% or 90% full-length sequences, and more preferably at least 95%
full-length sequences. The cDNA libraries can be normalized to increase the
representation of rare sequences. Low or moderate stringency hybridization conditions
are typically, but not exclusively, employed with sequences having a reduced sequence
identity relative to complementary sequences. Moderate and high stringency conditions
can optionally be employed for sequences of greater identity. Low stringency conditions
allow selective hybridization of sequences having about 70% sequence identity and can
be employed to identify orthologous or paralogous sequences.
                                              35

[00117]     Optionally, polynucleotides of this invention will encode at least a portion of
an antibody encoded by the polynucleotides described herein. The polynucleotides of this
invention embrace nucleic acid sequences that can be employed for selective
hybridization to a polynucleotide encoding an antibody of the present invention. See,
e.g., Ausubel, supra; Colligan, supra, each entirely incorporated herein by reference.
[00118]     Construction of Nucleic Acids
[00119]     The isolated nucleic acids of the present invention can be made using (a)
recombinant methods, (b) synthetic techniques, (c) purification techniques, or
combinations thereof, as well-known in the art.
[00120]     The nucleic acids can conveniently comprise sequences in addition to a
polynucleotide of the present invention. For example, a multi-cloning site comprising
one or more endonuclease restriction sites can be inserted into the nucleic acid to aid in
isolation of the polynucleotide. Also, translatable sequences can be inserted to aid in the
isolation of the translated polynucleotide of the present invention. For example, a hexa
histidine marker sequence provides a convenient means to purify the proteins of the
present invention. The nucleic acid of the present invention--excluding the coding
sequence--is optionally a vector, adapter, or linker for cloning and/or expression of a
polynucleotide of the present invention.
[00121]     Additional sequences can be added to such cloning and/or expression
sequences to optimize their function in cloning and/or expression, to aid in isolation of
the polynucleotide, or to improve the introduction of the polynucleotide into a cell. Use
of cloning vectors, expression vectors, adapters, and linkers is well known in the art. (See,
e.g., Ausubel, supra; or Sambrook, supra).
[00122]     Recombinant Methods for Constructing Nucleic Acids
[00123]     The isolated nucleic acid compositions of this invention, such as RNA, cDNA,
genomic DNA, or any combination thereof, can be obtained from biological sources using
any number of cloning methodologies known to those of skill in the art. In some
embodiments, oligonucleotide probes that selectively hybridize, under stringent
conditions, to the polynucleotides of the present invention are used to identify the desired
sequence in a cDNA or genomic DNA library. The isolation of RNA, and construction of
                                              36

cDNA and genomic libraries, is well known to those of ordinary skill in the art. (See, e.g.,
Ausubel, supra; or Sambrook, supra).
[00124]     Nucleic Acid Screening and Isolation Methods
[00125]     A cDNA or genomic library can be screened using a probe based upon the
sequence of a polynucleotide of the present invention, such as those disclosed herein.
Probes can be used to hybridize with genomic DNA or cDNA sequences to isolate
homologous genes in the same or different organisms. Those of skill in the art will
appreciate that various degrees of stringency of hybridization can be employed in the
assay; and either the hybridization or the wash medium can be stringent. As the
conditions for hybridization become more stringent, there must be a greater degree of
complementarity between the probe and the target for duplex formation to occur. The
degree of stringency can be controlled by one or more of temperature, ionic strength, pH
and the presence of a partially denaturing solvent such as formamide. For example, the
stringency of hybridization is conveniently varied by changing the polarity of the reactant
solution through, for example, manipulation of the concentration of formamide within the
range of 0% to 50%. The degree of complementarity (sequence identity) required for
detectable binding will vary in accordance with the stringency of the hybridization
medium and/or wash medium. The degree of complementarity will optimally be 100%,
or 70-100%, or any range or value therein. However, it should be understood that minor
sequence variations in the probes and primers can be compensated for by reducing the
stringency of the hybridization and/or wash medium.
[00126]     Methods of amplification of RNA or DNA are well known in the art and can
be used according to the present invention without undue experimentation, based on the
teaching and guidance presented herein.
[00127]     Known methods of DNA or RNA amplification include, but are not limited to,
polymerase chain reaction (PCR) and related amplification processes (see, e.g., U.S. Pat.
Nos. 4,683,195, 4,683,202, 4,800,159, 4,965,188, to Mullis, et al.; 4,795,699 and
4,921,794 to Tabor, et al; 5,142,033 to Innis; 5,122,464 to Wilson, et al.; 5,091,310 to
Innis; 5,066,584 to Gyllensten, et al; 4,889,818 to Gelfand, et al; 4,994,370 to Silver, et
al; 4,766,067 to Biswas; 4,656,134 to Ringold) and RNA mediated amplification that uses
                                              37

anti-sense RNA to the target sequence as a template for double-stranded DNA synthesis
(U.S. Pat. No. 5,130,238 to Malek, et al., with the tradename NASBA), the entire contents
of which references are incorporated herein by reference. (See, e.g., Ausubel, supra; or
Sambrook, supra.)
[00128]      For instance, polymerase chain reaction (PCR) technology can be used to
amplify the sequences of polynucleotides of the present invention and related genes
directly from genomic DNA or cDNA libraries. PCR and other in vitro amplification
methods can also be useful, for example, to clone nucleic acid sequences that code for
proteins to be expressed, to make nucleic acids to use as probes for detecting the presence
of the desired mRNA in samples, for nucleic acid sequencing, or for other purposes.
Examples of techniques sufficient to direct persons of skill through in vitro amplification
methods are found in Berger, supra, Sambrook, supra, and Ausubel, supra, as well as
Mullis, et al., U.S. Pat. No. 4,683,202 (1987); and Innis, et al., PCR Protocols A Guide to
Methods and Applications, Eds., Academic Press Inc., San Diego, Calif (1990).
Commercially available kits for genomic PCR amplification are known in the art. See,
e.g., Advantage-GC Genomic PCR Kit (Clontech). Additionally, e.g., the T4 gene 32
protein (Boehringer Mannheim) can be used to improve yield of long PCR products.
[00129]      Synthetic Methods for Constructing Nucleic Acids
[00130]      The isolated nucleic acids of the present invention can also be prepared by
direct chemical synthesis by known methods (see, e.g., Ausubel, et al., supra). Chemical
synthesis generally produces a single-stranded oligonucleotide, which can be converted
into double-stranded DNA by hybridization with a complementary sequence, or by
polymerization with a DNA polymerase using the single strand as a template. One of
skill in the art will recognize that while chemical synthesis of DNA can be limited to
sequences of about 100 or more bases, longer sequences can be obtained by the ligation
of shorter sequences.
[00131]      Recombinant Expression Cassettes
[00132]      The present invention further provides recombinant expression cassettes
comprising a nucleic acid of the present invention. A nucleic acid sequence of the present
invention, for example a cDNA or a genomic sequence encoding an antibody of the
                                               38

present invention, can be used to construct a recombinant expression cassette that can be
introduced into at least one desired host cell. A recombinant expression cassette will
typically comprise a polynucleotide of the present invention operably linked to
transcriptional initiation regulatory sequences that will direct the transcription of the
polynucleotide in the intended host cell. Both heterologous and non-heterologous (i.e.,
endogenous) promoters can be employed to direct expression of the nucleic acids of the
present invention.
[00133]      In some embodiments, isolated nucleic acids that serve as promoter, enhancer,
or other elements can be introduced in the appropriate position (upstream, downstream or
in intron) of a non-heterologous form of a polynucleotide of the present invention so as to
up or down regulate expression of a polynucleotide of the present invention. For
example, endogenous promoters can be altered in vivo or in vitro by mutation, deletion
and/or substitution.
[00134]      Vectors And Host Cells
[00135]      The present invention also relates to vectors that include isolated nucleic acid
molecules of the present invention, host cells that are genetically engineered with the
recombinant vectors, and the production of at least one anti-CD22 antibody by
recombinant techniques, as is well known in the art. See, e.g., Sambrook, et al., supra;
Ausubel, et al., supra, each entirely incorporated herein by reference.
[00136]      The polynucleotides can optionally be joined to a vector containing a
selectable marker for propagation in a host. Generally, a plasmid vector is introduced in a
precipitate, such as a calcium phosphate precipitate, or in a complex with a charged lipid.
If the vector is a virus, it can be packaged in vitro using an appropriate packaging cell line
and then transduced into host cells.
[00137]      The DNA insert should be operatively linked to an appropriate promoter. The
expression constructs will further contain sites for transcription initiation, termination
and, in the transcribed region, a ribosome binding site for translation. The coding portion
of the mature transcripts expressed by the constructs will preferably include a translation
initiating at the beginning and a termination codon (e.g., UAA, UGA or UAG)
                                               39

appropriately positioned at the end of the mRNA to be translated, with UAA and UAG
preferred for mammalian or eukaryotic cell expression.
[00138]     Expression vectors will preferably but optionally include at least one
selectable marker. Such markers include, e.g., but not limited to, methotrexate (MTX),
dihydrofolate reductase (DHFR, U.S. Pat. Nos. 4,399,216; 4,634,665; 4,656,134;
4,956,288; 5,149,636; 5,179,017, ampicillin, neomycin (G418), mycophenolic acid, or
glutamine synthetase (GS, U.S. Pat. Nos. 5,122,464; 5,770,359; 5,827,739) resistance for
eukaryotic cell culture, and tetracycline or ampicillin resistance genes for culturing in E.
coli and other bacteria or prokaryotics (the above patents are entirely incorporated hereby
by reference). Appropriate culture mediums and conditions for the above-described host
cells are known in the art. Suitable vectors will be readily apparent to the skilled artisan.
Introduction of a vector construct into a host cell can be effected by calcium phosphate
transfection, DEAE-dextran mediated transfection, cationic lipid-mediated transfection,
electroporation, transduction, infection or other known methods. Such methods are
described in the art, such as Sambrook, supra, Chapters 1-4 and 16-18; Ausubel, supra,
Chapters 1, 9, 13, 15, 16.
[00139]     At least one antibody of the present invention can be expressed in a modified
form, such as a fusion protein, and can include not only secretion signals, but also
additional heterologous functional regions. For instance, a region of additional amino
acids, particularly charged amino acids, can be added to the N-terminus of an antibody to
improve stability and persistence in the host cell, during purification, or during
subsequent handling and storage. Also, peptide moieties can be added to an antibody of
the present invention to facilitate purification. Such regions can be removed prior to final
preparation of an antibody or at least one fragment thereof Such methods are described
in many standard laboratory manuals, such as Sambrook, supra, Chapters 17.29-17.42 and
18.1-18.74; Ausubel, supra, Chapters 16, 17 and 18.
[00140]     Those of ordinary skill in the art are knowledgeable in the numerous
expression systems available for expression of a nucleic acid encoding a protein of the
present invention.
                                               40

[00141]      Alternatively, nucleic acids of the present invention can be expressed in a host
cell by turning on (by manipulation) in a host cell that contains endogenous DNA
encoding an antibody of the present invention. Such methods are well known in the art,
e.g., as described in U.S. Pat. Nos. 5,580,734, 5,641,670, 5,733,746, and 5,733,761,
entirely incorporated herein by reference.
[00142]      Illustrative of cell cultures useful for the production of the antibodies,
specified portions or variants thereof, are mammalian cells. Mammalian cell systems
often will be in the form of monolayers of cells although mammalian cell suspensions or
bioreactors can also be used. A number of suitable host cell lines capable of expressing
intact glycosylated proteins have been developed in the art, and include the COS-1 (e.g.,
ATCC CRL 1650), COS-7 (e.g., ATCC CRL-1651), HEK293, BHK21 (e.g., ATCC
CRL-10), CHO (e.g., ATCC CRL 1610) and BSC-1 (e.g., ATCC CRL-26) cell lines,
Cos-7 cells, CHO cells, hep G2 cells, P3X63Ag8.653, SP2/0-Agl4, 293 cells, HeLa cells
and the like, which are readily available from, for example, American Type Culture
Collection, Manassas, Va. (www.atcc.org). Preferred host cells include cells of lymphoid
origin such as myeloma and lymphoma cells. Particularly preferred host cells are
P3X63Ag8.653 cells (ATCC Accession Number CRL-1580) and SP2/0-Agl4 cells
(ATCC Accession Number CRL-1851). In a particularly preferred embodiment, the
recombinant cell is a P3X63Ab8.653 or a SP2/0-Agl4 cell.
[00143]      Expression vectors for these cells can include one or more of the following
expression control sequences, such as, but not limited to an origin of replication; a
promoter (e.g., late or early SV40 promoters, the CMV promoter (U.S. Pat. Nos.
5,168,062; 5,385,839), an HSV tk promoter, a pgk (phosphoglycerate kinase) promoter,
an EF-1 alpha promoter (U.S. Pat. No. 5,266,491), at least one human immunoglobulin
promoter; an enhancer, and/or processing information sites, such as ribosome binding
sites, RNA splice sites, polyadenylation sites (e.g., an SV40 large T Ag poly A addition
site), and transcriptional terminator sequences. See, e.g., Ausubel et al., supra; Sambrook,
et al., supra. Other cells useful for production of nucleic acids or proteins of the present
invention are known and/or available, for instance, from the American Type Culture
Collection Catalogue of Cell Lines and Hybridomas (www.atcc.org) or other known or
commercial sources.
                                                 41

[00144]      When eukaryotic host cells are employed, polyadenlyation or transcription
terminator sequences are typically incorporated into the vector. An example of a
terminator sequence is the polyadenlyation sequence from the bovine growth hormone
gene. Sequences for accurate splicing of the transcript can also be included. An example
of a splicing sequence is the VP1 intron from SV40 (Sprague, et al., J. Virol. 45:773-781
(1983)). Additionally, gene sequences to control replication in the host cell can be
incorporated into the vector, as known in the art.
[00145]      Production of an Antibody
[00146]      At least one Anti-CD22 antibody of the present invention can be optionally
produced by a cell line, a mixed cell line, an immortalized cell or clonal population of
immortalized cells, as well known in the art. See, e.g., Ausubel, et al., ed., Current
Protocols in Molecular Biology, John Wiley & Sons, Inc., NY, N.Y. (1987-2001);
Sambrook, et al., Molecular Cloning: A Laboratory Manual, 2.sup.nd Edition, Cold
Spring Harbor, N.Y. (1989); Harlow and Lane, antibodies, a Laboratory Manual, Cold
Spring Harbor, N.Y. (1989). Colligan, et al., eds., Current Protocols in Immunology, John
Wiley & Sons, Inc., NY (1994-2001); Colligan et al., Current Protocols in Protein
Science, John Wiley & Sons, NY, N.Y., (1997-2001), each entirely incorporated herein
by reference.
[00147]      In one approach, a hybridoma is produced by fusing a suitable immortal cell
line (e.g., a myeloma cell line such as, but not limited to, Sp2/0, Sp2/0-AG14, NSO, NS1,
NS2, AE-1, L.5, >243, P3X63Ag8.653, Sp2 SA3, Sp2 MAI, Sp2 SS1, Sp2 SA5, U937,
MLA 144, ACT IV, MOLT4, DA-1, JURKAT, WEHI, K-562, COS, RAJI, NIH 3T3,
HL-60, MLA 144, NAMAIWA, NEURO 2A), or the like, or heteromylomas, fusion
products thereof, or any cell or fusion cell derived therefrom, or any other suitable cell
line as known in the art. See, e.g., www.atcc.org, www.lifetech.com., and the like, with
antibody producing cells, such as, but not limited to, isolated or cloned spleen, peripheral
blood, lymph, tonsil, or other immune or B cell containing cells, or any other cells
expressing heavy or light chain constant or variable or framework or CDR sequences,
either as endogenous or heterologous nucleic acid, as recombinant or endogenous, viral,
bacterial, algal, prokaryotic, amphibian, insect, reptilian, fish, mammalian, rodent, equine,
ovine, goat, sheep, primate, eukaryotic, genomic DNA, cDNA, rDNA, mitochondrial
                                              42

DNA or RNA, chloroplast DNA or RNA, hnRNA, mRNA, tRNA, single, double or triple
stranded, hybridized, and the like or any combination thereof. See, e.g., Ausubel, supra,
and Colligan, Immunology, supra, chapter 2, entirely incorporated herein by reference.
[00148]     Any other suitable host cell can also be used for expressing heterologous or
endogenous nucleic acid encoding an antibody, specified fragment or variant thereof, of
the present invention. The fused cells (hybridomas) or recombinant cells can be isolated
using selective culture conditions or other suitable known methods, and cloned by
limiting dilution or cell sorting, or other known methods. Cells which produce antibodies
with the desired specificity can be selected by a suitable assay (e.g., ELISA).
[00149]     Antibodies of the present invention can also be prepared using at least one
anti-CD22 antibody encoding nucleic acid to provide transgenic animals or mammals,
such as goats, cows, horses, sheep, and the like, that produce such antibodies in their
milk. Such animals can be provided using known methods. See, e.g., but not limited to,
U.S. Pat. Nos. 5,827,690; 5,849,992; 4,873,316; 5,849,992; 5,994,616, 5,565,362;
5,304,489, and the like, each of which is entirely incorporated herein by reference.
[00150]     Antibodies of the present invention can additionally be prepared using at least
one Anti-CD22 antibody encoding nucleic acid to provide transgenic plants and cultured
plant cells (e.g., but not limited to tobacco and maize) that produce such antibodies,
specified portions or variants in the plant parts or in cells cultured therefrom. As a non
limiting example, transgenic tobacco leaves expressing recombinant proteins have been
successfully used to provide large amounts of recombinant proteins, e.g., using an
inducible promoter. See, e.g., Cramer et al., Cuff. Top. Microbol. Immunol. 240:95-118
(1999) and references cited therein. Also, transgenic maize have been used to express
mammalian proteins at commercial production levels, with biological activities equivalent
to those produced in other recombinant systems or purified from natural sources. See,
e.g., Hood et al., Adv. Exp. Med. Biol. 464:127-147 (1999) and references cited therein.
Antibodies have also been produced in large amounts from transgenic plant seeds
including antibody fragments, such as single chain antibodies (scFv's), including tobacco
seeds and potato tubers. See, e.g., Conrad et al., Plant Mol. Biol. 38:101-109 (1998) and
references cited therein. Thus, antibodies of the present invention can also be produced
using transgenic plants, according to known methods. See also, e.g., Fischer et al.,
                                               43

Biotechnol. Apple. Biochem. 30:99-108 (October, 1999), Ma et al., Trends Biotechnol.
13:522-7 (1995); Ma et al., Plant Physiol. 109:341-6 (1995); Whitelam et al., Biochem
Soc. Trans. 22:940-944 (1994); and references cited therein. Each of the above
references is entirely incorporated herein by reference.
[00151]     Purification of an Antibody
[00152]     An Anti-CD22 antibody can be recovered and purified from recombinant cell
cultures by well-known methods including, but not limited to, protein A purification,
protein G purification, ammonium sulfate or ethanol precipitation, acid extraction, anion
or cation exchange chromatography, phosphocellulose chromatography, hydrophobic
interaction chromatography, affinity chromatography, hydroxylapatite chromatography
and lectin chromatography. High performance liquid chromatography ("HPLC") can also
be employed for purification. See, e.g., Colligan, Current Protocols in Immunology, or
Current Protocols in Protein Science, John Wiley & Sons, NY, N.Y., (1997-2001), e.g.,
chapters 1, 4, 6, 8, 9, and 10, each entirely incorporated herein by reference.
[00153]     Antibodies of the present invention include naturally purified products,
products of chemical synthetic procedures, and products produced by recombinant
techniques from a eukaryotic host, including, for example, yeast, higher plant, insect and
mammalian cells. Depending upon the host employed in a recombinant production
procedure, the antibody of the present invention can be glycosylated or can be non
glycosylated, with glycosylated preferred. Such methods are described in many standard
laboratory manuals, such as Sambrook, supra, Sections 17.37-17.42; Ausubel, supra,
Chapters 10, 12, 13, 16, 18 and 20, Colligan, Protein Science, supra, Chapters 12-14, all
entirely incorporated herein by reference.
[00154]     Purified antibodies can be characterized by, for example, ELISA, ELISPOT,
flow cytometry, immunocytology, Biacore@ analysis, Sapidyne KinExATM kinetic
exclusion assay, SDS-PAGE and Western blot, or by HPLC analysis as well as by a
number of other functional assays disclosed herein.
[00155]     Cloning and Expression of CD22 antibody in Mammalian Cells
[00156]     A typical mammalian expression vector contains at least one promoter
element, which mediates the initiation of transcription of mRNA, the antibody coding
                                               44

sequence, and signals required for the termination of transcription and polyadenylation of
the transcript. Additional elements include enhancers, Kozak sequences and intervening
sequences flanked by donor and acceptor sites for RNA splicing. Highly efficient
transcription can be achieved with the early and late promoters from SV40, the long
terminal repeats (LTRS) from retroviruses, e.g., RSV, HTLVI, HIVI and the early
promoter of the cytomegalovirus (CMV). However, cellular elements can also be used
(e.g., the human actin promoter). Suitable expression vectors for use in practicing the
present invention include, for example, vectors such as pIRESlneo, pRetro-Off, pRetro
On, PLXSN, or pLNCX (Clonetech Labs, Palo Alto, Calif.), pcDNA3.1 (+/-),
pcDNA/Zeo (+/-) or pcDNA3. 1/Hygro (+/-) (Invitrogen), PSVL and PMSG (Pharmacia,
Uppsala, Sweden), pRSVcat (ATCC 37152), pSV2dhfr (ATCC 37146) and pBC12MI
(ATCC 67109). Mammalian host cells that could be used include human Hela 293, H9
and Jurkat cells, mouse NIH3T3 and C127 cells, Cos 1, Cos 7 and CV 1, quail QC1-3
cells, mouse L cells and Chinese hamster ovary (CHO) cells.
[00157]     Alternatively, the gene can be expressed in stable cell lines that contain the
gene integrated into a chromosome. The co-transfection with a selectable marker such as
dhfr, gpt, neomycin, or hygromycin allows the identification and isolation of the
transfected cells.
[00158]     The transfected gene can also be amplified to express large amounts of the
encoded antibody. The DHFR (dihydrofolate reductase) marker is useful to develop cell
lines that carry several hundred or even several thousand copies of the gene of interest.
Another useful selection marker is the enzyme glutamine synthase (GS) (Murphy, et al.,
Biochem. J. 227:277-279 (1991); Bebbington, et al., Bio/Technology 10:169-175 (1992)).
Using these markers, the mammalian cells are grown in selective medium and the cells
with the highest resistance are selected. These cell lines contain the amplified gene(s)
integrated into a chromosome. Chinese hamster ovary (CHO) and NSO cells are often
used for the production of antibodies.
[00159]      Cloning and Expression in CHO Cells
[00160]     The isolated variable and constant region encoding DNA and the
dephosphorylated vector are ligated with T4 DNA ligase. E. coli HB101 or XL-1 Blue
                                             45

cells are then transformed and bacteria are identified that contain the fragment inserted
into plasmid pC4 using, for instance, restriction enzyme analysis.
[00161]      Chinese hamster ovary (CHO) cells lacking an active DHFR gene are used for
transfection. 5 ptg of the expression plasmid pC4 is cotransfected with 0.5 p[g of the
plasmid pSV2-neo using lipofectin. The plasmid pSV2neo contains a dominant
selectable marker, the neo gene from Tn5 encoding an enzyme that confers resistance to a
group of antibiotics including G418. The cells are seeded in alpha minus MEM
supplemented with 1 ptg/ml G418. After 2 days, the cells are trypsinized and seeded in
hybridoma cloning plates (Greiner, Germany) in alpha minus MEM supplemented with
10, 25, or 50 ng/ml of methotrexate plus 1 ptg/ml G418. After about 10-14 days single
clones are trypsinized and then seeded in 6-well petri dishes or 10 ml flasks using
different concentrations of methotrexate (50 nM, 100 nM, 200 nM, 400 nM, 800 nM).
Clones growing at the highest concentrations of methotrexate are then transferred to new
6-well plates containing even higher concentrations of methotrexate (1 mM, 2 mM, 5
mM, 10 mM, 20 mM). The same procedure is repeated until clones are obtained that
grow at a concentration of 100-200 mM. Expression of the desired gene product is
analyzed, for instance, by SDS-PAGE and Western blot, ELISA, or by reverse phase
HPLC analysis.
[00162]      Anti-CD22 Antibody Compositions
[00163]      The present invention also provides at least one Anti-CD22 antibody
composition comprising at least one, at least two, at least three, at least four, at least five,
at least six or more Anti-CD22 antibodies thereof, as described herein and/or as known in
the art that are provided in a non-naturally occurring composition, mixture or form. Such
compositions comprise non-naturally occurring compositions comprising at least one or
two full length, C- and/or N-terminally deleted variants, domains, fragments, or specified
variants, of the anti-CD22 antibody amino acid sequence selected from the group
consisting of 70-100% of the contiguous amino acids of the CDR regions of the
antibodies described herein, or specified fragments, domains or variants thereof
Preferred Anti-CD22 antibody compositions include at least one or two full length,
fragments, domains or variants as at least one CDR or LBR containing portions of the
anti-CD22 antibody sequences described herein. Further preferred compositions
                                              46

comprise 40-99% of at least one of 70-100% of a CDR region of an Anti-CD22 Ab
described herein. Such composition percentages are by weight, volume, concentration,
molarity, or molality as liquid or dry solutions, mixtures, suspension, emulsions or
colloids, as known in the art or as described herein.
[00164]     Anti-CD22 antibody compositions of the present invention can further
comprise at least one of any suitable and effective amount of a composition or
pharmaceutical composition comprising at least one Anti-CD22 antibody to a cell, tissue,
organ, animal or patient in need of such modulation, treatment or therapy, optionally
further comprising at least one selected from at least one TNF antagonist (e.g., but not
limited to a TNF antibody or fragment a soluble TNF receptor or fragment, fusion
proteins thereof, or a small molecule TNF antagonist), an antirheumatic (e.g.,
methotrexate, auranofin, aurothioglucose, azathioprine, etanercept, gold sodium
thiomalate, hydroxychloroquine sulfate, leflunomide, sulfasalzine), a muscle relaxant, a
narcotic, a non-steroid anti-inflammatory drug (NSAID), an analgesic, an anesthetic, a
sedative, a local anethetic, a neuromuscular blocker, an antimicrobial (e.g.,
aminoglycoside, an antifungal, an antiparasitic, an antiviral, a carbapenem, cephalosporin,
a flurorquinolone, a macrolide, a penicillin, a sulfonamide, a tetracycline, another
antimicrobial), an antipsoriatic, a corticosteriod, an anabolic steroid, a diabetes related
agent, a mineral, a nutritional, a thyroid agent, a vitamin, a calcium related hormone, an
antidiarrheal, an antitussive, an antiemetic, an antiulcer, a laxative, an anticoagulant, an
erythropieitin (e.g., epoetin alpha), a filgrastim (e.g., G-CSF, Neupogen), a sargramostim
(GM-CSF, Leukine), an immunization, an immunoglobulin, an immunosuppressive (e.g.,
basiliximab, cyclosporine, daclizumab), a growth hormone, a hormone replacement drug,
an estrogen receptor modulator, a mydriatic, a cycloplegic, an alkylating agent, an
antimetabolite, a mitotic inhibitor, a radiopharmaceutical, an antidepressant, antimanic
agent, an antipsychotic, an anxiolytic, a hypnotic, a sympathomimetic, a stimulant,
donepezil, tacrine, an asthma medication, a beta agonist, an inhaled steroid, a leukotriene
inhibitor, a methylxanthine, a cromolyn, an epinephrine or analog, domase alpha
(Pulmozyme), a cytokine or a cytokine antagonist. Non-limiting examples of such
cytokines include, but are not limited to, any of IL-I to IL-34. Suitable dosages are well
known in the art. See, e.g., Wells et al., eds., Pharmacotherapy Handbook, 2.sup.nd
                                                47

Edition, Appleton and Lange, Stamford, Conn. (2000); PDR Pharmacopoeia, Tarascon
Pocket Pharmacopoeia 2000, Deluxe Edition, Tarascon Publishing, Loma Linda, Calif.
(2000), each of which references are entirely incorporated herein by reference.
[00165]      Anti-CD22 antibody compounds, compositions or combinations of the present
invention can further comprise at least one of any suitable auxiliary, such as, but not
limited to, diluent, binder, stabilizer, buffers, salts, lipophilic solvents, preservative,
adjuvant or the like. Pharmaceutically acceptable auxiliaries are preferred. Non-limiting
examples of, and methods of preparing such sterile solutions are well known in the art,
such as, but limited to, Gennaro, Ed., Remington 's Pharmaceutical Sciences,         1 8 th Edition,
Mack Publishing Co. (Easton, Pa.) 1990. Pharmaceutically acceptable carriers can be
routinely selected that are suitable for the mode of administration, solubility and/or
stability of the anti-CD22 antibody, fragment or variant composition as well known in the
art or as described herein.
[00166]      Pharmaceutical excipients and additives useful in the present composition
include but are not limited to proteins, peptides, amino acids, lipids, and carbohydrates
(e.g., sugars, including monosaccharides, di-, tri-, tetra-, and oligosaccharides; derivatized
sugars such as alditols, aldonic acids, esterified sugars and the like; and polysaccharides
or sugar polymers), which can be present singly or in combination, comprising alone or in
combination 1-99.99% by weight or volume. Exemplary protein excipients include
serum albumin such as human serum albumin (HSA), recombinant human albumin
(rHA), gelatin, casein, and the like. Representative amino acid/antibody components,
which can also function in a buffering capacity, include alanine, glycine, arginine,
betaine, histidine, glutamic acid, aspartic acid, cysteine, lysine, leucine, isoleucine, valine,
methionine, phenylalanine, aspartame, and the like. One preferred amino acid is glycine.
[00167]      Carbohydrate excipients suitable for use in the invention include, for example,
monosaccharides such as fructose, maltose, galactose, glucose, D-mannose, sorbose, and
the like; disaccharides, such as lactose, sucrose, trehalose, cellobiose, and the like;
polysaccharides, such as raffinose, melezitose, maltodextrins, dextrans, starches, and the
like; and alditols, such as mannitol, xylitol, maltitol, lactitol, xylitol sorbitol (glucitol),
                                                48

myoinositol and the like. Preferred carbohydrate excipients for use in the present
invention are mannitol, trehalose, and raffinose.
[00168]     Anti-CD22 antibody compositions can also include a buffer or a pH adjusting
agent; typically, the buffer is a salt prepared from an organic acid or base. Representative
buffers include organic acid salts such as salts of citric acid, ascorbic acid, gluconic acid,
carbonic acid, tartaric acid, succinic acid, acetic acid, or phthalic acid; Tris, tromethamine
hydrochloride, or phosphate buffers. Preferred buffers for use in the present compositions
are organic acid salts such as citrate.
[00169]     Additionally, Anti-CD22 antibody compositions of the invention can include
polymeric excipients/additives such as polyvinylpyrrolidones, ficolls (a polymeric sugar),
dextrates (e.g., cyclodextrins, such as 2-hydroxypropyl-.beta.-cyclodextrin), polyethylene
glycols, flavoring agents, antimicrobial agents, sweeteners, antioxidants, antistatic agents,
surfactants (e.g., polysorbates such as "TWEEN 20" and "TWEEN 80"), lipids (e.g.,
phospholipids, fatty acids), steroids (e.g., cholesterol), and chelating agents (e.g., EDTA).
[00170]     These and additional known pharmaceutical excipients and/or additives
suitable for use in the Anti-CD22 antibody, portion or variant compositions according to
the invention are known in the art, e.g., as listed in "Remington: The Science & Practice
of Pharmacy", 19.sup.th ed., Williams & Williams, (1995), and in the "Physician's Desk
Reference", 52"ded., Medical Economics, Montvale, N.J. (1998), the disclosures of which
are entirely incorporated herein by reference. Preferred carrier or excipient materials are
carbohydrates (e.g., saccharides and alditols) and buffers (e.g., citrate) or polymeric
agents.
                                               49

[00171]      Formulations
[00172]      As noted above, the invention provides for stable formulations, which is
preferably a phosphate buffer with saline or a chosen salt, as well as preserved solutions
and formulations containing a preservative as well as multi-use preserved formulations
suitable for pharmaceutical or veterinary use, comprising at least one Anti-CD22 antibody
in a pharmaceutically acceptable formulation. Preserved formulations contain at least one
known preservative or optionally selected from the group consisting of at least one
phenol, m-cresol, p-cresol, o-cresol, chlorocresol, benzyl alcohol, phenylmercuric nitrite,
phenoxyethanol, formaldehyde, chlorobutanol, magnesium chloride (e.g., hexahydrate),
alkylparaben (methyl, ethyl, propyl, butyl and the like), benzalkonium chloride,
benzethonium chloride, sodium dehydroacetate and thimerosal, or mixtures thereof in an
aqueous diluent. Any suitable concentration or mixture can be used as known in the art,
such as 0.001-5%, or any range or value therein, such as, but not limited to 0.001, 0.003,
0.005, 0.009, 0.01, 0.02, 0.03, 0.05, 0.09, 0.1, 0.2, 0.3, 0.4., 0.5, 0.6, 0.7, 0.8, 0.9, 1.0, 1.1,
1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8, 1.9, 2.0, 2.1, 2.2, 2.3, 2.4, 2.5, 2.6, 2.7, 2.8, 2.9, 3.0, 3.1,
3.2, 3.3, 3.4, 3.5, 3.6, 3.7, 3.8, 3.9, 4.0, 4.3, 4.5, 4.6, 4.7, 4.8, 4.9, or any range or value
therein. Non-limiting examples include, no preservative, 0.1-2% m-cresol (e.g., 0.2, 0.3.
0.4, 0.5, 0.9, 1.0%), 0.1-3% benzyl alcohol (e.g., 0.5, 0.9, 1.1., 1.5, 1.9, 2.0, 2.5%), 0.001
0.5% thimerosal (e.g., 0.005, 0.01), 0.001-2.0% phenol (e.g., 0.05, 0.25, 0.28, 0.5, 0.9,
1.0%), 0.0005-1.0% alkylparaben(s) (e.g., 0.00075, 0.0009, 0.001, 0.002, 0.005, 0.0075,
0.009, 0.01, 0.02, 0.05, 0.075, 0.09, 0.1, 0.2, 0.3, 0.5, 0.75, 0.9, 1.0%), and the like.
[00173]      As noted above, the invention provides an article of manufacture, comprising
packaging material and at least one vial comprising a solution of at least one Anti-CD22
antibody with the prescribed buffers and/or preservatives, optionally in an aqueous
diluent, wherein said packaging material comprises a label that indicates that such
solution can be held over a period of 1, 2, 3, 4, 5, 6, 9, 12, 18, 20, 24, 30, 36, 40, 48, 54,
60, 66, 72 hours or greater. The invention further comprises an article of manufacture,
comprising packaging material, a first vial comprising lyophilized at least one Anti-CD22
antibody, and a second vial comprising an aqueous diluent of prescribed buffer or
preservative, wherein said packaging material comprises a label that instructs a patient to
                                                  50

reconstitute the at least one Anti-CD22 antibody in the aqueous diluent to form a solution
that can be held over a period of twenty-four hours or greater.
[00174]      The at least one Anti-CD22 antibody used in accordance with the present
invention can be produced by recombinant means, including from mammalian cell or
transgenic preparations, or can be purified from other biological sources, as described
herein or as known in the art.
[00175]      The range of at least one Anti-CD22 antibody in the product of the present
invention includes amounts yielding upon reconstitution, if in a wet/dry system,
concentrations from about 1.0 microgram/ml to about 1000 mg/ml, although lower and
higher concentrations are operable and are dependent on the intended delivery vehicle,
e.g., solution formulations will differ from transdermal patch, pulmonary, transmucosal,
or osmotic or micro pump methods.
[00176]      Preferably, the aqueous diluent optionally further comprises a
pharmaceutically acceptable preservative. Preferred preservatives include those selected
from the group consisting of phenol, m-cresol, p-cresol, o-cresol, chlorocresol, benzyl
alcohol, alkylparaben (methyl, ethyl, propyl, butyl and the like), benzalkonium chloride,
benzethonium chloride, sodium dehydroacetate and thimerosal, or mixtures thereof. The
concentration of preservative used in the formulation is a concentration sufficient to yield
an anti-microbial effect. Such concentrations are dependent on the preservative selected
and are readily determined by the skilled artisan.
[00177]      Other excipients, e.g. isotonicity agents, buffers, antioxidants, preservative
enhancers, can be optionally and preferably added to the diluent. An isotonicity agent,
such as glycerin, is commonly used at known concentrations. A physiologically tolerated
buffer is preferably added to provide improved pH control. The formulations can cover a
wide range of pHs, such as from about pH 4 to about pH 10, and preferred ranges from
about pH 5 to about pH 9, and a most preferred range of about 6.0 to about 8.0.
Preferably the formulations of the present invention have pH between about 6.8 and about
7.8. Preferred buffers include phosphate buffers, most preferably sodium phosphate,
particularly phosphate buffered saline (PBS).
                                               51

[00178]     Other additives, such as a pharmaceutically acceptable solubilizers like Tween
20 (polyoxyethylene (20) sorbitan monolaurate), Tween 40 (polyoxyethylene (20)
sorbitan monopalmitate), Tween 80 (polyoxyethylene (20) sorbitan monooleate), Pluronic
F68 (polyoxyethylene polyoxypropylene block copolymers), and PEG (polyethylene
glycol) or non-ionic surfactants such as polysorbate 20 or 80 or poloxamer 184 or 188,
Pluronic.RTM. polyls, other block co-polymers, and chelators such as EDTA and EGTA
can optionally be added to the formulations or compositions to reduce aggregation. These
additives are particularly useful if a pump or plastic container is used to administer the
formulation. The presence of pharmaceutically acceptable surfactant mitigates the
propensity for the protein to aggregate.
[00179]     The formulations of the present invention can be prepared by a process which
comprises mixing at least one anti-CD22 antibody and a preservative selected from the
group consisting of phenol, m-cresol, p-cresol, o-cresol, chlorocresol, benzyl alcohol,
alkylparaben, (methyl, ethyl, propyl, butyl and the like), benzalkonium chloride,
benzethonium chloride, sodium dehydroacetate and thimerosal or mixtures thereof in an
aqueous diluent. Mixing the at least one anti-CD22 antibody and preservative in an
aqueous diluent is carried out using conventional dissolution and mixing procedures. To
prepare a suitable formulation, for example, a measured amount of at least one anti-CD22
antibody in buffered solution is combined with the desired preservative in a buffered
solution in quantities sufficient to provide the protein and preservative at the desired
concentrations. Variations of this process would be recognized by one of ordinary skill in
the art. For example, the order the components are added, whether additional additives
are used, the temperature and pH at which the formulation is prepared, are all factors that
can be optimized for the concentration and means of administration used.
[00180]     The claimed formulations can be provided to patients as clear solutions or as
dual vials comprising a vial of lyophilized at least one Anti-CD22 antibody that is
reconstituted with a second vial containing water, a preservative and/or excipients,
preferably a phosphate buffer and/or saline and a chosen salt, in an aqueous diluent.
Either a single solution vial or dual vial requiring reconstitution can be reused multiple
times and can suffice for a single or multiple cycles of patient treatment and thus can
provide a more convenient treatment regimen than currently available.
                                               52

[00181]     The present claimed articles of manufacture are useful for administration over
a period of immediately to twenty-four hours or greater. Accordingly, the presently
claimed articles of manufacture offer significant advantages to the patient. Formulations
of the invention can optionally be safely stored at temperatures of from about 2 to about
40' C and retain the biologically activity of the protein for extended periods of time, thus,
allowing a package label indicating that the solution can be held and/or used over a period
of 6, 12, 18, 24, 36, 48, 72, or 96 hours or greater. If preserved diluent is used, such label
can include use up to 1-12 months, one-half, one and a half, and/or two years.
[00182]     The solutions of at least one Anti-CD22 antibody in the invention can be
prepared by a process that comprises mixing at least one antibody in an aqueous diluent.
Mixing is carried out using conventional dissolution and mixing procedures. To prepare a
suitable diluent, for example, a measured amount of at least one antibody in water or
buffer is combined in quantities sufficient to provide the protein and optionally a
preservative or buffer at the desired concentrations. Variations of this process would be
recognized by one of ordinary skill in the art. For example, the order the components are
added, whether additional additives are used, the temperature and pH at which the
formulation is prepared, are all factors that can be optimized for the concentration and
means of administration used.
[00183]     The claimed products can be provided to patients as clear solutions or as dual
vials comprising a vial of lyophilized at least one Anti-CD22 antibody that is
reconstituted with a second vial containing the aqueous diluent. Either a single solution
vial or dual vial requiring reconstitution can be reused multiple times and can suffice for a
single or multiple cycles of patient treatment and thus provides a more convenient
treatment regimen than currently available.
[00184]     The claimed products can be provided indirectly to patients by providing to
pharmacies, clinics, or other such institutions and facilities, clear solutions or dual vials
comprising a vial of lyophilized at least one Anti-CD22 antibody that is reconstituted
with a second vial containing the aqueous diluent. The clear solution in this case can be
up to one liter or even larger in size, providing a large reservoir from which smaller
portions of the at least one antibody solution can be retrieved one or multiple times for
                                               53

transfer into smaller vials and provided by the pharmacy or clinic to their customers
and/or patients.
[00185]     Recognized devices comprising these single vial systems include those pen
injector devices for delivery of a solution such as BD Pens, BD Autojector.RTM.,
Humaject.RTM., NovoPen.RTM., B-D.RTM.Pen, AutoPen.RTM., and OptiPen.RTM.,
GenotropinPen.RTM., Genotronorm Pen.RTM., Humatro Pen.RTM., Reco-Pen.RTM.,
Roferon Pen.RTM., Biojector.RTM., iject.RTM., J-tip Needle-Free Injector.RTM.,
Intraject.RTM., Medi-Ject.RTM., e.g., as made or developed by Becton Dickensen
(Franklin Lakes, N.J., www.bectondickenson.com), Disetronic (Burgdorf, Switzerland,
www.disetronic.com; Bioject, Portland, Oreg. (www.bioject.com); National Medical
Products, Weston Medical (Peterborough, UK, www.weston-medical.com), Medi-Ject
Corp (Minneapolis, Minn., www.mediject.com). Recognized devices comprising a dual
vial system include those pen-injector systems for reconstituting a lyophilized drug in a
cartridge for delivery of the reconstituted solution such as the HumatroPen.RTM.
[00186]     The products presently claimed include packaging material. The packaging
material provides, in addition to the information required by the regulatory agencies, the
conditions under which the product can be used. The packaging material of the present
invention provides instructions to the patient to reconstitute the at least one Anti-CD22
antibody in the aqueous diluent to form a solution and to use the solution over a period of
2-24 hours or greater for the two vial, wet/dry, product. For the single vial, solution
product, the label indicates that such solution can be used over a period of 2-24 hours or
greater. The presently claimed products are useful for human pharmaceutical product
use.
[00187]     The formulations of the present invention can be prepared by a process that
comprises mixing at least one Anti-CD22 antibody and a selected buffer, preferably a
phosphate buffer containing saline or a chosen salt. Mixing the at least one antibody and
buffer in an aqueous diluent is carried out using conventional dissolution and mixing
procedures. To prepare a suitable formulation, for example, a measured amount of at
least one antibody in water or buffer is combined with the desired buffering agent in
water in quantities sufficient to provide the protein and buffer at the desired
concentrations. Variations of this process would be recognized by one of ordinary skill in
                                              54

the art. For example, the order the components are added, whether additional additives
are used, the temperature and pH at which the formulation is prepared, are all factors that
can be optimized for the concentration and means of administration used.
[00188]      The claimed stable or preserved formulations can be provided to patients as
clear solutions or as dual vials comprising a vial of lyophilized at least one Anti-CD22
antibody that is reconstituted with a second vial containing a preservative or buffer and
excipients in an aqueous diluent. Either a single solution vial or dual vial requiring
reconstitution can be reused multiple times and can suffice for a single or multiple cycles
of patient treatment and thus provides a more convenient treatment regimen than
currently available.
[00189]      At least one Anti-CD22 antibody in either the stable or presented formulations
or solutions described herein, can be administered to a patient in accordance with the
present invention via a variety of delivery methods including SC or IM injection;
transdermal, pulmonary, transmucosal, implant, osmotic pump, cartridge, micro pump, or
other means appreciated by the skilled artisan, as well-known in the art.
[00190]      Therapeutic Applications
[00191]      CD22 is a member of the Siglec sialic acid binding protein receptor
superfamily that expressed is a highly specific manner on developing B-cells and on a
variety of B-cell cancers including lymphomas and acute and chronic lymphocytic
leukemias (Crocker et al, Nature Reviews Immunology 7, 255-266, 2007). Anti-CD22
antibodies have been found to negatively regulate growth of CD22 expressing B-cells and
are implicated in the treatment of a variety of diseases. CD22 antibodies have been tested
in clinical trials in patients with B-cell dependent autoimmune diseases and in patients
with CD22-expressing hematologic cancers. Certain antibodies have been shown to
induce tyrosine phosphorylation of CD22, a process that stimulates negative growth
signals that block cell replication. In addition, CD22 antibodies have been shown to be
internalized within the intracellular secretion pathway and lysosomes. Therefore, a high
affinity human antibody to CD22 that has potent negative growth regulation properties
that is rapidly internalized would be desirable to be used in CD22 related diseases such as
hematologic cancers, SLE, rheumatoid arthritis, multiple slcerosis as well as other B-cell
                                               55

dependent autoimmune diseases.. Anti-CD22 Abs or any derivatives of these mAbs
including chimeric or humanized, or fragments can be used treatment of non-Hodgkin's
lymphoma, other lymphomas and lymphoproliferative disorders, acute and chronic
lymphocytic leukemias and other diseases in which CD22 has been implicated. These
antibodies can be used either as a single agent or in combination with other therapeutic
agents. They can also be used in combination with other tumor-immunomodulating
agents such as IL-2, IL-12 and/or IFNalpha. Additionally, the Anti-CD22 antibodies can
be used in combination with other monoclonal antibodies such as anti-TNF-a, IL-12/IL
23, IL-2, GpIIb/IIIa receptor, CD52, CD20, RSV proteins, HER2/neu receptor, and the
like; as well as with commercially approved antibodies including Rituxan, Herceptin,
Mylotarg, Campath, Zevalin, Bexxar, Erbitux, Avastin and Vectibix.
[00192]     These antibodies can be used either as a single agent or in combination with
other therapeutic agents. They can also be used in combination with other tumor
immunomodulating agents such as IL-2, IL-12, GM-CSF and/or IFNalpha. Additionally,
the Anti-CD22 antibodies can be used in combination with other monoclonal antibodies
such as anti-TNF-a, IL-12/IL-23, IL-2, GpIIb/IIIa receptor, CD52, CD20, RSV proteins,
HER2/neu receptor, and the like; as well as with commercially approved antibodies
including Rituxan, Herceptin, Mylotarg, Campath, Zevalin, Bexxar, Erbitux, Avastin and
Vectibix.
[00193]     Thus, the present invention also provides a method for modulating or treating
at least one CD22 related disease, in a cell, tissue, organ, animal, or patient, as known in
the art or as described herein, using at least one anti-CD22 antibody of the present
invention.
[00194]      CD22 is known to be expressed at high levels on B-cell cancers and dysplasias
and may regulate autocrine or a paracrine mechanism involving induction of apoptosis of
the malignant cells. B-cell cancers expressing CD22 at high levels include, but is not
limited to, diffuse large B-cell lymphomas (DLBC), follicular lymphomas, Acute and
chronic B-cell lymphocytic leukemias (ALL/CLL), mucosal associated lymphoid tract
lymphomas (MALT), Mantle cell lymphoma, Burkitt lymphoma and other
lymphoplasmocytic proliferactions (WHO classification of tumours, 2001). Anti-CD22
antibodies could therefore be used to treat these diseases alone or in combinantion with
                                               56

other chemotherapeutic and B-cell targeted biotherapeutics. In addition, other B-cell
dependent autoimmune disease in which B-cell producted autoantibody formation is
implicated is disease, such as systemic lupus erythematosus (SLE), Rheumatoid arthritis
(RA), multiple sclerosis (MS), could be treated with anti-CD22 antibodies.
The ability, of antibodies directed to CD22 to modulate tumor cell survival and disease
progression was confirmed by the inhibitory effects of an anti-CD22 mAb on tumor
growth both in vitro and in vivo. It was reported that binding of certain anti CD22
antibodies to CD22 expressing lymphoma cells can inhibit growth in vitro (Stein et al
Epitope specificity of the anti-B-cell lymphoma monoclonal antibody, LL2. Cancer
Immunol. Immunother., 37:293, 1993).         The murine anti-CD22 MAb (originally
designated EPB-2 and now called LL2) can be humanized and used for imaging and
treatment of NHL or chronic lymphatic leukemia. Immunohistological studies revealed
that LL2 is reactive with virtually all cases of NHL, including diffuse and nodular, poorly
differentiated lymphocytic lymphomas, and histiocytic large cell lymphomas. LL2 has a
highly restricted specificity, being reactive with only the B-cell population of the
germinal center of normal lymph nodes and the white pulp of the spleen, but not with
megakaryocytes, myeloid, or erythroid cells in the bone marrow. Moreover, LL2 is not
reactive with any peripheral blood cells, including the blood's normal B cells, or with any
other normal tissue. LL2 also has other unique features related to its target antigen,
differentiating it from other anti-B-cell lymphoma antibodies. In vitro studies have
demonstrated clearly that LL2 is internalized after binding to its CD22 target antigen on
the surface of Raji lymphoma cell lines, and that the antigen is reexpressed rapidly on the
cell surface. A humanized for of murine monoclonal antibody, known as Epratuzumab,
has immunomodulatory and growth modulatory effects on human lymphoma cell lines
(Carnahan et al., Molecular Immunology 44: 1331, 2007) al. 2001). Anti-CD22
monoclonal antibody
[00195]      CD22 can also be a prognostic factor and a marker for malignancies. CD22 is
expressed at high levels in virtually all lymphomas, and on most ALL and CLL B-cell
leukemias. CD22 expression in increased in patient tumors following treatment of the
CD20 target therapeutic antibody Rituxan suggesting CD22 target antibodies could be
                                              57

used to treat Rituxan resistant and relapsed patients (Micallef et al., Blood 118:4053,
2011).
[00196]      CD22 is hypothesized to be a causative factor in cancer-related morbidity such
as asthenia/cachexia and bone resorption. Tumor-induced cachexia (Cahlin et al. 2000)
and bone resorption (subsequent hypercalcemia) (Sandhu et al. 1999) were found to be
diminished in CD22 knockout mice. Cancer-associated depression and cerebral edema
secondary to brain tumors have also been associated with high levels of CD22
(Musselman et al. 2001). Anti-CD22 antibodies of the invention also can inhibit human
melanoma and human prostate carcinoma induced cachexia in nude mice.
[00197]     The present invention includes a method for modulating or treating at least one
malignant disease in a cell, tissue, organ, animal or patient, including, but not limited to,
at least one of: non-Hodgkin's lymphoma, Burkit lymphoma, leukemia, acute leukemia,
acute lymphoblastic leukemia (ALL), B-cell, chronic lymphocytic leukemia (CLL), and
hairy cell leukemia. Such a method can optionally be used in combination with, by
administering before, concurrently or after administration of such CD22 antibody,
radiation therapy, an anti-angiogenic agent, a chemotherapeutic agent, a farnesyl
transferase inhibitor or the like.
[00198]     The present invention also provides a method for modulating or treating at
least one CD22 mediated immune related disease, in a cell, tissue, organ, animal, or
patient including, but not limited to, at least one of rheumatoid arthritis, juvenile
rheumatoid arthritis, systemic onset juvenile rheumatoid arthritis, psoriatic arthritis,
ankylosing spondilitis, gastric ulcer, seronegative arthropathies, asteoarthritis,
inflammatory bowel disease, ulverative colitis, systemic lupus erythematosis,
antiphospholipid syndrome, iridocyclitis/uveitis/optic neuritis, idiopathic pulmonary
fibrosis, systemic vasculitis/wegener's granulomatosis, sarcoidosis, orchitis/vasectomy
reversal procedures, allergic/atopic diseases, asthma, allergic rhinitis, eczema, allergic
contact dermatitis, allergic conjunctivitis, hypersensitivity pneumonitis, transplants, organ
transplant rejection, graft-versus-host disease, systemic inflammatory response syndrome,
sepsis syndrome, gram positive sepsis, gram negative sepsis, culture negative sepsis,
fungal sepsis, neutropenic fever, urosepsis, meningococcemia, trauma/hemorrhage, bums,
ionizing radiation exposure, acute pancreatitis, adult respiratory distress syndrome,
                                                58

rheumatoid arthritis, alcohol-induced hepatitis, chronic inflammatory pathologies,
sarcoidosis, Crohn's pathology, sickle cell anemia, diabetes, nephrosis, atopic diseases,
hypersensitity reactions, allergic rhinitis, hay fever, perennial rhinitis, conjunctivitis,
endometriosis, asthma, urticaria, systemic anaphalaxis, dermatitis, pernicious anemia,
hemolytic disease, thrombocytopenia, graft rejection of any organ or tissue, kidney
transplant rejection, heart transplant rejection, liver transplant rejection, pancreas
transplant rejection, lung transplant rejection, bone marrow transplant (BMT) rejection,
skin allograft rejection, cartilage transplant rejection, hone graft rejection, small bowel
transplant rejection, fetal thymus implant rejection, parathyroid transplant rejection,
xenograft rejection of any organ or tissue, allograft rejection, anti-receptor
hypersensitivity reactions, Graves disease, Raynoud's disease, type B insulin-resistant
diabetes, asthma, myasthenia gravis, antibody-meditated cytotoxicity, type III
hypersensitivity reactions, systemic lupus erythematosus, POEMS syndrome
(polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy, and skin
changes syndrome), polyneuropathy, organomegaly, endocrinopathy, monoclonal
gammopathy, skin changes syndrome, antiphospholipid syndrome, pemphigus,
scleroderma, mixed connective tissue disease, idiopathic Addison's disease, diabetes
mellitus, chronic active hepatitis, primary billiary cirrhosis, vitiligo, vasculitis, post-MI
cardiotomy syndrome, type IV hypersensitivity, contact dermatitis, hypersensitivity
pneumonitis, allograft rejection, granulomas due to intracellular organisms, drug
sensitivity, metabolic/idiopathic, Wilson's disease, hemachromatosis, alpha-i -antitrypsin
deficiency, diabetic retinopathy, hashimoto's thyroiditis, osteoporosis, hypothalamic
pituitary-adrenal axis evaluation, primary biliary cirrhosis, thyroiditis, encephalomyelitis,
cachexia, cystic fibrosis, neonatal chronic lung disease, chronic obstructive pulmonary
disease (COPD), familial hematophagocytic lymphohistiocytosis, dermatologic
conditions, psoriasis, alopecia, nephrotic syndrome, nephritis, glomerular nephritis, acute
renal failure, hemodialysis, uremia, toxicity, preeclampsia, okt3 therapy, anti-cd3 therapy,
cytokine therapy, chemotherapy, radiation therapy (e.g., including but not limited to
asthenia, anemia, cachexia, and the like), chronic salicylate intoxication, sleep apnea,
obesity, heart failure, sinusitis, inflammatory bowel disease, and the like. See, e.g., the
Merck Manual, 12th-17th Editions, Merck & Company, Rahway, N.J. (1972, 1977, 1982,
1987, 1992, 1999), Pharmacotherapy Handbook, Wells et al., eds., Second Edition,
                                               59

Appleton and Lange, Stamford, Conn. (1998, 2000), each entirely incorporated by
reference. ;
[00199]     Therapeutic Treatments
[00200]     Any method of the present invention can comprise a method for treating a
CD22 mediated disorder, comprising administering an effective amount of a composition
or pharmaceutical composition comprising at least one Anti-CD22 antibody to a cell,
tissue, organ, animal or patient in need of such modulation, treatment or therapy. Such a
method can optionally further comprise co-administration or combination therapy for
treating such immune diseases, wherein the administering of said at least one Anti-CD22
antibody, specified portion or variant thereof, further comprises administering, before
concurrently, and/or after, at least one agent as described above.
[00201]     Typically, treatment of pathologic conditions is effected by administering an
effective amount or dosage of at least one Anti-CD22 antibody composition that total, on
average, a range from at least about 0.01 to 500 milligrams of at least one Anti-CD22
antibody per kilogram of patient per dose, and preferably from at least about 0.1 to 100
milligrams antibody/kilogram of patient per single or multiple administration, depending
upon the specific activity of contained in the composition. Alternatively, the effective
serum concentration can comprise 0.1-5000 .mu.g/ml serum concentration per single or
multiple administration. Suitable dosages are known to medical practitioners and will, of
course, depend upon the particular disease state, specific activity of the composition being
administered, and the particular patient undergoing treatment in some instances, to
achieve the desired therapeutic amount, it can be necessary to provide for repeated
administration, i.e., repeated individual administrations of a particular monitored or
metered dose, where the individual administrations are repeated until the desired daily
dose or effect is achieved.
[00202]     Preferred doses can optionally include 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9,
1,2, 3,4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27,
28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51,
52,53,54,55,56,57,58,59,60,62,63,64,65,66,67,68,69,70,71,72,73,74,75,76,
77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99
                                                60

and/or 100-500 mg/kg/administration, or any range, value or fraction thereof, or to
achieve a serum concentration of 0.1, 0.5, 0.9, 1.0, 1.1, 1.2, 1.5, 1.9, 2.0, 2.5, 2.9, 3.0, 3.5,
3.9, 4.0, 4.5, 4.9, 5.0, 5.5, 5.9, 6.0, 6.5, 6.9, 7.0, 7.5, 7.9, 8.0, 8.5, 8.9, 9.0, 9.5, 9.9, 10,
10.5, 10.9, 11, 11.5, 11.9, 20, 12.5, 12.9, 13.0, 13.5, 13.9, 14.0, 14.5, 4.9, 5.0, 5.5., 5.9,
6.0, 6.5, 6.9, 7.0, 7.5, 7.9, 8.0, 8.5, 8.9, 9.0, 9.5, 9.9, 10, 10.5, 10.9, 11, 11.5, 11.9, 12,
12.5, 12.9, 13.0, 13.5, 13.9, 14, 14.5, 15, 15.5, 15.9, 1.6, 16.5, 16.9, 17, 17.5, 17.9, 18,
18.5, 18.9, 19, 19.5, 19.9, 20, 20.5, 20.9, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 35, 40, 45,
50,55,60,65,70,75, 80, 85,90,96, 100,200,300,400,500,600,700, 800,900, 1000,
1500, 2000, 2500, 3000, 3500, 4000, 4500, and/or 5000 ptg/ml serum concentration per
single or multiple administration, or any range, value or fraction thereof
[00203]      Alternatively, the dosage administered can vary depending upon known
factors, such as the pharmacodynamic characteristics of the particular agent, and its mode
and route of administration; age, health, and weight of the recipient; nature and extent of
symptoms, kind of concurrent treatment, frequency of treatment, and the effect desired.
Usually a dosage of active ingredient can be about 0.1 to 100 milligrams per kilogram of
body weight. Ordinarily 0.1 to 50, and preferably 0.1 to 10 milligrams per kilogram per
administration or in sustained release form is effective to obtain desired results.
[00204]      As a non-limiting example, treatment of humans or animals can be provided as
a one-time or periodic dosage of at least one antibody of the present invention 0.1 to 100
mg/kg, such as 0.5, 0.9, 1.0, 1.1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17,
18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 40, 45, 50, 60, 70, 80, 90 or 100 mg/kg,
per day, on at least one of day 1, 2,3,4,5,6,7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19,
20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, or 40, or
alternatively or additionally, at least one of week 1, 2, 3, 4,5, 6, 7, 8, 9, 10, 11, 12, 13, 14,
15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38,
39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, or 52, or alternatively or additionally, at
least one of 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 years, or
any combination thereof, using single, infusion or repeated doses.
[00205]      Dosage forms (composition) suitable for internal administration generally
contain from about 0.1 milligram to about 500 milligrams of active ingredient per unit or
container. In these pharmaceutical compositions the active ingredient will ordinarily be
                                                  61

present in an amount of about 0.5-99.999% by weight based on the total weight of the
composition.
[00206]     Parenteral Formulations and Administration
[00207]     For parenteral administration, the antibody can be formulated as a solution,
suspension, emulsion or lyophilized powder in association, or separately provided, with a
pharmaceutically acceptable parenteral vehicle. Examples of such vehicles are water,
saline, Ringer's solution, dextrose solution, and 1 -10% human serum albumin.
Liposomes and nonaqueous vehicles such as fixed oils can also be used. The vehicle or
lyophilized powder can contain additives that maintain isotonicity (e.g., sodium chloride,
mannitol) and chemical stability (e.g., buffers and preservatives). The formulation is
sterilized by known or suitable techniques.
[00208]     Suitable pharmaceutical carriers are described in the most recent edition of
Remington's Pharmaceutical Sciences, A. Osol, a standard reference text in this field.
[00209]     Formulations for parenteral administration can contain as common excipients
sterile water or saline, polyalkylene glycols such as polyethylene glycol, oils of vegetable
origin, hydrogenated naphthalenes and the like. Aqueous or oily suspensions for injection
can be prepared by using an appropriate emulsifier or humidifier and a suspending agent,
according to known methods. Agents for injection can be a non-toxic, non-orally
administrable diluting agent such as aqueous solution or a sterile injectable solution or
suspension in a solvent. As the usable vehicle or solvent, water, Ringer's solution,
isotonic saline, etc. are allowed; as an ordinary solvent, or suspending solvent, sterile
involatile oil can be used. For these purposes, any kind of involatile oil and fatty acid can
be used, including natural or synthetic or semisynthetic fatty oils or fatty acids; natural or
synthetic or semisynthetic mono- or di- or tri-glycerides. Parental administration is
known in the art and includes, but is not limited to, conventional means of injections, a
gas pressured needle-less injection device as described in U.S. Pat. No. 5,851,198, and a
laser perforator device as described in U.S. Pat. No. 5,839,446 entirely incorporated
herein by reference.
                                              62

[00210]     Alternative Delivery
[00211]     The invention further relates to the administration of at least one Anti-CD22
antibody by parenteral, subcutaneous, intramuscular, intravenous, intrarticular,
intrabronchial, intraabdominal, intracapsular, intracartilaginous, intracavitary, intracelial,
intracelebellar, intracerebroventricular, intracolic, intracervical, intragastric, intrahepatic,
intramyocardial, intraosteal, intrapelvic, intrapericardiac, intraperitoneal, intrapleural,
intraprostatic, intrapulmonary, intrarectal, intrarenal, intraretinal, intraspinal,
intrasynovial, intrathoracic, intrauterine, intravesical, bolus, vaginal, rectal, buccal,
sublingual, intranasal, or transdermal means. At least one Anti-CD22 antibody
composition can be prepared for use for parenteral (subcutaneous, intramuscular or
intravenous) or any other administration particularly in the form of liquid solutions or
suspensions; for use in vaginal or rectal administration particularly in semisolid forms
such as, but not limited to, creams and suppositories; for buccal, or sublingual
administration such as, but not limited to, in the form of tablets or capsules; or
intranasally such as, but not limited to, the form of powders, nasal drops or aerosols or
certain agents; or transdermally such as not limited to a gel, ointment, lotion, suspension
or patch delivery system with chemical enhancers such as dimethyl sulfoxide to either
modify the skin structure or to increase the drug concentration in the transdermal patch
(Junginger, et al. In "Drug Permeation Enhancement"; Hsieh, D. S., Eds., pp. 59-90,
Marcel Dekker, Inc. New York 1994, entirely incorporated herein by reference), or with
oxidizing agents that enable the application of formulations containing proteins and
peptides onto the skin (WO 98/53847), or applications of electric fields to create transient
transport pathways such as electroporation, or to increase the mobility of charged drugs
through the skin such as iontophoresis, or application of ultrasound such as sonophoresis
(U.S. Pat. Nos. 4,309,989 and 4,767,402) (the above publications and patents being
entirely incorporated herein by reference).
[00212]     Pulmonary/Nasal Administration
[00213]     For pulmonary administration, preferably at least one Anti-CD22 antibody
composition is delivered in a particle size effective for reaching the lower airways of the
lung or sinuses. According to the invention, at least one Anti-CD22 antibody can be
delivered by any of a variety of inhalation or nasal devices known in the art for
                                               63

administration of a therapeutic agent by inhalation. These devices capable of depositing
aerosolized formulations in the sinus cavity or alveoli of a patient include metered dose
inhalers, nebulizers, dry powder generators, sprayers, and the like. Other devices suitable
for directing the pulmonary or nasal administration of antibodies are also known in the
art. All such devices can use of formulations suitable for the administration for the
dispensing of antibody in an aerosol. Such aerosols can be comprised of either solutions
(both aqueous and non aqueous) or solid particles. Metered dose inhalers like the
Ventolin.RTM. metered dose inhaler, typically use a propellent gas and require actuation
during inspiration (See, e.g., WO 94/16970, WO 98/35888). Dry powder inhalers like
Turbuhaler.TM. (Astra), Rotahaler.RTM. (Glaxo), Diskus.RTM. (Glaxo), Spiros.TM.
inhaler (Dura), devices marketed by Inhale Therapeutics, and the Spinhaler.RTM. powder
inhaler (Fisons), use breath-actuation of a mixed powder (U.S. Pat. No. 4,668,218 Astra,
EP 237507 Astra, WO 97/25086 Glaxo, WO 94/08552 Dura, U.S. Pat. No. 5,458,135
Inhale, WO 94/06498 Fisons, entirely incorporated herein by reference). Nebulizers like
AERx.TM. Aradigm, the Ultravent.RTM. nebulizer (Mallinckrodt), and the Acorn
II.RTM. nebulizer (Marquest Medical Products) (U.S. Pat. No. 5,404,871 Aradigm, WO
97/22376), the above references entirely incorporated herein by reference, produce
aerosols from solutions, while metered dose inhalers, dry powder inhalers, etc. generate
small particle aerosols. These specific examples of commercially available inhalation
devices are intended to be a representative of specific devices suitable for the practice of
this invention, and are not intended as limiting the scope of the invention. Preferably, a
composition comprising at least one Anti-CD22 antibody is delivered by a dry powder
inhaler or a sprayer. There are several desirable features of an inhalation device for
administering at least one antibody of the present invention. For example, delivery by the
inhalation device is advantageously reliable, reproducible, and accurate. The inhalation
device can optionally deliver small dry particles, e.g. less than about 10 Im, preferably
about 1-5 pm, for good respirability.
[00214]     Administration of CD22 Antibody Compositions as a Spray
[00215]     A spray including CD22 antibody composition protein can be produced by
forcing a suspension or solution of at least one Anti-CD22 antibody through a nozzle
under pressure. The nozzle size and configuration, the applied pressure, and the liquid
                                              64

feed rate can be chosen to achieve the desired output and particle size. An electrospray
can be produced, for example, by an electric field in connection with a capillary or nozzle
feed. Advantageously, particles of at least one Anti-CD22 antibody composition protein
delivered by a sprayer have a particle size less than about 10 Pm, preferably in the range
of about 1 gm to about 5 pm, and most preferably about 2 ptm to about 3 ptm.
[00216]     Formulations of at least one Anti-CD22 antibody composition protein suitable
for use with a sprayer typically include antibody composition protein in an aqueous
solution at a concentration of about 0.1 mg to about 100 mg of at least one Anti-CD22
antibody composition protein per ml of solution or mg/gm, or any range or value therein,
e.g., but not limited to, 0.1, 0.2., 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10,
11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 40, 45, 50, 60,
70, 80, 90 or 100 mg/ml or mg/gm. The formulation can include agents such as an
excipient, a buffer, an isotonicity agent, a preservative, a surfactant, and, preferably, zinc.
The formulation can also include an excipient or agent for stabilization of the antibody
composition protein, such as a buffer, a reducing agent, a bulk protein, or a carbohydrate.
Bulk proteins useful in formulating antibody composition proteins include albumin,
protamine, or the like. Typical carbohydrates useful in formulating antibody composition
proteins include sucrose, mannitol, lactose, trehalose, glucose, or the like. The antibody
composition protein formulation can also include a surfactant, which can reduce or
prevent surface-induced aggregation of the antibody composition protein caused by
atomization of the solution in forming an aerosol. Various conventional surfactants can
be employed, such as polyoxyethylene fatty acid esters and alcohols, and polyoxy
ethylene sorbitol fatty acid esters. Amounts will generally range between 0.001 and 14%
by weight of the formulation. Especially preferred surfactants for purposes of this
invention are polyoxyethylene sorbitan monooleate, polysorbate 80, polysorbate 20, or
the like. Additional agents known in the art for formulation of a protein such as CD22
antibodies, or specified portions, or variants, can also be included in the formulation.
[00217]     Administration of CD22 Antibody Compositions by a Nebulizer
[00218]     Antibody composition protein can be administered by a nebulizer, such as jet
nebulizer or an ultrasonic nebulizer. Typically, in ajet nebulizer, a compressed air source
is used to create a high-velocity air jet through an orifice. As the gas expands beyond the
                                                  65

nozzle, a low-pressure region is created, which draws a solution of antibody composition
protein through a capillary tube connected to a liquid reservoir. The liquid stream from
the capillary tube is sheared into unstable filaments and droplets as it exits the tube,
creating the aerosol. A range of configurations, flow rates, and baffle types can be
employed to achieve the desired performance characteristics from a given jet nebulizer.
In an ultrasonic nebulizer, high-frequency electrical energy is used to create vibrational,
mechanical energy, typically employing a piezoelectric transducer. This energy is
transmitted to the formulation of antibody composition protein either directly or through a
coupling fluid, creating an aerosol including the antibody composition protein.
Advantageously, particles of antibody composition protein delivered by a nebulizer have
a particle size less than about 10 ptm, preferably in the range of about 1 ptm to about 5
ptm, and most preferably about 2 ptm to about 3 ptm.
[00219]      Formulations of at least one Anti-CD22 antibody suitable for use with a
nebulizer, either jet or ultrasonic, typically include a concentration of about 0.1 mg to
about 100 mg of at least one Anti-CD22 antibody protein per ml of solution. The
formulation can include agents such as an excipient, a buffer, an isotonicity agent, a
preservative, a surfactant, and, preferably, zinc. The formulation can also include an
excipient or agent for stabilization of the at least one Anti-CD22 antibody composition
protein, such as a buffer, a reducing agent, a bulk protein, or a carbohydrate. Bulk
proteins useful in formulating at least one Anti-CD22 antibody composition proteins
include albumin, protamine, or the like. Typical carbohydrates useful in formulating at
least one anti-CD22 antibody include sucrose, mannitol, lactose, trehalose, glucose, or the
like. The at least one Anti-CD22 antibody formulation can also include a surfactant,
which can reduce or prevent surface-induced aggregation of the at least one Anti-CD22
antibody caused by atomization of the solution in forming an aerosol. Various
conventional surfactants can be employed, such as polyoxyethylene fatty acid esters and
alcohols, and polyoxyethylene sorbital fatty acid esters. Amounts will generally range
between 0.001 and 4% by weight of the formulation. Especially preferred surfactants for
purposes of this invention are polyoxyethylene sorbitan mono-oleate, polysorbate 80,
polysorbate 20, or the like. Additional agents known in the art for formulation of a
protein such as antibody protein can also be included in the formulation.
                                                66

[00220]     Administration of CD22 Antibody Compositions by a Metered Dose
Inhaler
[00221]     In a metered dose inhaler (MDI), a propellant, at least one Anti-CD22
antibody, and any excipients or other additives are contained in a canister as a mixture
including a liquefied compressed gas. Actuation of the metering valve releases die
mixture as an aerosol, preferably containing particles in the size range of less than about
10 ptm, preferably about 1 ptm to about 5 ptm, and most preferably about 2 p[m to about 3
ptm. The desired aerosol particle size can be obtained by employing a formulation of
antibody composition protein produced by various methods known to those of skill in the
art, including jet-milling, spray drying, critical point condensation, or the like. Preferred
metered dose inhalers include those manufactured by 3M or Glaxo and employing a
hydrofluorocarbon propellant.
[00222]     Formulations of at least one Anti-CD22 antibody for use with a metered-dose
inhaler device will generally include a finely divided powder containing at least one Anti
CD22 antibody as a suspension in a non-aqueous medium, for example, suspended in a
propellant with the aid of a surfactant. The propellant can be any conventional material
employed for this purpose, such as chlorofluorocarbon, a hydrochlorofluorocarbon, a
hydrofluorocarbon, or a hydrocarbon, including trichlorofluoromethane,
dichlorodifluoromethane, dichlorotetrafluoroethanol and 1,1,1,2-tetrafluoroethane, HFA
134a (hydrofluoroalkane- 134a), HFA-227 (hydrofluoroalkane-227), or the like.
Preferably the propellant is a hydrofluorocarbon. The surfactant can be chosen to
stabilize the at least one anti-CD22 antibody as a suspension in the propellant, to protect
the active agent against chemical degradation, and the like. Suitable surfactants include
sorbitan trioleate, soya lecithin, oleic acid, or the like. In some cases solution aerosols are
preferred using solvents such as ethanol. Additional agents known in the art for
formulation of a protein can also be included in the formulation.
[00223]      One of ordinary skill in the art will recognize that the methods of the current
invention can be achieved by pulmonary administration of at least one Anti-CD22
antibody compositions via devices not described herein.
                                                67

[00224]      Oral Formulations and Administration
[00225]     Formulations for oral administration rely on the co-administration of adjuvants
(e.g., resorcinols and nonionic surfactants such as polyoxyethylene oleyl ether and n
hexadecylpolyethylene ether) to increase artificially the permeability of the intestinal
walls, as well as the co-administration of enzymatic inhibitors (e.g., pancreatic trypsin
inhibitors, diisopropylfluorophosphate (DFF) and trasylol) to inhibit enzymatic
degradation. The active constituent compound of the solid-type dosage form for oral
administration can be mixed with at least one additive, including sucrose, lactose,
cellulose, mannitol, trehalose, raffinose, maltitol, dextran, starches, agar, arginates,
chitins, chitosans, pectins, gum tragacanth, gum arabic, gelatin, collagen, casein, albumin,
synthetic or semisynthetic polymer, and glyceride. These dosage forms can also contain
other type(s) of additives, e.g., inactive diluting agent, lubricant such as magnesium
stearate, paraben, preserving agent such as sorbic acid, ascorbic acid, alpha.-tocopherol,
antioxidant such as cysteine, disintegrator, binder, thickener, buffering agent, sweetening
agent, flavoring agent, perfuming agent, etc.
[00226]     Tablets and pills can be further processed into enteric-coated preparations. The
liquid preparations for oral administration include emulsion, syrup, elixir, suspension and
solution preparations allowable for medical use. These preparations can contain inactive
diluting agents ordinarily used in said field, e.g., water. Liposomes have also been
described as drug deliver systems for insulin and heparin (U.S. Pat. No. 4,239,754).
More recently, microspheres of artificial polymers of mixed amino acids (proteinoids)
have been used to deliver pharmaceuticals (U.S. Pat. No. 4,925,673). Furthermore,
carrier compounds described in U.S. Pat. No, 5,879,681 and U.S. Pat. No. 5,5,871,753 are
used to deliver biologically active agents orally are known in the art.
[00227]     Mucosal Formulations and Administration
[00228]     For absorption through mucosal surfaces, compositions and methods of
administering at least one Anti-CD22 antibody include an emulsion comprising a
plurality of submicron particles, a mucoadhesive macromolecule, a bioactive peptide, and
an aqueous continuous phase, which promotes absorption through mucosal surfaces by
achieving mucoadhesion of the emulsion particles (U.S. Pat. No. 5,514,670). Mucous
                                                68

surfaces suitable for application of the emulsions of the present invention can include
corneal, conjunctival, buccal, sublingual, nasal, vaginal, pulmonary, stomachic, intestinal,
and rectal routes of administration. Formulations for vaginal or rectal administration, e.g.
suppositories, can contain as excipients, for example, polyalkyleneglycols, vaseline,
cocoa butter, and the like. Formulations for intranasal administration can be solid and
contain as excipients, for example, lactose or can be aqueous or oily solutions of nasal
drops. For buccal administration excipients include sugars, calcium stearate, magnesium
stearate, pregelinatined starch, and the like (U.S. Pat. No. 5,849,695).
[00229]      Transdermal Formulations and Administration
[00230]      For transdermal administration, the at least one Anti-CD22 antibody is
encapsulated in a delivery device such as a liposome or polymeric nanoparticles,
microparticle, microcapsule, or microspheres (referred to collectively as microparticles
unless otherwise stated). A number of suitable devices are known, including
microparticles made of synthetic polymers such as polyhydroxy acids such as polylactic
acid, polyglycolic acid and copolymers thereof, polyorthoesters, polyanhydrides, and
polyphosphazenes, and natural polymers such as collagen, polyamino acids, albumin and
other proteins, alginate and other polysaccharides, and combinations thereof (U.S. Pat.
No. 5,814,599).
[00231]      Prolonged Administration and Formulations
[00232]      It can be sometimes desirable to deliver the compounds of the present
invention to the subject over prolonged periods of time, for example, for periods of one
week to one year from a single administration. Various slow release, depot or implant
dosage forms can be utilized. For example, a dosage form can contain a pharmaceutically
acceptable non-toxic salt of the compounds that has a low degree of solubility in body
fluids, for example, (a) an acid addition salt with a polybasic acid such as phosphoric
acid, sulfuric acid, citric acid, tartaric acid, tannic acid, pamoic acid, alginic acid,
polyglutamic acid, naphthalene mono- or di-sulfonic acids, polygalacturonic acid, and the
like; (b) a salt with a polyvalent metal cation such as zinc, calcium, bismuth, barium,
magnesium, aluminum, copper, cobalt, nickel, cadmium and the like, or with an organic
cation formed from e.g., N,N'-dibenzyl-ethylenediamine or ethylenediamine; or (c)
                                                  69

combinations of (a) and (b) e.g. a zinc tannate salt. Additionally, the compounds of the
present invention or, preferably, a relatively insoluble salt such as those just described,
can be formulated in a gel, for example, an aluminum monostearate gel with, e.g. sesame
oil, suitable for injection. Particularly preferred salts are zinc salts, zinc tannate salts,
pamoate salts, and the like. Another type of slow release depot formulation for injection
would contain the compound or salt dispersed for encapsulated in a slow degrading, non
toxic, non-antigenic polymer such as a polylactic acid/polyglycolic acid polymer for
example as described in U.S. Pat. No. 3,773,919. The compounds or, preferably,
relatively insoluble salts such as those described above can also be formulated in
cholesterol matrix silastic pellets, particularly for use in animals. Additional slow release,
depot or implant formulations, e.g. gas or liquid liposomes are known in the literature
(U.S. Pat. No. 5,770,222 and "Sustained and Controlled Release Drug Delivery Systems",
J. R. Robinson ed., Marcel Dekker, Inc., N.Y., 1978).
Abbreviations:
BSA--bovine serum albumin
EIA--enzyme immunoassay
FBS--fetal bovine serum
H20 2--hydrogen peroxide
HRP--horseradish peroxidase
Ig--immunoglobulin
CD22-ICD22
IP--intraperitoneal
IV--intravenous
Mab--monoclonal antibody
OD--optical density
OPD--o-Phenylenediamine dihydrochloride
PEG--polyethylene glycol
PSA--penicillin, streptomycin, amphotericin
RT--room temperature
SQ--subcutaneous
v/v--volume per volume
                                                70

w/v--weight per volume
[00233]     Example 1. Affinity and Quantitation ELISAs.
[00234]     Nunc-Immuno MaxiSorp 96 well plates were coated with 100 pl of 2 pg/ml,
0.2 pg/ml, 0.02 pg/ml or 0.002 pg/ml recombinant CD22 extracellular domain
(PeproTech, Inc. catalog number 100-01 in coating solution (sodium bicarbonate in PBS).
The plates were covered with plate sealer and incubated at 4'C overnight. Plates were
emptied and the residual liquid tapped out on paper towels. 200 pl washing solution
(0.05% Tween-20 in PBS) was added and shaken at 200 RPM for 5 min at room
temperature. The plates were emptied and residual liquid tapped out on paper towels.
200 pl blocking solution (2% Carnation milk in PBS) was added and shaken at 200 RPM
for one hour at room temperature. Plates were emptied and residual liquid tapped out on
paper towels. 100 pl of diluted samples containing VM1000, VM1001, VM1002,
VM1003, VM1004, VM1005, VM1006, VM1007, VM1008, VM1009, VM1010,
VM1011, VM1012, VM1013, VM1014, and VM1015antibodies for ELISA were used.
The samples were shaken at 200 RPM for one hour at room temperature; plates emptied
and residual liquid tapped out on paper towels. 200 d washing solution (0.05% Tween
20 in PBS) was added, shaken at 200 RPM for 5 min at room temperature; plates emptied
and residual liquid tapped out on paper towels. This process was repeated three times.
100 tl of 1:2500 dilution of anti-human IgG conjugated with HRP diluted in block
solution (2% Carnation milk in PBS) was added for all samples. 100 pl of 1:2500
dilution of anti-rabbit IgG conjugated with HRP diluted in block solution (2% Carnation
milk in PBS) was added for control antibody. The contents were shaken at 200 RPM for
one hour at room temperature, plates emptied and residue liquid tapped out on paper
towels. 200 pl washing solution (0.05% Tween-20 in PBS) was added, shaken at 200
RPM for 5 min at room temperature; plates emptied and residual liquid tapped out on
paper towels. This process was repeated three times. 100 [il TMB substrate solution was
added, and incubated at room temperature. The reaction was stopped with 1 N HCl, and
the plate read at 450 nm to determine relative binding affinity (Figure 17).
                                             71

[00235]     Quantitation ELISA
[00236]    Example 2.. CHO-S Cells Transfection
[00237]     One week before transfection, CHO-S cells (Invitrogen) were transferred to
monolayer culture in serum supplemented Dulbecco's Modified Eagle Medium (D
MEM) (Invitrogen). One day before transfection, cells are plated 0.4 x 105 cells in 100
uL of serum supplemented D-MEM per transfection sample in 96 well formats. Prepared
DNA-Lipofectamine complexes for each transfection sample. Diluted 0.25 ug of DNA in
25 uL Opti-MEM Reduced Serum Medium and mixed gently, and incubated at room
temperature for 5 min. Diluted 0.5 uL Lipofectamine 2000 (Invitrogen) in 25 uL Opti
MEM Reduced Serum Medium. Mixed gently and incubated at room temperature for 5
min. Combined the diluted DNA with the diluted Lipofectamine. Mixed gently and
incubated for 20 min at room temperature. Added the 50 uL DNA-Lipofectamine
complexes to each well containing cells and medium. Mixed gently by rocking the plate.
Incubated the cells at 37C in a 5% CO 2 incubator overnight. Aspirated medium in each
well. Added 100 uL of serum supplemented D-MEM to each well. Collected supernatant
for ELISA assay and cell lysate for beta-galactosidase assay.
[00238]    Example 3. Antibody Purification from Cell Culture supernatant.
[00239]    The following buffers were prepared in a standard fashion. Binding buffer 10
mM Na 2HPO 4/NaH 2PO 4, pH 7.0. Elution Buffer: 12.5 mM Citric Acid, pH 2.7 (use Na3
citrate). Neutralization Buffer: 0.5 M Na 2HPO 4/NaH 2PO 4 , pH 8.0. 20% Ethanol and
water. All buffers were filtered before use (0.45 ptm). Supernatants were purified using
an AKTA TM FPLC T M system fitted with a HiTrapTMProtein G Sepharose HP (lmL
volume) column. For Sample loading, loading tubes are rinsed with ethanol (20 mL, 5
mL/min), then binding buffer (20 mL, 5 mL/min). Protein G column is attached to
system and rinsed with binding buffer (10 mL, 1 mL/mn). The sample is loaded at 1
mL/min or slower (for overnight loading). After loading, the column is detached and
loading tubes are rinsed with water (20 mL, 5 mL/mn) and then 20% ethanol (20 mL, 5
mL/min). For antibody purification, the AKTA system was washed (pump A and all
tubing) with binding buffer. Collection tubes were prepared for fraction collection by
adding 50 ptl Neutralization buffer to each tube. The protein G column was attached to
                                             72

the system. The flow was set to 1 mL/min, and run until baseline was stable. The
column valve was switched to position 3. The column was washed with binding buffer
(10 mL minimum) until baseline was reached. The pump was stopped and washed with
water, then with Elution buffer. The flow was set to 1 ml/min, and run until baseline was
stable. The column valve was switched to position 3 and the fraction collector was
started (0.5 mL fractions). Fractions were collected until base line was reached at which
point the system was stopped. The elution profile was copied to the clipboard and into
WORD document. The pump was washed with water; then with binding buffer. The
protein G column was washed with binding buffer (10 mL). The pump was washed with
20% Ethanol. The column was washed with 20% Ethanol (20 mL) stored in the
coldroom.
[00240]     The antibodies were reconstituted in sterile IX PBS, pH 7.4, 0.02% sodium
azide, 10 mg/mL BSA. The antigen was CD22 (21,000 kDa) in four separate vials at 0.5
mg, 1 mg, 0.5 mg and 0.5 mg, was diluted with sterile IX PBS, pH 7.4, 0.02% sodium
azide to 375 ug/mL, 1 mg/mL, 500 ug/mL and 500 ug/mL. The label, Cy5-conjugated
AffiniPure goat anti-human IgG (H+L), Cy5, 1.5 pg/mL, was purchased from Jackson
ImmunoResearch (West Grove, PA). The label was reconstituted in sterile IX PBS, pH
7.4, 0.02% sodium azide, and diluted to 0.500 mg/mL. The Running Buffer was IX PBS,
pH 7.4, 0.02% sodium azide. The Sample Buffer was IX PBS, pH 7.4, 0.02% sodium
azide, 1 mg/mL Bovine Serum Albumin (BSA). The PMMA beads (Part#
440197/Lot3257) were provided by Sapidyne Instruments, Inc. (Boise, ID) and coated
with capture reagent in the following fashion. Beads were aliquoted dry into 200 mg
portions and rocked in 1 mL coating solution (30 ug/mL BAP001 in running buffer) for 2
hours. Beads were then rocked 1 hour in blocking solution (10 mg/mL BSA in running
buffer) and stored at 4'C.
[00241]     For Equilibrium Analysis, PMMA beads coated with CD22 were used to
capture a portion of the free receptor from equilibrated sample of receptor (anti-CD22
antibody) and ligand (antigen; CD22). For each data point a fresh column of ligand
coated beads was introduced into the flow cell. The equilibrated sample was rapidly
drawn past the column to minimize the contact time with the immobilized ligand. This
ensured the contact time with the immobilized ligand does not disrupt the sample
                                             73

equilibrium. The immobilized ligand thus acted as a probe to capture free receptor in
solution. Captured antibodies were detected with fluorescently labeled anti-human
secondary antibody. Unbound reagents were washed away, leaving a signal that is
proportional to free receptor in the equilibrated sample. The fluorescence was converted
to voltage that is directly proportional to the amount of free receptor (antibody) in the
equilibrated sample. Experiments were run at both high and low concentrations of
receptor, then utilized together in an n-curve analysis for optimal results. For the Direct
Method of Kinetic Analysis, the same immobilized ligand (CD22 coated PMMA) was
used as the capture reagent for kinetic experiments as for equilibrium experiments. The
amount of free receptor (antibody) in the sample was measured pre-equilibrium, yielding
data points that monitor the decrease in free receptor (antibody) over time as the sample
moves toward equilibrium. Figure 33 shows a table with data from Sapidyne analysis of
the top 10 hits for anti-IL6 antibodies BAPOO1-clone I to BAPOO1-clone 10 compared to
BA003 (CNTO136).
[00242]     Example 4. Surface Plasmon Resonance determination of affinity
constants to recombinant CD22 extracellular domain of the anti-CD22 Antibodies of
the Invention.
[00243]     BlAcore 3000, GE Healthcare was used to determine binding curves and
kinetic parameters. An anti-human Fc (1.8 mg/ml) was diluted to a concentration of
50ug/ml in NaOAc buffer (10 mM, pH 4.8) and coupled to the carboxymethylated
dextran matrix of a CM-5 sensor chip using the manufacturer's amine-coupling chemistry
as described in the BlAcore systems manual. Using the surface preparation wizard aiming
for 10000RU, the carboxyl groups on the sensor surfaces were first activated with
NHS/EDC followed by the addition of the anti-human Fc. The remaining activated
groups were blocked by the injection of IM ethanolamine. Each of the flow cells was
coupled individually. Employing these conditions, the four flow cell surfaces containing
7554-9571 RU of anti-human Fc were prepared. In preliminary experiments, it was
determine that three injections (15 ul at 30 ul/min) 100 mM H3 PO 4 /0.05%0 CHAPS would
efficiently remove the bound immunoglobulin and preserve the binding capacity of the
immobilized anti-human Fc.
                                               74

[00244]     Experiments were performed on the BlAcore 3000 at 25'C and a flow rate of
30 ul/min. The antibody candidate was dissolved in HBS (10 mM HEPES with 0. 15M
NaCl, 3.4 mM EDTA, and 0.05% surfactant P20 at pH 7.4) at 5ug/ml. The analyte,
CD22, was dissolved in HBS at 0.25, 0.125, 0.062, 0.031 and 0.015 ug/ml. 3*30 ul of 5
ug/ml of antibody BAOO 1 was flowed over its respective flow cell followed by injections
of 240 ul of each CD22 concentration at 30ul/min (association phase) and an
uninterrupted 1200 seconds of buffer flow (dissociation phase). The surface of the chip
was regenerated by three sequential injections of 15 ul each with 100 m M H 3PO 4 /0.05%
CHAPS. The injections of HBS serve as a reference (blank sensogram) for the subtraction
of bulk refractive indices for analysis. Using the 1:1 model in BlAevaluation 4.1, both a
local fit and global fit was done for both dissociation (kd, [s- 1] and association (ka, [M 1 s
1] )and the dissociation constant (KD, [M]) calculated (kd/ka).
100245]     Analysis was done using BlAeveluation version 3.0. Kinetic constants were
derived from sensogram data by fitting the experimental curves to the rate equations
derived from models of the interaction mechanisms. A global analysis using a 1:1 binding
model with local RUmax fit, the ka, kd, and KD were determined.
[00246]     The following equations were utilized:
[00247]     Ab   +    Ag   -  AbAg
             K      -  [AbAg]       _   1
[00248]           -   [Ab] [Ag]        Kd.
[00249]       Biacore data for humanized anti-CD22 monoclonal antibodies before
affinity maturation is set forth in Figure 18 (BA006G). After BA600G affinity
maturation and subsequent humanization selected clones were tested by Biacore analysis
as shown in Figure 18.
[00250]     Example 5. Anti-CD22 selected anti-CD22 antibodies bind to cell surface
CD22 expressed in lymphoma cell lines and induce internalization.
[00251]     The CD22 protein has been shown to be expressed in developing B cells and
in most human non-Hodgkin's lymphoma cell lines, including Dauid, RAMOS and RAJI
                                               75

B cell ines (Knowles D. M., Chadburn A., Inghirami G. Immunophenotypic markers
useful in the diagnosis and classification of hematopoietic neoplasms Knowles D. M. eds.
. Neoplastic Hematopathology, 73-95, Williams & Wilkins Baltimore 1992). Binding of
anti-CD22 antibodies to B cell lines, or primary B cells from healthy individuals and
patients with non-Hodgkin's lymphoma (NHL), results in rapid internalization of the
CD22/antibody complex. Internalization appears to be faster at early time points in cell
lines than in primary B cells and NHL patient-derived B cells, but the maximum
internalization reached is comparable for all B cell populations after several hours of
treatment and appears to reach saturation at higher antibody concentrations.
[00252]     Anti-CD22 monoclonal antibodies selected herein, clones VM1000, VM1001,
VM1002, VM1003, VM1004, VM1005, VM1006, VM1007, VM1008, VM1009,
VM1010, VM1011, VM1012, VM1013, VM1014, and VM1015 of the invention, were
tested for their ability to bind cell surface expressed CD22 in Daudi, RAMOS and RAJI B
lymphoma cell lines as determined by fuorescent activated cell sorting analysis. Cell
cultures were maintained in exponential growth in RPMI 1640 media containing 10:\%
fetal bovine serum prior to analysis. Anti-CD22 expression levels were determined by
ELISA and FACS analysis using commercially available anti-CD22 antibodies
conjugated to phycoerythrin (PE) (Becton Dickenson, catalog number 340708). For
basline surface expression, 1 X 10e6 Daudi cells (for example) were incubated with PBS
containing 2%FBS and 12 ug/ul anti-CD22-PE conjugate for 45 min on ince, then washed
with ice-cold PBS-FBS solution. Cells were then analyzed by FACS using standard
procedures to quantitate surface binding in the target cell population.
[00253]     In parallel, Daudi cells, 1 X 10e6 were treated with similar concentrations of
the selected anti-CD22 Mab clones VM1000, VM1001, VM1002, VM1003, VM1004,
VM1005, VM1006, VM1007, VM1008, VM1009, VM1010, VM101 1, VM1012,
VM1013, VM1014, and VM1015 of the invention.in PBS-FBS solution for 20 hours at 37
C to allow for binding and internalization. After this period, the cells were washed, and
then exposed to 12 ug/ml anti-CD22-PE conjugate in PBS-FBS solution on ice. Under
thes conditions, residual surface CD22 would be detected and quantitated using FACS
analysis as described above. Shown in Figure19A is a typical result for an anti-CD22
antibody of the invention. After exposure for 20 hours there is a decrease in surface
                                                76

CD22 expressions as mseasured as a shift in the fluorescent population to the left
indicating lower levels of detection. The decrese in the relative amounts of CD22 surface
express can be expressed as a ration of the two populations.
Shown in Figure 19B are the results of evaluation of a panel of anti-CD22 antibodies for
their ability to internalize CD22 receptor upon exposure for 20 hours at 37 C and
determined by the percentage shift in anti-CD22-PE conjugate binding after prior
exposure. A spectrum of changes in CD22 expression is detected as visulatixed by the
shift in the CD22 positive population to the left. Quantitation of the extent of
internalization is shown if Figure 20. Individual anti-CD22 clones selected anti-CD22
Mab clones VM1000, VM1001, VM1002, VM1003, VM1004, VM1005, VM1006,
VM1007, VM1008, VM1009, VM1010, VM101 1, VM1012, VM1013, VM1014, and
VM1015 of the invention were analysed as described above and the relative extent of
CD22 internalization was expressed as a percent shift in the population over baseline
following antibody exposure.
[00254]      Measurement of rapid internalization of anti-CD22 antibodies of the invention
by quantitative confocal immunofluorescent microscopy in lymphoma cell lines.
[00255]      Daudi cells were maintained under conditions of exponential growth in RPMI
1640 media containing 10% FBA at 37 C, and then harvested for analysis. Selected
antiCD22 selected anti-CD22 Mab clones VM1000, VM1001, VM1002, VM1003,
VM1004, VM1005, VM1006, VM1007, VM1008, VM1009, VM1010, VM1011,
VM1012,VM1013, VM1014, and VM1015 of the invention were directly conjugated to
FITC using the Zenon labeling complex (Molecular Probes) using the manufacturer's
recommended procedures. Approximately 1 X 10e7 Daudi cells were resuspended in
PBS containing 5 ug/ml labeled anti-CD22 antibody and incubated for 45 minutes on ice.
Cells then washed twice in PBS-FBS solution at 0 C. Cells were then incubated in RPMI
1640 media containing 10% FBS for varying periods at 37 C, harvested and washed in
PBS at 0 C. The cells were then briefly fixed in 4% paraformaldehyde solution for 5 min
at room temperature, then washed in PBS containing 0.05% Triton X-100. Cell pellets
were collected by centrifugation and resupended in a minimal volume of FBS neat, and
then applied to glass microscope slides. Prior to analysis, slides were treated with
mounting fluid containing the nuclear stain DAPI, then coverslips were applied.
                                             77

Confocal images were recorded using an ACAS Ultima confocal microscope (Meridian
Instruments, Inc., Okemos, MI) and represent 1-pm sections through the center of a focal
plane using a 100x oil immersion objective.
 [00256]    The Anti-CD22 monoclonal antibodies selected clones VM1000, VM1001,
VM1002, VM1003, VM1004, VM1005, VM1006, VM1007, VM1008, VM1009,
VM1O1O, VM101 1, VM1012, VM1013, VM1014, and VM1015 of the invention were
analysed for their ability to be rapidly internalized into the intracellular compartment as
judged by immunoflourescent signal on the cell surface versus the intracellular endo
cytotic compartment. The antibodies of the invention were compared to BA006H, and
humanized version of the murine monoclonal antibody LL2. In this example, Figure
21A, the anti-CD22 antibodies of the invention bind to CD22 protein expressed on the
surface of Daudi cells by approximately 20-fold compared to BA006H as judged by
relative mean fluorescence (RMF), and are virtually completely internalized within the
cell with 90 minutes, localizing predominantly to within the perinuclear golgi apparatus
and associated lysozomes. Shown in Figure 21B is a chart of the RMF surface binding
values obtained in this manner for individual anti-CD22 antibodies of the invention.
 [00257]    Stimulation of CD22 tyrosine phosphorylation following treatment of CD22
positive lymphoma cell lines Anti-CD22 monoclonal antibodies selected clones VM1000,
VM1001, VM1002, VM1003, VM1004, VM1005, VM1006, VM1007, VM1008,
VM1009, VM1O1O, VM1O11, VM1012, VM1013, VM1014, and VM1015 of the
invention. Anti-CD22 antibodies have previously been shown to bind to cells epressing
CD22 and stimulate the tyrosine phosphorylation of they cytoplasmic region of the
receptor (Carnahan et al, Clin Cancer Res September 1, 2003 9; 3982s). This bioactivity
of anti-CD22 antibodies has been associated with negativel regulation of the BCR
signaling complex resulting in decreased lymphoma cell growth and induction of cell
death. The anti-CD22 antbodies selected were therefore analyzed for their ability to
stimulate CD22 tyrosine phosphorylation upon exposure to receptor expressing cell lines.
Daudi cells were maintained in exponential growth by culturing in RPMI 1640 containing
 10% FBS before harvesting and treatment with anti- CD22 antibodies. The treated cells
were then lysed with detergent buffer and CD22 was immunoprecipitated using anti
CD22 BA006H then subjected to SDS-PAGE and Western blot analysis. The resulting
                                               78

blots were then probed with anti-phosphotyrosine antibodies (4G 10) or with rabbit
polyclonal anti-CD22 (Santa Cruz, Catalog number SC-7932. Figures 22 A anb B show
the result of these analyses. The ratio of tyrosine phospohrylated CD22 protein to total
CD22 are indicated below each antibody treatment. As a control, Daudi cells were
treated with an anti-IgM antibody to engage and stimulate the B-cell receptor complex as
a means to saturate the potential to trans-phosphorylate the CD22 cytoplasmic domain.
[00258]      Cross-reactivity. The surface protein CD22 is known to be expressed on the
surface of developing B-cells and on lymphoma and leukemia cells derived from the B
cell lineages. The anti-CD22 antibodies of the present invention were evaluated for
ability to cross-react with CD22 expressed on murine and rodent B-cells. Results indicate
that there is no appreciable binding to the rodent form of the protein. Anti-CD22
antibodies of the present invention were also evaluated for cross reactivity to primate
species, cynomologus macaques (Macacafascicularis).Peripheral blood lymphocytes
(PBMC's) isolated from cynomologus macaques (source Primate Biologicals, Inc.,
Bethesda, MD) (enriched for CD22 positive B-cells) were analyzed. Anti-CD22
antibodies of the present invention (the anti-CD22 antibody designated as "VM101" in
the data herein) were directly labeled with the fluorescent molecule phycoerythrin (PE).
To test for positive staining, approximately 2.5 X 10e6 PBMC's for each test condition
were washed in PBS then resuspended in PBS containing 10% fetal bovine serum (FBS).
Cells were then exposed to either no antibody, anti-CD22 PE-labeled antibody (20
ug/ml), or anti-human CD20-FITC conjugated antibody which has been shown to cross
reacted with cynomologus CD20 (Miltenyl Biotech, catalog number 130-091-108 at 1:10
dilution of stock reagent), then incubated at 0 C for 60 min. The cells for each test
condition were washed in PBS, and then fixed with 4% formaldehyde in PBS for 10 min
at room temperature. The cells were then resuspended in 0.5 ml of PBS containing 2%
FBS then analyzed for CD22 and CD20 surface staining by fluorescent activated cell
sorting (FACS) analysis (Figures 23A-23C). Cells treated with no antibody did not have
an appreciable shift in fluorescent intensity in either the FITC or PE channels (Figure
23A), whereas cell stained with VM101-PE contained a CD22 positive population (Figure
23B). Similarly, cells stained with anti-CD20-FIT contained a CD20 positive population
(Figure 23C). Cells stained with both VM1O1-PE and CD20-FITC antibodies have a
                                              79

double labeled population as one would expect based on the expression patterns of both
antigen in PBMC's (Figure ID). VM101 specifically recognizes the cynomologus CD22
protein.
[00259]     Relative expression of Anti-CD22 antibodies. Anti-CD22 antibodies of the
present invention were expressed in mammalian cells to determine if they have properties
that are consistent with high level production in manufacturing processes to produce
material for clinical studies. The expression of anti-CD22 antibodies of the present
invention (Antibody 1, Antibody 2 and Antibody 3) were compared to a control antibody
("Control"), a humanized CD22 antibody. The resulting cells expressing each CD22
antibody were cultured for equivalent periods in mammalian cell culture conditions and
the conditioned media was tested for the presence and yield of monoclonal antibody. The
results were compared to a marketed antibody that is expressed at high level during these
conditions (trastuzumab, also known as Hereceptin) and serves as a comparator. Table I
shows the results of this test for expression and manufacturability under these conditions.
                                              80

The claims defining the invention are as follows:
         1.     An expression vector comprising a nucleotide sequence encoding an
antibody or antibody fragment that binds to human CD22,
        wherein the antibody or antibody fragment comprises:
        a heavy chain variable region having three complementarity determining regions
(CDR1, CDR2, and CDR3), wherein the complementarity determining region 1 (CDR1)
has at least 90% sequence identity with a complementarity determining region 1 (CDR1)
of a heavy chain variable region of VM1000 (SEQ ID NO: 49), the complementarity
determining region 2 (CDR2) has at least 90% sequence identity with a complementarity
determining region 2 (CDR2) of the heavy chain variable region of VM1000 (SEQ ID
NO: 49), the complementarity determining region 3 (CDR3) has at least 90% sequence
identity with a complementarity determining region 3 (CDR3) of the heavy chain variable
region of VM1000 (SEQ ID NO: 49);
        a light chain variable region having three complementarity determining regions
(CDR4, CDR5, and CDR6), wherein the complementarity determining region 4 (CDR4)
has at least 90% sequence identity with a complementarity determining region 4 (CDR4)
of a light chain variable region of VM1000 or VM1015 (SEQ ID NO: 17 or 32), the
complementarity determining region 5 (CDR5) has at least 90% sequence identity with a
complementarity determining region 5 (CDR5) of the light chain variable region of
VM1000 (SEQ ID NO: 17), the complementarity determining region 6 (CDR6) has at
least 90% sequence identity with a complementarity determining region 6 (CDR6) of the
light chain variable region of VM1000 (SEQ ID NO: 17) ; and
        a heavy chain constant region and a light chain constant region derived from one
or more human antibodies, wherein the heavy chain constant region is associated with the
heavy chain variable region and the light chain constant region is associated with the light
chain variable region.
        2.       The expression vector of claim 1, wherein the antibody or antibody
fragment comprises a heavy chain variable region having the amino acid sequence of
SEQ ID NO: 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, or 64; a light chain
variable region having the amino acid sequence of SEQ ID NO: 17, 18, 19, 20, 21, 22, 23,
24, 25, 26, 27, 28, 29, 30, 31, or 32.
                                              81

         3.     The expression vector of any one of claims 1-2, further comprising a
selectable marker.
         4.     The expression vector of claim 3, wherein the selectable marker is selected
from markers of methotrexate, dihydrofolate reductase, ampicillin, neomycin (G418),
mycophenolic acid, glutamine synthetase, tetracycline resistance gene and ampicillin
resistance gene.
         5.      The expression vector of any one of claims 1-4, wherein the expression
vector is selected from a plasmid and a viral vector.
         6.     The expression vector of any one of claims 1-5, further comprising an
adaptor, a linker, and a recombinant expression cassette.
         7.      The expression vector of any one of claims 1-6, wherein the nucleotide
sequence is operatively linked to a promoter.
         8.      The expression vector of any one of claims 1-7, wherein the expression
vector expresses the antibody or antibody fragment in a modified form.
         9.      The expression vector of claim 8, wherein the modified form is a fusion
protein comprising the antibody or antibody fragment.
          10.   The expression vector of claim 9, wherein the fusion protein comprises a
secretion signal and a heterologous functional region.
          11.    The expression vector of claim 10, wherein the heterologous functional
region has a function of improving stability of the antibody or antibody fragment, or
facilitating purification of the antibody or antibody fragment.
                                              82

         12.     The expression vector of any one of claims 1-11, wherein said antibody or
antibody fragment competitively inhibits in vivo the binding to human CD22 of an anti
CD22 murine antibody.
         13.     The expression vector of any one of claims 1-12, wherein said antibody or
antibody fragment binds CD22 with an affinity (Kd) of at least 10-9 M, or at least 10-1 M,
or at least 10-42 M.
         14.     The expression vector of any one of claims 1-13, wherein the antibody or
antibody fragment substantially neutralizes at least one activity of at least one CD22.
         15.     A host cell comprising the expression vector of any one of claims 1-14.
         16.     The host cell of claim 15, wherein the host cell is a prokaryotic host cell or
eukaryotic host cell.
         17.     The host cell of claim 16, wherein the host cell is selected from COS-1,
COS-7, HEK293, BHK21, CHO, BSC-1, Hep G2, 653, SP2/0, 293, HeLa, myeloma,
lymphoma cells, and a derivative, immortalized or transformed cell thereof.
         18.     A method for producing an antibody or antibody fragment, comprising a
step of translating the nucleotide sequence in the expression vector of any one of claims
1-14.
         19.     An antibody or antibody fragment produced by the method of claim 18.
        20.      A composition comprising the antibody or antibody fragment of claim 19,
and a carrier or diluent.
        21.      The composition of claim 20, wherein the carrier is selected from sterile
water and sterile buffered water.
                                              83

        22.    The composition of any one of claims 20-21, further comprising at least
one preservative selected from phenol, m-cresol, p-cresol, o-cresol, chlorocresol, benzyl
alcohol, phenylmercuric nitrite, phenoxyethanol, formaldehyde, chlorobutanol,
magnesium chloride, alkylparaben, benzalkonium chloride, benzethonium chloride,
sodium dehydroacetate and thimerosal, and mixtures thereof.
        23.    The composition of any one of claims 20-22, wherein the concentration of
the antibody or antibody fragment is about 0.1 mg/ml to about 100 mg/ml.
        24.    The composition of any one of claims 20-22, further comprising an
isotonicity agent or a physiologically acceptable buffer.
                                             84

<removed-apn> <removed-date>
<removed-apn> <removed-date>
<removed-apn> <removed-date>
<removed-apn> <removed-date>
<removed-apn> <removed-date>
<removed-apn> <removed-date>
<removed-apn> <removed-date>
<removed-apn> <removed-date>
<removed-apn> <removed-date>
<removed-apn> <removed-date>
<removed-apn> <removed-date>
<removed-apn> <removed-date>
<removed-apn> <removed-date>
<removed-apn> <removed-date>
<removed-apn> <removed-date>
<removed-apn> <removed-date>
<removed-apn> <removed-date>
<removed-apn> <removed-date>
<removed-apn> <removed-date>
<removed-apn> <removed-date>
<removed-apn> <removed-date>
<removed-apn> <removed-date>
<removed-apn> <removed-date>
<removed-apn> <removed-date>
<removed-apn> <removed-date>
                                        <U+2725> <U+2701><U+2702> <U+2704><U+260E>   <U+2706><U+271D><U+2725><U+271E><U+271D><U+2704><U+271F>
<removed-date>
              <U+2741><U+2720><U+2720><U+2721><U+261B>   <U+2725><U+261E><U+270C><U+270D><U+270E><U+270F> <U+2711><U+2712><U+2713>
              <U+2741><U+2720><U+2714><U+2721><U+261B>   <U+2715><U+2704><U+271E><U+271D><U+2716><U+260E><U+2717><U+2714><U+2714> <U+2715><U+2704><U+271E><U+271D><U+2718><U+2719><U+2717><U+271D> <U+2725>
              <U+2741><U+2720><U+271A><U+2721><U+261B>   <U+2718><U+271D><U+2715><U+271E><U+2716><U+2720><U+2721><U+2721><U+271B><U+271C><U+2719>
              <U+2741><U+2720><U+2722><U+2721><U+261B>   <U+2723><U+260E><U+271E><U+2724><U+2702><U+2725><U+2720><U+271A><U+2724><U+271A><U+2726><U+271A><U+271B><U+2721>
<removed-apn>
              <U+2741><U+2720><U+2722><U+2720><U+261B>   <U+2714><U+2721><U+2720><U+271A><U+2716><U+2721><U+2722><U+2716><U+2714><U+2727>
              <U+2741><U+2720><U+2727><U+2721><U+261B>   <U+2727><U+2722>
              <U+2741><U+2720><U+271B><U+2721><U+261B>   <U+2723><U+2712><U+270E><U+2605><U+2729><U+270E><U+271D><U+2729> <U+272A><U+2605><U+270D><U+272B><U+272C><U+270C><U+2729> <U+271A><U+272D><U+272E>
              <U+2741><U+2714><U+2720><U+2721><U+261B>   <U+2720>
              <U+2741><U+2714><U+2720><U+2720><U+261B>   <U+271A><U+2720><U+2726>
              <U+2741><U+2714><U+2720><U+2714><U+261B>   <U+2717><U+2704><U+2715>
              <U+2741><U+2714><U+2720><U+271A><U+261B>   <U+2715><U+270D><U+270E><U+272C><U+272F><U+272C><U+2730><U+272C><U+2712><U+2731> <U+2725><U+2605><U+2732><U+2733><U+2605><U+2729><U+2730><U+2605>
              <U+2741><U+2714><U+2714><U+2721><U+261B>
              <U+2741><U+2714><U+2714><U+271A><U+261B>   <U+2712><U+2729><U+270E><U+272C><U+2734><U+270C><U+2735><U+2713>
              <U+2741><U+2722><U+2721><U+2721><U+261B> <U+2720>
              <U+2763><U+2712><U+2712><U+2712><U+270E><U+270E><U+2763><U+270E><U+2763><U+270E> <U+270E><U+2763><U+2712><U+2730><U+2712><U+2730><U+2712><U+2763><U+270E><U+2730> <U+270E><U+2730><U+2730><U+2712><U+2763><U+2730><U+2730><U+2712><U+2730><U+2730> <U+2730><U+270E><U+2763><U+270E><U+2730><U+270E><U+270E><U+270E><U+2763><U+270E> <U+2730><U+270E><U+2730><U+2730><U+2712><U+2763><U+2763><U+2763><U+2763><U+2712> <U+2712><U+2712><U+2763><U+2712><U+2763><U+2730><U+2730><U+2712><U+2730><U+2730>
              <U+2727><U+2721>
              <U+2730><U+270E><U+2730><U+270E><U+2730><U+2730><U+270E><U+2763><U+2730><U+2712> <U+2712><U+2763><U+270E><U+2730><U+2730><U+2712><U+2763><U+270E><U+2730><U+2712> <U+2712><U+2712><U+2763><U+270E><U+2763><U+270E><U+270E><U+270E><U+270E><U+2712> <U+270E><U+2712><U+2730><U+2712><U+2763><U+270E><U+2763><U+2730><U+2712><U+2763> <U+270E><U+2763><U+2763><U+2712><U+2763><U+2712><U+2712><U+2763><U+2712><U+2712> <U+2730><U+270E><U+2712><U+2730><U+270E><U+270E><U+2763><U+2763><U+2730><U+2730>
              <U+2720><U+2714><U+2721>
              <U+270E><U+2763><U+2763><U+270E><U+2712><U+270E><U+2730><U+2712><U+2763><U+2730> <U+2712><U+2763><U+2712><U+2712><U+2712><U+2730><U+2730><U+2712><U+2763><U+2763> <U+2763><U+2712><U+2712><U+2712><U+2763><U+2730><U+270E><U+2730><U+2730><U+270E> <U+2712><U+2712><U+2763><U+2730><U+270E><U+2730><U+2730><U+270E><U+2763><U+2712> <U+270E><U+2730><U+270E><U+2712><U+270E><U+270E><U+2763><U+2763><U+2763><U+2730> <U+2712><U+270E><U+2730><U+2730><U+2712><U+2730><U+270E><U+2712><U+2763><U+2763>
              <U+2720><U+2726><U+2721>
              <U+2763><U+2712><U+2712><U+2712><U+2763><U+2763><U+2763><U+2763><U+2763><U+2763> <U+270E><U+2730><U+2730><U+2730><U+2712><U+270E><U+2730><U+2712><U+2712><U+2763> <U+2763><U+270E><U+270E><U+2730><U+2712><U+2763><U+270E><U+2763><U+2763><U+2712> <U+2712><U+2763><U+270E><U+2763><U+2763><U+2712><U+270E><U+2730><U+270E><U+2763> <U+2763><U+2763><U+2712><U+2730><U+2712><U+2763><U+2712><U+270E><U+270E><U+270E> <U+270E><U+2712><U+2730><U+270E><U+270E><U+270E><U+2730><U+2712><U+2730><U+2730>
              <U+2714><U+2722><U+2721>
              <U+2712><U+270E><U+2730><U+2712><U+2763><U+2730><U+2712><U+2763><U+2730><U+2730> <U+270E><U+2763><U+2730><U+2712><U+2763><U+2730><U+2730><U+270E><U+2763><U+2712> <U+2712><U+2763><U+2712><U+270E><U+2712><U+270E><U+270E><U+2763><U+2730><U+2712> <U+2712><U+2730><U+2712><U+270E><U+2712><U+270E><U+270E><U+2712><U+2730><U+270E> <U+2763><U+270E><U+2712><U+2712><U+2763><U+2730><U+2712><U+2712><U+270E><U+2712> <U+2730><U+2730><U+270E><U+2730><U+270E><U+2730><U+2730><U+270E><U+2730><U+2763>
              <U+271A><U+2721><U+2721>
                                                   1

              <U+270E><U+2763><U+2763><U+2712><U+2730><U+2763><U+270E><U+270E><U+2730><U+2763> <U+2763><U+2730><U+2730><U+2712><U+2712><U+2763><U+2763><U+2763>
<removed-date>
              <U+271A><U+2720><U+2726>
              <U+2741><U+2714><U+2720><U+2721><U+261B>   <U+2714>
              <U+2741><U+2714><U+2720><U+2720><U+261B>   <U+271A><U+2720><U+2726>
              <U+2741><U+2714><U+2720><U+2714><U+261B>   <U+2717><U+2704><U+2715>
              <U+2741><U+2714><U+2720><U+271A><U+261B>   <U+2715><U+270D><U+270E><U+272C><U+272F><U+272C><U+2730><U+272C><U+2712><U+2731> <U+2725><U+2605><U+2732><U+2733><U+2605><U+2729><U+2730><U+2605>
<removed-apn>
              <U+2741><U+2714><U+2714><U+2721><U+261B>
              <U+2741><U+2714><U+2714><U+271A><U+261B>   <U+2712><U+2729><U+270E><U+272C><U+2734><U+270C><U+2735><U+2713>
              <U+2741><U+2722><U+2721><U+2721><U+261B> <U+2714>
              <U+2763><U+2712><U+2712><U+2712><U+270E><U+270E><U+2763><U+270E><U+2763><U+270E> <U+270E><U+2763><U+2712><U+2730><U+2712><U+2730><U+2712><U+2763><U+270E><U+2730> <U+270E><U+2730><U+2730><U+2712><U+2763><U+2730><U+2730><U+2712><U+2730><U+2730> <U+2730><U+270E><U+2763><U+270E><U+2730><U+270E><U+270E><U+270E><U+2763><U+270E> <U+2730><U+270E><U+2730><U+2730><U+2712><U+2763><U+2763><U+2763><U+2763><U+2712> <U+2712><U+2712><U+2763><U+2712><U+2763><U+2730><U+2730><U+2712><U+2730><U+2730>
              <U+2727><U+2721>
              <U+2730><U+270E><U+2730><U+270E><U+2730><U+2730><U+270E><U+2763><U+2730><U+2712> <U+2712><U+2763><U+270E><U+2730><U+2730><U+2712><U+2763><U+270E><U+2730><U+2712> <U+2712><U+2712><U+2763><U+270E><U+2763><U+270E><U+270E><U+270E><U+270E><U+2712> <U+270E><U+2712><U+2730><U+2712><U+2763><U+270E><U+2763><U+2730><U+2712><U+2763> <U+270E><U+2763><U+2763><U+2712><U+2763><U+2712><U+2712><U+2763><U+2712><U+2712> <U+2730><U+270E><U+2712><U+2730><U+270E><U+270E><U+2763><U+2763><U+2730><U+2730>
              <U+2720><U+2714><U+2721>
              <U+270E><U+2763><U+2763><U+270E><U+2712><U+2730><U+2730><U+2712><U+2763><U+2730> <U+2712><U+2763><U+2712><U+2712><U+2712><U+2730><U+2730><U+270E><U+2763><U+2763> <U+2730><U+2730><U+2712><U+2763><U+2763><U+2730><U+270E><U+2730><U+2730><U+2730> <U+2712><U+2763><U+2763><U+2730><U+270E><U+2730><U+2730><U+270E><U+2730><U+2712> <U+270E><U+2730><U+270E><U+2712><U+270E><U+270E><U+2763><U+2763><U+2763><U+2730> <U+2712><U+270E><U+2730><U+2730><U+2712><U+2730><U+270E><U+2712><U+2763><U+2763>
              <U+2720><U+2726><U+2721>
              <U+2763><U+2712><U+2712><U+2712><U+2763><U+2763><U+2763><U+2763><U+2763><U+2712> <U+270E><U+2730><U+2730><U+2730><U+2712><U+2763><U+2712><U+2730><U+2712><U+2763> <U+2763><U+270E><U+270E><U+2730><U+2712><U+2763><U+270E><U+2763><U+2763><U+2730> <U+2712><U+2763><U+270E><U+2763><U+2763><U+2763><U+270E><U+2730><U+270E><U+2763> <U+2763><U+2763><U+2712><U+2730><U+2712><U+2763><U+2712><U+2730><U+270E><U+270E> <U+2730><U+2712><U+2730><U+270E><U+2730><U+270E><U+2730><U+2712><U+2730><U+2730>
              <U+2714><U+2722><U+2721>
              <U+2712><U+270E><U+2730><U+2712><U+2763><U+2730><U+2712><U+2763><U+2712><U+2730> <U+270E><U+2763><U+2763><U+2712><U+2763><U+2730><U+2730><U+270E><U+2763><U+2712> <U+2712><U+2763><U+2712><U+270E><U+270E><U+270E><U+270E><U+2763><U+2730><U+2712> <U+2763><U+270E><U+2763><U+270E><U+2712><U+270E><U+270E><U+2712><U+2730><U+270E> <U+2763><U+270E><U+2712><U+2712><U+2763><U+2730><U+2712><U+2712><U+270E><U+2712> <U+2730><U+2730><U+270E><U+2730><U+270E><U+2730><U+2730><U+270E><U+2730><U+2763>
              <U+271A><U+2721><U+2721>
              <U+270E><U+2763><U+2763><U+2712><U+2730><U+2763><U+270E><U+270E><U+2730><U+2763> <U+2763><U+2730><U+2730><U+2712><U+2712><U+2763><U+2763><U+2763>
              <U+271A><U+2720><U+2726>
              <U+2741><U+2714><U+2720><U+2721><U+261B>   <U+271A>
              <U+2741><U+2714><U+2720><U+2720><U+261B>   <U+271A><U+2720><U+2726>
              <U+2741><U+2714><U+2720><U+2714><U+261B>   <U+2717><U+2704><U+2715>
              <U+2741><U+2714><U+2720><U+271A><U+261B>   <U+2715><U+270D><U+270E><U+272C><U+272F><U+272C><U+2730><U+272C><U+2712><U+2731> <U+2725><U+2605><U+2732><U+2733><U+2605><U+2729><U+2730><U+2605>
              <U+2741><U+2714><U+2714><U+2721><U+261B>
              <U+2741><U+2714><U+2714><U+271A><U+261B>   <U+2712><U+2729><U+270E><U+272C><U+2734><U+270C><U+2735><U+2713>
                                                 2

              <U+2741><U+2722><U+2721><U+2721><U+261B> <U+271A>
<removed-date>
              <U+2763><U+2712><U+2712><U+2712><U+270E><U+270E><U+2763><U+270E><U+2763><U+270E> <U+270E><U+2763><U+2712><U+2730><U+2712><U+2730><U+2712><U+2763><U+270E><U+2730> <U+270E><U+2730><U+2730><U+2712><U+2763><U+2730><U+2730><U+2712><U+2730><U+2730> <U+2730><U+270E><U+2763><U+270E><U+2730><U+270E><U+270E><U+270E><U+2763><U+270E> <U+2730><U+270E><U+2730><U+2730><U+2712><U+2763><U+2763><U+2763><U+2763><U+2712> <U+2712><U+2712><U+2763><U+2712><U+2763><U+2730><U+2730><U+2712><U+2730><U+2730>
              <U+2727><U+2721>
              <U+2730><U+270E><U+2730><U+270E><U+2730><U+2730><U+270E><U+2763><U+2730><U+2712> <U+2712><U+2763><U+270E><U+2730><U+2730><U+2712><U+2763><U+270E><U+2730><U+2712> <U+2712><U+2712><U+2763><U+270E><U+2763><U+270E><U+270E><U+270E><U+270E><U+2712> <U+270E><U+2712><U+2730><U+2712><U+2763><U+270E><U+2763><U+2730><U+2712><U+2763> <U+270E><U+2763><U+2763><U+2712><U+2763><U+2712><U+2712><U+2763><U+2712><U+2712> <U+2730><U+270E><U+2712><U+2730><U+270E><U+270E><U+2763><U+2763><U+2730><U+2730>
              <U+2720><U+2714><U+2721>
              <U+270E><U+2763><U+2763><U+270E><U+2712><U+2730><U+2730><U+2712><U+2763><U+2730> <U+2712><U+2763><U+2712><U+2712><U+2712><U+2730><U+2730><U+270E><U+2763><U+2763> <U+2730><U+2730><U+2712><U+2763><U+2763><U+2730><U+270E><U+2730><U+2730><U+2730> <U+2712><U+2763><U+2763><U+2730><U+270E><U+2730><U+2730><U+270E><U+2730><U+2712> <U+270E><U+2730><U+270E><U+2712><U+270E><U+270E><U+2763><U+2763><U+2763><U+2730> <U+2712><U+270E><U+2730><U+2730><U+2712><U+2730><U+270E><U+2712><U+2763><U+2763>
              <U+2720><U+2726><U+2721>
<removed-apn>
              <U+2763><U+2712><U+2712><U+2712><U+2763><U+2763><U+2763><U+2763><U+2763><U+2712> <U+270E><U+2730><U+2730><U+2730><U+2712><U+2763><U+2712><U+2730><U+2712><U+2763> <U+2763><U+270E><U+270E><U+2730><U+2712><U+2763><U+270E><U+2763><U+2763><U+2730> <U+2712><U+2763><U+270E><U+2763><U+2763><U+2763><U+270E><U+2730><U+270E><U+2763> <U+2763><U+2763><U+2712><U+2730><U+2712><U+2763><U+2712><U+2730><U+270E><U+270E> <U+2730><U+2712><U+2730><U+270E><U+2730><U+270E><U+2730><U+2712><U+2730><U+2730>
              <U+2714><U+2722><U+2721>
              <U+2712><U+270E><U+2730><U+2712><U+2763><U+2730><U+2712><U+2763><U+2712><U+2730> <U+270E><U+2763><U+2763><U+2712><U+2763><U+2730><U+2730><U+270E><U+2763><U+2712> <U+2712><U+2763><U+2712><U+270E><U+270E><U+270E><U+270E><U+2763><U+2730><U+2712> <U+2763><U+270E><U+2763><U+270E><U+2712><U+270E><U+270E><U+2712><U+2730><U+270E> <U+2763><U+270E><U+2712><U+2712><U+2763><U+2730><U+2712><U+2712><U+270E><U+2712> <U+2730><U+2730><U+270E><U+2730><U+270E><U+2730><U+2730><U+270E><U+2730><U+2763>
              <U+271A><U+2721><U+2721>
              <U+270E><U+2763><U+2763><U+2712><U+2730><U+2763><U+270E><U+270E><U+2730><U+2763> <U+2763><U+2730><U+2730><U+2712><U+2712><U+2763><U+2763><U+2763>
              <U+271A><U+2720><U+2726>
              <U+2741><U+2714><U+2720><U+2721><U+261B>   <U+2722>
              <U+2741><U+2714><U+2720><U+2720><U+261B>   <U+271A><U+2720><U+2726>
              <U+2741><U+2714><U+2720><U+2714><U+261B>   <U+2717><U+2704><U+2715>
              <U+2741><U+2714><U+2720><U+271A><U+261B>   <U+2715><U+270D><U+270E><U+272C><U+272F><U+272C><U+2730><U+272C><U+2712><U+2731> <U+2725><U+2605><U+2732><U+2733><U+2605><U+2729><U+2730><U+2605>
              <U+2741><U+2714><U+2714><U+2721><U+261B>
              <U+2741><U+2714><U+2714><U+271A><U+261B>   <U+2712><U+2729><U+270E><U+272C><U+2734><U+270C><U+2735><U+2713>
              <U+2741><U+2722><U+2721><U+2721><U+261B> <U+2722>
              <U+2763><U+2712><U+2712><U+2712><U+270E><U+270E><U+2763><U+270E><U+2763><U+270E> <U+270E><U+2763><U+2712><U+2730><U+2712><U+2730><U+2712><U+2763><U+270E><U+2730> <U+270E><U+2730><U+2730><U+2712><U+2763><U+2730><U+2730><U+2712><U+2730><U+2730> <U+2730><U+270E><U+2763><U+270E><U+2730><U+270E><U+270E><U+270E><U+2763><U+270E> <U+2730><U+270E><U+2730><U+2730><U+2712><U+2763><U+2763><U+2763><U+2763><U+2712> <U+2712><U+2712><U+2763><U+2712><U+2763><U+2730><U+2730><U+2712><U+2730><U+2730>
              <U+2727><U+2721>
              <U+2730><U+270E><U+2730><U+270E><U+2730><U+2730><U+270E><U+2763><U+2730><U+2712> <U+2712><U+2763><U+270E><U+2730><U+2730><U+2712><U+2763><U+270E><U+2730><U+2712> <U+2712><U+2712><U+2763><U+270E><U+2763><U+270E><U+270E><U+270E><U+270E><U+2712> <U+270E><U+2712><U+2730><U+2712><U+2763><U+270E><U+2763><U+2730><U+2712><U+2763> <U+270E><U+2763><U+2763><U+2712><U+2763><U+2712><U+2712><U+2763><U+2712><U+2712> <U+2730><U+270E><U+2712><U+2730><U+270E><U+270E><U+2763><U+2763><U+2730><U+2730>
              <U+2720><U+2714><U+2721>
              <U+270E><U+2763><U+2763><U+270E><U+2712><U+2730><U+2730><U+2712><U+2763><U+2730> <U+2712><U+2763><U+2712><U+2712><U+2712><U+2730><U+2730><U+270E><U+2763><U+2763> <U+2730><U+2730><U+2712><U+2763><U+2763><U+2730><U+270E><U+2730><U+2730><U+2730> <U+2712><U+2763><U+2763><U+2730><U+270E><U+2730><U+2730><U+270E><U+2730><U+2712> <U+270E><U+2730><U+270E><U+2712><U+270E><U+270E><U+2763><U+2763><U+2763><U+2730> <U+2712><U+270E><U+2730><U+2730><U+2712><U+2730><U+270E><U+2712><U+2763><U+2763>
              <U+2720><U+2726><U+2721>
              <U+2763><U+2712><U+2712><U+2712><U+2763><U+2763><U+2763><U+2763><U+2763><U+2712> <U+270E><U+2730><U+2730><U+2730><U+2712><U+2763><U+2712><U+2730><U+2712><U+2763> <U+2763><U+270E><U+270E><U+2730><U+2712><U+2763><U+270E><U+2763><U+2763><U+2730> <U+2712><U+2763><U+270E><U+2763><U+2763><U+2763><U+270E><U+2730><U+270E><U+2763> <U+2763><U+2763><U+2712><U+2730><U+2712><U+2763><U+2712><U+2730><U+270E><U+270E> <U+2730><U+2712><U+2730><U+270E><U+2730><U+270E><U+2730><U+2712><U+2730><U+2730>
              <U+2714><U+2722><U+2721>
                                                  3

<removed-date>
              <U+2712><U+270E><U+2730><U+2712><U+2763><U+2730><U+2712><U+2763><U+2712><U+2730> <U+270E><U+2763><U+2763><U+2712><U+2763><U+2730><U+2730><U+270E><U+2763><U+2712> <U+2712><U+2763><U+2712><U+270E><U+270E><U+270E><U+270E><U+2763><U+2730><U+2712> <U+2763><U+270E><U+2763><U+270E><U+2712><U+270E><U+270E><U+2712><U+2730><U+270E> <U+2763><U+270E><U+2712><U+2712><U+2763><U+2730><U+2712><U+2712><U+270E><U+2712> <U+2730><U+2730><U+270E><U+2730><U+270E><U+2730><U+2730><U+270E><U+2730><U+2763>
              <U+271A><U+2721><U+2721>
              <U+270E><U+2763><U+2763><U+2712><U+2730><U+2763><U+270E><U+270E><U+2730><U+2763> <U+2763><U+2730><U+2730><U+2712><U+2712><U+2763><U+2763><U+2763>
              <U+271A><U+2720><U+2726>
              <U+2741><U+2714><U+2720><U+2721><U+261B>   <U+272E>
<removed-apn>
              <U+2741><U+2714><U+2720><U+2720><U+261B>   <U+271A><U+2720><U+2726>
              <U+2741><U+2714><U+2720><U+2714><U+261B>   <U+2717><U+2704><U+2715>
              <U+2741><U+2714><U+2720><U+271A><U+261B>   <U+2715><U+270D><U+270E><U+272C><U+272F><U+272C><U+2730><U+272C><U+2712><U+2731> <U+2725><U+2605><U+2732><U+2733><U+2605><U+2729><U+2730><U+2605>
              <U+2741><U+2714><U+2714><U+2721><U+261B>
              <U+2741><U+2714><U+2714><U+271A><U+261B>   <U+2712><U+2729><U+270E><U+272C><U+2734><U+270C><U+2735><U+2713>
              <U+2741><U+2722><U+2721><U+2721><U+261B> <U+272E>
              <U+2763><U+2712><U+2712><U+2712><U+270E><U+270E><U+2763><U+270E><U+2763><U+270E> <U+270E><U+2763><U+2712><U+2730><U+2712><U+2730><U+2712><U+2763><U+270E><U+2730> <U+270E><U+2730><U+2730><U+2712><U+2763><U+2730><U+2730><U+2712><U+2730><U+2730> <U+2730><U+270E><U+2763><U+270E><U+2730><U+270E><U+270E><U+270E><U+2763><U+270E> <U+2730><U+270E><U+2730><U+2730><U+2712><U+2763><U+2763><U+2763><U+2763><U+2712> <U+2712><U+2712><U+2763><U+2712><U+2763><U+2730><U+2730><U+2712><U+2730><U+2730>
              <U+2727><U+2721>
              <U+2730><U+270E><U+2730><U+270E><U+2730><U+2730><U+270E><U+2763><U+2730><U+2712> <U+2712><U+2763><U+270E><U+2730><U+2730><U+2712><U+2763><U+270E><U+2730><U+2712> <U+2712><U+2712><U+2763><U+270E><U+2763><U+270E><U+270E><U+270E><U+270E><U+2712> <U+270E><U+2712><U+2730><U+2712><U+2763><U+270E><U+2763><U+2730><U+2712><U+2763> <U+270E><U+2763><U+2763><U+2712><U+2763><U+2712><U+2712><U+2763><U+2712><U+2712> <U+2730><U+270E><U+2712><U+2730><U+270E><U+270E><U+2763><U+2763><U+2730><U+2730>
              <U+2720><U+2714><U+2721>
              <U+270E><U+2763><U+2763><U+270E><U+2712><U+270E><U+2730><U+2712><U+2763><U+2730> <U+2712><U+2763><U+2712><U+2712><U+2712><U+2730><U+2730><U+2712><U+2763><U+2763> <U+2763><U+2712><U+2712><U+2712><U+2763><U+2730><U+270E><U+2730><U+2730><U+270E> <U+2712><U+2712><U+2763><U+2730><U+270E><U+2730><U+2730><U+270E><U+2763><U+2712> <U+270E><U+2730><U+270E><U+2712><U+270E><U+270E><U+2763><U+2763><U+2763><U+2730> <U+2712><U+270E><U+2730><U+2730><U+2712><U+2730><U+270E><U+2712><U+2763><U+2763>
              <U+2720><U+2726><U+2721>
              <U+2763><U+2712><U+2712><U+2712><U+2763><U+2763><U+2763><U+2763><U+2763><U+2712> <U+270E><U+2730><U+2730><U+2730><U+2712><U+2763><U+2712><U+2730><U+2712><U+2763> <U+2763><U+270E><U+270E><U+2730><U+2712><U+2763><U+270E><U+2763><U+2763><U+2730> <U+2712><U+2763><U+270E><U+2763><U+2763><U+2763><U+270E><U+2730><U+270E><U+2763> <U+2763><U+2763><U+2712><U+2730><U+2712><U+2763><U+2712><U+2730><U+270E><U+270E> <U+2730><U+2712><U+2730><U+270E><U+2730><U+270E><U+2730><U+2712><U+2730><U+2730>
              <U+2714><U+2722><U+2721>
              <U+2712><U+270E><U+2730><U+2712><U+2763><U+2730><U+2712><U+2763><U+2712><U+2730> <U+270E><U+2763><U+2763><U+2712><U+2763><U+2730><U+2730><U+270E><U+2763><U+2712> <U+2712><U+2763><U+2712><U+270E><U+270E><U+270E><U+270E><U+2763><U+2730><U+2712> <U+2763><U+270E><U+2763><U+270E><U+2712><U+270E><U+270E><U+2712><U+2730><U+270E> <U+2763><U+270E><U+2712><U+2712><U+2763><U+2730><U+2712><U+2712><U+270E><U+2712> <U+2730><U+2730><U+270E><U+2730><U+270E><U+2730><U+2730><U+270E><U+2730><U+2763>
              <U+271A><U+2721><U+2721>
              <U+270E><U+2763><U+2763><U+2712><U+2730><U+2763><U+270E><U+270E><U+2730><U+2763> <U+2763><U+2730><U+2730><U+2712><U+2712><U+2763><U+2763><U+2763>
              <U+271A><U+2720><U+2726>
              <U+2741><U+2714><U+2720><U+2721><U+261B>   <U+2727>
              <U+2741><U+2714><U+2720><U+2720><U+261B>   <U+271A><U+2720><U+2726>
              <U+2741><U+2714><U+2720><U+2714><U+261B>   <U+2717><U+2704><U+2715>
              <U+2741><U+2714><U+2720><U+271A><U+261B>   <U+2715><U+270D><U+270E><U+272C><U+272F><U+272C><U+2730><U+272C><U+2712><U+2731> <U+2725><U+2605><U+2732><U+2733><U+2605><U+2729><U+2730><U+2605>
                                                 4

<removed-date>
              <U+2741><U+2714><U+2714><U+2721><U+261B>
              <U+2741><U+2714><U+2714><U+271A><U+261B>   <U+2712><U+2729><U+270E><U+272C><U+2734><U+270C><U+2735><U+2713>
              <U+2741><U+2722><U+2721><U+2721><U+261B> <U+2727>
              <U+2763><U+2730><U+2730><U+2712><U+270E><U+2730><U+2730><U+2712><U+2763><U+270E> <U+270E><U+2763><U+2712><U+2730><U+2730><U+2730><U+2712><U+2763><U+270E><U+2730> <U+270E><U+2730><U+2730><U+2712><U+270E><U+2730><U+2730><U+270E><U+2730><U+2730> <U+2730><U+270E><U+2763><U+270E><U+2730><U+270E><U+2763><U+2730><U+2712><U+270E> <U+2730><U+270E><U+2763><U+270E><U+2712><U+2763><U+2763><U+2712><U+2763><U+2712> <U+2730><U+2712><U+2763><U+2712><U+2763><U+270E><U+2730><U+2712><U+2730><U+2730>
              <U+2727><U+2721>
              <U+2712><U+270E><U+2730><U+2712><U+2730><U+270E><U+270E><U+2763><U+2730><U+2712> <U+2712><U+2763><U+270E><U+2730><U+2730><U+2712><U+2763><U+270E><U+2730><U+2712> <U+2712><U+2712><U+2763><U+270E><U+2763><U+270E><U+270E><U+270E><U+270E><U+2712> <U+270E><U+2712><U+2730><U+2712><U+2763><U+270E><U+2763><U+2730><U+2712><U+2763> <U+270E><U+2763><U+2763><U+2712><U+2763><U+2712><U+2712><U+2763><U+2712><U+2712> <U+2730><U+270E><U+2712><U+2730><U+270E><U+270E><U+2763><U+2763><U+2730><U+2730>
<removed-apn>
              <U+2720><U+2714><U+2721>
              <U+270E><U+2763><U+2763><U+270E><U+2712><U+2730><U+2730><U+2712><U+2763><U+2730> <U+2712><U+2763><U+2712><U+2712><U+2712><U+2730><U+2730><U+270E><U+2763><U+2763> <U+2730><U+2730><U+2712><U+2763><U+2763><U+2730><U+270E><U+2730><U+2730><U+2730> <U+2712><U+2763><U+2763><U+2730><U+270E><U+2730><U+2730><U+270E><U+2730><U+2712> <U+270E><U+2730><U+270E><U+2712><U+270E><U+270E><U+2763><U+2763><U+2763><U+2730> <U+2712><U+270E><U+2730><U+2730><U+2712><U+2730><U+270E><U+2712><U+2763><U+2763>
              <U+2720><U+2726><U+2721>
              <U+2763><U+2712><U+2712><U+2712><U+2763><U+2763><U+2763><U+2763><U+2763><U+2763> <U+270E><U+2730><U+2730><U+2730><U+2712><U+270E><U+2730><U+2712><U+2712><U+2763> <U+2763><U+270E><U+270E><U+2730><U+2712><U+2763><U+2730><U+2763><U+2763><U+2730> <U+2712><U+2763><U+270E><U+2763><U+2763><U+2712><U+270E><U+2730><U+270E><U+2763> <U+2763><U+2763><U+2712><U+2730><U+2712><U+2763><U+2712><U+270E><U+270E><U+270E> <U+2730><U+2712><U+2730><U+270E><U+2730><U+270E><U+2730><U+2712><U+2730><U+2730>
              <U+2714><U+2722><U+2721>
              <U+2712><U+270E><U+2730><U+2712><U+2763><U+2730><U+2712><U+2763><U+2730><U+2730> <U+270E><U+2763><U+2730><U+2712><U+2763><U+2730><U+2730><U+270E><U+2763><U+2712> <U+2712><U+2763><U+2712><U+270E><U+270E><U+270E><U+270E><U+2763><U+2730><U+2712> <U+2712><U+2730><U+270E><U+270E><U+2712><U+270E><U+270E><U+2712><U+2730><U+270E> <U+2763><U+270E><U+2712><U+2712><U+2763><U+2730><U+2712><U+2712><U+270E><U+2712> <U+2730><U+2730><U+270E><U+2730><U+270E><U+2730><U+2730><U+270E><U+2730><U+2763>
              <U+271A><U+2721><U+2721>
              <U+270E><U+2763><U+2763><U+2712><U+2730><U+2763><U+270E><U+270E><U+2730><U+2763> <U+2763><U+2730><U+2730><U+2712><U+2712><U+2763><U+2763><U+2763>
              <U+271A><U+2720><U+2726>
              <U+2741><U+2714><U+2720><U+2721><U+261B>   <U+271B>
              <U+2741><U+2714><U+2720><U+2720><U+261B>   <U+271A><U+2720><U+2726>
              <U+2741><U+2714><U+2720><U+2714><U+261B>   <U+2717><U+2704><U+2715>
              <U+2741><U+2714><U+2720><U+271A><U+261B>   <U+2715><U+270D><U+270E><U+272C><U+272F><U+272C><U+2730><U+272C><U+2712><U+2731> <U+2725><U+2605><U+2732><U+2733><U+2605><U+2729><U+2730><U+2605>
              <U+2741><U+2714><U+2714><U+2721><U+261B>
              <U+2741><U+2714><U+2714><U+271A><U+261B>   <U+2712><U+2729><U+270E><U+272C><U+2734><U+2735><U+2713>
              <U+2741><U+2722><U+2721><U+2721><U+261B> <U+271B>
              <U+2763><U+2712><U+2730><U+2712><U+270E><U+2730><U+2730><U+2712><U+2763><U+2712> <U+270E><U+2763><U+2712><U+2730><U+2730><U+2730><U+2712><U+2763><U+270E><U+2730> <U+270E><U+2730><U+2730><U+2712><U+270E><U+2730><U+2730><U+270E><U+2730><U+2730> <U+2730><U+270E><U+2763><U+270E><U+2730><U+270E><U+2763><U+2730><U+2712><U+270E> <U+2730><U+270E><U+2763><U+270E><U+2712><U+2763><U+2763><U+2712><U+2763><U+2712> <U+2730><U+2712><U+2763><U+2712><U+2763><U+270E><U+2730><U+2712><U+2730><U+2730>
              <U+2727><U+2721>
              <U+2712><U+270E><U+2730><U+2712><U+2730><U+270E><U+270E><U+2763><U+2730><U+2712> <U+2712><U+2763><U+270E><U+2730><U+2730><U+2712><U+2763><U+270E><U+2730><U+2712> <U+2712><U+2712><U+2763><U+270E><U+2763><U+270E><U+270E><U+270E><U+270E><U+2712> <U+270E><U+2712><U+2730><U+2712><U+2763><U+270E><U+2763><U+2730><U+2712><U+2763> <U+270E><U+2763><U+2763><U+2712><U+2763><U+2712><U+2712><U+2763><U+2712><U+2712> <U+2730><U+270E><U+2712><U+2730><U+270E><U+270E><U+2763><U+2763><U+2730><U+2730>
              <U+2720><U+2714><U+2721>
                                                 5

              <U+270E><U+2763><U+2763><U+270E><U+2712><U+270E><U+2730><U+2712><U+2763><U+2730> <U+2712><U+2763><U+2712><U+2712><U+2712><U+2730><U+2730><U+2712><U+2763><U+2763> <U+2763><U+2712><U+2712><U+2712><U+2763><U+2730><U+270E><U+2730><U+2730><U+270E> <U+2712><U+2712><U+2763><U+2730><U+270E><U+2730><U+2730><U+270E><U+2763><U+2712> <U+270E><U+2730><U+270E><U+2712><U+270E><U+270E><U+2763><U+2763><U+2763><U+2730> <U+2712><U+270E><U+2730><U+2730><U+2712><U+2730><U+270E><U+2712><U+2763><U+2763>
<removed-date>
              <U+2720><U+2726><U+2721>
              <U+2763><U+2712><U+2712><U+2712><U+2763><U+2763><U+2763><U+2763><U+2763><U+2712> <U+270E><U+2730><U+2730><U+2730><U+2712><U+2763><U+2712><U+2730><U+2712><U+2763> <U+2763><U+270E><U+270E><U+2730><U+2712><U+2763><U+270E><U+2763><U+2763><U+2730> <U+2712><U+2763><U+270E><U+2763><U+2763><U+2763><U+270E><U+2730><U+270E><U+2763> <U+2763><U+2763><U+2712><U+2730><U+2712><U+2763><U+2712><U+2730><U+270E><U+270E> <U+2730><U+2712><U+2730><U+270E><U+2730><U+270E><U+2730><U+2712><U+2730><U+2730>
              <U+2714><U+2722><U+2721>
              <U+2712><U+270E><U+2730><U+2712><U+2763><U+2730><U+2712><U+2763><U+2712><U+2730> <U+270E><U+2763><U+2763><U+2712><U+2763><U+2730><U+2730><U+270E><U+2763><U+2712> <U+2712><U+2763><U+2712><U+270E><U+270E><U+270E><U+270E><U+2763><U+2730><U+2712> <U+2763><U+270E><U+2763><U+270E><U+2712><U+270E><U+270E><U+2712><U+2730><U+270E> <U+2763><U+270E><U+2712><U+2712><U+2763><U+2730><U+2712><U+2712><U+270E><U+2712> <U+2730><U+2730><U+270E><U+2730><U+270E><U+2730><U+2730><U+270E><U+2730><U+2763>
              <U+271A><U+2721><U+2721>
<removed-apn>
              <U+270E><U+2763><U+2763><U+2712><U+2730><U+2763><U+270E><U+270E><U+2730><U+2763> <U+2763><U+2730><U+2730><U+2712><U+2712><U+2763><U+2763><U+2763>
              <U+271A><U+2720><U+2726>
              <U+2741><U+2714><U+2720><U+2721><U+261B>   <U+2726>
              <U+2741><U+2714><U+2720><U+2720><U+261B>   <U+271A><U+2720><U+2726>
              <U+2741><U+2714><U+2720><U+2714><U+261B>   <U+2717><U+2704><U+2715>
              <U+2741><U+2714><U+2720><U+271A><U+261B>   <U+2715><U+270D><U+270E><U+272C><U+272F><U+272C><U+2730><U+272C><U+2712><U+2731> <U+2725><U+2605><U+2732><U+2733><U+2605><U+2729><U+2730><U+2605>
              <U+2741><U+2714><U+2714><U+2721><U+261B>
              <U+2741><U+2714><U+2714><U+271A><U+261B>   <U+2712><U+2729><U+270E><U+272C><U+2734><U+270C><U+2735><U+2713>
              <U+2741><U+2722><U+2721><U+2721><U+261B> <U+2726>
              <U+2763><U+2730><U+2730><U+2712><U+270E><U+2730><U+2730><U+2712><U+2763><U+270E> <U+270E><U+2763><U+2712><U+2730><U+2730><U+2730><U+2712><U+2763><U+270E><U+2730> <U+270E><U+2730><U+2730><U+2712><U+270E><U+2730><U+2730><U+270E><U+2730><U+2730> <U+2730><U+270E><U+2763><U+270E><U+2730><U+270E><U+2763><U+2730><U+2712><U+270E> <U+2730><U+270E><U+2763><U+270E><U+2712><U+2763><U+2763><U+2712><U+2763><U+2712> <U+2730><U+2712><U+2763><U+2712><U+2763><U+270E><U+2730><U+2712><U+2730><U+2730>
              <U+2727><U+2721>
              <U+2712><U+270E><U+2730><U+2712><U+2730><U+270E><U+270E><U+2763><U+2730><U+2712> <U+2712><U+2763><U+270E><U+2730><U+2730><U+2712><U+2763><U+270E><U+2730><U+2712> <U+2712><U+2712><U+2763><U+270E><U+2763><U+270E><U+270E><U+270E><U+270E><U+2712> <U+270E><U+2712><U+2730><U+2712><U+2763><U+270E><U+2763><U+2730><U+2712><U+2763> <U+270E><U+2763><U+2763><U+2712><U+2763><U+2712><U+2712><U+2763><U+2712><U+2712> <U+2730><U+270E><U+2712><U+2730><U+270E><U+270E><U+2763><U+2763><U+2730><U+2730>
              <U+2720><U+2714><U+2721>
              <U+270E><U+2763><U+2763><U+270E><U+2712><U+270E><U+2730><U+2712><U+2763><U+2730> <U+2712><U+2763><U+2712><U+2712><U+2712><U+2730><U+2730><U+2712><U+2763><U+2763> <U+2763><U+2712><U+2712><U+2712><U+2763><U+2730><U+270E><U+2730><U+2730><U+270E> <U+2712><U+2712><U+2763><U+2730><U+270E><U+2730><U+2730><U+270E><U+2763><U+2712> <U+270E><U+2730><U+270E><U+2712><U+270E><U+270E><U+2763><U+2763><U+2763><U+2730> <U+2712><U+270E><U+2730><U+2730><U+2712><U+2730><U+270E><U+2712><U+2763><U+2763>
              <U+2720><U+2726><U+2721>
              <U+2763><U+2712><U+2712><U+2712><U+2763><U+2763><U+2763><U+2763><U+2763><U+2763> <U+270E><U+2730><U+2730><U+2730><U+2730><U+270E><U+2730><U+2763><U+2712><U+2763> <U+2763><U+270E><U+270E><U+2730><U+2712><U+2763><U+270E><U+2763><U+2763><U+2730> <U+2712><U+2763><U+270E><U+2763><U+2763><U+2712><U+270E><U+2730><U+270E><U+2763> <U+2763><U+2763><U+2712><U+2730><U+2712><U+2763><U+2712><U+270E><U+270E><U+270E> <U+2730><U+2712><U+2730><U+2730><U+270E><U+270E><U+270E><U+2712><U+2730><U+2730>
              <U+2714><U+2722><U+2721>
              <U+2712><U+270E><U+2730><U+2712><U+2763><U+270E><U+2712><U+2763><U+2730><U+2730> <U+270E><U+2763><U+2763><U+2712><U+2712><U+2763><U+2730><U+270E><U+2763><U+2712> <U+2712><U+2763><U+2712><U+270E><U+2763><U+2730><U+270E><U+2763><U+2730><U+2712> <U+2712><U+2730><U+2712><U+270E><U+2712><U+270E><U+270E><U+2712><U+2730><U+270E> <U+2763><U+270E><U+2712><U+2712><U+2763><U+2730><U+2712><U+2712><U+270E><U+2712> <U+2730><U+2730><U+270E><U+2730><U+270E><U+2730><U+2730><U+270E><U+2730><U+2763>
              <U+271A><U+2721><U+2721>
              <U+270E><U+2763><U+2763><U+2712><U+2730><U+2763><U+270E><U+270E><U+2730><U+2763> <U+2763><U+2730><U+2730><U+2712><U+2712><U+2763><U+2763><U+2763>
              <U+271A><U+2720><U+2726>
                                                 6

<removed-date>
              <U+2741><U+2714><U+2720><U+2721><U+261B>   <U+2741>
              <U+2741><U+2714><U+2720><U+2720><U+261B>   <U+271A><U+2720><U+2726>
              <U+2741><U+2714><U+2720><U+2714><U+261B>   <U+2717><U+2704><U+2715>
              <U+2741><U+2714><U+2720><U+271A><U+261B>   <U+2715><U+270D><U+270E><U+272C><U+272F><U+272C><U+2730><U+272C><U+2712><U+2731> <U+2725><U+2605><U+2732><U+2733><U+2605><U+2729><U+2730><U+2605>
              <U+2741><U+2714><U+2714><U+2721><U+261B>
              <U+2741><U+2714><U+2714><U+271A><U+261B>   <U+2712><U+2729><U+270E><U+272C><U+2734><U+270C><U+2735><U+2713>
<removed-apn>
              <U+2741><U+2722><U+2721><U+2721><U+261B> <U+2741>
              <U+2763><U+2712><U+2730><U+2712><U+270E><U+2730><U+2730><U+2712><U+2763><U+2712> <U+270E><U+2763><U+2712><U+2730><U+2730><U+2730><U+2712><U+2763><U+270E><U+2730> <U+270E><U+2730><U+2730><U+2712><U+270E><U+2730><U+2730><U+270E><U+2730><U+2730> <U+2730><U+270E><U+2763><U+270E><U+2730><U+270E><U+2763><U+2730><U+2712><U+270E> <U+2730><U+270E><U+2763><U+270E><U+2712><U+2763><U+2763><U+2712><U+2763><U+2712> <U+2730><U+2712><U+2763><U+2712><U+2763><U+270E><U+2730><U+2712><U+2730><U+2730>
              <U+2727><U+2721>
              <U+2712><U+270E><U+2730><U+2712><U+2730><U+270E><U+270E><U+2763><U+2730><U+2712> <U+2712><U+2763><U+270E><U+2730><U+2730><U+2712><U+2763><U+270E><U+2730><U+2712> <U+2712><U+2712><U+2763><U+270E><U+2763><U+270E><U+270E><U+270E><U+270E><U+2712> <U+270E><U+2712><U+2730><U+2712><U+2763><U+270E><U+2763><U+2730><U+2712><U+2763> <U+270E><U+2763><U+2763><U+2712><U+2763><U+2712><U+2712><U+2763><U+2712><U+2712> <U+2730><U+270E><U+2712><U+2730><U+270E><U+270E><U+2763><U+2763><U+2730><U+2730>
              <U+2720><U+2714><U+2721>
              <U+270E><U+2763><U+2763><U+270E><U+2712><U+2730><U+2730><U+2712><U+2763><U+2730> <U+2712><U+2763><U+2712><U+2712><U+2712><U+2730><U+2730><U+270E><U+2763><U+2763> <U+2730><U+2730><U+2712><U+2763><U+2763><U+2730><U+270E><U+2730><U+2730><U+2730> <U+2712><U+2763><U+2763><U+2730><U+270E><U+2730><U+2730><U+270E><U+2730><U+2712> <U+270E><U+2730><U+270E><U+2712><U+270E><U+270E><U+2763><U+2763><U+2763><U+2730> <U+2712><U+270E><U+2730><U+2730><U+2712><U+2730><U+270E><U+2712><U+2763><U+2763>
              <U+2720><U+2726><U+2721>
              <U+2763><U+2712><U+2712><U+2712><U+2763><U+2763><U+2763><U+2763><U+2763><U+2712> <U+270E><U+2730><U+2730><U+2730><U+2712><U+2763><U+2712><U+2730><U+2712><U+2763> <U+2763><U+270E><U+270E><U+2730><U+2712><U+2763><U+270E><U+2763><U+2763><U+2730> <U+2712><U+2763><U+270E><U+2763><U+2763><U+2763><U+270E><U+2730><U+270E><U+2763> <U+2763><U+2763><U+2712><U+2730><U+2712><U+2763><U+2712><U+2730><U+270E><U+270E> <U+2730><U+2712><U+2730><U+270E><U+2730><U+270E><U+2730><U+2712><U+2730><U+2730>
              <U+2714><U+2722><U+2721>
              <U+2712><U+270E><U+2730><U+2712><U+2763><U+2730><U+2712><U+2763><U+2712><U+2730> <U+270E><U+2763><U+2763><U+2712><U+2763><U+2730><U+2730><U+270E><U+2763><U+2712> <U+2712><U+2763><U+2712><U+270E><U+270E><U+270E><U+270E><U+2763><U+2730><U+2712> <U+2763><U+270E><U+2763><U+270E><U+2712><U+270E><U+270E><U+2712><U+2730><U+270E> <U+2763><U+270E><U+2712><U+2712><U+2763><U+2730><U+2712><U+2712><U+270E><U+2712> <U+2730><U+2730><U+270E><U+2730><U+270E><U+2730><U+2730><U+270E><U+2730><U+2763>
              <U+271A><U+2721><U+2721>
              <U+270E><U+2763><U+2763><U+2712><U+2730><U+2763><U+270E><U+270E><U+2730><U+2763> <U+2763><U+2730><U+2730><U+2712><U+2712><U+2763><U+2763><U+2763>
              <U+271A><U+2720><U+2726>
              <U+2741><U+2714><U+2720><U+2721><U+261B>   <U+2720><U+2721>
              <U+2741><U+2714><U+2720><U+2720><U+261B>   <U+271A><U+2720><U+2726>
              <U+2741><U+2714><U+2720><U+2714><U+261B>   <U+2717><U+2704><U+2715>
              <U+2741><U+2714><U+2720><U+271A><U+261B>   <U+2715><U+270D><U+270E><U+272C><U+272F><U+272C><U+2730><U+272C><U+2712><U+2731> <U+2725><U+2605><U+2732><U+2733><U+2605><U+2729><U+2730><U+2605>
              <U+2741><U+2714><U+2714><U+2721><U+261B>
              <U+2741><U+2714><U+2714><U+271A><U+261B>   <U+2712><U+2729><U+270E><U+272C><U+2734><U+270C><U+2735><U+2713>
              <U+2741><U+2722><U+2721><U+2721><U+261B> <U+2720><U+2721>
              <U+2763><U+2712><U+2712><U+2712><U+270E><U+270E><U+2763><U+270E><U+2763><U+270E> <U+270E><U+2763><U+2712><U+2730><U+2712><U+2730><U+2712><U+2763><U+270E><U+2730> <U+270E><U+2730><U+2730><U+2712><U+2763><U+2730><U+2730><U+2712><U+2730><U+2730> <U+2730><U+270E><U+2763><U+270E><U+2730><U+270E><U+270E><U+270E><U+2763><U+270E> <U+2730><U+270E><U+2730><U+2730><U+2712><U+2763><U+2763><U+2763><U+2763><U+2712> <U+2712><U+2712><U+2763><U+2712><U+2763><U+2730><U+2730><U+2712><U+2730><U+2730>
              <U+2727><U+2721>
                                                  7

<removed-date>
              <U+2730><U+270E><U+2730><U+270E><U+2730><U+2730><U+270E><U+2763><U+2730><U+2712> <U+2712><U+2763><U+270E><U+2730><U+2730><U+2712><U+2763><U+270E><U+2730><U+2712> <U+2712><U+2712><U+2763><U+270E><U+2763><U+270E><U+270E><U+270E><U+270E><U+2712> <U+270E><U+2712><U+2730><U+2712><U+2763><U+270E><U+2763><U+2730><U+2712><U+2763> <U+270E><U+2763><U+2763><U+2712><U+2763><U+2712><U+2712><U+2763><U+2712><U+2712> <U+2730><U+270E><U+2712><U+2730><U+270E><U+270E><U+2763><U+2763><U+2730><U+2730>
              <U+2720><U+2714><U+2721>
              <U+270E><U+2763><U+2763><U+270E><U+2712><U+270E><U+2730><U+2712><U+2763><U+2730> <U+2712><U+2763><U+2712><U+2712><U+2712><U+2730><U+2730><U+2712><U+2763><U+2763> <U+2763><U+2712><U+2712><U+2712><U+2763><U+2730><U+270E><U+2730><U+2730><U+270E> <U+2712><U+2712><U+2763><U+2730><U+270E><U+2730><U+2730><U+270E><U+2763><U+2712> <U+270E><U+2730><U+270E><U+2712><U+270E><U+270E><U+2763><U+2763><U+2763><U+2730> <U+2712><U+270E><U+2730><U+2730><U+2712><U+2730><U+270E><U+2712><U+2763><U+2763>
              <U+2720><U+2726><U+2721>
              <U+2763><U+2712><U+2712><U+2712><U+2763><U+2763><U+2763><U+2763><U+2763><U+2763> <U+270E><U+2730><U+2730><U+2730><U+2730><U+270E><U+2730><U+2763><U+2712><U+2763> <U+2763><U+270E><U+270E><U+2730><U+2712><U+2763><U+270E><U+2763><U+2763><U+2730> <U+2712><U+2763><U+270E><U+2763><U+2763><U+2712><U+270E><U+2730><U+270E><U+2763> <U+2763><U+2763><U+2712><U+2730><U+2712><U+2763><U+2712><U+270E><U+270E><U+270E> <U+2730><U+2712><U+2730><U+2730><U+270E><U+270E><U+270E><U+2712><U+2730><U+2730>
              <U+2714><U+2722><U+2721>
<removed-apn>
              <U+2712><U+270E><U+2730><U+2712><U+2763><U+270E><U+2712><U+2763><U+2730><U+2730> <U+270E><U+2763><U+2763><U+2712><U+2712><U+2763><U+2730><U+270E><U+2763><U+2712> <U+2712><U+2763><U+2712><U+270E><U+2763><U+2730><U+270E><U+2763><U+2730><U+2712> <U+2712><U+2730><U+2712><U+270E><U+2712><U+270E><U+270E><U+2712><U+2730><U+270E> <U+2763><U+270E><U+2712><U+2712><U+2763><U+2730><U+2712><U+2712><U+270E><U+2712> <U+2730><U+2730><U+270E><U+2730><U+270E><U+2730><U+2730><U+270E><U+2730><U+2763>
              <U+271A><U+2721><U+2721>
              <U+270E><U+2763><U+2763><U+2712><U+2730><U+2763><U+270E><U+270E><U+2730><U+2763> <U+2763><U+2730><U+2730><U+2712><U+2712><U+2763><U+2763><U+2763>
              <U+271A><U+2720><U+2726>
              <U+2741><U+2714><U+2720><U+2721><U+261B>   <U+2720><U+2720>
              <U+2741><U+2714><U+2720><U+2720><U+261B>   <U+271A><U+2720><U+2726>
              <U+2741><U+2714><U+2720><U+2714><U+261B>   <U+2717><U+2704><U+2715>
              <U+2741><U+2714><U+2720><U+271A><U+261B>   <U+2715><U+270D><U+270E><U+272C><U+272F><U+272C><U+2730><U+272C><U+2712><U+2731> <U+2725><U+2605><U+2732><U+2733><U+2605><U+2729><U+2730><U+2605>
              <U+2741><U+2714><U+2714><U+2721><U+261B>
              <U+2741><U+2714><U+2714><U+271A><U+261B>   <U+2712><U+2729><U+270E><U+272C><U+2734><U+270C><U+2735><U+2713>
              <U+2741><U+2722><U+2721><U+2721><U+261B> <U+2720><U+2720>
              <U+2763><U+2712><U+2712><U+2712><U+270E><U+270E><U+2763><U+270E><U+2763><U+270E> <U+270E><U+2763><U+2712><U+2730><U+2712><U+2730><U+2712><U+2763><U+270E><U+2730> <U+270E><U+2730><U+2730><U+2712><U+2763><U+2730><U+2730><U+2712><U+2730><U+2730> <U+2730><U+270E><U+2763><U+270E><U+2730><U+270E><U+270E><U+270E><U+2763><U+270E> <U+2730><U+270E><U+2730><U+2730><U+2712><U+2763><U+2763><U+2763><U+2763><U+2712> <U+2712><U+2712><U+2763><U+2712><U+2763><U+2730><U+2730><U+2712><U+2730><U+2730>
              <U+2727><U+2721>
              <U+2730><U+270E><U+2730><U+270E><U+2730><U+2730><U+270E><U+2763><U+2730><U+2712> <U+2712><U+2763><U+270E><U+2730><U+2730><U+2712><U+2763><U+270E><U+2730><U+2712> <U+2712><U+2712><U+2763><U+270E><U+2763><U+270E><U+270E><U+270E><U+270E><U+2712> <U+270E><U+2712><U+2730><U+2712><U+2763><U+270E><U+2763><U+2730><U+2712><U+2763> <U+270E><U+2763><U+2763><U+2712><U+2763><U+2712><U+2712><U+2763><U+2712><U+2712> <U+2730><U+270E><U+2712><U+2730><U+270E><U+270E><U+2763><U+2763><U+2730><U+2730>
              <U+2720><U+2714><U+2721>
              <U+270E><U+2763><U+2763><U+270E><U+2712><U+270E><U+2730><U+2712><U+2763><U+2730> <U+2712><U+2763><U+2712><U+2712><U+2712><U+2730><U+2730><U+2712><U+2763><U+2763> <U+2763><U+2712><U+2712><U+2712><U+2763><U+2730><U+270E><U+2730><U+2730><U+270E> <U+2712><U+2712><U+2763><U+2730><U+270E><U+2730><U+2730><U+270E><U+2763><U+2712> <U+270E><U+2730><U+270E><U+2712><U+270E><U+270E><U+2763><U+2763><U+2763><U+2730> <U+2712><U+270E><U+2730><U+2730><U+2712><U+2730><U+270E><U+2712><U+2763><U+2763>
              <U+2720><U+2726><U+2721>
              <U+2763><U+2712><U+2712><U+2712><U+2763><U+2763><U+2763><U+2763><U+2763><U+2763> <U+270E><U+2730><U+2730><U+2730><U+2712><U+270E><U+2730><U+2712><U+2712><U+2763> <U+2763><U+270E><U+270E><U+2730><U+2712><U+2763><U+270E><U+2763><U+2763><U+2712> <U+2712><U+2763><U+270E><U+2763><U+2763><U+2712><U+270E><U+2730><U+270E><U+2763> <U+2763><U+2763><U+2712><U+2730><U+2712><U+2763><U+2712><U+270E><U+270E><U+270E> <U+270E><U+2712><U+2730><U+270E><U+270E><U+270E><U+2730><U+2712><U+2730><U+2730>
              <U+2714><U+2722><U+2721>
              <U+2712><U+270E><U+2730><U+2712><U+2763><U+2730><U+2712><U+2763><U+2730><U+2730> <U+270E><U+2763><U+2730><U+2712><U+2763><U+2730><U+2730><U+270E><U+2763><U+2712> <U+2712><U+2763><U+2712><U+270E><U+2712><U+270E><U+270E><U+2763><U+2730><U+2712> <U+2712><U+2730><U+2712><U+270E><U+2712><U+270E><U+270E><U+2712><U+2730><U+270E> <U+2763><U+270E><U+2712><U+2712><U+2763><U+2730><U+2712><U+2712><U+270E><U+2712> <U+2730><U+2730><U+270E><U+2730><U+270E><U+2730><U+2730><U+270E><U+2730><U+2763>
              <U+271A><U+2721><U+2721>
                                                  8

<removed-date>
              <U+270E><U+2763><U+2763><U+2712><U+2730><U+2763><U+270E><U+270E><U+2730><U+2763> <U+2763><U+2730><U+2730><U+2712><U+2712><U+2763><U+2763><U+2763>
              <U+271A><U+2720><U+2726>
              <U+2741><U+2714><U+2720><U+2721><U+261B>   <U+2720><U+2714>
              <U+2741><U+2714><U+2720><U+2720><U+261B>   <U+271A><U+2720><U+2726>
              <U+2741><U+2714><U+2720><U+2714><U+261B>   <U+2717><U+2704><U+2715>
              <U+2741><U+2714><U+2720><U+271A><U+261B>   <U+2715><U+270D><U+270E><U+272C><U+272F><U+272C><U+2730><U+272C><U+2712><U+2731> <U+2725><U+2605><U+2732><U+2733><U+2605><U+2729><U+2730><U+2605>
<removed-apn>
              <U+2741><U+2714><U+2714><U+2721><U+261B>
              <U+2741><U+2714><U+2714><U+271A><U+261B>   <U+2712><U+2729><U+270E><U+272C><U+2734><U+270C><U+2735><U+2713>
              <U+2741><U+2722><U+2721><U+2721><U+261B> <U+2720><U+2714>
              <U+2763><U+2712><U+2712><U+2712><U+270E><U+270E><U+2763><U+270E><U+2763><U+270E> <U+270E><U+2763><U+2712><U+2730><U+2712><U+2730><U+2712><U+2763><U+270E><U+2730> <U+270E><U+2730><U+2730><U+2712><U+2763><U+2730><U+2730><U+2712><U+2730><U+2730> <U+2730><U+270E><U+2763><U+270E><U+2730><U+270E><U+270E><U+270E><U+2763><U+270E> <U+2730><U+270E><U+2730><U+2730><U+2712><U+2763><U+2763><U+2763><U+2763><U+2712> <U+2712><U+2712><U+2763><U+2712><U+2763><U+2730><U+2730><U+2712><U+2730><U+2730>
              <U+2727><U+2721>
              <U+2730><U+270E><U+2730><U+270E><U+2730><U+2730><U+270E><U+2763><U+2730><U+2712> <U+2712><U+2763><U+270E><U+2730><U+2730><U+2712><U+2763><U+270E><U+2730><U+2712> <U+2712><U+2712><U+2763><U+270E><U+2763><U+270E><U+270E><U+270E><U+270E><U+2712> <U+270E><U+2712><U+2730><U+2712><U+2763><U+270E><U+2763><U+2730><U+2712><U+2763> <U+270E><U+2763><U+2763><U+2712><U+2763><U+2712><U+2712><U+2763><U+2712><U+2712> <U+2730><U+270E><U+2712><U+2730><U+270E><U+270E><U+2763><U+2763><U+2730><U+2730>
              <U+2720><U+2714><U+2721>
              <U+270E><U+2763><U+2763><U+270E><U+2712><U+2730><U+2730><U+2712><U+2763><U+2730> <U+2712><U+2763><U+2712><U+2712><U+2712><U+2730><U+2730><U+270E><U+2763><U+2763> <U+2730><U+2730><U+2712><U+2763><U+2763><U+2730><U+270E><U+2730><U+2730><U+2730> <U+2712><U+2763><U+2763><U+2730><U+270E><U+2730><U+2730><U+270E><U+2730><U+2712> <U+270E><U+2730><U+270E><U+2712><U+270E><U+270E><U+2763><U+2763><U+2763><U+2730> <U+2712><U+270E><U+2730><U+2730><U+2712><U+2730><U+270E><U+2712><U+2763><U+2763>
              <U+2720><U+2726><U+2721>
              <U+2763><U+2712><U+2712><U+2712><U+2763><U+2763><U+2763><U+2763><U+2763><U+2712> <U+270E><U+2730><U+2730><U+2730><U+2712><U+2763><U+2712><U+2730><U+2712><U+2763> <U+2763><U+270E><U+270E><U+2730><U+2712><U+2763><U+270E><U+2763><U+2763><U+2730> <U+2712><U+2763><U+270E><U+2763><U+2763><U+2763><U+270E><U+2730><U+270E><U+2763> <U+2763><U+2763><U+2712><U+2730><U+2712><U+2763><U+2712><U+2730><U+270E><U+270E> <U+2730><U+2712><U+2730><U+270E><U+2730><U+270E><U+2730><U+2712><U+2730><U+2730>
              <U+2714><U+2722><U+2721>
              <U+2712><U+270E><U+2730><U+2712><U+2763><U+2730><U+2712><U+2763><U+2712><U+2730> <U+270E><U+2763><U+2763><U+2712><U+2763><U+2730><U+2730><U+270E><U+2763><U+2712> <U+2712><U+2763><U+2712><U+270E><U+270E><U+270E><U+270E><U+2763><U+2730><U+2712> <U+2763><U+270E><U+2763><U+270E><U+2712><U+270E><U+270E><U+2712><U+2730><U+270E> <U+2763><U+270E><U+2712><U+2712><U+2763><U+2730><U+2712><U+2712><U+270E><U+2712> <U+2730><U+2730><U+270E><U+2730><U+270E><U+2730><U+2730><U+270E><U+2730><U+2763>
              <U+271A><U+2721><U+2721>
              <U+270E><U+2763><U+2763><U+2712><U+2730><U+2763><U+270E><U+270E><U+2730><U+2763> <U+2763><U+2730><U+2730><U+2712><U+2712><U+2763><U+2763><U+2763>
              <U+271A><U+2720><U+2726>
              <U+2741><U+2714><U+2720><U+2721><U+261B>   <U+2720><U+271A>
              <U+2741><U+2714><U+2720><U+2720><U+261B>   <U+271A><U+2720><U+2726>
              <U+2741><U+2714><U+2720><U+2714><U+261B>   <U+2717><U+2704><U+2715>
              <U+2741><U+2714><U+2720><U+271A><U+261B>   <U+2715><U+270D><U+270E><U+272C><U+272F><U+272C><U+2730><U+272C><U+2712><U+2731> <U+2725><U+2605><U+2732><U+2733><U+2605><U+2729><U+2730><U+2605>
              <U+2741><U+2714><U+2714><U+2721><U+261B>
              <U+2741><U+2714><U+2714><U+271A><U+261B>   <U+2712><U+2729><U+270E><U+272C><U+2734><U+270C><U+2735><U+2713>
                                                 9

<removed-date>
              <U+2741><U+2722><U+2721><U+2721><U+261B> <U+2720><U+271A>
              <U+2763><U+2712><U+2712><U+2712><U+270E><U+270E><U+2763><U+270E><U+2763><U+270E> <U+270E><U+2763><U+2712><U+2730><U+2712><U+2730><U+2712><U+2763><U+270E><U+2730> <U+270E><U+2730><U+2730><U+2712><U+2763><U+2730><U+2730><U+2712><U+2730><U+2730> <U+2730><U+270E><U+2763><U+270E><U+2730><U+270E><U+2763><U+270E><U+2763><U+270E> <U+2730><U+270E><U+2730><U+2730><U+2712><U+2763><U+2763><U+2763><U+2763><U+2712> <U+2712><U+2712><U+2763><U+2712><U+2763><U+2730><U+2730><U+2712><U+2730><U+2730>
              <U+2727><U+2721>
              <U+2730><U+270E><U+2730><U+270E><U+2730><U+2730><U+270E><U+2763><U+2730><U+2712> <U+2712><U+2763><U+270E><U+2730><U+2730><U+2712><U+2763><U+270E><U+2730><U+2712> <U+2712><U+2712><U+2763><U+270E><U+2763><U+270E><U+270E><U+270E><U+270E><U+2712> <U+270E><U+2712><U+2730><U+2712><U+2763><U+270E><U+2763><U+2730><U+2712><U+2763> <U+270E><U+2763><U+2763><U+2712><U+2763><U+2712><U+2712><U+2763><U+2712><U+2712> <U+2730><U+270E><U+2712><U+2730><U+270E><U+270E><U+2763><U+2763><U+2730><U+2730>
              <U+2720><U+2714><U+2721>
              <U+270E><U+2763><U+2763><U+270E><U+2712><U+2730><U+2730><U+2712><U+2763><U+2730> <U+2712><U+2763><U+2712><U+2712><U+2712><U+2730><U+2730><U+270E><U+2763><U+2763> <U+2730><U+2730><U+2712><U+2763><U+2763><U+2730><U+270E><U+2730><U+2730><U+2730> <U+2712><U+2763><U+2763><U+2730><U+270E><U+2730><U+2730><U+270E><U+2730><U+2712> <U+270E><U+2730><U+270E><U+2712><U+270E><U+270E><U+2763><U+2763><U+2763><U+2730> <U+2712><U+270E><U+2730><U+2730><U+2712><U+2730><U+270E><U+2712><U+2763><U+2763>
<removed-apn>
              <U+2720><U+2726><U+2721>
              <U+2763><U+2712><U+2712><U+2712><U+2763><U+2763><U+2763><U+2763><U+2763><U+2763> <U+270E><U+2730><U+2730><U+2730><U+2712><U+270E><U+2730><U+2712><U+2712><U+2763> <U+2763><U+270E><U+270E><U+2730><U+2712><U+2763><U+270E><U+2763><U+2763><U+2712> <U+2712><U+2763><U+270E><U+2763><U+2763><U+2712><U+270E><U+2730><U+270E><U+2763> <U+2763><U+2763><U+2712><U+2730><U+2712><U+2763><U+2712><U+270E><U+270E><U+270E> <U+270E><U+2712><U+2730><U+270E><U+270E><U+270E><U+2730><U+2712><U+2730><U+2730>
              <U+2714><U+2722><U+2721>
              <U+2712><U+270E><U+2730><U+2712><U+2763><U+2730><U+2712><U+2763><U+2730><U+2730> <U+270E><U+2763><U+2730><U+2712><U+2763><U+2730><U+2730><U+270E><U+2763><U+2712> <U+2712><U+2763><U+2712><U+270E><U+2712><U+270E><U+270E><U+2763><U+2730><U+2712> <U+2712><U+2730><U+2712><U+270E><U+2712><U+270E><U+270E><U+2712><U+2730><U+270E> <U+2763><U+270E><U+2712><U+2712><U+2763><U+2730><U+2712><U+2712><U+270E><U+2712> <U+2730><U+2730><U+270E><U+2730><U+270E><U+2730><U+2730><U+270E><U+2730><U+2763>
              <U+271A><U+2721><U+2721>
              <U+270E><U+2763><U+2763><U+2712><U+2730><U+2763><U+270E><U+270E><U+2730><U+2763> <U+2763><U+2730><U+2730><U+2712><U+2712><U+2763><U+2763><U+2763>
              <U+271A><U+2720><U+2726>
              <U+2741><U+2714><U+2720><U+2721><U+261B>   <U+2720><U+2722>
              <U+2741><U+2714><U+2720><U+2720><U+261B>   <U+271A><U+2720><U+2726>
              <U+2741><U+2714><U+2720><U+2714><U+261B>   <U+2717><U+2704><U+2715>
              <U+2741><U+2714><U+2720><U+271A><U+261B>   <U+2715><U+270D><U+270E><U+272C><U+272F><U+272C><U+2730><U+272C><U+2712><U+2731> <U+2725><U+2605><U+2732><U+2733><U+2605><U+2729><U+2730><U+2605>
              <U+2741><U+2714><U+2714><U+2721><U+261B>
              <U+2741><U+2714><U+2714><U+271A><U+261B>   <U+2712><U+2729><U+270E><U+272C><U+2734><U+270C><U+2735><U+2713>
              <U+2741><U+2722><U+2721><U+2721><U+261B> <U+2720><U+2722>
              <U+2763><U+2730><U+2730><U+2712><U+270E><U+2730><U+2730><U+2712><U+2763><U+270E> <U+270E><U+2763><U+2712><U+2730><U+2730><U+2730><U+2712><U+2763><U+270E><U+2730> <U+270E><U+2730><U+2730><U+2712><U+270E><U+2730><U+2730><U+270E><U+2730><U+2730> <U+2730><U+270E><U+2763><U+270E><U+2730><U+270E><U+2763><U+2730><U+2712><U+270E> <U+2730><U+270E><U+2763><U+270E><U+2712><U+2763><U+2763><U+2712><U+2763><U+2712> <U+2730><U+2712><U+2763><U+2712><U+2763><U+270E><U+2730><U+2712><U+2730><U+2730>
              <U+2727><U+2721>
              <U+2712><U+270E><U+2730><U+2712><U+2730><U+270E><U+270E><U+2763><U+2730><U+2712> <U+2712><U+2763><U+270E><U+2730><U+2730><U+2712><U+2763><U+270E><U+2730><U+2712> <U+2712><U+2712><U+2763><U+270E><U+2763><U+270E><U+270E><U+270E><U+270E><U+2712> <U+270E><U+2712><U+2730><U+2712><U+2763><U+270E><U+2763><U+2730><U+2712><U+2763> <U+270E><U+2763><U+2763><U+2712><U+2763><U+2712><U+2712><U+2763><U+2712><U+2712> <U+2730><U+270E><U+2712><U+2730><U+270E><U+270E><U+2763><U+2763><U+2730><U+2730>
              <U+2720><U+2714><U+2721>
              <U+270E><U+2763><U+2763><U+270E><U+2712><U+2730><U+2730><U+2712><U+2763><U+2730> <U+2712><U+2763><U+2712><U+2712><U+2712><U+2730><U+2730><U+270E><U+2763><U+2763> <U+2730><U+2730><U+2712><U+2763><U+2763><U+2730><U+270E><U+2730><U+2730><U+2730> <U+2712><U+2763><U+2763><U+2730><U+270E><U+2730><U+2730><U+270E><U+2730><U+2712> <U+270E><U+2730><U+270E><U+2712><U+270E><U+270E><U+2763><U+2763><U+2763><U+2730> <U+2712><U+270E><U+2730><U+2730><U+2712><U+2730><U+270E><U+2712><U+2763><U+2763>
              <U+2720><U+2726><U+2721>
                                                 10

              <U+2763><U+2712><U+2712><U+2712><U+2763><U+2763><U+2763><U+2763><U+2763><U+2763> <U+270E><U+2730><U+2730><U+2730><U+2712><U+270E><U+2730><U+2712><U+2712><U+2763> <U+2763><U+270E><U+270E><U+2730><U+2712><U+2763><U+2730><U+2763><U+2763><U+2730> <U+2712><U+2763><U+270E><U+2763><U+2763><U+2712><U+270E><U+2730><U+270E><U+2763> <U+2763><U+2763><U+2712><U+2730><U+2712><U+2763><U+2712><U+270E><U+270E><U+270E> <U+2730><U+2712><U+2730><U+270E><U+2730><U+270E><U+2730><U+2712><U+2730><U+2730>
<removed-date>
              <U+2714><U+2722><U+2721>
              <U+2712><U+270E><U+2730><U+2712><U+2763><U+2730><U+2712><U+2763><U+2730><U+2730> <U+270E><U+2763><U+2730><U+2712><U+2763><U+2730><U+2730><U+270E><U+2763><U+2712> <U+2712><U+2763><U+2712><U+270E><U+270E><U+270E><U+270E><U+2763><U+2730><U+2712> <U+2712><U+2730><U+270E><U+270E><U+2712><U+270E><U+270E><U+2712><U+2730><U+270E> <U+2763><U+270E><U+2712><U+2712><U+2763><U+2730><U+2712><U+2712><U+270E><U+2712> <U+2730><U+2730><U+270E><U+2730><U+270E><U+2730><U+2730><U+270E><U+2730><U+2763>
              <U+271A><U+2721><U+2721>
              <U+270E><U+2763><U+2763><U+2712><U+2730><U+2763><U+270E><U+270E><U+2730><U+2763> <U+2763><U+2730><U+2730><U+2712><U+2712><U+2763><U+2763><U+2763>
              <U+271A><U+2720><U+2726>
<removed-apn>
              <U+2741><U+2714><U+2720><U+2721><U+261B>   <U+2720><U+272E>
              <U+2741><U+2714><U+2720><U+2720><U+261B>   <U+271A><U+2720><U+2726>
              <U+2741><U+2714><U+2720><U+2714><U+261B>   <U+2717><U+2704><U+2715>
              <U+2741><U+2714><U+2720><U+271A><U+261B>   <U+2715><U+270D><U+270E><U+272C><U+272F><U+272C><U+2730><U+272C><U+2712><U+2731> <U+2725><U+2605><U+2732><U+2733><U+2605><U+2729><U+2730><U+2605>
              <U+2741><U+2714><U+2714><U+2721><U+261B>
              <U+2741><U+2714><U+2714><U+271A><U+261B>   <U+2712><U+2729><U+270E><U+272C><U+2734><U+270C><U+2735><U+2713>
              <U+2741><U+2722><U+2721><U+2721><U+261B> <U+2720><U+272E>
              <U+2763><U+2712><U+2712><U+2712><U+270E><U+270E><U+2763><U+270E><U+2763><U+270E> <U+270E><U+2763><U+2712><U+2730><U+2712><U+2730><U+2712><U+2763><U+270E><U+2730> <U+270E><U+2730><U+2730><U+2712><U+2763><U+2730><U+2730><U+2712><U+2730><U+2730> <U+2730><U+270E><U+2763><U+2763><U+2730><U+2730><U+270E><U+270E><U+2763><U+270E> <U+2730><U+2730><U+2730><U+2730><U+270E><U+2763><U+2763><U+2763><U+2763><U+2712> <U+2712><U+2712><U+2712><U+2712><U+2763><U+2730><U+2730><U+2730><U+2730><U+2730>
              <U+2727><U+2721>
              <U+2730><U+270E><U+2730><U+270E><U+2730><U+2730><U+270E><U+2763><U+2763><U+2712> <U+2712><U+2763><U+270E><U+2730><U+2730><U+2712><U+2763><U+270E><U+2730><U+2712> <U+2712><U+2712><U+2763><U+270E><U+2763><U+270E><U+270E><U+270E><U+270E><U+2712> <U+270E><U+2712><U+2730><U+2712><U+2763><U+270E><U+2763><U+2763><U+2712><U+2763> <U+270E><U+2763><U+2763><U+2712><U+2712><U+2712><U+2712><U+2763><U+2712><U+2712> <U+2730><U+270E><U+2712><U+2730><U+270E><U+270E><U+2763><U+2763><U+2730><U+2730>
              <U+2720><U+2714><U+2721>
              <U+270E><U+2763><U+2763><U+270E><U+2712><U+270E><U+2730><U+2712><U+2763><U+2730> <U+2712><U+2763><U+2712><U+2712><U+2712><U+2730><U+2730><U+2712><U+2763><U+2763> <U+2763><U+2712><U+2712><U+2712><U+2763><U+2730><U+270E><U+2730><U+2730><U+270E> <U+2712><U+2712><U+2763><U+2730><U+270E><U+2730><U+2730><U+270E><U+2763><U+2712> <U+270E><U+2730><U+270E><U+2712><U+270E><U+270E><U+2763><U+2763><U+2763><U+2730> <U+2712><U+270E><U+2730><U+2730><U+2712><U+2730><U+270E><U+2712><U+2763><U+2763>
              <U+2720><U+2726><U+2721>
              <U+2763><U+2712><U+2712><U+2712><U+2763><U+2763><U+2763><U+2763><U+2763><U+2763> <U+270E><U+2730><U+2730><U+2730><U+2730><U+270E><U+2730><U+2730><U+2712><U+2763> <U+2763><U+270E><U+270E><U+2730><U+2712><U+2763><U+270E><U+2763><U+2763><U+2730> <U+2712><U+2763><U+270E><U+2763><U+2763><U+2712><U+270E><U+2730><U+270E><U+2763> <U+2763><U+2763><U+2712><U+2730><U+2712><U+2763><U+2712><U+270E><U+270E><U+270E> <U+2730><U+2712><U+2730><U+270E><U+2730><U+270E><U+2730><U+2712><U+2730><U+2730>
              <U+2714><U+2722><U+2721>
              <U+2712><U+270E><U+2730><U+2712><U+2763><U+2730><U+2712><U+2763><U+2730><U+2730> <U+270E><U+2763><U+2730><U+2712><U+2712><U+2763><U+2730><U+270E><U+2763><U+2712> <U+2712><U+2763><U+2712><U+270E><U+270E><U+270E><U+270E><U+2763><U+2730><U+2712> <U+2712><U+2730><U+270E><U+270E><U+2712><U+270E><U+270E><U+2712><U+2730><U+270E> <U+2763><U+270E><U+2712><U+2712><U+2763><U+2730><U+2712><U+2712><U+270E><U+2712> <U+2730><U+2730><U+270E><U+2730><U+270E><U+2730><U+2730><U+270E><U+2730><U+2763>
              <U+271A><U+2721><U+2721>
              <U+270E><U+2763><U+2763><U+2712><U+2730><U+2763><U+270E><U+270E><U+2730><U+2763> <U+2763><U+2730><U+2730><U+2712><U+2712><U+2763><U+2763><U+2763>
              <U+271A><U+2720><U+2726>
              <U+2741><U+2714><U+2720><U+2721><U+261B>   <U+2720><U+2727>
              <U+2741><U+2714><U+2720><U+2720><U+261B>   <U+271A><U+2720><U+2726>
                                                 11

              <U+2741><U+2714><U+2720><U+2714><U+261B>   <U+2717><U+2704><U+2715>
<removed-date>
              <U+2741><U+2714><U+2720><U+271A><U+261B>   <U+2715><U+270D><U+270E><U+272C><U+272F><U+272C><U+2730><U+272C><U+2712><U+2731> <U+2725><U+2605><U+2732><U+2733><U+2605><U+2729><U+2730><U+2605>
              <U+2741><U+2714><U+2714><U+2721><U+261B>
              <U+2741><U+2714><U+2714><U+271A><U+261B>   <U+2712><U+2729><U+270E><U+272C><U+2734><U+270C><U+2735><U+2713>
              <U+2741><U+2722><U+2721><U+2721><U+261B> <U+2720><U+2727>
              <U+2763><U+2712><U+2712><U+2712><U+270E><U+270E><U+2763><U+270E><U+2763><U+270E> <U+270E><U+2763><U+2712><U+2730><U+2712><U+2730><U+2712><U+2763><U+270E><U+2730> <U+270E><U+2730><U+2730><U+2712><U+2763><U+2730><U+2730><U+2712><U+2730><U+2730> <U+2730><U+270E><U+2763><U+2763><U+2730><U+2730><U+270E><U+270E><U+2763><U+270E> <U+2730><U+2730><U+2730><U+2730><U+270E><U+2763><U+2763><U+2763><U+2763><U+2712> <U+2712><U+2712><U+2712><U+2712><U+2763><U+2730><U+2730><U+2730><U+2730><U+2730>
              <U+2727><U+2721>
<removed-apn>
              <U+2730><U+270E><U+2730><U+270E><U+2730><U+2730><U+270E><U+2763><U+2763><U+2712> <U+2712><U+2763><U+270E><U+2730><U+2730><U+2712><U+2763><U+270E><U+2730><U+2712> <U+2712><U+2712><U+2763><U+270E><U+2763><U+270E><U+270E><U+270E><U+270E><U+2712> <U+270E><U+2712><U+2730><U+2712><U+2763><U+270E><U+2763><U+2763><U+2712><U+2763> <U+270E><U+2763><U+2763><U+2712><U+2712><U+2712><U+2712><U+2763><U+2712><U+2712> <U+2730><U+270E><U+2712><U+2730><U+270E><U+270E><U+2763><U+2763><U+2730><U+2730>
              <U+2720><U+2714><U+2721>
              <U+270E><U+2763><U+2763><U+270E><U+2712><U+270E><U+2730><U+2712><U+2763><U+2730> <U+2712><U+2763><U+2712><U+2712><U+2712><U+2730><U+2730><U+2712><U+2763><U+2763> <U+2763><U+2712><U+2712><U+2712><U+2763><U+2730><U+270E><U+2730><U+2730><U+270E> <U+2712><U+2712><U+2763><U+2730><U+270E><U+2730><U+2730><U+270E><U+2763><U+2712> <U+270E><U+2730><U+270E><U+2712><U+270E><U+270E><U+2763><U+2763><U+2763><U+2730> <U+2712><U+270E><U+2730><U+2730><U+2712><U+2730><U+270E><U+2712><U+2763><U+2763>
              <U+2720><U+2726><U+2721>
              <U+2763><U+2712><U+2712><U+2712><U+2763><U+2763><U+2763><U+2763><U+2763><U+2763> <U+270E><U+2730><U+2730><U+2730><U+2730><U+270E><U+2730><U+2730><U+2712><U+2763> <U+2763><U+270E><U+270E><U+2730><U+2712><U+2763><U+270E><U+2763><U+2763><U+2730> <U+2712><U+2763><U+270E><U+2763><U+2763><U+2712><U+270E><U+2730><U+270E><U+2763> <U+2763><U+2763><U+2712><U+2730><U+2712><U+2763><U+2712><U+270E><U+270E><U+270E> <U+2730><U+2712><U+2730><U+270E><U+2730><U+270E><U+2730><U+2712><U+2730><U+2730>
              <U+2714><U+2722><U+2721>
              <U+2712><U+270E><U+2730><U+2712><U+2763><U+2730><U+2712><U+2763><U+2730><U+2730> <U+270E><U+2763><U+2730><U+2712><U+2712><U+2763><U+2730><U+270E><U+2763><U+2712> <U+2712><U+2763><U+2712><U+270E><U+270E><U+270E><U+270E><U+2763><U+2730><U+2712> <U+2712><U+2730><U+270E><U+270E><U+2712><U+270E><U+270E><U+2712><U+2730><U+270E> <U+2763><U+270E><U+2712><U+2712><U+2763><U+2730><U+2712><U+2712><U+270E><U+2712> <U+2730><U+2730><U+270E><U+2730><U+270E><U+2730><U+2730><U+270E><U+2730><U+2763>
              <U+271A><U+2721><U+2721>
              <U+270E><U+2763><U+2763><U+2712><U+2730><U+2763><U+270E><U+270E><U+2730><U+2763> <U+2763><U+2730><U+2730><U+2712><U+2712><U+2763><U+2763><U+2763>
              <U+271A><U+2720><U+2726>
              <U+2741><U+2714><U+2720><U+2721><U+261B>   <U+2720><U+271B>
              <U+2741><U+2714><U+2720><U+2720><U+261B>   <U+2720><U+2721><U+2727>
              <U+2741><U+2714><U+2720><U+2714><U+261B>   <U+2723><U+2741><U+271E>
              <U+2741><U+2714><U+2720><U+271A><U+261B>   <U+2715><U+270D><U+270E><U+272C><U+272F><U+272C><U+2730><U+272C><U+2712><U+2731> <U+2725><U+2605><U+2732><U+2733><U+2605><U+2729><U+2730><U+2605>
              <U+2741><U+2714><U+2714><U+2721><U+261B>
              <U+2741><U+2714><U+2714><U+271A><U+261B>   <U+2712><U+2729><U+270E><U+272C><U+2734><U+270C><U+2735><U+2713>
              <U+2741><U+2722><U+2721><U+2721><U+261B>   <U+2720><U+271B>
              <U+271F><U+2731><U+2733> <U+271D><U+2731><U+2605> <U+25CF><U+2712><U+2731> <U+2706><U+2605><U+2733> <U+271E><U+261E><U+270D> <U+271F><U+2731><U+2729> <U+2725><U+2605><U+270D> <U+2723><U+270D><U+270C> <U+2715><U+2731><U+2712> <U+271E><U+261E><U+270D> <U+2706><U+2605><U+2733> <U+2725><U+2605><U+270D> <U+2706><U+2605><U+2733> <U+2725><U+2605><U+270D> <U+2723><U+270D><U+270C> <U+271F><U+2731><U+2713>
              <U+2720>               <U+272E>                   <U+2720><U+2721>                  <U+2720><U+272E>
                                                 12

              <U+271F><U+2731><U+2733> <U+2715><U+270D><U+2763> <U+2715><U+2731><U+2712> <U+271E><U+261E><U+270D> <U+2706><U+2605><U+2733> <U+2725><U+2605><U+270D> <U+260E><U+2713><U+272B> <U+2706><U+2713><U+272B> <U+2725><U+2605><U+270D> <U+2725><U+2605><U+270D> <U+271F><U+2731><U+2729> <U+2725><U+2605><U+270D> <U+25CF><U+2712><U+2731> <U+2706><U+2605><U+2733> <U+271E><U+2713><U+270D> <U+2725><U+2605><U+270D>
<removed-date>
                          <U+2714><U+2721>                  <U+2714><U+272E>                  <U+271A><U+2721>
              <U+2715><U+2731><U+2712> <U+25CF><U+2712><U+2731> <U+271F><U+2731><U+2733> <U+2706><U+2713><U+272B> <U+2715><U+272B><U+2729> <U+271E><U+2713><U+270D> <U+2706><U+2605><U+2733> <U+2715><U+2731><U+2712> <U+271E><U+270D><U+2746> <U+271E><U+2713><U+270D> <U+271F><U+2731><U+2729> <U+271F><U+2731><U+2729> <U+2706><U+2713><U+272B> <U+2723><U+270D><U+270C> <U+271F><U+2731><U+2713> <U+2706><U+2713><U+272B>
                      <U+271A><U+272E>                  <U+2722><U+2721>                  <U+2722><U+272E>
              <U+2715><U+2731><U+2712> <U+2723><U+270D><U+270C> <U+2706><U+2713><U+272B> <U+2706><U+2605><U+2733> <U+2706><U+2605><U+2733> <U+271D><U+2731><U+2605> <U+271E><U+2713><U+270D> <U+271E><U+270D><U+2746> <U+2715><U+2731><U+2712> <U+2725><U+2605><U+270D> <U+271E><U+261E><U+270D> <U+2715><U+270D><U+2763> <U+271F><U+2731><U+2733> <U+2715><U+270D><U+2763> <U+271F><U+2731><U+2713> <U+25CF><U+2712><U+2731>
<removed-apn>
                  <U+272E><U+2721>                  <U+272E><U+272E>                  <U+2727><U+2721>
              <U+2723><U+270D><U+270C> <U+2725><U+2605><U+270D> <U+2715><U+270D><U+2763> <U+2723><U+261E><U+2605> <U+2725><U+2605><U+270D> <U+271F><U+2731><U+2713> <U+2725><U+2605><U+270D> <U+271F><U+2731><U+2713> <U+2725><U+2605><U+270D> <U+271F><U+2731><U+2713> <U+271E><U+261E><U+270D> <U+2715><U+272B><U+2746> <U+2723><U+261E><U+2605> <U+271E><U+261E><U+270D> <U+2723><U+261E><U+2605> <U+271E><U+261E><U+270D>
              <U+2727><U+272E>                  <U+271B><U+2721>                  <U+271B><U+272E>                  <U+2726><U+2721>
              <U+271D><U+2731><U+2605> <U+2725><U+2605><U+270D> <U+2725><U+2605><U+270D> <U+2706><U+2605><U+2733> <U+271F><U+2731><U+2729> <U+2723><U+270D><U+270C> <U+271F><U+2731><U+2733> <U+2715><U+272B><U+2746> <U+271D><U+2731><U+2605> <U+2715><U+2731><U+2712> <U+271E><U+261E><U+270D> <U+271E><U+2713><U+270D> <U+271E><U+2713><U+270D> <U+260E><U+2713><U+272B> <U+2706><U+2713><U+272B> <U+271F><U+2731><U+2729>
                              <U+2726><U+272E>                  <U+2741><U+2721>                  <U+2741><U+272E>
              <U+271E><U+2713><U+270D> <U+2706><U+2605><U+2733> <U+2725><U+2605><U+270D> <U+2725><U+2605><U+270D> <U+271E><U+270D><U+2746> <U+271E><U+261E><U+270D> <U+2723><U+261E><U+2605> <U+271F><U+2731><U+2713> <U+271F><U+2731><U+2729> <U+271F><U+2731><U+2713>
                          <U+2720><U+2721><U+2721>                 <U+2720><U+2721><U+272E>
              <U+2741><U+2714><U+2720><U+2721><U+261B>   <U+2720><U+2726>
              <U+2741><U+2714><U+2720><U+2720><U+261B>   <U+2720><U+2721><U+2727>
              <U+2741><U+2714><U+2720><U+2714><U+261B>   <U+2723><U+2741><U+271E>
              <U+2741><U+2714><U+2720><U+271A><U+261B>   <U+2715><U+270D><U+270E><U+272C><U+272F><U+272C><U+2730><U+272C><U+2712><U+2731> <U+2725><U+2605><U+2732><U+2733><U+2605><U+2729><U+2730><U+2605>
              <U+2741><U+2714><U+2714><U+2721><U+261B>
              <U+2741><U+2714><U+2714><U+271A><U+261B>    <U+271D><U+25CF><U+2706><U+271E><U+2701><U+2725><U+2723><U+2715><U+271E><U+2706><U+2725><U+2706><U+2725><U+2723><U+271F> <U+2741><U+2715><U+271E><U+2706><U+2725><U+260E><U+2741><U+2725><U+2725><U+2701><U+2725><U+25CF><U+2706> <U+2725><U+2715><U+25CF> <U+2741><U+2704> <U+2706><U+2715><U+271C> <U+2701><U+2701><U+2741><U+2723><U+271F><U+2701><U+2715><U+2723><U+2741><U+2706><U+2706><U+271D> <U+271C><U+2715><U+2725><U+271E><U+2741> <U+2741><U+271F><U+271D><U+2723>
                      <U+2717><U+2741><U+2725><U+2725><U+271F><U+2725><U+271F><U+2725><U+271F><U+271E><U+2717><U+2725><U+271E><U+2706><U+271E><U+271D><U+2725><U+2741><U+2706> <U+2723> <U+2717><U+2725><U+2715><U+25CF> <U+260E><U+2741><U+2701> <U+2706><U+2725><U+2725><U+271C><U+271E><U+2725><U+271F><U+2701><U+271F>
              <U+2741><U+2722><U+2721><U+2721><U+261B>   <U+2720><U+2726>
              <U+271F><U+2731><U+2733> <U+271D><U+2731><U+2605> <U+25CF><U+2712><U+2731> <U+2706><U+2605><U+2733> <U+271E><U+261E><U+270D> <U+271F><U+2731><U+2729> <U+2725><U+2605><U+270D> <U+2723><U+270D><U+270C> <U+2715><U+2731><U+2712> <U+271E><U+261E><U+270D> <U+2706><U+2605><U+2733> <U+2725><U+2605><U+270D> <U+2706><U+2605><U+2733> <U+2725><U+2605><U+270D> <U+2723><U+270D><U+270C> <U+271F><U+2731><U+2713>
              <U+2720>               <U+272E>                   <U+2720><U+2721>                  <U+2720><U+272E>
              <U+271F><U+2731><U+2733> <U+2715><U+270D><U+2763> <U+2715><U+2731><U+2712> <U+271E><U+261E><U+270D> <U+2706><U+2605><U+2733> <U+2725><U+2605><U+270D> <U+260E><U+2713><U+272B> <U+2706><U+2713><U+272B> <U+2725><U+2605><U+270D> <U+2725><U+2605><U+270D> <U+271F><U+2731><U+2729> <U+2725><U+2605><U+270D> <U+25CF><U+2712><U+2731> <U+2706><U+2605><U+2733> <U+271E><U+2713><U+270D> <U+2725><U+2605><U+270D>
                                                 13

                           <U+2714><U+2721>                 <U+2714><U+272E>                  <U+271A><U+2721>
<removed-date>
              <U+2715><U+2731><U+2712> <U+25CF><U+2712><U+2731> <U+271F><U+2731><U+2733> <U+2706><U+2713><U+272B> <U+2715><U+272B><U+2729> <U+271E><U+2713><U+270D> <U+2706><U+2605><U+2733> <U+2715><U+2731><U+2712> <U+271E><U+270D><U+2746> <U+271E><U+2713><U+270D> <U+271F><U+2731><U+2729> <U+271F><U+2731><U+2729> <U+2706><U+2713><U+272B> <U+2723><U+270D><U+270C> <U+271F><U+2731><U+2713> <U+271F><U+2731><U+2729>
                      <U+271A><U+272E>                  <U+2722><U+2721>                  <U+2722><U+272E>
              <U+2715><U+2731><U+2712> <U+2723><U+270D><U+270C> <U+2715><U+270D><U+2763> <U+2706><U+2605><U+2733> <U+2706><U+2605><U+2733> <U+271D><U+2731><U+2605> <U+271E><U+2713><U+270D> <U+271E><U+270D><U+2746> <U+2715><U+2731><U+2712> <U+2725><U+2605><U+270D> <U+271E><U+261E><U+270D> <U+2715><U+270D><U+2763> <U+271F><U+2731><U+2733> <U+2715><U+270D><U+2763> <U+271F><U+2731><U+2713> <U+271D><U+2731><U+2605>
                  <U+272E><U+2721>                  <U+272E><U+272E>                  <U+2727><U+2721>
<removed-apn>
              <U+2723><U+270D><U+270C> <U+2715><U+272B><U+2746> <U+2715><U+270D><U+2763> <U+2723><U+261E><U+2605> <U+2725><U+2605><U+270D> <U+271F><U+2731><U+2713> <U+2725><U+2605><U+270D> <U+271F><U+2731><U+2713> <U+2725><U+2605><U+270D> <U+271F><U+2731><U+2713> <U+271E><U+261E><U+270D> <U+2715><U+272B><U+2746> <U+2723><U+261E><U+2605> <U+271E><U+261E><U+270D> <U+2706><U+2605><U+2733> <U+271E><U+261E><U+270D>
              <U+2727><U+272E>                  <U+271B><U+2721>                  <U+271B><U+272E>                  <U+2726><U+2721>
              <U+271D><U+2731><U+2605> <U+2725><U+2605><U+270D> <U+2715><U+270D><U+2763> <U+2706><U+2605><U+2733> <U+271F><U+2731><U+2733> <U+2723><U+270D><U+270C> <U+271F><U+2731><U+2733> <U+2715><U+272B><U+2746> <U+2723><U+261E><U+2605> <U+2715><U+2731><U+2712> <U+25CF><U+2712><U+2731> <U+271E><U+2713><U+270D> <U+271E><U+2713><U+270D> <U+260E><U+2713><U+272B> <U+2706><U+2713><U+272B> <U+271F><U+2731><U+2729>
                              <U+2726><U+272E>                  <U+2741><U+2721>                  <U+2741><U+272E>
              <U+271E><U+2713><U+270D> <U+2706><U+2605><U+2733> <U+2725><U+2605><U+270D> <U+2725><U+2605><U+270D> <U+271E><U+270D><U+2746> <U+271E><U+261E><U+270D> <U+2723><U+261E><U+2605> <U+271F><U+2731><U+2713> <U+271F><U+2731><U+2729> <U+271F><U+2731><U+2713>
                          <U+2720><U+2721><U+2721>                 <U+2720><U+2721><U+272E>
              <U+2741><U+2714><U+2720><U+2721><U+261B>   <U+2720><U+2741>
              <U+2741><U+2714><U+2720><U+2720><U+261B>   <U+2720><U+2721><U+2727>
              <U+2741><U+2714><U+2720><U+2714><U+261B>   <U+2723><U+2741><U+271E>
              <U+2741><U+2714><U+2720><U+271A><U+261B>   <U+2715><U+270D><U+270E><U+272C><U+272F><U+272C><U+2730><U+272C><U+2712><U+2731> <U+2725><U+2605><U+2732><U+2733><U+2605><U+2729><U+2730><U+2605>
              <U+2741><U+2714><U+2714><U+2721><U+261B>
              <U+2741><U+2714><U+2714><U+271A><U+261B>   <U+2712><U+2729><U+270E><U+272C><U+2734><U+270C><U+2735><U+2713>
              <U+2741><U+2722><U+2721><U+2721><U+261B>   <U+2720><U+2741>
              <U+271F><U+2731><U+2733> <U+271D><U+2731><U+2605> <U+25CF><U+2712><U+2731> <U+2706><U+2605><U+2733> <U+271E><U+261E><U+270D> <U+271F><U+2731><U+2729> <U+2725><U+2605><U+270D> <U+2723><U+270D><U+270C> <U+2715><U+2731><U+2712> <U+271E><U+261E><U+270D> <U+2706><U+2605><U+2733> <U+2725><U+2605><U+270D> <U+2706><U+2605><U+2733> <U+2725><U+2605><U+270D> <U+2723><U+270D><U+270C> <U+271F><U+2731><U+2713>
              <U+2720>               <U+272E>                   <U+2720><U+2721>                  <U+2720><U+272E>
              <U+271F><U+2731><U+2733> <U+2715><U+270D><U+2763> <U+2715><U+2731><U+2712> <U+271E><U+261E><U+270D> <U+2706><U+2605><U+2733> <U+2725><U+2605><U+270D> <U+260E><U+2713><U+272B> <U+2706><U+2713><U+272B> <U+2725><U+2605><U+270D> <U+2725><U+2605><U+270D> <U+271F><U+2731><U+2729> <U+2725><U+2605><U+270D> <U+25CF><U+2712><U+2731> <U+2706><U+2605><U+2733> <U+271E><U+2713><U+270D> <U+2725><U+2605><U+270D>
                          <U+2714><U+2721>                  <U+2714><U+272E>                  <U+271A><U+2721>
                                                   14

<removed-date>
              <U+2715><U+2731><U+2712> <U+25CF><U+2712><U+2731> <U+271F><U+2731><U+2733> <U+2706><U+2713><U+272B> <U+2715><U+272B><U+2729> <U+271E><U+2713><U+270D> <U+2706><U+2605><U+2733> <U+2715><U+2731><U+2712> <U+271E><U+270D><U+2746> <U+271E><U+2713><U+270D> <U+271F><U+2731><U+2729> <U+271F><U+2731><U+2729> <U+2706><U+2713><U+272B> <U+2723><U+270D><U+270C> <U+271F><U+2731><U+2713> <U+271F><U+2731><U+2729>
                      <U+271A><U+272E>                  <U+2722><U+2721>                  <U+2722><U+272E>
              <U+2715><U+2731><U+2712> <U+2723><U+270D><U+270C> <U+2715><U+270D><U+2763> <U+2706><U+2605><U+2733> <U+2706><U+2605><U+2733> <U+271D><U+2731><U+2605> <U+271E><U+2713><U+270D> <U+271E><U+270D><U+2746> <U+2715><U+2731><U+2712> <U+2725><U+2605><U+270D> <U+271E><U+261E><U+270D> <U+2715><U+270D><U+2763> <U+271F><U+2731><U+2733> <U+2715><U+270D><U+2763> <U+271F><U+2731><U+2713> <U+271D><U+2731><U+2605>
                  <U+272E><U+2721>                  <U+272E><U+272E>                  <U+2727><U+2721>
<removed-apn>
              <U+2723><U+270D><U+270C> <U+2715><U+272B><U+2746> <U+2715><U+270D><U+2763> <U+2723><U+261E><U+2605> <U+2725><U+2605><U+270D> <U+271F><U+2731><U+2713> <U+2725><U+2605><U+270D> <U+271F><U+2731><U+2713> <U+2725><U+2605><U+270D> <U+271F><U+2731><U+2713> <U+271E><U+261E><U+270D> <U+2715><U+272B><U+2746> <U+2723><U+261E><U+2605> <U+271E><U+261E><U+270D> <U+2706><U+2605><U+2733> <U+271E><U+261E><U+270D>
              <U+2727><U+272E>                  <U+271B><U+2721>                  <U+271B><U+272E>                  <U+2726><U+2721>
              <U+271D><U+2731><U+2605> <U+2725><U+2605><U+270D> <U+2715><U+270D><U+2763> <U+2706><U+2605><U+2733> <U+271F><U+2731><U+2733> <U+2723><U+270D><U+270C> <U+271F><U+2731><U+2733> <U+2715><U+272B><U+2746> <U+2723><U+261E><U+2605> <U+2715><U+2731><U+2712> <U+25CF><U+2712><U+2731> <U+271E><U+2713><U+270D> <U+271E><U+2713><U+270D> <U+260E><U+2713><U+272B> <U+2706><U+2713><U+272B> <U+271F><U+2731><U+2729>
                              <U+2726><U+272E>                  <U+2741><U+2721>                  <U+2741><U+272E>
              <U+271E><U+2713><U+270D> <U+2706><U+2605><U+2733> <U+2725><U+2605><U+270D> <U+2725><U+2605><U+270D> <U+271E><U+270D><U+2746> <U+271E><U+261E><U+270D> <U+2723><U+261E><U+2605> <U+271F><U+2731><U+2713> <U+271F><U+2731><U+2729> <U+271F><U+2731><U+2713>
                          <U+2720><U+2721><U+2721>                 <U+2720><U+2721><U+272E>
              <U+2741><U+2714><U+2720><U+2721><U+261B>   <U+2714><U+2721>
              <U+2741><U+2714><U+2720><U+2720><U+261B>   <U+2720><U+2721><U+2727>
              <U+2741><U+2714><U+2720><U+2714><U+261B>   <U+2723><U+2741><U+271E>
              <U+2741><U+2714><U+2720><U+271A><U+261B>   <U+2715><U+270D><U+270E><U+272C><U+272F><U+272C><U+2730><U+272C><U+2712><U+2731> <U+2725><U+2605><U+2732><U+2733><U+2605><U+2729><U+2730><U+2605>
              <U+2741><U+2714><U+2714><U+2721><U+261B>
              <U+2741><U+2714><U+2714><U+271A><U+261B>   <U+2712><U+2729><U+270E><U+272C><U+2734><U+270C><U+2735><U+2713>
              <U+2741><U+2722><U+2721><U+2721><U+261B>   <U+2714><U+2721>
              <U+271F><U+2731><U+2733> <U+271D><U+2731><U+2605> <U+25CF><U+2712><U+2731> <U+2706><U+2605><U+2733> <U+271E><U+261E><U+270D> <U+271F><U+2731><U+2729> <U+2725><U+2605><U+270D> <U+2723><U+270D><U+270C> <U+2715><U+2731><U+2712> <U+271E><U+261E><U+270D> <U+2706><U+2605><U+2733> <U+2725><U+2605><U+270D> <U+2706><U+2605><U+2733> <U+2725><U+2605><U+270D> <U+2723><U+270D><U+270C> <U+271F><U+2731><U+2713>
              <U+2720>               <U+272E>                   <U+2720><U+2721>                  <U+2720><U+272E>
              <U+271F><U+2731><U+2733> <U+2715><U+270D><U+2763> <U+2715><U+2731><U+2712> <U+271E><U+261E><U+270D> <U+2706><U+2605><U+2733> <U+2725><U+2605><U+270D> <U+260E><U+2713><U+272B> <U+2706><U+2713><U+272B> <U+2725><U+2605><U+270D> <U+2725><U+2605><U+270D> <U+271F><U+2731><U+2729> <U+2725><U+2605><U+270D> <U+25CF><U+2712><U+2731> <U+2706><U+2605><U+2733> <U+271E><U+2713><U+270D> <U+2725><U+2605><U+270D>
                          <U+2714><U+2721>                  <U+2714><U+272E>                  <U+271A><U+2721>
              <U+2715><U+2731><U+2712> <U+25CF><U+2712><U+2731> <U+271F><U+2731><U+2733> <U+2706><U+2713><U+272B> <U+2715><U+272B><U+2729> <U+271E><U+2713><U+270D> <U+2706><U+2605><U+2733> <U+2715><U+2731><U+2712> <U+271E><U+270D><U+2746> <U+271E><U+2713><U+270D> <U+271F><U+2731><U+2729> <U+271F><U+2731><U+2729> <U+2706><U+2713><U+272B> <U+2723><U+270D><U+270C> <U+271F><U+2731><U+2713> <U+271F><U+2731><U+2729>
                                                 15

                      <U+271A><U+272E>                    <U+2722><U+2721>               <U+2722><U+272E>
<removed-date>
              <U+2715><U+2731><U+2712> <U+2723><U+270D><U+270C> <U+2715><U+270D><U+2763> <U+2706><U+2605><U+2733> <U+2706><U+2605><U+2733> <U+271D><U+2731><U+2605> <U+271E><U+2713><U+270D> <U+271E><U+270D><U+2746> <U+2715><U+2731><U+2712> <U+2725><U+2605><U+270D> <U+271E><U+261E><U+270D> <U+2715><U+270D><U+2763> <U+271F><U+2731><U+2733> <U+2715><U+270D><U+2763> <U+271F><U+2731><U+2713> <U+271D><U+2731><U+2605>
                  <U+272E><U+2721>                  <U+272E><U+272E>                  <U+2727><U+2721>
              <U+2723><U+270D><U+270C> <U+2715><U+272B><U+2746> <U+2715><U+270D><U+2763> <U+2723><U+261E><U+2605> <U+2725><U+2605><U+270D> <U+271F><U+2731><U+2713> <U+2725><U+2605><U+270D> <U+271F><U+2731><U+2713> <U+2725><U+2605><U+270D> <U+271F><U+2731><U+2713> <U+271E><U+261E><U+270D> <U+2715><U+272B><U+2746> <U+2723><U+261E><U+2605> <U+271E><U+261E><U+270D> <U+2706><U+2605><U+2733> <U+271E><U+261E><U+270D>
              <U+2727><U+272E>                  <U+271B><U+2721>                  <U+271B><U+272E>                  <U+2726><U+2721>
<removed-apn>
              <U+271D><U+2731><U+2605> <U+2725><U+2605><U+270D> <U+2715><U+270D><U+2763> <U+2706><U+2605><U+2733> <U+271F><U+2731><U+2733> <U+2723><U+270D><U+270C> <U+271F><U+2731><U+2733> <U+2715><U+272B><U+2746> <U+2723><U+261E><U+2605> <U+2715><U+2731><U+2712> <U+25CF><U+2712><U+2731> <U+271E><U+2713><U+270D> <U+271E><U+2713><U+270D> <U+260E><U+2713><U+272B> <U+2706><U+2713><U+272B> <U+271F><U+2731><U+2729>
                              <U+2726><U+272E>                  <U+2741><U+2721>                  <U+2741><U+272E>
              <U+271E><U+2713><U+270D> <U+2706><U+2605><U+2733> <U+2725><U+2605><U+270D> <U+2725><U+2605><U+270D> <U+271E><U+270D><U+2746> <U+271E><U+261E><U+270D> <U+2723><U+261E><U+2605> <U+271F><U+2731><U+2713> <U+271F><U+2731><U+2729> <U+271F><U+2731><U+2713>
                          <U+2720><U+2721><U+2721>                 <U+2720><U+2721><U+272E>
              <U+2741><U+2714><U+2720><U+2721><U+261B>   <U+2714><U+2720>
              <U+2741><U+2714><U+2720><U+2720><U+261B>   <U+2720><U+2721><U+2727>
              <U+2741><U+2714><U+2720><U+2714><U+261B>   <U+2723><U+2741><U+271E>
              <U+2741><U+2714><U+2720><U+271A><U+261B>   <U+2715><U+270D><U+270E><U+272C><U+272F><U+272C><U+2730><U+272C><U+2712><U+2731> <U+2725><U+2605><U+2732><U+2733><U+2605><U+2729><U+2730><U+2605>
              <U+2741><U+2714><U+2714><U+2721><U+261B>
              <U+2741><U+2714><U+2714><U+271A><U+261B>   <U+2712><U+2729><U+270E><U+272C><U+2734><U+270C><U+2735><U+2713>
              <U+2741><U+2722><U+2721><U+2721><U+261B>   <U+2714><U+2720>
              <U+271F><U+2731><U+2733> <U+271D><U+2731><U+2605> <U+25CF><U+2712><U+2731> <U+2706><U+2605><U+2733> <U+271E><U+261E><U+270D> <U+271F><U+2731><U+2729> <U+2725><U+2605><U+270D> <U+2723><U+270D><U+270C> <U+2715><U+2731><U+2712> <U+271E><U+261E><U+270D> <U+2706><U+2605><U+2733> <U+2725><U+2605><U+270D> <U+2706><U+2605><U+2733> <U+2725><U+2605><U+270D> <U+2723><U+270D><U+270C> <U+271F><U+2731><U+2713>
              <U+2720>               <U+272E>                   <U+2720><U+2721>                  <U+2720><U+272E>
              <U+271F><U+2731><U+2733> <U+2715><U+270D><U+2763> <U+2715><U+2731><U+2712> <U+271E><U+261E><U+270D> <U+2706><U+2605><U+2733> <U+2725><U+2605><U+270D> <U+260E><U+2713><U+272B> <U+2706><U+2713><U+272B> <U+2725><U+2605><U+270D> <U+2725><U+2605><U+270D> <U+271F><U+2731><U+2729> <U+2725><U+2605><U+270D> <U+25CF><U+2712><U+2731> <U+2706><U+2605><U+2733> <U+271E><U+2713><U+270D> <U+2725><U+2605><U+270D>
                          <U+2714><U+2721>                  <U+2714><U+272E>                  <U+271A><U+2721>
              <U+2715><U+2731><U+2712> <U+25CF><U+2712><U+2731> <U+271F><U+2731><U+2733> <U+2706><U+2713><U+272B> <U+2715><U+272B><U+2729> <U+271E><U+2713><U+270D> <U+2706><U+2605><U+2733> <U+2715><U+2731><U+2712> <U+271E><U+270D><U+2746> <U+271E><U+2713><U+270D> <U+271F><U+2731><U+2729> <U+271F><U+2731><U+2729> <U+2706><U+2713><U+272B> <U+2723><U+270D><U+270C> <U+271F><U+2731><U+2713> <U+2706><U+2713><U+272B>
                      <U+271A><U+272E>                  <U+2722><U+2721>                  <U+2722><U+272E>
                                                 16

<removed-date>
              <U+2715><U+2731><U+2712> <U+2723><U+270D><U+270C> <U+2706><U+2713><U+272B> <U+2706><U+2605><U+2733> <U+2706><U+2605><U+2733> <U+271D><U+2731><U+2605> <U+271E><U+2713><U+270D> <U+271E><U+270D><U+2746> <U+2715><U+2731><U+2712> <U+2725><U+2605><U+270D> <U+271E><U+261E><U+270D> <U+2715><U+270D><U+2763> <U+271F><U+2731><U+2733> <U+2715><U+270D><U+2763> <U+271F><U+2731><U+2713> <U+271D><U+2731><U+2605>
                  <U+272E><U+2721>                  <U+272E><U+272E>                  <U+2727><U+2721>
              <U+2723><U+270D><U+270C> <U+2715><U+272B><U+2746> <U+2715><U+270D><U+2763> <U+2723><U+261E><U+2605> <U+2725><U+2605><U+270D> <U+271F><U+2731><U+2713> <U+2725><U+2605><U+270D> <U+271F><U+2731><U+2713> <U+2725><U+2605><U+270D> <U+271F><U+2731><U+2713> <U+271E><U+261E><U+270D> <U+2715><U+272B><U+2746> <U+2723><U+261E><U+2605> <U+271E><U+261E><U+270D> <U+2706><U+2605><U+2733> <U+271E><U+261E><U+270D>
              <U+2727><U+272E>                  <U+271B><U+2721>                  <U+271B><U+272E>                  <U+2726><U+2721>
<removed-apn>
              <U+271D><U+2731><U+2605> <U+2725><U+2605><U+270D> <U+2715><U+270D><U+2763> <U+2706><U+2605><U+2733> <U+271F><U+2731><U+2733> <U+2723><U+270D><U+270C> <U+271F><U+2731><U+2733> <U+2715><U+272B><U+2746> <U+2723><U+261E><U+2605> <U+2715><U+2731><U+2712> <U+25CF><U+2712><U+2731> <U+271E><U+2713><U+270D> <U+271E><U+2713><U+270D> <U+260E><U+2713><U+272B> <U+2706><U+2713><U+272B> <U+271F><U+2731><U+2729>
                              <U+2726><U+272E>                  <U+2741><U+2721>                  <U+2741><U+272E>
              <U+271E><U+2713><U+270D> <U+2706><U+2605><U+2733> <U+2725><U+2605><U+270D> <U+2725><U+2605><U+270D> <U+271E><U+270D><U+2746> <U+271E><U+261E><U+270D> <U+2723><U+261E><U+2605> <U+271F><U+2731><U+2713> <U+271F><U+2731><U+2729> <U+271F><U+2731><U+2713>
                          <U+2720><U+2721><U+2721>                 <U+2720><U+2721><U+272E>
              <U+2741><U+2714><U+2720><U+2721><U+261B>   <U+2714><U+2714>
              <U+2741><U+2714><U+2720><U+2720><U+261B>   <U+2720><U+2721><U+2727>
              <U+2741><U+2714><U+2720><U+2714><U+261B>   <U+2723><U+2741><U+271E>
              <U+2741><U+2714><U+2720><U+271A><U+261B>   <U+2715><U+270D><U+270E><U+272C><U+272F><U+272C><U+2730><U+272C><U+2712><U+2731> <U+2725><U+2605><U+2732><U+2733><U+2605><U+2729><U+2730><U+2605>
              <U+2741><U+2714><U+2714><U+2721><U+261B>
              <U+2741><U+2714><U+2714><U+271A><U+261B>   <U+2712><U+2729><U+270E><U+272C><U+2734><U+270C><U+2735><U+2713>
              <U+2741><U+2722><U+2721><U+2721><U+261B>   <U+2714><U+2714>
              <U+2715><U+2731><U+2712> <U+271D><U+2731><U+2605> <U+271F><U+2731><U+2729> <U+2706><U+2605><U+2733> <U+271E><U+261E><U+270D> <U+271F><U+2731><U+2729> <U+2725><U+2605><U+270D> <U+2723><U+270D><U+270C> <U+2725><U+2605><U+270D> <U+2725><U+2605><U+270D> <U+2706><U+2605><U+2733> <U+2725><U+2605><U+270D> <U+2715><U+2731><U+2712> <U+2725><U+2605><U+270D> <U+25CF><U+2712><U+2731> <U+271F><U+2731><U+2713>
              <U+2720>               <U+272E>                   <U+2720><U+2721>                  <U+2720><U+272E>
              <U+2715><U+272B><U+2746> <U+2715><U+270D><U+2763> <U+25CF><U+2712><U+2731> <U+271E><U+261E><U+270D> <U+271D><U+2731><U+2605> <U+271E><U+261E><U+270D> <U+260E><U+2713><U+272B> <U+2706><U+2713><U+272B> <U+2725><U+2605><U+270D> <U+2725><U+2605><U+270D> <U+271F><U+2731><U+2729> <U+2725><U+2605><U+270D> <U+25CF><U+2712><U+2731> <U+2706><U+2605><U+2733> <U+271E><U+2713><U+270D> <U+2725><U+2605><U+270D>
                          <U+2714><U+2721>                  <U+2714><U+272E>                  <U+271A><U+2721>
              <U+2715><U+2731><U+2712> <U+25CF><U+2712><U+2731> <U+271F><U+2731><U+2733> <U+2706><U+2713><U+272B> <U+2715><U+272B><U+2729> <U+271E><U+2713><U+270D> <U+2706><U+2605><U+2733> <U+2715><U+2731><U+2712> <U+271E><U+270D><U+2746> <U+271E><U+2713><U+270D> <U+271F><U+2731><U+2729> <U+271F><U+2731><U+2729> <U+2706><U+2713><U+272B> <U+2723><U+270D><U+270C> <U+271F><U+2731><U+2713> <U+271F><U+2731><U+2729>
                      <U+271A><U+272E>                  <U+2722><U+2721>                  <U+2722><U+272E>
              <U+2715><U+2731><U+2712> <U+2723><U+270D><U+270C> <U+2715><U+270D><U+2763> <U+2706><U+2605><U+2733> <U+2706><U+2605><U+2733> <U+271D><U+2731><U+2605> <U+271E><U+2713><U+270D> <U+271E><U+270D><U+2746> <U+2715><U+2731><U+2712> <U+2725><U+2605><U+270D> <U+271E><U+261E><U+270D> <U+2715><U+270D><U+2763> <U+271F><U+2731><U+2733> <U+2715><U+270D><U+2763> <U+271F><U+2731><U+2713> <U+25CF><U+2712><U+2731>
                                                 17

                  <U+272E><U+2721>                    <U+272E><U+272E>                <U+2727><U+2721>
<removed-date>
              <U+2723><U+270D><U+270C> <U+2725><U+2605><U+270D> <U+2715><U+270D><U+2763> <U+2723><U+261E><U+2605> <U+2725><U+2605><U+270D> <U+271F><U+2731><U+2713> <U+2725><U+2605><U+270D> <U+271F><U+2731><U+2713> <U+2725><U+2605><U+270D> <U+271F><U+2731><U+2713> <U+271E><U+261E><U+270D> <U+2715><U+272B><U+2746> <U+2723><U+261E><U+2605> <U+271E><U+261E><U+270D> <U+2706><U+2605><U+2733> <U+271E><U+261E><U+270D>
              <U+2727><U+272E>                  <U+271B><U+2721>                  <U+271B><U+272E>                  <U+2726><U+2721>
              <U+271D><U+2731><U+2605> <U+2725><U+2605><U+270D> <U+2725><U+2605><U+270D> <U+2706><U+2605><U+2733> <U+271F><U+2731><U+2729> <U+2723><U+270D><U+270C> <U+271F><U+2731><U+2733> <U+2715><U+272B><U+2746> <U+2723><U+261E><U+2605> <U+2715><U+2731><U+2712> <U+271E><U+261E><U+270D> <U+271E><U+2713><U+270D> <U+271E><U+2713><U+270D> <U+260E><U+2713><U+272B> <U+2706><U+2713><U+272B> <U+271F><U+2731><U+2729>
                              <U+2726><U+272E>                  <U+2741><U+2721>                  <U+2741><U+272E>
<removed-apn>
              <U+271E><U+2713><U+270D> <U+2706><U+2605><U+2733> <U+2725><U+2605><U+270D> <U+2725><U+2605><U+270D> <U+271E><U+270D><U+2746> <U+271E><U+261E><U+270D> <U+2723><U+261E><U+2605> <U+271F><U+2731><U+2713> <U+271F><U+2731><U+2729> <U+271F><U+2731><U+2713>
                          <U+2720><U+2721><U+2721>                 <U+2720><U+2721><U+272E>
              <U+2741><U+2714><U+2720><U+2721><U+261B>    <U+2714><U+271A>
              <U+2741><U+2714><U+2720><U+2720><U+261B>    <U+2720><U+2721><U+2727>
              <U+2741><U+2714><U+2720><U+2714><U+261B>    <U+2723><U+2741><U+271E>
              <U+2741><U+2714><U+2720><U+271A><U+261B>    <U+2715><U+270D><U+270E><U+272C><U+272F><U+272C><U+2730><U+272C><U+2712><U+2731> <U+2725><U+2605><U+2732><U+2733><U+2605><U+2729><U+2730><U+2605>
              <U+2741><U+2714><U+2714><U+2721><U+261B>
              <U+2741><U+2714><U+2714><U+271A><U+261B>    <U+2712><U+2729><U+270E><U+272C><U+2734><U+270C><U+2735><U+2713>
              <U+2741><U+2722><U+2721><U+2721><U+261B>    <U+2714><U+271A>
              <U+2715><U+272B><U+2746> <U+271D><U+2731><U+2605> <U+271F><U+2731><U+2729> <U+2746><U+2605><U+270E> <U+271E><U+261E><U+270D> <U+271F><U+2731><U+2729> <U+2725><U+2605><U+270D> <U+2723><U+270D><U+270C> <U+2725><U+2605><U+270D> <U+2725><U+2605><U+270D> <U+2706><U+2605><U+2733> <U+2725><U+2605><U+270D> <U+2715><U+2731><U+2712> <U+2725><U+2605><U+270D> <U+25CF><U+2712><U+2731> <U+271F><U+2731><U+2713>
              <U+2720>               <U+272E>                   <U+2720><U+2721>                  <U+2720><U+272E>
              <U+2715><U+272B><U+2746> <U+2715><U+270D><U+2763> <U+25CF><U+2712><U+2731> <U+271E><U+261E><U+270D> <U+271D><U+2731><U+2605> <U+271E><U+261E><U+270D> <U+260E><U+2713><U+272B> <U+2706><U+2713><U+272B> <U+2725><U+2605><U+270D> <U+2725><U+2605><U+270D> <U+271F><U+2731><U+2729> <U+2725><U+2605><U+270D> <U+25CF><U+2712><U+2731> <U+2706><U+2605><U+2733> <U+271E><U+2713><U+270D> <U+2725><U+2605><U+270D>
                          <U+2714><U+2721>                  <U+2714><U+272E>                  <U+271A><U+2721>
              <U+2715><U+2731><U+2712> <U+25CF><U+2712><U+2731> <U+271F><U+2731><U+2733> <U+2706><U+2713><U+272B> <U+2715><U+272B><U+2729> <U+271E><U+2713><U+270D> <U+2706><U+2605><U+2733> <U+2715><U+2731><U+2712> <U+271E><U+270D><U+2746> <U+271E><U+2713><U+270D> <U+271F><U+2731><U+2729> <U+271F><U+2731><U+2729> <U+2706><U+2713><U+272B> <U+2723><U+270D><U+270C> <U+271F><U+2731><U+2713> <U+2706><U+2713><U+272B>
                      <U+271A><U+272E>                  <U+2722><U+2721>                  <U+2722><U+272E>
              <U+2715><U+2731><U+2712> <U+2723><U+270D><U+270C> <U+2706><U+2713><U+272B> <U+2706><U+2605><U+2733> <U+2706><U+2605><U+2733> <U+271D><U+2731><U+2605> <U+271E><U+2713><U+270D> <U+271E><U+270D><U+2746> <U+2715><U+2731><U+2712> <U+2725><U+2605><U+270D> <U+271E><U+261E><U+270D> <U+2715><U+270D><U+2763> <U+271F><U+2731><U+2733> <U+2715><U+270D><U+2763> <U+271F><U+2731><U+2713> <U+271D><U+2731><U+2605>
                  <U+272E><U+2721>                  <U+272E><U+272E>                  <U+2727><U+2721>
                                                 18

<removed-date>
              <U+2723><U+270D><U+270C> <U+2715><U+272B><U+2746> <U+2715><U+270D><U+2763> <U+2723><U+261E><U+2605> <U+2725><U+2605><U+270D> <U+271F><U+2731><U+2713> <U+2725><U+2605><U+270D> <U+271F><U+2731><U+2713> <U+2725><U+2605><U+270D> <U+271F><U+2731><U+2713> <U+271E><U+261E><U+270D> <U+2715><U+272B><U+2746> <U+2723><U+261E><U+2605> <U+271E><U+261E><U+270D> <U+2706><U+2605><U+2733> <U+271E><U+261E><U+270D>
              <U+2727><U+272E>                  <U+271B><U+2721>                  <U+271B><U+272E>                  <U+2726><U+2721>
              <U+271D><U+2731><U+2605> <U+2725><U+2605><U+270D> <U+2715><U+270D><U+2763> <U+2706><U+2605><U+2733> <U+271F><U+2731><U+2733> <U+2723><U+270D><U+270C> <U+271F><U+2731><U+2733> <U+2715><U+272B><U+2746> <U+2723><U+261E><U+2605> <U+2715><U+2731><U+2712> <U+25CF><U+2712><U+2731> <U+271E><U+2713><U+270D> <U+271E><U+2713><U+270D> <U+260E><U+2713><U+272B> <U+2706><U+2713><U+272B> <U+271F><U+2731><U+2729>
                              <U+2726><U+272E>                  <U+2741><U+2721>                  <U+2741><U+272E>
<removed-apn>
              <U+271E><U+2713><U+270D> <U+2706><U+2605><U+2733> <U+2725><U+2605><U+270D> <U+2725><U+2605><U+270D> <U+271E><U+270D><U+2746> <U+271E><U+261E><U+270D> <U+2723><U+261E><U+2605> <U+271F><U+2731><U+2713> <U+271F><U+2731><U+2729> <U+271F><U+2731><U+2713>
                          <U+2720><U+2721><U+2721>                 <U+2720><U+2721><U+272E>
              <U+2741><U+2714><U+2720><U+2721><U+261B>   <U+2714><U+2722>
              <U+2741><U+2714><U+2720><U+2720><U+261B>   <U+2720><U+2721><U+2727>
              <U+2741><U+2714><U+2720><U+2714><U+261B>   <U+2723><U+2741><U+271E>
              <U+2741><U+2714><U+2720><U+271A><U+261B>   <U+2715><U+270D><U+270E><U+272C><U+272F><U+272C><U+2730><U+272C><U+2712><U+2731> <U+2725><U+2605><U+2732><U+2733><U+2605><U+2729><U+2730><U+2605>
              <U+2741><U+2714><U+2714><U+2721><U+261B>
              <U+2741><U+2714><U+2714><U+271A><U+261B>   <U+2712><U+2729><U+270E><U+272C><U+2734><U+270C><U+2735><U+2713>
              <U+2741><U+2722><U+2721><U+2721><U+261B>   <U+2714><U+2722>
              <U+2715><U+2731><U+2712> <U+271D><U+2731><U+2605> <U+271F><U+2731><U+2729> <U+2706><U+2605><U+2733> <U+271E><U+261E><U+270D> <U+271F><U+2731><U+2729> <U+2725><U+2605><U+270D> <U+2723><U+270D><U+270C> <U+2725><U+2605><U+270D> <U+2725><U+2605><U+270D> <U+2706><U+2605><U+2733> <U+2725><U+2605><U+270D> <U+2715><U+2731><U+2712> <U+2725><U+2605><U+270D> <U+25CF><U+2712><U+2731> <U+271F><U+2731><U+2713>
              <U+2720>               <U+272E>                   <U+2720><U+2721>                  <U+2720><U+272E>
              <U+2715><U+272B><U+2746> <U+2715><U+270D><U+2763> <U+25CF><U+2712><U+2731> <U+271E><U+261E><U+270D> <U+271D><U+2731><U+2605> <U+271E><U+261E><U+270D> <U+260E><U+2713><U+272B> <U+2706><U+2713><U+272B> <U+2725><U+2605><U+270D> <U+2725><U+2605><U+270D> <U+271F><U+2731><U+2729> <U+2725><U+2605><U+270D> <U+25CF><U+2712><U+2731> <U+2706><U+2605><U+2733> <U+271E><U+2713><U+270D> <U+2725><U+2605><U+270D>
                          <U+2714><U+2721>                  <U+2714><U+272E>                  <U+271A><U+2721>
              <U+2715><U+2731><U+2712> <U+25CF><U+2712><U+2731> <U+271F><U+2731><U+2733> <U+2706><U+2713><U+272B> <U+2715><U+272B><U+2729> <U+271E><U+2713><U+270D> <U+2706><U+2605><U+2733> <U+2715><U+2731><U+2712> <U+271E><U+270D><U+2746> <U+271E><U+2713><U+270D> <U+271F><U+2731><U+2729> <U+271F><U+2731><U+2729> <U+2706><U+2713><U+272B> <U+2723><U+270D><U+270C> <U+271F><U+2731><U+2713> <U+2706><U+2713><U+272B>
                      <U+271A><U+272E>                  <U+2722><U+2721>                  <U+2722><U+272E>
              <U+2715><U+2731><U+2712> <U+2723><U+270D><U+270C> <U+2706><U+2713><U+272B> <U+2706><U+2605><U+2733> <U+2706><U+2605><U+2733> <U+271D><U+2731><U+2605> <U+271E><U+2713><U+270D> <U+271E><U+270D><U+2746> <U+2715><U+2731><U+2712> <U+2725><U+2605><U+270D> <U+271E><U+261E><U+270D> <U+2715><U+270D><U+2763> <U+271F><U+2731><U+2733> <U+2715><U+270D><U+2763> <U+271F><U+2731><U+2713> <U+25CF><U+2712><U+2731>
                  <U+272E><U+2721>                  <U+272E><U+272E>                  <U+2727><U+2721>
              <U+2723><U+270D><U+270C> <U+2725><U+2605><U+270D> <U+2715><U+270D><U+2763> <U+2723><U+261E><U+2605> <U+2725><U+2605><U+270D> <U+271F><U+2731><U+2713> <U+2725><U+2605><U+270D> <U+271F><U+2731><U+2713> <U+2725><U+2605><U+270D> <U+271F><U+2731><U+2713> <U+271E><U+261E><U+270D> <U+2715><U+272B><U+2746> <U+2723><U+261E><U+2605> <U+271E><U+261E><U+270D> <U+2723><U+261E><U+2605> <U+271E><U+261E><U+270D>
                                                 19

              <U+2727><U+272E>                   <U+271B><U+2721>                   <U+271B><U+272E>                <U+2726><U+2721>
<removed-date>
              <U+271D><U+2731><U+2605> <U+2725><U+2605><U+270D> <U+2725><U+2605><U+270D> <U+2706><U+2605><U+2733> <U+271F><U+2731><U+2733> <U+2715><U+2731><U+2712> <U+271F><U+2731><U+2733> <U+2715><U+272B><U+2746> <U+2715><U+2731><U+2712> <U+2715><U+2731><U+2712> <U+271E><U+261E><U+270D> <U+271E><U+2713><U+270D> <U+271E><U+2713><U+270D> <U+260E><U+2713><U+272B> <U+2706><U+2713><U+272B> <U+271F><U+2731><U+2729>
                              <U+2726><U+272E>                  <U+2741><U+2721>                  <U+2741><U+272E>
              <U+271E><U+2713><U+270D> <U+2706><U+2605><U+2733> <U+2725><U+2605><U+270D> <U+2725><U+2605><U+270D> <U+271E><U+270D><U+2746> <U+271E><U+261E><U+270D> <U+2723><U+261E><U+2605> <U+271F><U+2731><U+2713> <U+271F><U+2731><U+2729> <U+271F><U+2731><U+2713>
                          <U+2720><U+2721><U+2721>                 <U+2720><U+2721><U+272E>
<removed-apn>
              <U+2741><U+2714><U+2720><U+2721><U+261B>   <U+2714><U+272E>
              <U+2741><U+2714><U+2720><U+2720><U+261B>   <U+2720><U+2721><U+2727>
              <U+2741><U+2714><U+2720><U+2714><U+261B>   <U+2723><U+2741><U+271E>
              <U+2741><U+2714><U+2720><U+271A><U+261B>   <U+2715><U+270D><U+270E><U+272C><U+272F><U+272C><U+2730><U+272C><U+2712><U+2731> <U+2725><U+2605><U+2732><U+2733><U+2605><U+2729><U+2730><U+2605>
              <U+2741><U+2714><U+2714><U+2721><U+261B>
              <U+2741><U+2714><U+2714><U+271A><U+261B>   <U+2712><U+2729><U+270E><U+272C><U+2734><U+270C><U+2735><U+2713>
              <U+2741><U+2722><U+2721><U+2721><U+261B>   <U+2714><U+272E>
              <U+2715><U+272B><U+2746> <U+271D><U+2731><U+2605> <U+271F><U+2731><U+2729> <U+2746><U+2605><U+270E> <U+271E><U+261E><U+270D> <U+271F><U+2731><U+2729> <U+2725><U+2605><U+270D> <U+2723><U+270D><U+270C> <U+2725><U+2605><U+270D> <U+2725><U+2605><U+270D> <U+2706><U+2605><U+2733> <U+2725><U+2605><U+270D> <U+2715><U+2731><U+2712> <U+2725><U+2605><U+270D> <U+25CF><U+2712><U+2731> <U+271F><U+2731><U+2713>
              <U+2720>               <U+272E>                   <U+2720><U+2721>                  <U+2720><U+272E>
              <U+2715><U+272B><U+2746> <U+2715><U+270D><U+2763> <U+25CF><U+2712><U+2731> <U+271E><U+261E><U+270D> <U+271D><U+2731><U+2605> <U+271E><U+261E><U+270D> <U+260E><U+2713><U+272B> <U+2706><U+2713><U+272B> <U+2725><U+2605><U+270D> <U+2725><U+2605><U+270D> <U+271F><U+2731><U+2729> <U+2725><U+2605><U+270D> <U+25CF><U+2712><U+2731> <U+2706><U+2605><U+2733> <U+271E><U+2713><U+270D> <U+2725><U+2605><U+270D>
                          <U+2714><U+2721>                  <U+2714><U+272E>                  <U+271A><U+2721>
              <U+2715><U+2731><U+2712> <U+25CF><U+2712><U+2731> <U+271F><U+2731><U+2733> <U+2706><U+2713><U+272B> <U+2715><U+272B><U+2729> <U+271E><U+2713><U+270D> <U+2706><U+2605><U+2733> <U+2715><U+2731><U+2712> <U+271E><U+270D><U+2746> <U+271E><U+2713><U+270D> <U+271F><U+2731><U+2729> <U+271F><U+2731><U+2729> <U+2706><U+2713><U+272B> <U+2723><U+270D><U+270C> <U+271F><U+2731><U+2713> <U+271F><U+2731><U+2729>
                      <U+271A><U+272E>                  <U+2722><U+2721>                  <U+2722><U+272E>
              <U+2715><U+2731><U+2712> <U+2723><U+270D><U+270C> <U+2715><U+270D><U+2763> <U+2706><U+2605><U+2733> <U+2706><U+2605><U+2733> <U+271D><U+2731><U+2605> <U+271E><U+2713><U+270D> <U+271E><U+270D><U+2746> <U+2715><U+2731><U+2712> <U+2725><U+2605><U+270D> <U+271E><U+261E><U+270D> <U+2715><U+270D><U+2763> <U+271F><U+2731><U+2733> <U+2715><U+270D><U+2763> <U+271F><U+2731><U+2713> <U+271D><U+2731><U+2605>
                  <U+272E><U+2721>                  <U+272E><U+272E>                  <U+2727><U+2721>
              <U+2723><U+270D><U+270C> <U+2715><U+272B><U+2746> <U+2715><U+270D><U+2763> <U+2723><U+261E><U+2605> <U+2725><U+2605><U+270D> <U+271F><U+2731><U+2713> <U+2725><U+2605><U+270D> <U+271F><U+2731><U+2713> <U+2725><U+2605><U+270D> <U+271F><U+2731><U+2713> <U+271E><U+261E><U+270D> <U+2715><U+272B><U+2746> <U+2723><U+261E><U+2605> <U+271E><U+261E><U+270D> <U+2706><U+2605><U+2733> <U+271E><U+261E><U+270D>
              <U+2727><U+272E>                  <U+271B><U+2721>                  <U+271B><U+272E>                  <U+2726><U+2721>
                                                 20

<removed-date>
              <U+271D><U+2731><U+2605> <U+2725><U+2605><U+270D> <U+2715><U+270D><U+2763> <U+2706><U+2605><U+2733> <U+271F><U+2731><U+2733> <U+2723><U+270D><U+270C> <U+271F><U+2731><U+2733> <U+2715><U+272B><U+2746> <U+2723><U+261E><U+2605> <U+2715><U+2731><U+2712> <U+25CF><U+2712><U+2731> <U+271E><U+2713><U+270D> <U+271E><U+2713><U+270D> <U+260E><U+2713><U+272B> <U+2706><U+2713><U+272B> <U+271F><U+2731><U+2729>
                              <U+2726><U+272E>                  <U+2741><U+2721>                  <U+2741><U+272E>
              <U+271E><U+2713><U+270D> <U+2706><U+2605><U+2733> <U+2725><U+2605><U+270D> <U+2725><U+2605><U+270D> <U+271E><U+270D><U+2746> <U+271E><U+261E><U+270D> <U+2723><U+261E><U+2605> <U+271F><U+2731><U+2713> <U+271F><U+2731><U+2729> <U+271F><U+2731><U+2713>
                          <U+2720><U+2721><U+2721>                 <U+2720><U+2721><U+272E>
<removed-apn>
              <U+2741><U+2714><U+2720><U+2721><U+261B>   <U+2714><U+2727>
              <U+2741><U+2714><U+2720><U+2720><U+261B>   <U+2720><U+2721><U+2727>
              <U+2741><U+2714><U+2720><U+2714><U+261B>   <U+2723><U+2741><U+271E>
              <U+2741><U+2714><U+2720><U+271A><U+261B>   <U+2715><U+270D><U+270E><U+272C><U+272F><U+272C><U+2730><U+272C><U+2712><U+2731> <U+2725><U+2605><U+2732><U+2733><U+2605><U+2729><U+2730><U+2605>
              <U+2741><U+2714><U+2714><U+2721><U+261B>
              <U+2741><U+2714><U+2714><U+271A><U+261B>   <U+2712><U+2729><U+270E><U+272C><U+2734><U+270C><U+2735><U+2713>
              <U+2741><U+2722><U+2721><U+2721><U+261B>   <U+2714><U+2727>
              <U+271F><U+2731><U+2733> <U+271D><U+2731><U+2605> <U+25CF><U+2712><U+2731> <U+2706><U+2605><U+2733> <U+271E><U+261E><U+270D> <U+271F><U+2731><U+2729> <U+2725><U+2605><U+270D> <U+2723><U+270D><U+270C> <U+2715><U+2731><U+2712> <U+271E><U+261E><U+270D> <U+2706><U+2605><U+2733> <U+2725><U+2605><U+270D> <U+2706><U+2605><U+2733> <U+2725><U+2605><U+270D> <U+2723><U+270D><U+270C> <U+271F><U+2731><U+2713>
              <U+2720>               <U+272E>                   <U+2720><U+2721>                  <U+2720><U+272E>
              <U+271F><U+2731><U+2733> <U+2715><U+270D><U+2763> <U+2715><U+2731><U+2712> <U+271E><U+261E><U+270D> <U+2706><U+2605><U+2733> <U+2725><U+2605><U+270D> <U+260E><U+2713><U+272B> <U+2706><U+2713><U+272B> <U+2725><U+2605><U+270D> <U+2725><U+2605><U+270D> <U+271F><U+2731><U+2729> <U+2725><U+2605><U+270D> <U+25CF><U+2712><U+2731> <U+2706><U+2605><U+2733> <U+271E><U+2713><U+270D> <U+2725><U+2605><U+270D>
                          <U+2714><U+2721>                  <U+2714><U+272E>                  <U+271A><U+2721>
              <U+2715><U+2731><U+2712> <U+25CF><U+2712><U+2731> <U+271F><U+2731><U+2733> <U+2706><U+2713><U+272B> <U+2715><U+272B><U+2729> <U+271E><U+2713><U+270D> <U+2706><U+2605><U+2733> <U+2715><U+2731><U+2712> <U+271E><U+270D><U+2746> <U+271E><U+2713><U+270D> <U+271F><U+2731><U+2729> <U+271F><U+2731><U+2729> <U+2706><U+2713><U+272B> <U+2723><U+270D><U+270C> <U+271F><U+2731><U+2713> <U+2706><U+2713><U+272B>
                      <U+271A><U+272E>                  <U+2722><U+2721>                  <U+2722><U+272E>
              <U+2715><U+2731><U+2712> <U+2723><U+270D><U+270C> <U+2706><U+2713><U+272B> <U+2706><U+2605><U+2733> <U+2706><U+2605><U+2733> <U+271D><U+2731><U+2605> <U+271E><U+2713><U+270D> <U+271E><U+270D><U+2746> <U+2715><U+2731><U+2712> <U+2725><U+2605><U+270D> <U+271E><U+261E><U+270D> <U+2715><U+270D><U+2763> <U+271F><U+2731><U+2733> <U+2715><U+270D><U+2763> <U+271F><U+2731><U+2713> <U+25CF><U+2712><U+2731>
                  <U+272E><U+2721>                  <U+272E><U+272E>                  <U+2727><U+2721>
              <U+2723><U+270D><U+270C> <U+2725><U+2605><U+270D> <U+2715><U+270D><U+2763> <U+2723><U+261E><U+2605> <U+2725><U+2605><U+270D> <U+271F><U+2731><U+2713> <U+2725><U+2605><U+270D> <U+271F><U+2731><U+2713> <U+2725><U+2605><U+270D> <U+271F><U+2731><U+2713> <U+271E><U+261E><U+270D> <U+2715><U+272B><U+2746> <U+2723><U+261E><U+2605> <U+271E><U+261E><U+270D> <U+2723><U+261E><U+2605> <U+271E><U+261E><U+270D>
              <U+2727><U+272E>                  <U+271B><U+2721>                  <U+271B><U+272E>                  <U+2726><U+2721>
              <U+271D><U+2731><U+2605> <U+2725><U+2605><U+270D> <U+2725><U+2605><U+270D> <U+2706><U+2605><U+2733> <U+271F><U+2731><U+2733> <U+2715><U+2731><U+2712> <U+271F><U+2731><U+2733> <U+2715><U+272B><U+2746> <U+2715><U+2731><U+2712> <U+2715><U+2731><U+2712> <U+271E><U+261E><U+270D> <U+271E><U+2713><U+270D> <U+271E><U+2713><U+270D> <U+260E><U+2713><U+272B> <U+2706><U+2713><U+272B> <U+271F><U+2731><U+2729>
                                                 21

                                 <U+2726><U+272E>              <U+2741><U+2721>                  <U+2741><U+272E>
<removed-date>
              <U+271E><U+2713><U+270D> <U+2706><U+2605><U+2733> <U+2725><U+2605><U+270D> <U+2725><U+2605><U+270D> <U+271E><U+270D><U+2746> <U+271E><U+261E><U+270D> <U+2723><U+261E><U+2605> <U+271F><U+2731><U+2713> <U+271F><U+2731><U+2729> <U+271F><U+2731><U+2713>
                          <U+2720><U+2721><U+2721>                 <U+2720><U+2721><U+272E>
              <U+2741><U+2714><U+2720><U+2721><U+261B>   <U+2714><U+271B>
              <U+2741><U+2714><U+2720><U+2720><U+261B>   <U+2720><U+2721><U+2727>
<removed-apn>
              <U+2741><U+2714><U+2720><U+2714><U+261B>   <U+2723><U+2741><U+271E>
              <U+2741><U+2714><U+2720><U+271A><U+261B>   <U+2715><U+270D><U+270E><U+272C><U+272F><U+272C><U+2730><U+272C><U+2712><U+2731> <U+2725><U+2605><U+2732><U+2733><U+2605><U+2729><U+2730><U+2605>
              <U+2741><U+2714><U+2714><U+2721><U+261B>
              <U+2741><U+2714><U+2714><U+271A><U+261B>   <U+2712><U+2729><U+270E><U+272C><U+2734><U+270C><U+2735><U+2713>
              <U+2741><U+2722><U+2721><U+2721><U+261B>   <U+2714><U+271B>
              <U+271F><U+2731><U+2733> <U+271D><U+2731><U+2605> <U+25CF><U+2712><U+2731> <U+2706><U+2605><U+2733> <U+271E><U+261E><U+270D> <U+271F><U+2731><U+2729> <U+2725><U+2605><U+270D> <U+2723><U+270D><U+270C> <U+2715><U+2731><U+2712> <U+271E><U+261E><U+270D> <U+2706><U+2605><U+2733> <U+2725><U+2605><U+270D> <U+2706><U+2605><U+2733> <U+2725><U+2605><U+270D> <U+2723><U+270D><U+270C> <U+271F><U+2731><U+2713>
              <U+2720>               <U+272E>                   <U+2720><U+2721>                  <U+2720><U+272E>
              <U+271F><U+2731><U+2733> <U+2715><U+270D><U+2763> <U+2715><U+2731><U+2712> <U+271E><U+261E><U+270D> <U+2706><U+2605><U+2733> <U+2725><U+2605><U+270D> <U+260E><U+2713><U+272B> <U+2706><U+2713><U+272B> <U+2725><U+2605><U+270D> <U+2725><U+2605><U+270D> <U+271F><U+2731><U+2729> <U+2725><U+2605><U+270D> <U+25CF><U+2712><U+2731> <U+2706><U+2605><U+2733> <U+271E><U+2713><U+270D> <U+2725><U+2605><U+270D>
                          <U+2714><U+2721>                  <U+2714><U+272E>                  <U+271A><U+2721>
              <U+2715><U+2731><U+2712> <U+25CF><U+2712><U+2731> <U+271F><U+2731><U+2733> <U+2706><U+2713><U+272B> <U+2715><U+272B><U+2729> <U+271E><U+2713><U+270D> <U+2706><U+2605><U+2733> <U+2715><U+2731><U+2712> <U+271E><U+270D><U+2746> <U+271E><U+2713><U+270D> <U+271F><U+2731><U+2729> <U+271F><U+2731><U+2729> <U+2706><U+2713><U+272B> <U+2723><U+270D><U+270C> <U+271F><U+2731><U+2713> <U+2706><U+2713><U+272B>
                      <U+271A><U+272E>                  <U+2722><U+2721>                  <U+2722><U+272E>
              <U+2715><U+2731><U+2712> <U+2723><U+270D><U+270C> <U+2706><U+2713><U+272B> <U+2706><U+2605><U+2733> <U+2706><U+2605><U+2733> <U+271D><U+2731><U+2605> <U+271E><U+2713><U+270D> <U+271E><U+270D><U+2746> <U+2715><U+2731><U+2712> <U+2725><U+2605><U+270D> <U+271E><U+261E><U+270D> <U+2715><U+270D><U+2763> <U+271F><U+2731><U+2733> <U+2715><U+270D><U+2763> <U+271F><U+2731><U+2713> <U+25CF><U+2712><U+2731>
                  <U+272E><U+2721>                  <U+272E><U+272E>                  <U+2727><U+2721>
              <U+2723><U+270D><U+270C> <U+2725><U+2605><U+270D> <U+2715><U+270D><U+2763> <U+2723><U+261E><U+2605> <U+2725><U+2605><U+270D> <U+271F><U+2731><U+2713> <U+2725><U+2605><U+270D> <U+271F><U+2731><U+2713> <U+2725><U+2605><U+270D> <U+271F><U+2731><U+2713> <U+271E><U+261E><U+270D> <U+2715><U+272B><U+2746> <U+2723><U+261E><U+2605> <U+271E><U+261E><U+270D> <U+2723><U+261E><U+2605> <U+271E><U+261E><U+270D>
              <U+2727><U+272E>                  <U+271B><U+2721>                  <U+271B><U+272E>                  <U+2726><U+2721>
              <U+271D><U+2731><U+2605> <U+2725><U+2605><U+270D> <U+2725><U+2605><U+270D> <U+2706><U+2605><U+2733> <U+271F><U+2731><U+2729> <U+2723><U+270D><U+270C> <U+271F><U+2731><U+2733> <U+2715><U+272B><U+2746> <U+271D><U+2731><U+2605> <U+2715><U+2731><U+2712> <U+271E><U+261E><U+270D> <U+271E><U+2713><U+270D> <U+271E><U+2713><U+270D> <U+260E><U+2713><U+272B> <U+2706><U+2713><U+272B> <U+271F><U+2731><U+2729>
                              <U+2726><U+272E>                  <U+2741><U+2721>                  <U+2741><U+272E>
                                                 22

<removed-date>
              <U+271E><U+2713><U+270D> <U+2706><U+2605><U+2733> <U+2725><U+2605><U+270D> <U+2725><U+2605><U+270D> <U+271E><U+270D><U+2746> <U+271E><U+261E><U+270D> <U+2723><U+261E><U+2605> <U+271F><U+2731><U+2713> <U+271F><U+2731><U+2729> <U+271F><U+2731><U+2713>
                          <U+2720><U+2721><U+2721>                 <U+2720><U+2721><U+272E>
              <U+2741><U+2714><U+2720><U+2721><U+261B>   <U+2714><U+2726>
              <U+2741><U+2714><U+2720><U+2720><U+261B>   <U+2720><U+2721><U+2727>
              <U+2741><U+2714><U+2720><U+2714><U+261B>   <U+2723><U+2741><U+271E>
              <U+2741><U+2714><U+2720><U+271A><U+261B>   <U+2715><U+270D><U+270E><U+272C><U+272F><U+272C><U+2730><U+272C><U+2712><U+2731> <U+2725><U+2605><U+2732><U+2733><U+2605><U+2729><U+2730><U+2605>
<removed-apn>
              <U+2741><U+2714><U+2714><U+2721><U+261B>
              <U+2741><U+2714><U+2714><U+271A><U+261B>   <U+2712><U+2729><U+270E><U+272C><U+2734><U+270C><U+2735><U+2713>
              <U+2741><U+2722><U+2721><U+2721><U+261B>   <U+2714><U+2726>
              <U+271F><U+2731><U+2733> <U+271D><U+2731><U+2605> <U+25CF><U+2712><U+2731> <U+2706><U+2605><U+2733> <U+271E><U+261E><U+270D> <U+271F><U+2731><U+2729> <U+2725><U+2605><U+270D> <U+2723><U+270D><U+270C> <U+2715><U+2731><U+2712> <U+271E><U+261E><U+270D> <U+2706><U+2605><U+2733> <U+2725><U+2605><U+270D> <U+2706><U+2605><U+2733> <U+2725><U+2605><U+270D> <U+2723><U+270D><U+270C> <U+271F><U+2731><U+2713>
              <U+2720>               <U+272E>                   <U+2720><U+2721>                  <U+2720><U+272E>
              <U+271F><U+2731><U+2733> <U+2715><U+270D><U+2763> <U+2715><U+2731><U+2712> <U+271E><U+261E><U+270D> <U+2706><U+2605><U+2733> <U+2725><U+2605><U+270D> <U+260E><U+2713><U+272B> <U+2706><U+2713><U+272B> <U+2725><U+2605><U+270D> <U+2725><U+2605><U+270D> <U+271F><U+2731><U+2729> <U+2725><U+2605><U+270D> <U+25CF><U+2712><U+2731> <U+2706><U+2605><U+2733> <U+271E><U+2713><U+270D> <U+2725><U+2605><U+270D>
                          <U+2714><U+2721>                  <U+2714><U+272E>                  <U+271A><U+2721>
              <U+2715><U+2731><U+2712> <U+25CF><U+2712><U+2731> <U+271F><U+2731><U+2733> <U+2706><U+2713><U+272B> <U+2715><U+272B><U+2729> <U+271E><U+2713><U+270D> <U+2706><U+2605><U+2733> <U+2715><U+2731><U+2712> <U+271E><U+270D><U+2746> <U+271E><U+2713><U+270D> <U+271F><U+2731><U+2729> <U+271F><U+2731><U+2729> <U+2706><U+2713><U+272B> <U+2723><U+270D><U+270C> <U+271F><U+2731><U+2713> <U+271F><U+2731><U+2729>
                      <U+271A><U+272E>                  <U+2722><U+2721>                  <U+2722><U+272E>
              <U+2715><U+2731><U+2712> <U+2723><U+270D><U+270C> <U+2715><U+270D><U+2763> <U+2706><U+2605><U+2733> <U+2706><U+2605><U+2733> <U+271D><U+2731><U+2605> <U+271E><U+2713><U+270D> <U+271E><U+270D><U+2746> <U+2715><U+2731><U+2712> <U+2725><U+2605><U+270D> <U+271E><U+261E><U+270D> <U+2715><U+270D><U+2763> <U+271F><U+2731><U+2733> <U+2715><U+270D><U+2763> <U+271F><U+2731><U+2713> <U+271D><U+2731><U+2605>
                  <U+272E><U+2721>                  <U+272E><U+272E>                  <U+2727><U+2721>
              <U+2723><U+270D><U+270C> <U+2715><U+272B><U+2746> <U+2715><U+270D><U+2763> <U+2723><U+261E><U+2605> <U+2725><U+2605><U+270D> <U+271F><U+2731><U+2713> <U+2725><U+2605><U+270D> <U+271F><U+2731><U+2713> <U+2725><U+2605><U+270D> <U+271F><U+2731><U+2713> <U+271E><U+261E><U+270D> <U+2715><U+272B><U+2746> <U+2723><U+261E><U+2605> <U+271E><U+261E><U+270D> <U+2706><U+2605><U+2733> <U+271E><U+261E><U+270D>
              <U+2727><U+272E>                  <U+271B><U+2721>                  <U+271B><U+272E>                  <U+2726><U+2721>
              <U+271D><U+2731><U+2605> <U+2725><U+2605><U+270D> <U+2715><U+270D><U+2763> <U+2706><U+2605><U+2733> <U+271F><U+2731><U+2733> <U+2723><U+270D><U+270C> <U+271F><U+2731><U+2733> <U+2715><U+272B><U+2746> <U+2723><U+261E><U+2605> <U+2715><U+2731><U+2712> <U+25CF><U+2712><U+2731> <U+271E><U+2713><U+270D> <U+271E><U+2713><U+270D> <U+260E><U+2713><U+272B> <U+2706><U+2713><U+272B> <U+271F><U+2731><U+2729>
                              <U+2726><U+272E>                  <U+2741><U+2721>                  <U+2741><U+272E>
              <U+271E><U+2713><U+270D> <U+2706><U+2605><U+2733> <U+2725><U+2605><U+270D> <U+2725><U+2605><U+270D> <U+271E><U+270D><U+2746> <U+271E><U+261E><U+270D> <U+2723><U+261E><U+2605> <U+271F><U+2731><U+2713> <U+271F><U+2731><U+2729> <U+271F><U+2731><U+2713>
                                                 23

                           <U+2720><U+2721><U+2721>                <U+2720><U+2721><U+272E>
<removed-date>
              <U+2741><U+2714><U+2720><U+2721><U+261B>   <U+2714><U+2741>
              <U+2741><U+2714><U+2720><U+2720><U+261B>   <U+2720><U+2721><U+2727>
              <U+2741><U+2714><U+2720><U+2714><U+261B>   <U+2723><U+2741><U+271E>
              <U+2741><U+2714><U+2720><U+271A><U+261B>   <U+2715><U+270D><U+270E><U+272C><U+272F><U+272C><U+2730><U+272C><U+2712><U+2731> <U+2725><U+2605><U+2732><U+2733><U+2605><U+2729><U+2730><U+2605>
              <U+2741><U+2714><U+2714><U+2721><U+261B>
<removed-apn>
              <U+2741><U+2714><U+2714><U+271A><U+261B>   <U+2712><U+2729><U+270E><U+272C><U+2734><U+270C><U+2735><U+2713>
              <U+2741><U+2722><U+2721><U+2721><U+261B>   <U+2714><U+2741>
              <U+271F><U+2731><U+2733> <U+271D><U+2731><U+2605> <U+25CF><U+2712><U+2731> <U+2706><U+2605><U+2733> <U+271E><U+261E><U+270D> <U+271F><U+2731><U+2729> <U+2725><U+2605><U+270D> <U+2723><U+270D><U+270C> <U+2715><U+2731><U+2712> <U+271E><U+261E><U+270D> <U+2706><U+2605><U+2733> <U+2725><U+2605><U+270D> <U+25CF><U+2712><U+2731> <U+2725><U+2605><U+270D> <U+2723><U+270D><U+270C> <U+271F><U+2731><U+2713>
              <U+2720>               <U+272E>                   <U+2720><U+2721>                  <U+2720><U+272E>
              <U+271F><U+2731><U+2733> <U+2715><U+270D><U+2763> <U+2715><U+2731><U+2712> <U+271E><U+261E><U+270D> <U+2706><U+2605><U+2733> <U+2725><U+2605><U+270D> <U+260E><U+2713><U+272B> <U+2706><U+2713><U+272B> <U+2725><U+2605><U+270D> <U+2725><U+2605><U+270D> <U+271F><U+2731><U+2729> <U+2725><U+2605><U+270D> <U+25CF><U+2712><U+2731> <U+2706><U+2605><U+2733> <U+271E><U+2713><U+270D> <U+2725><U+2605><U+270D>
                          <U+2714><U+2721>                  <U+2714><U+272E>                  <U+271A><U+2721>
              <U+2715><U+2731><U+2712> <U+25CF><U+2712><U+2731> <U+271F><U+2731><U+2733> <U+2706><U+2713><U+272B> <U+2715><U+272B><U+2729> <U+271E><U+2713><U+270D> <U+2706><U+2605><U+2733> <U+2715><U+2731><U+2712> <U+271E><U+270D><U+2746> <U+271E><U+2713><U+270D> <U+271F><U+2731><U+2729> <U+271F><U+2731><U+2729> <U+2706><U+2713><U+272B> <U+2723><U+270D><U+270C> <U+271F><U+2731><U+2713> <U+271F><U+2731><U+2729>
                      <U+271A><U+272E>                  <U+2722><U+2721>                  <U+2722><U+272E>
              <U+2715><U+2731><U+2712> <U+2723><U+270D><U+270C> <U+2715><U+270D><U+2763> <U+2706><U+2605><U+2733> <U+2706><U+2605><U+2733> <U+271D><U+2731><U+2605> <U+271E><U+2713><U+270D> <U+271E><U+270D><U+2746> <U+2715><U+2731><U+2712> <U+2725><U+2605><U+270D> <U+271E><U+261E><U+270D> <U+2715><U+270D><U+2763> <U+271F><U+2731><U+2733> <U+2715><U+270D><U+2763> <U+271F><U+2731><U+2713> <U+25CF><U+2712><U+2731>
                  <U+272E><U+2721>                  <U+272E><U+272E>                  <U+2727><U+2721>
              <U+2723><U+270D><U+270C> <U+2725><U+2605><U+270D> <U+2715><U+270D><U+2763> <U+2723><U+261E><U+2605> <U+2725><U+2605><U+270D> <U+271F><U+2731><U+2713> <U+2725><U+2605><U+270D> <U+271F><U+2731><U+2713> <U+2725><U+2605><U+270D> <U+271F><U+2731><U+2713> <U+271E><U+261E><U+270D> <U+2715><U+272B><U+2746> <U+2723><U+261E><U+2605> <U+271E><U+261E><U+270D> <U+2723><U+261E><U+2605> <U+271E><U+261E><U+270D>
              <U+2727><U+272E>                  <U+271B><U+2721>                  <U+271B><U+272E>                  <U+2726><U+2721>
              <U+271D><U+2731><U+2605> <U+2725><U+2605><U+270D> <U+2725><U+2605><U+270D> <U+2706><U+2605><U+2733> <U+271F><U+2731><U+2729> <U+2723><U+270D><U+270C> <U+271F><U+2731><U+2733> <U+2715><U+272B><U+2746> <U+271D><U+2731><U+2605> <U+2715><U+2731><U+2712> <U+271E><U+261E><U+270D> <U+271E><U+2713><U+270D> <U+271E><U+2713><U+270D> <U+260E><U+2713><U+272B> <U+2706><U+2713><U+272B> <U+271F><U+2731><U+2729>
                              <U+2726><U+272E>                  <U+2741><U+2721>                  <U+2741><U+272E>
              <U+271E><U+2713><U+270D> <U+2706><U+2605><U+2733> <U+2725><U+2605><U+270D> <U+2725><U+2605><U+270D> <U+271E><U+270D><U+2746> <U+271E><U+261E><U+270D> <U+2723><U+261E><U+2605> <U+271F><U+2731><U+2713> <U+271F><U+2731><U+2729> <U+271F><U+2731><U+2713>
                          <U+2720><U+2721><U+2721>                 <U+2720><U+2721><U+272E>
                                                    24

<removed-date>
              <U+2741><U+2714><U+2720><U+2721><U+261B>   <U+271A><U+2721>
              <U+2741><U+2714><U+2720><U+2720><U+261B>   <U+2720><U+2721><U+2727>
              <U+2741><U+2714><U+2720><U+2714><U+261B>   <U+2723><U+2741><U+271E>
              <U+2741><U+2714><U+2720><U+271A><U+261B>   <U+2715><U+270D><U+270E><U+272C><U+272F><U+272C><U+2730><U+272C><U+2712><U+2731> <U+2725><U+2605><U+2732><U+2733><U+2605><U+2729><U+2730><U+2605>
              <U+2741><U+2714><U+2714><U+2721><U+261B>
              <U+2741><U+2714><U+2714><U+271A><U+261B>   <U+2712><U+2729><U+270E><U+272C><U+2734><U+270C><U+2735><U+2713>
<removed-apn>
              <U+2741><U+2722><U+2721><U+2721><U+261B>   <U+271A><U+2721>
              <U+2715><U+2731><U+2712> <U+271D><U+2731><U+2605> <U+271F><U+2731><U+2729> <U+2706><U+2605><U+2733> <U+271E><U+261E><U+270D> <U+271F><U+2731><U+2729> <U+2725><U+2605><U+270D> <U+2723><U+270D><U+270C> <U+2725><U+2605><U+270D> <U+2725><U+2605><U+270D> <U+2706><U+2605><U+2733> <U+2725><U+2605><U+270D> <U+2715><U+2731><U+2712> <U+2725><U+2605><U+270D> <U+25CF><U+2712><U+2731> <U+271F><U+2731><U+2713>
              <U+2720>               <U+272E>                   <U+2720><U+2721>                  <U+2720><U+272E>
              <U+2715><U+272B><U+2746> <U+2715><U+270D><U+2763> <U+25CF><U+2712><U+2731> <U+271E><U+261E><U+270D> <U+271D><U+2731><U+2605> <U+271E><U+261E><U+270D> <U+260E><U+2713><U+272B> <U+2706><U+2713><U+272B> <U+2725><U+2605><U+270D> <U+2725><U+2605><U+270D> <U+271F><U+2731><U+2729> <U+2725><U+2605><U+270D> <U+25CF><U+2712><U+2731> <U+2706><U+2605><U+2733> <U+271E><U+2713><U+270D> <U+2725><U+2605><U+270D>
                          <U+2714><U+2721>                  <U+2714><U+272E>                  <U+271A><U+2721>
              <U+2715><U+2731><U+2712> <U+25CF><U+2712><U+2731> <U+271F><U+2731><U+2733> <U+2706><U+2713><U+272B> <U+2715><U+272B><U+2729> <U+271E><U+2713><U+270D> <U+2706><U+2605><U+2733> <U+2715><U+2731><U+2712> <U+271E><U+270D><U+2746> <U+271E><U+2713><U+270D> <U+271F><U+2731><U+2729> <U+271F><U+2731><U+2729> <U+2706><U+2713><U+272B> <U+2723><U+270D><U+270C> <U+271F><U+2731><U+2713> <U+271F><U+2731><U+2729>
                      <U+271A><U+272E>                  <U+2722><U+2721>                  <U+2722><U+272E>
              <U+2715><U+2731><U+2712> <U+2723><U+270D><U+270C> <U+2715><U+270D><U+2763> <U+2706><U+2605><U+2733> <U+2706><U+2605><U+2733> <U+271D><U+2731><U+2605> <U+271E><U+2713><U+270D> <U+271E><U+270D><U+2746> <U+2715><U+2731><U+2712> <U+2725><U+2605><U+270D> <U+271E><U+261E><U+270D> <U+2715><U+270D><U+2763> <U+271F><U+2731><U+2733> <U+2715><U+270D><U+2763> <U+271F><U+2731><U+2713> <U+25CF><U+2712><U+2731>
                  <U+272E><U+2721>                  <U+272E><U+272E>                  <U+2727><U+2721>
              <U+2723><U+270D><U+270C> <U+2725><U+2605><U+270D> <U+2715><U+270D><U+2763> <U+2723><U+261E><U+2605> <U+2725><U+2605><U+270D> <U+271F><U+2731><U+2713> <U+2725><U+2605><U+270D> <U+271F><U+2731><U+2713> <U+2725><U+2605><U+270D> <U+271F><U+2731><U+2713> <U+271E><U+261E><U+270D> <U+2715><U+272B><U+2746> <U+2723><U+261E><U+2605> <U+271E><U+261E><U+270D> <U+2706><U+2605><U+2733> <U+271E><U+261E><U+270D>
              <U+2727><U+272E>                  <U+271B><U+2721>                  <U+271B><U+272E>                  <U+2726><U+2721>
              <U+271D><U+2731><U+2605> <U+2725><U+2605><U+270D> <U+2725><U+2605><U+270D> <U+2706><U+2605><U+2733> <U+271F><U+2731><U+2729> <U+2723><U+270D><U+270C> <U+271F><U+2731><U+2733> <U+2715><U+272B><U+2746> <U+2723><U+261E><U+2605> <U+2715><U+2731><U+2712> <U+271E><U+261E><U+270D> <U+271E><U+2713><U+270D> <U+271E><U+2713><U+270D> <U+260E><U+2713><U+272B> <U+2706><U+2713><U+272B> <U+271F><U+2731><U+2729>
                              <U+2726><U+272E>                  <U+2741><U+2721>                  <U+2741><U+272E>
              <U+271E><U+2713><U+270D> <U+2706><U+2605><U+2733> <U+2725><U+2605><U+270D> <U+2725><U+2605><U+270D> <U+271E><U+270D><U+2746> <U+271E><U+261E><U+270D> <U+2723><U+261E><U+2605> <U+271F><U+2731><U+2713> <U+271F><U+2731><U+2729> <U+271F><U+2731><U+2713>
                          <U+2720><U+2721><U+2721>                 <U+2720><U+2721><U+272E>
              <U+2741><U+2714><U+2720><U+2721><U+261B>   <U+271A><U+2720>
                                                 25

              <U+2741><U+2714><U+2720><U+2720><U+261B>   <U+2720><U+2721><U+2727>
<removed-date>
              <U+2741><U+2714><U+2720><U+2714><U+261B>   <U+2723><U+2741><U+271E>
              <U+2741><U+2714><U+2720><U+271A><U+261B>   <U+2715><U+270D><U+270E><U+272C><U+272F><U+272C><U+2730><U+272C><U+2712><U+2731> <U+2725><U+2605><U+2732><U+2733><U+2605><U+2729><U+2730><U+2605>
              <U+2741><U+2714><U+2714><U+2721><U+261B>
              <U+2741><U+2714><U+2714><U+271A><U+261B>   <U+2712><U+2729><U+270E><U+272C><U+2734><U+270C><U+2735><U+2713>
              <U+2741><U+2722><U+2721><U+2721><U+261B>   <U+271A><U+2720>
<removed-apn>
              <U+271F><U+2731><U+2733> <U+271D><U+2731><U+2605> <U+25CF><U+2712><U+2731> <U+2706><U+2605><U+2733> <U+271E><U+261E><U+270D> <U+271F><U+2731><U+2729> <U+2725><U+2605><U+270D> <U+2723><U+270D><U+270C> <U+2715><U+2731><U+2712> <U+271E><U+261E><U+270D> <U+2706><U+2605><U+2733> <U+2715><U+2731><U+2712> <U+2706><U+2605><U+2733> <U+2725><U+2605><U+270D> <U+2723><U+270D><U+270C> <U+271F><U+2731><U+2713>
              <U+2720>               <U+272E>                   <U+2720><U+2721>                  <U+2720><U+272E>
              <U+271F><U+2731><U+2733> <U+2706><U+2713><U+272B> <U+2715><U+2731><U+2712> <U+2723><U+270D><U+270C> <U+2706><U+2605><U+2733> <U+2725><U+2605><U+270D> <U+271E><U+270D><U+2746> <U+2706><U+2713><U+272B> <U+2725><U+2605><U+270D> <U+2725><U+2605><U+270D> <U+271F><U+2731><U+2729> <U+2725><U+2605><U+270D> <U+25CF><U+2712><U+2731> <U+2706><U+2605><U+2733> <U+271E><U+2713><U+270D> <U+2725><U+2605><U+270D>
                          <U+2714><U+2721>                  <U+2714><U+272E>                  <U+271A><U+2721>
              <U+271F><U+2731><U+2713> <U+25CF><U+2712><U+2731> <U+271F><U+2731><U+2733> <U+2706><U+2713><U+272B> <U+2715><U+272B><U+2729> <U+271E><U+2713><U+270D> <U+2706><U+2605><U+2733> <U+2715><U+2731><U+2712> <U+271E><U+270D><U+2746> <U+271E><U+2713><U+270D> <U+271F><U+2731><U+2729> <U+271F><U+2731><U+2729> <U+2706><U+2713><U+272B> <U+2723><U+270D><U+270C> <U+271F><U+2731><U+2713> <U+2706><U+2713><U+272B>
                      <U+271A><U+272E>                  <U+2722><U+2721>                  <U+2722><U+272E>
              <U+2715><U+2731><U+2712> <U+2723><U+270D><U+270C> <U+2706><U+2713><U+272B> <U+2706><U+2605><U+2733> <U+2706><U+2605><U+2733> <U+271D><U+2731><U+2605> <U+271E><U+2713><U+270D> <U+271E><U+270D><U+2746> <U+2715><U+2731><U+2712> <U+2725><U+2605><U+270D> <U+271E><U+261E><U+270D> <U+2715><U+270D><U+2763> <U+271F><U+2731><U+2733> <U+2715><U+270D><U+2763> <U+271F><U+2731><U+2713> <U+25CF><U+2712><U+2731>
                  <U+272E><U+2721>                  <U+272E><U+272E>                  <U+2727><U+2721>
              <U+2723><U+270D><U+270C> <U+2725><U+2605><U+270D> <U+2715><U+270D><U+2763> <U+2723><U+261E><U+2605> <U+2725><U+2605><U+270D> <U+271F><U+2731><U+2713> <U+2725><U+2605><U+270D> <U+271F><U+2731><U+2713> <U+2725><U+2605><U+270D> <U+271F><U+2731><U+2713> <U+271E><U+261E><U+270D> <U+2715><U+272B><U+2746> <U+2723><U+261E><U+2605> <U+271E><U+261E><U+270D> <U+2706><U+2605><U+2733> <U+271E><U+261E><U+270D>
              <U+2727><U+272E>                  <U+271B><U+2721>                  <U+271B><U+272E>                  <U+2726><U+2721>
              <U+271D><U+2731><U+2605> <U+2725><U+2605><U+270D> <U+2725><U+2605><U+270D> <U+2706><U+2605><U+2733> <U+271F><U+2731><U+2729> <U+2715><U+2731><U+2712> <U+271F><U+2731><U+2733> <U+2715><U+272B><U+2746> <U+2723><U+261E><U+2605> <U+2715><U+2731><U+2712> <U+271E><U+261E><U+270D> <U+271E><U+2713><U+270D> <U+271E><U+2713><U+270D> <U+260E><U+2713><U+272B> <U+2706><U+2713><U+272B> <U+271F><U+2731><U+2729>
                              <U+2726><U+272E>                  <U+2741><U+2721>                  <U+2741><U+272E>
              <U+271E><U+2713><U+270D> <U+2706><U+2605><U+2733> <U+2725><U+2605><U+270D> <U+2725><U+2605><U+270D> <U+271E><U+270D><U+2746> <U+271E><U+261E><U+270D> <U+2723><U+261E><U+2605> <U+271F><U+2731><U+2713> <U+271F><U+2731><U+2729> <U+271F><U+2731><U+2713>
                          <U+2720><U+2721><U+2721>                 <U+2720><U+2721><U+272E>
              <U+2741><U+2714><U+2720><U+2721><U+261B>   <U+271A><U+2714>
              <U+2741><U+2714><U+2720><U+2720><U+261B>   <U+2720><U+2721><U+2727>
              <U+2741><U+2714><U+2720><U+2714><U+261B>   <U+2723><U+2741><U+271E>
                                                 26

              <U+2741><U+2714><U+2720><U+271A><U+261B>   <U+2715><U+270D><U+270E><U+272C><U+272F><U+272C><U+2730><U+272C><U+2712><U+2731> <U+2725><U+2605><U+2732><U+2733><U+2605><U+2729><U+2730><U+2605>
<removed-date>
              <U+2741><U+2714><U+2714><U+2721><U+261B>
              <U+2741><U+2714><U+2714><U+271A><U+261B>   <U+2712><U+2729><U+270E><U+272C><U+2734><U+270C><U+2735><U+2713>
              <U+2741><U+2722><U+2721><U+2721><U+261B>   <U+271A><U+2714>
              <U+271F><U+2731><U+2733> <U+271D><U+2731><U+2605> <U+25CF><U+2712><U+2731> <U+2706><U+2605><U+2733> <U+271E><U+261E><U+270D> <U+271F><U+2731><U+2729> <U+2725><U+2605><U+270D> <U+2723><U+270D><U+270C> <U+2715><U+2731><U+2712> <U+271E><U+261E><U+270D> <U+2706><U+2605><U+2733> <U+2715><U+2731><U+2712> <U+2706><U+2605><U+2733> <U+2725><U+2605><U+270D> <U+2723><U+270D><U+270C> <U+271F><U+2731><U+2713>
              <U+2720>               <U+272E>                   <U+2720><U+2721>                  <U+2720><U+272E>
<removed-apn>
              <U+271F><U+2731><U+2733> <U+2706><U+2713><U+272B> <U+2715><U+2731><U+2712> <U+2723><U+270D><U+270C> <U+2706><U+2605><U+2733> <U+2725><U+2605><U+270D> <U+271E><U+270D><U+2746> <U+2706><U+2713><U+272B> <U+2725><U+2605><U+270D> <U+2725><U+2605><U+270D> <U+271F><U+2731><U+2729> <U+2725><U+2605><U+270D> <U+25CF><U+2712><U+2731> <U+2706><U+2605><U+2733> <U+271E><U+2713><U+270D> <U+2725><U+2605><U+270D>
                          <U+2714><U+2721>                  <U+2714><U+272E>                  <U+271A><U+2721>
              <U+271F><U+2731><U+2713> <U+25CF><U+2712><U+2731> <U+271F><U+2731><U+2733> <U+2706><U+2713><U+272B> <U+2715><U+272B><U+2729> <U+271E><U+2713><U+270D> <U+2706><U+2605><U+2733> <U+2715><U+2731><U+2712> <U+271E><U+270D><U+2746> <U+271E><U+2713><U+270D> <U+271F><U+2731><U+2729> <U+271F><U+2731><U+2729> <U+2706><U+2713><U+272B> <U+2723><U+270D><U+270C> <U+271F><U+2731><U+2713> <U+2706><U+2713><U+272B>
                      <U+271A><U+272E>                  <U+2722><U+2721>                  <U+2722><U+272E>
              <U+2715><U+2731><U+2712> <U+2723><U+270D><U+270C> <U+2706><U+2713><U+272B> <U+2706><U+2605><U+2733> <U+2706><U+2605><U+2733> <U+271D><U+2731><U+2605> <U+271E><U+2713><U+270D> <U+271E><U+270D><U+2746> <U+2715><U+2731><U+2712> <U+2725><U+2605><U+270D> <U+271E><U+261E><U+270D> <U+2715><U+270D><U+2763> <U+271F><U+2731><U+2733> <U+2715><U+270D><U+2763> <U+271F><U+2731><U+2713> <U+25CF><U+2712><U+2731>
                  <U+272E><U+2721>                  <U+272E><U+272E>                  <U+2727><U+2721>
              <U+2723><U+270D><U+270C> <U+2725><U+2605><U+270D> <U+2715><U+270D><U+2763> <U+2723><U+261E><U+2605> <U+2725><U+2605><U+270D> <U+271F><U+2731><U+2713> <U+2725><U+2605><U+270D> <U+271F><U+2731><U+2713> <U+2725><U+2605><U+270D> <U+271F><U+2731><U+2713> <U+271E><U+261E><U+270D> <U+2715><U+272B><U+2746> <U+2723><U+261E><U+2605> <U+271E><U+261E><U+270D> <U+2706><U+2605><U+2733> <U+271E><U+261E><U+270D>
              <U+2727><U+272E>                  <U+271B><U+2721>                  <U+271B><U+272E>                  <U+2726><U+2721>
              <U+271D><U+2731><U+2605> <U+2725><U+2605><U+270D> <U+2725><U+2605><U+270D> <U+2706><U+2605><U+2733> <U+271F><U+2731><U+2729> <U+2715><U+2731><U+2712> <U+271F><U+2731><U+2733> <U+2715><U+272B><U+2746> <U+2723><U+261E><U+2605> <U+2715><U+2731><U+2712> <U+271E><U+261E><U+270D> <U+271E><U+2713><U+270D> <U+271E><U+2713><U+270D> <U+260E><U+2713><U+272B> <U+2706><U+2713><U+272B> <U+271F><U+2731><U+2729>
                              <U+2726><U+272E>                  <U+2741><U+2721>                  <U+2741><U+272E>
              <U+271E><U+2713><U+270D> <U+2706><U+2605><U+2733> <U+2725><U+2605><U+270D> <U+2725><U+2605><U+270D> <U+271E><U+270D><U+2746> <U+271E><U+261E><U+270D> <U+2723><U+261E><U+2605> <U+271F><U+2731><U+2713> <U+271F><U+2731><U+2729> <U+271F><U+2731><U+2713>
                          <U+2720><U+2721><U+2721>                 <U+2720><U+2721><U+272E>
              <U+2741><U+2714><U+2720><U+2721><U+261B>   <U+271A><U+271A>
              <U+2741><U+2714><U+2720><U+2720><U+261B>   <U+271A><U+2714><U+271B>
              <U+2741><U+2714><U+2720><U+2714><U+261B>   <U+2717><U+2704><U+2715>
              <U+2741><U+2714><U+2720><U+271A><U+261B>   <U+2715><U+270D><U+270E><U+272C><U+272F><U+272C><U+2730><U+272C><U+2712><U+2731> <U+2725><U+2605><U+2732><U+2733><U+2605><U+2729><U+2730><U+2605>
                                                 27

              <U+2741><U+2714><U+2714><U+2721><U+261B>
<removed-date>
              <U+2741><U+2714><U+2714><U+271A><U+261B>   <U+2712><U+2729><U+270E><U+272C><U+2734><U+270C><U+2735><U+2713>
              <U+2741><U+2722><U+2721><U+2721><U+261B> <U+271A><U+271A>
              <U+2730><U+2712><U+2763><U+2763><U+270E><U+270E><U+2730><U+2712><U+2763><U+2730> <U+270E><U+2763><U+2763><U+270E><U+2763><U+2730><U+2712><U+2763><U+270E><U+2730> <U+270E><U+2763><U+2763><U+2712><U+2763><U+2730><U+270E><U+2763><U+2712><U+2763> <U+2763><U+270E><U+2763><U+2712><U+2712><U+2763><U+2712><U+2712><U+2763><U+2730> <U+2730><U+270E><U+2763><U+2763><U+2763><U+2763><U+2730><U+2730><U+270E><U+2730> <U+2712><U+2763><U+270E><U+2763><U+2712><U+2712><U+2763><U+2763><U+270E><U+2730>
              <U+2727><U+2721>
              <U+270E><U+2730><U+2730><U+270E><U+2763><U+2730><U+2712><U+2712><U+2763><U+2763> <U+2730><U+270E><U+270E><U+2730><U+270E><U+2763><U+2763><U+2730><U+270E><U+2712> <U+2730><U+2763><U+270E><U+270E><U+270E><U+270E><U+270E><U+2712><U+2730><U+270E> <U+2712><U+2763><U+2730><U+270E><U+2712><U+2730><U+270E><U+2763><U+2763><U+2730> <U+270E><U+2763><U+2730><U+2712><U+2730><U+270E><U+2763><U+2763><U+2712><U+270E> <U+2730><U+2712><U+2763><U+2763><U+2730><U+2712><U+2763><U+270E><U+2730><U+2730>
              <U+2720><U+2714><U+2721>
<removed-apn>
              <U+2730><U+2730><U+2712><U+270E><U+2730><U+2763><U+2712><U+2763><U+2712><U+2763> <U+2763><U+2730><U+2730><U+270E><U+270E><U+2763><U+2712><U+2763><U+270E><U+2763> <U+2763><U+2730><U+270E><U+2763><U+2763><U+2763><U+270E><U+270E><U+2712><U+2730> <U+2712><U+270E><U+270E><U+2712><U+2712><U+270E><U+2730><U+2730><U+270E><U+2712> <U+2763><U+2763><U+2712><U+2712><U+270E><U+2763><U+2712><U+270E><U+270E><U+2712> <U+270E><U+2712><U+2730><U+270E><U+2763><U+2712><U+2763><U+270E><U+2712><U+2730>
              <U+2720><U+2726><U+2721>
              <U+2712><U+2712><U+270E><U+2730><U+2763><U+2763><U+2712><U+270E><U+270E><U+270E> <U+270E><U+2730><U+2712><U+2712><U+2763><U+2763><U+2763><U+2763><U+2712><U+2763> <U+2712><U+2730><U+270E><U+2730><U+2712><U+2730><U+2730><U+2712><U+270E><U+2730> <U+270E><U+2730><U+2730><U+2712><U+2712><U+2763><U+2763><U+2712><U+2730><U+2712> <U+2730><U+2730><U+270E><U+2730><U+2730><U+2712><U+2712><U+2712><U+2712><U+2712> <U+2730><U+2730><U+2712><U+2763><U+2763><U+270E><U+2763><U+2763><U+270E><U+2730>
              <U+2714><U+2722><U+2721>
              <U+2730><U+270E><U+270E><U+2712><U+2730><U+2712><U+2712><U+270E><U+2763><U+2712> <U+2730><U+2730><U+2712><U+2712><U+2730><U+2712><U+270E><U+2763><U+2763><U+2712> <U+2730><U+2730><U+2730><U+270E><U+2763><U+270E><U+2763><U+2763><U+2712><U+2730> <U+2712><U+2730><U+2712><U+2763><U+2730><U+2730><U+2712><U+2730><U+2763><U+270E> <U+2712><U+270E><U+270E><U+2712><U+2730><U+270E><U+2763><U+270E><U+2763><U+2730> <U+2712><U+2712><U+2763><U+2712><U+2712><U+2763><U+2763><U+2763><U+2763><U+2763>
              <U+271A><U+2721><U+2721>
              <U+2712><U+270E><U+270E><U+2712><U+2730><U+270E><U+2712><U+2730><U+2763><U+270E> <U+270E><U+2730><U+270E><U+2712><U+2730><U+270E><U+2763><U+2763><U+2763><U+2763> <U+2730><U+2730><U+2712><U+2763><U+2763><U+2763><U+2712>
              <U+271A><U+2714><U+271B>
              <U+2741><U+2714><U+2720><U+2721><U+261B>   <U+271A><U+2722>
              <U+2741><U+2714><U+2720><U+2720><U+261B>   <U+271A><U+2714><U+271B>
              <U+2741><U+2714><U+2720><U+2714><U+261B>   <U+2717><U+2704><U+2715>
              <U+2741><U+2714><U+2720><U+271A><U+261B>   <U+2715><U+270D><U+270E><U+272C><U+272F><U+272C><U+2730><U+272C><U+2712><U+2731> <U+2725><U+2605><U+2732><U+2733><U+2605><U+2729><U+2730><U+2605>
              <U+2741><U+2714><U+2714><U+2721><U+261B>
              <U+2741><U+2714><U+2714><U+271A><U+261B>   <U+2712><U+2729><U+270E><U+272C><U+2734><U+270C><U+2735><U+2713>
              <U+2741><U+2722><U+2721><U+2721><U+261B> <U+271A><U+2722>
              <U+2730><U+2712><U+2763><U+2763><U+270E><U+270E><U+2730><U+2712><U+2763><U+2730> <U+270E><U+2763><U+2763><U+270E><U+2763><U+2730><U+2712><U+2763><U+270E><U+2730> <U+270E><U+2763><U+2763><U+2712><U+2763><U+2730><U+270E><U+2763><U+2712><U+2763> <U+2763><U+270E><U+2763><U+2712><U+2712><U+2763><U+2712><U+2712><U+2763><U+2730> <U+2730><U+270E><U+2763><U+2763><U+2763><U+2763><U+2730><U+2730><U+270E><U+2730> <U+2712><U+2763><U+270E><U+2763><U+2712><U+2712><U+2763><U+2763><U+270E><U+2730>
              <U+2727><U+2721>
              <U+270E><U+2730><U+2730><U+270E><U+2763><U+2730><U+2712><U+2712><U+2763><U+2763> <U+2730><U+270E><U+270E><U+2730><U+270E><U+2763><U+2763><U+2730><U+270E><U+2712> <U+2730><U+2763><U+270E><U+270E><U+270E><U+270E><U+270E><U+2712><U+2730><U+270E> <U+2712><U+2763><U+2730><U+270E><U+2712><U+2730><U+270E><U+2763><U+2763><U+2730> <U+270E><U+2763><U+2730><U+2712><U+2730><U+270E><U+2763><U+2763><U+2712><U+270E> <U+2730><U+2712><U+2763><U+2763><U+2730><U+2712><U+2763><U+270E><U+2730><U+2730>
              <U+2720><U+2714><U+2721>
              <U+2730><U+2730><U+2712><U+270E><U+2730><U+2763><U+2712><U+2763><U+2712><U+2763> <U+2763><U+2730><U+2730><U+270E><U+270E><U+2763><U+2712><U+2763><U+270E><U+2763> <U+2763><U+2730><U+270E><U+2763><U+2763><U+2763><U+270E><U+270E><U+2712><U+2730> <U+2712><U+270E><U+270E><U+2712><U+2712><U+270E><U+2730><U+2730><U+270E><U+2712> <U+2763><U+2763><U+2712><U+2712><U+270E><U+2763><U+2712><U+270E><U+270E><U+2712> <U+270E><U+2712><U+2730><U+270E><U+2763><U+2712><U+2763><U+270E><U+2712><U+2730>
              <U+2720><U+2726><U+2721>
                                                 28

<removed-date>
              <U+2712><U+2712><U+270E><U+2730><U+2763><U+2763><U+2712><U+270E><U+270E><U+270E> <U+270E><U+2730><U+2712><U+2712><U+2763><U+2763><U+2763><U+2763><U+2712><U+2763> <U+2712><U+2730><U+270E><U+2730><U+2712><U+2730><U+2730><U+2712><U+270E><U+2730> <U+270E><U+2730><U+2730><U+2712><U+2712><U+2763><U+2763><U+2712><U+2730><U+2712> <U+2730><U+2730><U+270E><U+2730><U+2730><U+2712><U+2712><U+2712><U+2712><U+2712> <U+2730><U+2730><U+2712><U+2763><U+2763><U+270E><U+2763><U+2763><U+270E><U+2730>
              <U+2714><U+2722><U+2721>
              <U+2730><U+270E><U+270E><U+2712><U+2730><U+2712><U+2712><U+270E><U+2763><U+2712> <U+2730><U+2730><U+2712><U+2712><U+2730><U+2712><U+270E><U+2763><U+2763><U+2712> <U+2730><U+2730><U+2730><U+270E><U+2763><U+270E><U+2763><U+2763><U+2712><U+2730> <U+2712><U+2730><U+2712><U+2763><U+2730><U+2730><U+2712><U+2730><U+2763><U+270E> <U+2712><U+270E><U+270E><U+2712><U+2730><U+270E><U+2763><U+270E><U+2763><U+2730> <U+2712><U+2712><U+2763><U+2712><U+2712><U+2763><U+2763><U+2763><U+2763><U+2763>
              <U+271A><U+2721><U+2721>
              <U+2712><U+270E><U+270E><U+2712><U+2730><U+270E><U+2712><U+2730><U+2763><U+270E> <U+270E><U+2730><U+270E><U+2712><U+2730><U+270E><U+2763><U+2763><U+2763><U+2763> <U+2730><U+2730><U+2712><U+2763><U+2763><U+2763><U+2712>
              <U+271A><U+2714><U+271B>
<removed-apn>
              <U+2741><U+2714><U+2720><U+2721><U+261B>   <U+271A><U+272E>
              <U+2741><U+2714><U+2720><U+2720><U+261B>   <U+271A><U+2714><U+271B>
              <U+2741><U+2714><U+2720><U+2714><U+261B>   <U+2717><U+2704><U+2715>
              <U+2741><U+2714><U+2720><U+271A><U+261B>   <U+2715><U+270D><U+270E><U+272C><U+272F><U+272C><U+2730><U+272C><U+2712><U+2731> <U+2725><U+2605><U+2732><U+2733><U+2605><U+2729><U+2730><U+2605>
              <U+2741><U+2714><U+2714><U+2721><U+261B>
              <U+2741><U+2714><U+2714><U+271A><U+261B>   <U+2712><U+2729><U+270E><U+272C><U+2734><U+270C><U+2735><U+2713>
              <U+2741><U+2722><U+2721><U+2721><U+261B> <U+271A><U+272E>
              <U+2763><U+2712><U+2712><U+2763><U+270E><U+2763><U+2730><U+2712><U+2763><U+2730> <U+270E><U+2763><U+2763><U+270E><U+2763><U+2730><U+2712><U+2763><U+270E><U+2730> <U+270E><U+2763><U+2763><U+2712><U+2763><U+2730><U+2712><U+2763><U+2712><U+2763> <U+2763><U+270E><U+2763><U+2712><U+2712><U+2712><U+2712><U+2712><U+2763><U+2730> <U+2730><U+2730><U+2763><U+2763><U+2763><U+2763><U+2712><U+2763><U+270E><U+2730> <U+270E><U+2730><U+270E><U+2763><U+2712><U+2763><U+2763><U+2712><U+270E><U+2730>
              <U+2727><U+2721>
              <U+270E><U+2730><U+2730><U+270E><U+2763><U+270E><U+2712><U+2712><U+2763><U+2763> <U+2763><U+270E><U+270E><U+2730><U+270E><U+2763><U+2763><U+2730><U+270E><U+2712> <U+2730><U+2763><U+270E><U+270E><U+270E><U+270E><U+270E><U+2712><U+2730><U+270E> <U+2712><U+2763><U+2730><U+270E><U+2712><U+2730><U+270E><U+2763><U+2763><U+2730> <U+270E><U+2763><U+2730><U+2712><U+2730><U+270E><U+2763><U+2763><U+2763><U+270E> <U+2763><U+2730><U+2763><U+2712><U+2730><U+2712><U+2763><U+2763><U+2730><U+2730>
              <U+2720><U+2714><U+2721>
              <U+2730><U+2730><U+270E><U+2763><U+2763><U+2712><U+2730><U+2712><U+2712><U+2763> <U+2763><U+2763><U+2730><U+270E><U+270E><U+2763><U+2712><U+2763><U+270E><U+2763> <U+2763><U+2712><U+270E><U+2763><U+2763><U+2763><U+270E><U+270E><U+2712><U+2730> <U+2712><U+270E><U+270E><U+2712><U+2712><U+270E><U+2730><U+2730><U+270E><U+2712> <U+2763><U+2763><U+2712><U+2712><U+270E><U+2763><U+2712><U+270E><U+270E><U+2712> <U+270E><U+2712><U+2730><U+270E><U+2763><U+2712><U+2763><U+270E><U+2712><U+2730>
              <U+2720><U+2726><U+2721>
              <U+2712><U+2712><U+270E><U+2730><U+2763><U+2763><U+2712><U+270E><U+270E><U+270E> <U+270E><U+2730><U+2712><U+2712><U+2763><U+2763><U+2763><U+2763><U+2712><U+2763> <U+2712><U+2763><U+270E><U+2730><U+2712><U+2730><U+2763><U+2712><U+270E><U+270E> <U+2712><U+2730><U+2730><U+2763><U+2730><U+2763><U+2763><U+2712><U+2730><U+2712> <U+2712><U+2712><U+270E><U+2730><U+2730><U+2712><U+2730><U+2763><U+2712><U+2763> <U+2730><U+2712><U+2730><U+2712><U+2763><U+2730><U+2730><U+270E><U+2712><U+2730>
              <U+2714><U+2722><U+2721>
              <U+2712><U+270E><U+2763><U+2763><U+2712><U+2763><U+2730><U+270E><U+2763><U+2712> <U+2763><U+2730><U+2712><U+2763><U+2730><U+2730><U+270E><U+2763><U+2712><U+2763> <U+2712><U+270E><U+2730><U+270E><U+2763><U+2712><U+2763><U+2763><U+2712><U+2730> <U+2712><U+2730><U+2763><U+2763><U+2730><U+2730><U+2763><U+270E><U+2763><U+270E> <U+2712><U+270E><U+270E><U+2712><U+2730><U+270E><U+2763><U+270E><U+2763><U+2730> <U+2763><U+2712><U+2763><U+2712><U+2712><U+2763><U+2763><U+2763><U+2763><U+2763>
              <U+271A><U+2721><U+2721>
              <U+2712><U+270E><U+270E><U+2712><U+2730><U+270E><U+2712><U+2730><U+2763><U+270E> <U+270E><U+2730><U+270E><U+2712><U+2730><U+270E><U+2763><U+2763><U+2763><U+2763> <U+2730><U+2730><U+2712><U+2763><U+2763><U+2763><U+2712>
              <U+271A><U+2714><U+271B>
              <U+2741><U+2714><U+2720><U+2721><U+261B>   <U+271A><U+2727>
                                                 29

              <U+2741><U+2714><U+2720><U+2720><U+261B>   <U+271A><U+2714><U+271B>
<removed-date>
              <U+2741><U+2714><U+2720><U+2714><U+261B>   <U+2717><U+2704><U+2715>
              <U+2741><U+2714><U+2720><U+271A><U+261B>   <U+2715><U+270D><U+270E><U+272C><U+272F><U+272C><U+2730><U+272C><U+2712><U+2731> <U+2725><U+2605><U+2732><U+2733><U+2605><U+2729><U+2730><U+2605>
              <U+2741><U+2714><U+2714><U+2721><U+261B>
              <U+2741><U+2714><U+2714><U+271A><U+261B>   <U+2712><U+2729><U+270E><U+272C><U+2734><U+270C><U+2735><U+2713>
              <U+2741><U+2722><U+2721><U+2721><U+261B> <U+271A><U+2727>
              <U+2763><U+2712><U+2763><U+2763><U+270E><U+2730><U+2730><U+2712><U+2763><U+2730> <U+270E><U+2763><U+2763><U+270E><U+2712><U+2730><U+2712><U+2763><U+270E><U+2730> <U+270E><U+2763><U+2763><U+2763><U+2763><U+2730><U+270E><U+2763><U+2712><U+2763> <U+2763><U+270E><U+2763><U+2712><U+2712><U+2763><U+2712><U+2712><U+2763><U+2730> <U+2730><U+270E><U+2763><U+2763><U+2763><U+2763><U+2730><U+270E><U+2712><U+2730> <U+2712><U+2763><U+270E><U+2763><U+2712><U+2712><U+2712><U+2712><U+270E><U+2730>
<removed-apn>
              <U+2727><U+2721>
              <U+270E><U+2730><U+2730><U+270E><U+2763><U+2730><U+2712><U+2712><U+2763><U+2763> <U+270E><U+270E><U+270E><U+2730><U+270E><U+2763><U+2763><U+2730><U+270E><U+2712> <U+2730><U+2763><U+270E><U+270E><U+270E><U+270E><U+270E><U+2712><U+2730><U+270E> <U+2712><U+2763><U+2730><U+270E><U+2712><U+2730><U+270E><U+2763><U+2763><U+2730> <U+270E><U+2763><U+2730><U+2712><U+2730><U+270E><U+2763><U+2763><U+2712><U+270E> <U+2730><U+2712><U+2763><U+2763><U+2730><U+2712><U+2763><U+270E><U+2730><U+2730>
              <U+2720><U+2714><U+2721>
              <U+2730><U+2730><U+2712><U+270E><U+2730><U+2763><U+2712><U+2763><U+2712><U+2763> <U+2763><U+2730><U+2730><U+270E><U+270E><U+2763><U+2712><U+2763><U+270E><U+2763> <U+2763><U+2730><U+270E><U+2763><U+2763><U+2763><U+270E><U+270E><U+2712><U+2730> <U+2712><U+270E><U+270E><U+2712><U+2712><U+270E><U+2730><U+2730><U+270E><U+2712> <U+2763><U+2763><U+2712><U+2712><U+270E><U+2763><U+2712><U+270E><U+270E><U+2712> <U+270E><U+2712><U+2730><U+270E><U+2763><U+2712><U+2763><U+270E><U+2712><U+2730>
              <U+2720><U+2726><U+2721>
              <U+2712><U+2712><U+270E><U+2730><U+2763><U+2763><U+2712><U+270E><U+270E><U+270E> <U+270E><U+2730><U+2712><U+2712><U+2763><U+2763><U+2763><U+2763><U+2712><U+2763> <U+2712><U+270E><U+270E><U+270E><U+2763><U+270E><U+2730><U+270E><U+270E><U+2730> <U+270E><U+2730><U+2730><U+270E><U+270E><U+2763><U+2763><U+2712><U+2730><U+2712> <U+2730><U+2730><U+270E><U+2730><U+270E><U+2763><U+270E><U+2730><U+2712><U+2763> <U+2730><U+2712><U+2730><U+2763><U+2763><U+2730><U+2712><U+270E><U+2712><U+270E>
              <U+2714><U+2722><U+2721>
              <U+2730><U+270E><U+2763><U+2730><U+2712><U+2763><U+2712><U+270E><U+2730><U+270E> <U+2763><U+2730><U+2712><U+2763><U+2730><U+2730><U+270E><U+2712><U+2712><U+2712> <U+2763><U+2763><U+2730><U+270E><U+2763><U+2712><U+2763><U+2763><U+2712><U+2730> <U+2712><U+2730><U+270E><U+2763><U+2730><U+2730><U+2763><U+270E><U+2763><U+270E> <U+2712><U+270E><U+270E><U+2712><U+2730><U+270E><U+2763><U+270E><U+2763><U+2730> <U+2763><U+2712><U+2763><U+2712><U+2712><U+2763><U+2763><U+2763><U+2763><U+2763>
              <U+271A><U+2721><U+2721>
              <U+2712><U+270E><U+270E><U+2712><U+2730><U+270E><U+2712><U+2730><U+2763><U+270E> <U+270E><U+2730><U+270E><U+2712><U+2730><U+270E><U+2763><U+2763><U+2763><U+2763> <U+2730><U+2730><U+2712><U+2763><U+2763><U+2763><U+2712>
              <U+271A><U+2714><U+271B>
              <U+2741><U+2714><U+2720><U+2721><U+261B>   <U+271A><U+271B>
              <U+2741><U+2714><U+2720><U+2720><U+261B>   <U+271A><U+2714><U+271B>
              <U+2741><U+2714><U+2720><U+2714><U+261B>   <U+2717><U+2704><U+2715>
              <U+2741><U+2714><U+2720><U+271A><U+261B>   <U+2715><U+270D><U+270E><U+272C><U+272F><U+272C><U+2730><U+272C><U+2712><U+2731> <U+2725><U+2605><U+2732><U+2733><U+2605><U+2729><U+2730><U+2605>
              <U+2741><U+2714><U+2714><U+2721><U+261B>
              <U+2741><U+2714><U+2714><U+271A><U+261B>   <U+2712><U+2729><U+270E><U+272C><U+2734><U+270C><U+2735><U+2713>
              <U+2741><U+2722><U+2721><U+2721><U+261B> <U+271A><U+271B>
              <U+2763><U+2712><U+2763><U+2763><U+270E><U+2730><U+2730><U+2712><U+2763><U+2730> <U+270E><U+2763><U+2763><U+270E><U+2712><U+2730><U+2712><U+2763><U+270E><U+2730> <U+270E><U+2763><U+2763><U+2763><U+2763><U+2730><U+270E><U+2763><U+2712><U+2763> <U+2763><U+270E><U+2763><U+2712><U+2712><U+2763><U+2712><U+2712><U+2763><U+2730> <U+2730><U+270E><U+2763><U+2763><U+2763><U+2763><U+2730><U+270E><U+2712><U+2730> <U+2712><U+2763><U+270E><U+2763><U+2712><U+2712><U+2712><U+2712><U+270E><U+2730>
              <U+2727><U+2721>
                                                 30

              <U+270E><U+2730><U+2730><U+270E><U+2763><U+2730><U+2712><U+2712><U+2763><U+2763> <U+270E><U+270E><U+270E><U+2730><U+270E><U+2763><U+2763><U+2730><U+270E><U+2712> <U+2730><U+2763><U+270E><U+270E><U+270E><U+270E><U+270E><U+2712><U+2730><U+270E> <U+2712><U+2763><U+2730><U+270E><U+2712><U+2730><U+270E><U+2763><U+2763><U+2730> <U+270E><U+2763><U+2730><U+2712><U+2730><U+270E><U+2763><U+2763><U+2712><U+270E> <U+2730><U+2712><U+2763><U+2763><U+2730><U+2712><U+2763><U+270E><U+2730><U+2730>
<removed-date>
              <U+2720><U+2714><U+2721>
              <U+2730><U+2730><U+2712><U+270E><U+2730><U+2763><U+2712><U+2763><U+2712><U+2763> <U+2763><U+2730><U+2730><U+270E><U+270E><U+2763><U+2712><U+2763><U+270E><U+2763> <U+2763><U+2730><U+270E><U+2763><U+2763><U+2763><U+270E><U+270E><U+2712><U+2730> <U+2712><U+270E><U+270E><U+2712><U+2712><U+270E><U+2730><U+2730><U+270E><U+2712> <U+2763><U+2763><U+2712><U+2712><U+270E><U+2763><U+2712><U+270E><U+270E><U+2712> <U+270E><U+2712><U+2730><U+270E><U+2763><U+2712><U+2763><U+270E><U+2712><U+2730>
              <U+2720><U+2726><U+2721>
              <U+2712><U+2712><U+270E><U+2730><U+2763><U+2763><U+2712><U+270E><U+270E><U+270E> <U+270E><U+2730><U+2712><U+2712><U+2763><U+2763><U+2763><U+2763><U+2712><U+2763> <U+2712><U+270E><U+270E><U+270E><U+2763><U+270E><U+2730><U+270E><U+270E><U+2730> <U+270E><U+2730><U+2730><U+270E><U+270E><U+2763><U+2763><U+2712><U+2730><U+2712> <U+2730><U+2730><U+270E><U+2730><U+270E><U+2763><U+270E><U+2730><U+2712><U+2763> <U+2730><U+2712><U+2730><U+2763><U+2763><U+2730><U+2712><U+270E><U+2712><U+270E>
              <U+2714><U+2722><U+2721>
<removed-apn>
              <U+2730><U+270E><U+2763><U+2730><U+2712><U+2763><U+2712><U+270E><U+2730><U+270E> <U+2763><U+2730><U+2712><U+2763><U+2730><U+2730><U+270E><U+2712><U+2712><U+2712> <U+2763><U+2763><U+2730><U+270E><U+2763><U+2712><U+2763><U+2763><U+2712><U+2730> <U+2712><U+2730><U+270E><U+2763><U+2730><U+2730><U+2763><U+270E><U+2763><U+270E> <U+2712><U+270E><U+270E><U+2712><U+2730><U+270E><U+2763><U+270E><U+2763><U+2730> <U+2763><U+2712><U+2763><U+2712><U+2712><U+2763><U+2763><U+2763><U+2763><U+2763>
              <U+271A><U+2721><U+2721>
              <U+2712><U+270E><U+270E><U+2712><U+2730><U+270E><U+2712><U+2730><U+2763><U+270E> <U+270E><U+2730><U+270E><U+2712><U+2730><U+270E><U+2763><U+2763><U+2763><U+2763> <U+2730><U+2730><U+2712><U+2763><U+2763><U+2763><U+2712>
              <U+271A><U+2714><U+271B>
              <U+2741><U+2714><U+2720><U+2721><U+261B>   <U+271A><U+2726>
              <U+2741><U+2714><U+2720><U+2720><U+261B>   <U+271A><U+2714><U+271B>
              <U+2741><U+2714><U+2720><U+2714><U+261B>   <U+2717><U+2704><U+2715>
              <U+2741><U+2714><U+2720><U+271A><U+261B>   <U+2715><U+270D><U+270E><U+272C><U+272F><U+272C><U+2730><U+272C><U+2712><U+2731> <U+2725><U+2605><U+2732><U+2733><U+2605><U+2729><U+2730><U+2605>
              <U+2741><U+2714><U+2714><U+2721><U+261B>
              <U+2741><U+2714><U+2714><U+271A><U+261B>   <U+2712><U+2729><U+270E><U+272C><U+2734><U+270C><U+2735><U+2713>
              <U+2741><U+2722><U+2721><U+2721><U+261B> <U+271A><U+2726>
              <U+2763><U+2712><U+2763><U+2763><U+270E><U+2730><U+2730><U+2712><U+2763><U+2730> <U+270E><U+2763><U+2763><U+270E><U+2712><U+2730><U+2712><U+2763><U+270E><U+2730> <U+270E><U+2763><U+2763><U+2763><U+2763><U+2730><U+270E><U+2763><U+2712><U+2763> <U+2763><U+270E><U+2763><U+2712><U+2712><U+2763><U+2712><U+2712><U+2763><U+2730> <U+2730><U+270E><U+2763><U+2763><U+2763><U+2763><U+2730><U+270E><U+2712><U+2730> <U+2712><U+2763><U+270E><U+2763><U+2712><U+2712><U+2712><U+2712><U+270E><U+2730>
              <U+2727><U+2721>
              <U+270E><U+2730><U+2730><U+270E><U+2763><U+2730><U+2712><U+2712><U+2763><U+2763> <U+270E><U+270E><U+270E><U+2730><U+270E><U+2763><U+2763><U+2730><U+270E><U+2712> <U+2730><U+2763><U+270E><U+270E><U+270E><U+270E><U+270E><U+2712><U+2730><U+270E> <U+2712><U+2763><U+2730><U+270E><U+2712><U+2730><U+270E><U+2763><U+2763><U+2730> <U+270E><U+2763><U+2730><U+2712><U+2730><U+270E><U+2763><U+2763><U+2712><U+270E> <U+2730><U+2712><U+2763><U+2763><U+2730><U+2712><U+2763><U+270E><U+2730><U+2730>
              <U+2720><U+2714><U+2721>
              <U+2730><U+2730><U+2712><U+270E><U+2730><U+2763><U+2712><U+2763><U+2712><U+2763> <U+2763><U+2730><U+2730><U+270E><U+270E><U+2763><U+2712><U+2763><U+270E><U+2763> <U+2763><U+2730><U+270E><U+2763><U+2763><U+2763><U+270E><U+270E><U+2712><U+2730> <U+2712><U+270E><U+270E><U+2712><U+2712><U+270E><U+2730><U+2730><U+270E><U+2712> <U+2763><U+2763><U+2712><U+2712><U+270E><U+2763><U+2712><U+270E><U+270E><U+2712> <U+270E><U+2712><U+2730><U+270E><U+2763><U+2712><U+2763><U+270E><U+2712><U+2730>
              <U+2720><U+2726><U+2721>
              <U+2712><U+2712><U+270E><U+2730><U+2763><U+2763><U+2712><U+270E><U+270E><U+270E> <U+270E><U+2730><U+2712><U+2712><U+2763><U+2763><U+2763><U+2763><U+2712><U+2763> <U+2712><U+270E><U+270E><U+270E><U+2763><U+270E><U+2730><U+270E><U+270E><U+2730> <U+270E><U+2730><U+2730><U+270E><U+270E><U+2763><U+2763><U+2712><U+2730><U+2712> <U+2730><U+2730><U+270E><U+2730><U+270E><U+2763><U+270E><U+2730><U+2712><U+2763> <U+2730><U+2712><U+2730><U+2763><U+2763><U+2730><U+2712><U+270E><U+2712><U+270E>
              <U+2714><U+2722><U+2721>
              <U+2730><U+270E><U+2763><U+2730><U+2712><U+2763><U+2712><U+270E><U+2730><U+270E> <U+2763><U+2730><U+2712><U+2763><U+2730><U+2730><U+270E><U+2712><U+2712><U+2712> <U+2763><U+2763><U+2730><U+270E><U+2763><U+2712><U+2763><U+2763><U+2712><U+2730> <U+2712><U+2730><U+270E><U+2763><U+2730><U+2730><U+2763><U+270E><U+2763><U+270E> <U+2712><U+270E><U+270E><U+2712><U+2730><U+270E><U+2763><U+270E><U+2763><U+2730> <U+2763><U+2712><U+2763><U+2712><U+2712><U+2763><U+2763><U+2763><U+2763><U+2763>
              <U+271A><U+2721><U+2721>
                                                 31

              <U+2712><U+270E><U+270E><U+2712><U+2730><U+270E><U+2712><U+2730><U+2763><U+270E> <U+270E><U+2730><U+270E><U+2712><U+2730><U+270E><U+2763><U+2763><U+2763><U+2763> <U+2730><U+2730><U+2712><U+2763><U+2763><U+2763><U+2712>
<removed-date>
              <U+271A><U+2714><U+271B>
              <U+2741><U+2714><U+2720><U+2721><U+261B>   <U+271A><U+2741>
              <U+2741><U+2714><U+2720><U+2720><U+261B>   <U+271A><U+2714><U+271B>
              <U+2741><U+2714><U+2720><U+2714><U+261B>   <U+2717><U+2704><U+2715>
              <U+2741><U+2714><U+2720><U+271A><U+261B>   <U+2715><U+270D><U+270E><U+272C><U+272F><U+272C><U+2730><U+272C><U+2712><U+2731> <U+2725><U+2605><U+2732><U+2733><U+2605><U+2729><U+2730><U+2605>
<removed-apn>
              <U+2741><U+2714><U+2714><U+2721><U+261B>
              <U+2741><U+2714><U+2714><U+271A><U+261B>   <U+2712><U+2729><U+270E><U+272C><U+2734><U+270C><U+2735><U+2713>
              <U+2741><U+2722><U+2721><U+2721><U+261B> <U+271A><U+2741>
              <U+2730><U+2712><U+2763><U+2763><U+270E><U+270E><U+2730><U+2712><U+2763><U+2730> <U+270E><U+2763><U+2763><U+270E><U+2763><U+2730><U+2712><U+2763><U+270E><U+2730> <U+270E><U+2763><U+2763><U+2712><U+2763><U+2730><U+270E><U+2763><U+2712><U+2763> <U+2763><U+270E><U+2763><U+2712><U+2712><U+2763><U+2712><U+2712><U+2763><U+2730> <U+2730><U+270E><U+2763><U+2763><U+2763><U+2763><U+2730><U+2730><U+270E><U+2730> <U+2712><U+2763><U+270E><U+2763><U+2712><U+2712><U+2763><U+2763><U+270E><U+2730>
              <U+2727><U+2721>
              <U+270E><U+2730><U+2730><U+270E><U+2763><U+2730><U+2712><U+2712><U+2763><U+2763> <U+2730><U+270E><U+270E><U+2730><U+270E><U+2763><U+2763><U+2730><U+270E><U+2712> <U+2730><U+2763><U+270E><U+270E><U+270E><U+270E><U+270E><U+2712><U+2730><U+270E> <U+2712><U+2763><U+2730><U+270E><U+2712><U+2730><U+270E><U+2763><U+2763><U+2730> <U+270E><U+2763><U+2730><U+2712><U+2730><U+270E><U+2763><U+2763><U+2712><U+270E> <U+2730><U+2712><U+2763><U+2763><U+2730><U+2712><U+2763><U+270E><U+2730><U+2730>
              <U+2720><U+2714><U+2721>
              <U+2730><U+2730><U+2712><U+270E><U+2730><U+2763><U+2712><U+2763><U+2712><U+2763> <U+2763><U+2730><U+2730><U+270E><U+270E><U+2763><U+2712><U+2763><U+270E><U+2763> <U+2763><U+2730><U+270E><U+2763><U+2763><U+2763><U+270E><U+270E><U+2712><U+2730> <U+2712><U+270E><U+270E><U+2712><U+2712><U+270E><U+2730><U+2730><U+270E><U+2712> <U+2763><U+2763><U+2712><U+2712><U+270E><U+2763><U+2712><U+270E><U+270E><U+2712> <U+270E><U+2712><U+2730><U+270E><U+2763><U+2712><U+2763><U+270E><U+2712><U+2730>
              <U+2720><U+2726><U+2721>
              <U+2712><U+2712><U+270E><U+2730><U+2763><U+2763><U+2712><U+270E><U+270E><U+270E> <U+270E><U+2730><U+2712><U+2712><U+2763><U+2763><U+2763><U+2763><U+2712><U+2763> <U+2712><U+270E><U+270E><U+270E><U+2763><U+270E><U+2730><U+270E><U+270E><U+2730> <U+270E><U+2730><U+2730><U+270E><U+270E><U+2763><U+2763><U+2712><U+2730><U+2712> <U+2730><U+2730><U+270E><U+2730><U+270E><U+2763><U+270E><U+2730><U+2712><U+2763> <U+2730><U+2712><U+2730><U+2763><U+2763><U+2730><U+2712><U+270E><U+2712><U+270E>
              <U+2714><U+2722><U+2721>
              <U+2730><U+270E><U+2763><U+2730><U+2712><U+2763><U+2712><U+270E><U+2730><U+270E> <U+2763><U+2730><U+2712><U+2763><U+2730><U+2730><U+270E><U+2712><U+2712><U+2712> <U+2763><U+2763><U+2730><U+270E><U+2763><U+2712><U+2763><U+2763><U+2712><U+2730> <U+2712><U+2730><U+270E><U+2763><U+2730><U+2730><U+2763><U+270E><U+2763><U+270E> <U+2712><U+270E><U+270E><U+2712><U+2730><U+270E><U+2763><U+270E><U+2763><U+2730> <U+2763><U+2712><U+2763><U+2712><U+2712><U+2763><U+2763><U+2763><U+2763><U+2763>
              <U+271A><U+2721><U+2721>
              <U+2712><U+270E><U+270E><U+2712><U+2730><U+270E><U+2712><U+2730><U+2763><U+270E> <U+270E><U+2730><U+270E><U+2712><U+2730><U+270E><U+2763><U+2763><U+2763><U+2763> <U+2730><U+2730><U+2712><U+2763><U+2763><U+2763><U+2712>
              <U+271A><U+2714><U+271B>
              <U+2741><U+2714><U+2720><U+2721><U+261B>   <U+2722><U+2721>
              <U+2741><U+2714><U+2720><U+2720><U+261B>   <U+271A><U+2714><U+271B>
              <U+2741><U+2714><U+2720><U+2714><U+261B>   <U+2717><U+2704><U+2715>
              <U+2741><U+2714><U+2720><U+271A><U+261B>   <U+2715><U+270D><U+270E><U+272C><U+272F><U+272C><U+2730><U+272C><U+2712><U+2731> <U+2725><U+2605><U+2732><U+2733><U+2605><U+2729><U+2730><U+2605>
              <U+2741><U+2714><U+2714><U+2721><U+261B>
              <U+2741><U+2714><U+2714><U+271A><U+261B>   <U+2712><U+2729><U+270E><U+272C><U+2734><U+270C><U+2735><U+2713>
                                                 32

              <U+2741><U+2722><U+2721><U+2721><U+261B> <U+2722><U+2721>
<removed-date>
              <U+2730><U+2712><U+2763><U+2763><U+270E><U+270E><U+2730><U+2712><U+2763><U+2730> <U+270E><U+2763><U+2763><U+270E><U+2763><U+2730><U+2712><U+2763><U+270E><U+2730> <U+270E><U+2763><U+2763><U+2712><U+2763><U+2730><U+270E><U+2763><U+2712><U+2763> <U+2763><U+270E><U+2763><U+2712><U+2712><U+2763><U+2712><U+2712><U+2763><U+2730> <U+2730><U+270E><U+2763><U+2763><U+2763><U+2763><U+2730><U+2730><U+270E><U+2730> <U+2712><U+2763><U+270E><U+2763><U+2712><U+2712><U+2763><U+2763><U+270E><U+2730>
              <U+2727><U+2721>
              <U+270E><U+2730><U+2730><U+270E><U+2763><U+2730><U+2712><U+2712><U+2763><U+2763> <U+2730><U+270E><U+270E><U+2730><U+270E><U+2763><U+2763><U+2730><U+270E><U+2712> <U+2730><U+2763><U+270E><U+270E><U+270E><U+270E><U+270E><U+2712><U+2730><U+270E> <U+2712><U+2763><U+2730><U+270E><U+2712><U+2730><U+270E><U+2763><U+2763><U+2730> <U+270E><U+2763><U+2730><U+2712><U+2730><U+270E><U+2763><U+2763><U+2763><U+270E> <U+2763><U+2730><U+2763><U+2712><U+2730><U+2712><U+2763><U+2763><U+2730><U+270E>
              <U+2720><U+2714><U+2721>
              <U+2730><U+2763><U+270E><U+2763><U+2763><U+2712><U+2730><U+2712><U+2712><U+2730> <U+2763><U+2730><U+2730><U+270E><U+270E><U+2763><U+2712><U+2763><U+270E><U+2763> <U+2763><U+2712><U+270E><U+2712><U+2763><U+2763><U+270E><U+270E><U+2712><U+2730> <U+2712><U+270E><U+270E><U+2712><U+2712><U+270E><U+2730><U+2730><U+270E><U+2712> <U+2763><U+2763><U+2712><U+2712><U+270E><U+2763><U+2712><U+270E><U+270E><U+2712> <U+270E><U+2712><U+2730><U+270E><U+2763><U+2712><U+2763><U+270E><U+2712><U+2730>
              <U+2720><U+2726><U+2721>
<removed-apn>
              <U+2712><U+2712><U+270E><U+2730><U+2763><U+2763><U+2712><U+270E><U+270E><U+270E> <U+270E><U+2730><U+2712><U+2712><U+2763><U+2763><U+2763><U+2763><U+2712><U+2763> <U+2712><U+2763><U+270E><U+2730><U+2712><U+2730><U+2763><U+2712><U+270E><U+270E> <U+2712><U+2730><U+2730><U+2763><U+2730><U+2763><U+2763><U+2712><U+2730><U+2712> <U+2712><U+2712><U+270E><U+2730><U+2730><U+2712><U+2730><U+2763><U+2712><U+2763> <U+2730><U+2712><U+2730><U+2712><U+2763><U+2730><U+2730><U+270E><U+2712><U+2730>
              <U+2714><U+2722><U+2721>
              <U+2712><U+270E><U+2763><U+2763><U+2712><U+2763><U+2730><U+270E><U+2763><U+2712> <U+2763><U+2730><U+2712><U+2763><U+2730><U+2730><U+270E><U+2763><U+2712><U+2763> <U+2712><U+270E><U+2730><U+270E><U+2763><U+2712><U+2763><U+2763><U+2712><U+2730> <U+2712><U+2730><U+2763><U+2763><U+2730><U+2730><U+2763><U+270E><U+2763><U+270E> <U+2712><U+270E><U+270E><U+2712><U+2730><U+270E><U+2763><U+270E><U+2763><U+2730> <U+2763><U+2712><U+2763><U+2712><U+2712><U+2763><U+2763><U+2763><U+2763><U+2763>
              <U+271A><U+2721><U+2721>
              <U+2712><U+270E><U+270E><U+2712><U+2730><U+270E><U+2712><U+2730><U+2763><U+270E> <U+270E><U+2730><U+270E><U+2712><U+2730><U+270E><U+2763><U+2763><U+2763><U+2763> <U+2730><U+2730><U+2712><U+2763><U+2763><U+2763><U+2712>
              <U+271A><U+2714><U+271B>
              <U+2741><U+2714><U+2720><U+2721><U+261B>   <U+2722><U+2720>
              <U+2741><U+2714><U+2720><U+2720><U+261B>   <U+271A><U+2714><U+271B>
              <U+2741><U+2714><U+2720><U+2714><U+261B>   <U+2717><U+2704><U+2715>
              <U+2741><U+2714><U+2720><U+271A><U+261B>   <U+2715><U+270D><U+270E><U+272C><U+272F><U+272C><U+2730><U+272C><U+2712><U+2731> <U+2725><U+2605><U+2732><U+2733><U+2605><U+2729><U+2730><U+2605>
              <U+2741><U+2714><U+2714><U+2721><U+261B>
              <U+2741><U+2714><U+2714><U+271A><U+261B>   <U+2712><U+2729><U+270E><U+272C><U+2734><U+270C><U+2735><U+2713>
              <U+2741><U+2722><U+2721><U+2721><U+261B> <U+2722><U+2720>
              <U+2730><U+2712><U+2763><U+2763><U+270E><U+270E><U+2730><U+2712><U+2763><U+2730> <U+270E><U+2763><U+2763><U+270E><U+2763><U+2730><U+2712><U+2763><U+270E><U+2730> <U+270E><U+2763><U+2763><U+2712><U+2763><U+2730><U+270E><U+2763><U+2712><U+2763> <U+2763><U+270E><U+2763><U+2712><U+2712><U+2763><U+2712><U+2712><U+2763><U+2730> <U+2730><U+270E><U+2763><U+2763><U+2763><U+2763><U+2730><U+2730><U+270E><U+2730> <U+2712><U+2763><U+270E><U+2763><U+2712><U+2712><U+2763><U+2763><U+270E><U+2730>
              <U+2727><U+2721>
              <U+270E><U+2730><U+2730><U+270E><U+2763><U+2730><U+2712><U+2712><U+2763><U+2763> <U+2730><U+270E><U+270E><U+2730><U+270E><U+2763><U+2763><U+2730><U+270E><U+2712> <U+2730><U+2763><U+270E><U+270E><U+270E><U+270E><U+270E><U+2712><U+2730><U+270E> <U+2712><U+2763><U+2730><U+270E><U+2712><U+2730><U+270E><U+2763><U+2763><U+2730> <U+270E><U+2763><U+2730><U+2712><U+2730><U+270E><U+2763><U+2763><U+2763><U+270E> <U+2763><U+2730><U+2763><U+2712><U+2730><U+2712><U+2763><U+2763><U+2730><U+270E>
              <U+2720><U+2714><U+2721>
              <U+2730><U+2763><U+270E><U+2763><U+2763><U+2712><U+2730><U+2712><U+2712><U+2730> <U+2763><U+2730><U+2730><U+270E><U+270E><U+2763><U+2712><U+2763><U+270E><U+2763> <U+2763><U+2712><U+270E><U+2712><U+2763><U+2763><U+270E><U+270E><U+2712><U+2730> <U+2712><U+270E><U+270E><U+2712><U+2712><U+270E><U+2730><U+2730><U+270E><U+2712> <U+2763><U+2763><U+2712><U+2712><U+270E><U+2763><U+2712><U+270E><U+270E><U+2712> <U+270E><U+2712><U+2730><U+270E><U+2763><U+2712><U+2763><U+270E><U+2712><U+2730>
              <U+2720><U+2726><U+2721>
              <U+2712><U+2712><U+270E><U+2730><U+2763><U+2763><U+2712><U+270E><U+270E><U+270E> <U+270E><U+2730><U+2712><U+2712><U+2763><U+2763><U+2763><U+2763><U+2712><U+2763> <U+2712><U+2763><U+270E><U+2730><U+2712><U+2730><U+2763><U+2712><U+270E><U+270E> <U+2712><U+2730><U+2730><U+2763><U+2730><U+2763><U+2763><U+2712><U+2730><U+2712> <U+2712><U+2712><U+270E><U+2730><U+2730><U+2712><U+2730><U+2763><U+2712><U+2763> <U+2730><U+2712><U+2730><U+2712><U+2763><U+2730><U+2730><U+270E><U+2712><U+2730>
              <U+2714><U+2722><U+2721>
                                                 33

<removed-date>
              <U+2712><U+270E><U+2763><U+2763><U+2712><U+2763><U+2730><U+270E><U+2763><U+2712> <U+2763><U+2730><U+2712><U+2763><U+2730><U+2730><U+270E><U+2763><U+2712><U+2763> <U+2712><U+270E><U+2730><U+270E><U+2763><U+2712><U+2763><U+2763><U+2712><U+2730> <U+2712><U+2730><U+2763><U+2763><U+2730><U+2730><U+2763><U+270E><U+2763><U+270E> <U+2712><U+270E><U+270E><U+2712><U+2730><U+270E><U+2763><U+270E><U+2763><U+2730> <U+2763><U+2712><U+2763><U+2712><U+2712><U+2763><U+2763><U+2763><U+2763><U+2763>
              <U+271A><U+2721><U+2721>
              <U+2712><U+270E><U+270E><U+2712><U+2730><U+270E><U+2712><U+2730><U+2763><U+270E> <U+270E><U+2730><U+270E><U+2712><U+2730><U+270E><U+2763><U+2763><U+2763><U+2763> <U+2730><U+2730><U+2712><U+2763><U+2763><U+2763><U+2712>
              <U+271A><U+2714><U+271B>
              <U+2741><U+2714><U+2720><U+2721><U+261B>   <U+2722><U+2714>
<removed-apn>
              <U+2741><U+2714><U+2720><U+2720><U+261B>   <U+271A><U+2714><U+271B>
              <U+2741><U+2714><U+2720><U+2714><U+261B>   <U+2717><U+2704><U+2715>
              <U+2741><U+2714><U+2720><U+271A><U+261B>   <U+2715><U+270D><U+270E><U+272C><U+272F><U+272C><U+2730><U+272C><U+2712><U+2731> <U+2725><U+2605><U+2732><U+2733><U+2605><U+2729><U+2730><U+2605>
              <U+2741><U+2714><U+2714><U+2721><U+261B>
              <U+2741><U+2714><U+2714><U+271A><U+261B>   <U+2712><U+2729><U+270E><U+272C><U+2734><U+270C><U+2735><U+2713>
              <U+2741><U+2722><U+2721><U+2721><U+261B> <U+2722><U+2714>
              <U+2730><U+2712><U+2763><U+2763><U+270E><U+270E><U+2730><U+2712><U+2763><U+2730> <U+270E><U+2763><U+2763><U+270E><U+2763><U+2730><U+2712><U+2763><U+270E><U+2730> <U+270E><U+2763><U+2763><U+2712><U+2763><U+2730><U+270E><U+2763><U+2712><U+2763> <U+2763><U+270E><U+2763><U+2712><U+2712><U+2763><U+2712><U+2712><U+2763><U+2730> <U+2730><U+270E><U+2763><U+2763><U+2763><U+2763><U+2730><U+2730><U+270E><U+2730> <U+2712><U+2763><U+270E><U+2763><U+2712><U+2712><U+2763><U+2763><U+270E><U+2730>
              <U+2727><U+2721>
              <U+270E><U+2730><U+2730><U+270E><U+2763><U+2730><U+2712><U+2712><U+2763><U+2763> <U+2730><U+270E><U+270E><U+2730><U+270E><U+2763><U+2763><U+2730><U+270E><U+2712> <U+2730><U+2763><U+270E><U+270E><U+270E><U+270E><U+270E><U+2712><U+2730><U+270E> <U+2712><U+2763><U+2730><U+270E><U+2712><U+2730><U+270E><U+2763><U+2763><U+2730> <U+270E><U+2763><U+2730><U+2712><U+2730><U+270E><U+2763><U+2763><U+2712><U+270E> <U+2730><U+2712><U+2763><U+2763><U+2730><U+2712><U+2763><U+270E><U+2730><U+2730>
              <U+2720><U+2714><U+2721>
              <U+2730><U+2730><U+2712><U+270E><U+2730><U+2763><U+2712><U+2763><U+2712><U+2763> <U+2763><U+2730><U+2730><U+270E><U+270E><U+2763><U+2712><U+2763><U+270E><U+2763> <U+2763><U+2730><U+270E><U+2763><U+2763><U+2763><U+270E><U+270E><U+2712><U+2730> <U+2712><U+270E><U+270E><U+2712><U+2712><U+270E><U+2730><U+2730><U+270E><U+2712> <U+2763><U+2763><U+2712><U+2712><U+270E><U+2763><U+2712><U+270E><U+270E><U+2712> <U+270E><U+2712><U+2730><U+270E><U+2763><U+2712><U+2763><U+270E><U+2712><U+2730>
              <U+2720><U+2726><U+2721>
              <U+2712><U+2712><U+270E><U+2730><U+2763><U+2763><U+2712><U+270E><U+270E><U+270E> <U+270E><U+2730><U+2712><U+2712><U+2763><U+2763><U+2763><U+2763><U+2712><U+2763> <U+2712><U+270E><U+270E><U+270E><U+2763><U+270E><U+2730><U+270E><U+270E><U+2730> <U+270E><U+2730><U+2730><U+270E><U+270E><U+2763><U+2763><U+2712><U+2730><U+2712> <U+2730><U+2730><U+270E><U+2730><U+270E><U+2763><U+270E><U+2730><U+2712><U+2763> <U+2730><U+2712><U+2730><U+2763><U+2763><U+2730><U+2712><U+270E><U+2712><U+270E>
              <U+2714><U+2722><U+2721>
              <U+2730><U+270E><U+2763><U+2730><U+2712><U+2763><U+2712><U+270E><U+2730><U+270E> <U+2763><U+2730><U+2712><U+2763><U+2730><U+2730><U+270E><U+2712><U+2712><U+2712> <U+2763><U+2763><U+2730><U+270E><U+2763><U+2712><U+2763><U+2763><U+2712><U+2730> <U+2712><U+2730><U+270E><U+2763><U+2730><U+2730><U+2763><U+270E><U+2763><U+270E> <U+2712><U+270E><U+270E><U+2712><U+2730><U+270E><U+2763><U+270E><U+2763><U+2730> <U+2763><U+2712><U+2763><U+2712><U+2712><U+2763><U+2763><U+2763><U+2763><U+2763>
              <U+271A><U+2721><U+2721>
              <U+2712><U+270E><U+270E><U+2712><U+2730><U+270E><U+2712><U+2730><U+2763><U+270E> <U+270E><U+2730><U+270E><U+2712><U+2730><U+270E><U+2763><U+2763><U+2763><U+2763> <U+2730><U+2730><U+2712><U+2763><U+2763><U+2763><U+2712>
              <U+271A><U+2714><U+271B>
              <U+2741><U+2714><U+2720><U+2721><U+261B>   <U+2722><U+271A>
              <U+2741><U+2714><U+2720><U+2720><U+261B>   <U+271A><U+2714><U+271B>
              <U+2741><U+2714><U+2720><U+2714><U+261B>   <U+2717><U+2704><U+2715>
              <U+2741><U+2714><U+2720><U+271A><U+261B>   <U+2715><U+270D><U+270E><U+272C><U+272F><U+272C><U+2730><U+272C><U+2712><U+2731> <U+2725><U+2605><U+2732><U+2733><U+2605><U+2729><U+2730><U+2605>
                                                 34

<removed-date>
              <U+2741><U+2714><U+2714><U+2721><U+261B>
              <U+2741><U+2714><U+2714><U+271A><U+261B>   <U+2712><U+2729><U+270E><U+272C><U+2734><U+270C><U+2735><U+2713>
              <U+2741><U+2722><U+2721><U+2721><U+261B> <U+2722><U+271A>
              <U+2763><U+2712><U+2712><U+2763><U+270E><U+2763><U+2730><U+2712><U+2763><U+2730> <U+270E><U+2763><U+2763><U+270E><U+2763><U+2730><U+2712><U+2763><U+270E><U+2730> <U+270E><U+2763><U+2763><U+2712><U+2763><U+2730><U+2712><U+2763><U+2712><U+2763> <U+2763><U+270E><U+2763><U+2712><U+2712><U+2712><U+2712><U+2712><U+2763><U+2730> <U+2730><U+2730><U+2763><U+2763><U+2763><U+2763><U+2712><U+2763><U+270E><U+2730> <U+270E><U+2730><U+270E><U+2763><U+2712><U+2763><U+2763><U+2712><U+270E><U+2730>
              <U+2727><U+2721>
              <U+270E><U+2730><U+2730><U+270E><U+2763><U+270E><U+2712><U+2712><U+2763><U+2763> <U+270E><U+270E><U+270E><U+2730><U+270E><U+2763><U+2763><U+2730><U+270E><U+2712> <U+2730><U+2763><U+270E><U+270E><U+270E><U+270E><U+270E><U+2712><U+2730><U+270E> <U+2712><U+2763><U+2730><U+270E><U+2712><U+2730><U+270E><U+2763><U+2763><U+2730> <U+270E><U+2763><U+2730><U+2712><U+2730><U+270E><U+2763><U+2763><U+2712><U+270E> <U+2730><U+2712><U+2763><U+2763><U+2730><U+2712><U+2763><U+270E><U+2730><U+2730>
<removed-apn>
              <U+2720><U+2714><U+2721>
              <U+2730><U+2730><U+2712><U+270E><U+2730><U+2763><U+2712><U+2763><U+2712><U+2763> <U+2763><U+2730><U+2730><U+270E><U+270E><U+2763><U+2712><U+2763><U+270E><U+2763> <U+2763><U+2730><U+270E><U+2763><U+2763><U+2763><U+270E><U+270E><U+2712><U+2730> <U+2712><U+270E><U+270E><U+2712><U+2712><U+270E><U+2730><U+2730><U+270E><U+2712> <U+2763><U+2763><U+2712><U+2712><U+270E><U+2763><U+2712><U+270E><U+270E><U+2712> <U+270E><U+2712><U+2730><U+270E><U+2763><U+2712><U+2763><U+270E><U+2712><U+2730>
              <U+2720><U+2726><U+2721>
              <U+2712><U+2712><U+270E><U+2730><U+2763><U+2763><U+2712><U+270E><U+270E><U+270E> <U+270E><U+2730><U+2712><U+2712><U+2763><U+2763><U+2763><U+2763><U+2712><U+2763> <U+2712><U+270E><U+270E><U+2730><U+2712><U+2730><U+2730><U+2712><U+270E><U+2730> <U+270E><U+2730><U+2730><U+2712><U+2763><U+2712><U+2763><U+2712><U+2730><U+2712> <U+2712><U+2730><U+2763><U+2730><U+2730><U+2712><U+2712><U+2763><U+2712><U+2712> <U+2730><U+270E><U+2730><U+2712><U+2730><U+270E><U+2763><U+270E><U+2712><U+270E>
              <U+2714><U+2722><U+2721>
              <U+2730><U+270E><U+2763><U+2730><U+2712><U+2712><U+2712><U+270E><U+2763><U+2712> <U+2712><U+2730><U+2712><U+2763><U+2730><U+2730><U+270E><U+2763><U+2712><U+2763> <U+2712><U+2763><U+2730><U+2730><U+2763><U+2712><U+2763><U+2763><U+2712><U+2730> <U+2712><U+2730><U+2763><U+2763><U+2730><U+270E><U+2763><U+270E><U+2763><U+270E> <U+2712><U+270E><U+270E><U+2712><U+2730><U+270E><U+2763><U+270E><U+2763><U+2730> <U+2763><U+2712><U+2763><U+2712><U+2712><U+2763><U+2763><U+2763><U+2763><U+2763>
              <U+271A><U+2721><U+2721>
              <U+2712><U+270E><U+270E><U+2712><U+2730><U+270E><U+2712><U+2730><U+2763><U+270E> <U+270E><U+2730><U+270E><U+2712><U+2730><U+270E><U+2763><U+2763><U+2763><U+2763> <U+2730><U+2730><U+2712><U+2763><U+2763><U+2763><U+2712>
              <U+271A><U+2714><U+271B>
              <U+2741><U+2714><U+2720><U+2721><U+261B>   <U+2722><U+2722>
              <U+2741><U+2714><U+2720><U+2720><U+261B>   <U+271A><U+2714><U+271B>
              <U+2741><U+2714><U+2720><U+2714><U+261B>   <U+2717><U+2704><U+2715>
              <U+2741><U+2714><U+2720><U+271A><U+261B>   <U+2715><U+270D><U+270E><U+272C><U+272F><U+272C><U+2730><U+272C><U+2712><U+2731> <U+2725><U+2605><U+2732><U+2733><U+2605><U+2729><U+2730><U+2605>
              <U+2741><U+2714><U+2714><U+2721><U+261B>
              <U+2741><U+2714><U+2714><U+271A><U+261B>   <U+2712><U+2729><U+270E><U+272C><U+2734><U+270C><U+2735><U+2713>
              <U+2741><U+2722><U+2721><U+2721><U+261B> <U+2722><U+2722>
              <U+2730><U+2712><U+2763><U+2763><U+270E><U+2763><U+2730><U+2712><U+2763><U+2730> <U+270E><U+2763><U+2730><U+2712><U+2763><U+2763><U+2712><U+2763><U+270E><U+2730> <U+2763><U+2763><U+2763><U+2730><U+2730><U+2730><U+2712><U+2763><U+2763><U+2712> <U+2730><U+270E><U+2763><U+2763><U+270E><U+2763><U+2712><U+2712><U+2763><U+2730> <U+2730><U+270E><U+270E><U+2730><U+2712><U+2730><U+2712><U+2763><U+2712><U+2730> <U+2730><U+2730><U+270E><U+2763><U+270E><U+2730><U+2730><U+2730><U+270E><U+2730>
              <U+2727><U+2721>
              <U+2712><U+2730><U+2730><U+270E><U+2763><U+2730><U+2712><U+2730><U+270E><U+2763> <U+270E><U+2730><U+270E><U+2730><U+270E><U+2763><U+2763><U+2730><U+270E><U+2712> <U+2730><U+2763><U+270E><U+270E><U+270E><U+270E><U+270E><U+2712><U+2730><U+270E> <U+2712><U+2763><U+2730><U+270E><U+2712><U+2730><U+270E><U+2763><U+2763><U+2730> <U+270E><U+2763><U+2730><U+2712><U+2730><U+270E><U+2763><U+2763><U+2712><U+270E> <U+2730><U+2730><U+2763><U+2730><U+2730><U+2712><U+2763><U+2730><U+2730><U+2730>
              <U+2720><U+2714><U+2721>
                                                 35

              <U+2730><U+2730><U+2712><U+2763><U+2763><U+2763><U+2712><U+2712><U+2763><U+2763> <U+2763><U+2763><U+2730><U+270E><U+2763><U+2763><U+2712><U+2763><U+270E><U+2763> <U+2763><U+2712><U+270E><U+270E><U+2763><U+2763><U+270E><U+270E><U+2712><U+2730> <U+2712><U+270E><U+270E><U+2712><U+2712><U+270E><U+2730><U+2730><U+270E><U+2712> <U+2763><U+2763><U+2712><U+2712><U+270E><U+2763><U+2712><U+270E><U+270E><U+2712> <U+270E><U+2712><U+2730><U+270E><U+2763><U+2712><U+2763><U+270E><U+2712><U+2730>
<removed-date>
              <U+2720><U+2726><U+2721>
              <U+2712><U+2712><U+270E><U+2730><U+2763><U+2763><U+2712><U+270E><U+270E><U+270E> <U+270E><U+2730><U+2712><U+2712><U+2763><U+2763><U+2763><U+2763><U+2712><U+2763> <U+2712><U+2763><U+270E><U+2730><U+2712><U+2730><U+2763><U+2712><U+270E><U+270E> <U+2712><U+2730><U+2730><U+2763><U+2730><U+2763><U+2763><U+2712><U+2730><U+2712> <U+2712><U+2712><U+270E><U+2730><U+2730><U+2712><U+2730><U+2763><U+2712><U+2763> <U+2730><U+2712><U+2730><U+2712><U+2763><U+2730><U+2730><U+270E><U+2712><U+2730>
              <U+2714><U+2722><U+2721>
              <U+2712><U+270E><U+2763><U+2763><U+2712><U+2763><U+2730><U+270E><U+2763><U+2712> <U+2763><U+2730><U+2712><U+2763><U+2730><U+2730><U+270E><U+2763><U+2712><U+2763> <U+2712><U+270E><U+2730><U+270E><U+2763><U+2712><U+2763><U+2763><U+2712><U+2730> <U+2712><U+2730><U+2763><U+2763><U+2730><U+2730><U+2763><U+270E><U+2763><U+270E> <U+2712><U+270E><U+270E><U+2712><U+2730><U+270E><U+2763><U+270E><U+2763><U+2730> <U+2763><U+2712><U+2763><U+2712><U+2712><U+2763><U+2763><U+2763><U+2763><U+2763>
              <U+271A><U+2721><U+2721>
<removed-apn>
              <U+2712><U+270E><U+270E><U+2712><U+2730><U+270E><U+2712><U+2730><U+2763><U+270E> <U+270E><U+2730><U+270E><U+2712><U+2730><U+270E><U+2763><U+2763><U+2763><U+2763> <U+2730><U+2730><U+2712><U+2763><U+2763><U+2763><U+2712>
              <U+271A><U+2714><U+271B>
              <U+2741><U+2714><U+2720><U+2721><U+261B>   <U+2722><U+272E>
              <U+2741><U+2714><U+2720><U+2720><U+261B>   <U+271A><U+2714><U+271B>
              <U+2741><U+2714><U+2720><U+2714><U+261B>   <U+2717><U+2704><U+2715>
              <U+2741><U+2714><U+2720><U+271A><U+261B>   <U+2715><U+270D><U+270E><U+272C><U+272F><U+272C><U+2730><U+272C><U+2712><U+2731> <U+2725><U+2605><U+2732><U+2733><U+2605><U+2729><U+2730><U+2605>
              <U+2741><U+2714><U+2714><U+2721><U+261B>
              <U+2741><U+2714><U+2714><U+271A><U+261B>   <U+2712><U+2729><U+270E><U+272C><U+2734><U+270C><U+2735><U+2713>
              <U+2741><U+2722><U+2721><U+2721><U+261B> <U+2722><U+272E>
              <U+2730><U+2712><U+2763><U+2763><U+270E><U+270E><U+2730><U+2712><U+2763><U+2730> <U+270E><U+2763><U+2763><U+270E><U+2763><U+2730><U+2712><U+2763><U+270E><U+2730> <U+270E><U+2763><U+2763><U+2712><U+2763><U+2730><U+270E><U+2763><U+2712><U+2763> <U+2763><U+270E><U+2763><U+2712><U+2712><U+2763><U+2712><U+2712><U+2763><U+2730> <U+2730><U+270E><U+2763><U+2763><U+2763><U+2763><U+2730><U+2730><U+270E><U+2730> <U+2712><U+2763><U+270E><U+2763><U+2712><U+2712><U+2763><U+2763><U+270E><U+2730>
              <U+2727><U+2721>
              <U+270E><U+2730><U+2730><U+270E><U+2763><U+2730><U+2712><U+2712><U+2763><U+2763> <U+2730><U+270E><U+270E><U+2730><U+270E><U+2763><U+2763><U+2730><U+270E><U+2712> <U+2730><U+2763><U+270E><U+270E><U+270E><U+270E><U+270E><U+2712><U+2730><U+270E> <U+2712><U+2763><U+2730><U+270E><U+2712><U+2730><U+270E><U+2763><U+2763><U+2730> <U+270E><U+2763><U+2730><U+2712><U+2730><U+270E><U+2763><U+2763><U+2763><U+270E> <U+2763><U+2730><U+2763><U+2712><U+2730><U+2712><U+2763><U+2763><U+2730><U+2730>
              <U+2720><U+2714><U+2721>
              <U+2730><U+2730><U+270E><U+2763><U+2763><U+2712><U+2730><U+2712><U+2712><U+2763> <U+2763><U+2763><U+2730><U+270E><U+270E><U+2763><U+2712><U+2763><U+270E><U+2763> <U+2763><U+2712><U+270E><U+2763><U+2763><U+2763><U+270E><U+270E><U+2712><U+2730> <U+2712><U+270E><U+270E><U+2712><U+2712><U+270E><U+2730><U+2730><U+270E><U+2712> <U+2763><U+2763><U+2712><U+2712><U+270E><U+2763><U+2712><U+270E><U+270E><U+2712> <U+270E><U+2712><U+2730><U+270E><U+2763><U+2712><U+2763><U+270E><U+2712><U+2730>
              <U+2720><U+2726><U+2721>
              <U+2712><U+2712><U+270E><U+2730><U+2763><U+2763><U+2712><U+270E><U+270E><U+270E> <U+270E><U+2730><U+2712><U+2712><U+2763><U+2763><U+2763><U+2763><U+2712><U+2763> <U+2712><U+270E><U+270E><U+2730><U+2712><U+2730><U+2730><U+2712><U+270E><U+2730> <U+270E><U+2730><U+2730><U+2712><U+2763><U+2712><U+2763><U+2712><U+2730><U+2712> <U+2712><U+2730><U+2763><U+2730><U+2730><U+2712><U+2712><U+2763><U+2712><U+2712> <U+2730><U+270E><U+2730><U+2712><U+2730><U+270E><U+2763><U+270E><U+2712><U+270E>
              <U+2714><U+2722><U+2721>
              <U+2730><U+270E><U+2763><U+2730><U+2712><U+2712><U+2712><U+270E><U+2763><U+2712> <U+2712><U+2730><U+2712><U+2763><U+2730><U+2730><U+270E><U+2763><U+2712><U+2763> <U+2712><U+2763><U+2730><U+2730><U+2763><U+2712><U+2763><U+2763><U+2712><U+2730> <U+2712><U+2730><U+2763><U+2763><U+2730><U+270E><U+2763><U+270E><U+2763><U+270E> <U+2712><U+270E><U+270E><U+2712><U+2730><U+270E><U+2763><U+270E><U+2763><U+2730> <U+2763><U+2712><U+2763><U+2712><U+2712><U+2763><U+2763><U+2763><U+2763><U+2763>
              <U+271A><U+2721><U+2721>
              <U+2712><U+270E><U+270E><U+2712><U+2730><U+270E><U+2712><U+2730><U+2763><U+270E> <U+270E><U+2730><U+270E><U+2712><U+2730><U+270E><U+2763><U+2763><U+2763><U+2763> <U+2730><U+2730><U+2712><U+2763><U+2763><U+2763><U+2712>
              <U+271A><U+2714><U+271B>
                                                 36

<removed-date>
              <U+2741><U+2714><U+2720><U+2721><U+261B>   <U+2722><U+2727>
              <U+2741><U+2714><U+2720><U+2720><U+261B>   <U+271A><U+2714><U+271B>
              <U+2741><U+2714><U+2720><U+2714><U+261B>   <U+2717><U+2704><U+2715>
              <U+2741><U+2714><U+2720><U+271A><U+261B>   <U+2715><U+270D><U+270E><U+272C><U+272F><U+272C><U+2730><U+272C><U+2712><U+2731> <U+2725><U+2605><U+2732><U+2733><U+2605><U+2729><U+2730><U+2605>
              <U+2741><U+2714><U+2714><U+2721><U+261B>
              <U+2741><U+2714><U+2714><U+271A><U+261B>   <U+2712><U+2729><U+270E><U+272C><U+2734><U+270C><U+2735><U+2713>
<removed-apn>
              <U+2741><U+2722><U+2721><U+2721><U+261B> <U+2722><U+2727>
              <U+2730><U+2712><U+2763><U+2763><U+270E><U+2763><U+2730><U+2712><U+2763><U+2730> <U+270E><U+2763><U+2730><U+2712><U+2763><U+2763><U+2712><U+2763><U+270E><U+2730> <U+2763><U+2763><U+2763><U+2730><U+2730><U+2730><U+2712><U+2763><U+2763><U+2712> <U+2730><U+270E><U+2763><U+2763><U+270E><U+2763><U+2712><U+2712><U+2763><U+2730> <U+2730><U+270E><U+270E><U+2730><U+2712><U+2730><U+2712><U+2763><U+2712><U+2730> <U+2730><U+2730><U+270E><U+2763><U+270E><U+2730><U+2730><U+2730><U+270E><U+2730>
              <U+2727><U+2721>
              <U+2712><U+2730><U+2730><U+270E><U+2763><U+2730><U+2712><U+2730><U+270E><U+2763> <U+270E><U+2730><U+270E><U+2730><U+270E><U+2763><U+2763><U+2730><U+270E><U+2712> <U+2730><U+2763><U+270E><U+270E><U+270E><U+270E><U+270E><U+2712><U+2730><U+270E> <U+2712><U+2763><U+2730><U+270E><U+2712><U+2730><U+270E><U+2763><U+2763><U+2730> <U+270E><U+2763><U+2730><U+2712><U+2730><U+270E><U+2763><U+2763><U+2712><U+270E> <U+2730><U+2730><U+2763><U+2730><U+2730><U+2712><U+2763><U+2730><U+2730><U+2730>
              <U+2720><U+2714><U+2721>
              <U+2730><U+2730><U+2712><U+2763><U+2763><U+2763><U+2712><U+2712><U+2763><U+2763> <U+2763><U+2763><U+2730><U+270E><U+2763><U+2763><U+2712><U+2763><U+270E><U+2763> <U+2763><U+2712><U+270E><U+270E><U+2763><U+2763><U+270E><U+270E><U+2712><U+2730> <U+2712><U+270E><U+270E><U+2712><U+2712><U+270E><U+2730><U+2730><U+270E><U+2712> <U+2763><U+2763><U+2712><U+2712><U+270E><U+2763><U+2712><U+270E><U+270E><U+2712> <U+270E><U+2712><U+2730><U+270E><U+2763><U+2712><U+2763><U+270E><U+2712><U+2730>
              <U+2720><U+2726><U+2721>
              <U+2712><U+2712><U+270E><U+2730><U+2763><U+2763><U+2712><U+270E><U+270E><U+270E> <U+270E><U+2730><U+2712><U+2712><U+2763><U+2763><U+2763><U+2763><U+2712><U+2763> <U+2712><U+270E><U+270E><U+2730><U+2712><U+2730><U+2730><U+2712><U+270E><U+2730> <U+270E><U+2730><U+2730><U+2712><U+2763><U+2712><U+2763><U+2712><U+2730><U+2712> <U+2712><U+2730><U+2763><U+2730><U+2730><U+2712><U+2712><U+2763><U+2712><U+2712> <U+2730><U+270E><U+2730><U+2712><U+2730><U+270E><U+2763><U+270E><U+2712><U+270E>
              <U+2714><U+2722><U+2721>
              <U+2730><U+270E><U+2763><U+2730><U+2712><U+2712><U+2712><U+270E><U+2763><U+2712> <U+2712><U+2730><U+2712><U+2763><U+2730><U+2730><U+270E><U+2763><U+2712><U+2763> <U+2712><U+2763><U+2730><U+2730><U+2763><U+2712><U+2763><U+2763><U+2712><U+2730> <U+2712><U+2730><U+2763><U+2763><U+2730><U+270E><U+2763><U+270E><U+2763><U+270E> <U+2712><U+270E><U+270E><U+2712><U+2730><U+270E><U+2763><U+270E><U+2763><U+2730> <U+2763><U+2712><U+2763><U+2712><U+2712><U+2763><U+2763><U+2763><U+2763><U+2763>
              <U+271A><U+2721><U+2721>
              <U+2712><U+270E><U+270E><U+2712><U+2730><U+270E><U+2712><U+2730><U+2763><U+270E> <U+270E><U+2730><U+270E><U+2712><U+2730><U+270E><U+2763><U+2763><U+2763><U+2763> <U+2730><U+2730><U+2712><U+2763><U+2763><U+2763><U+2712>
              <U+271A><U+2714><U+271B>
              <U+2741><U+2714><U+2720><U+2721><U+261B>   <U+2722><U+271B>
              <U+2741><U+2714><U+2720><U+2720><U+261B>   <U+271A><U+2714><U+271B>
              <U+2741><U+2714><U+2720><U+2714><U+261B>   <U+2717><U+2704><U+2715>
              <U+2741><U+2714><U+2720><U+271A><U+261B>   <U+2715><U+270D><U+270E><U+272C><U+272F><U+272C><U+2730><U+272C><U+2712><U+2731> <U+2725><U+2605><U+2732><U+2733><U+2605><U+2729><U+2730><U+2605>
              <U+2741><U+2714><U+2714><U+2721><U+261B>
              <U+2741><U+2714><U+2714><U+271A><U+261B>   <U+2712><U+2729><U+270E><U+272C><U+2734><U+270C><U+2735><U+2713>
              <U+2741><U+2722><U+2721><U+2721><U+261B> <U+2722><U+271B>
              <U+2730><U+2712><U+2763><U+2763><U+270E><U+270E><U+2730><U+2712><U+2763><U+2730> <U+270E><U+2763><U+2763><U+270E><U+2763><U+2730><U+2712><U+2763><U+270E><U+2730> <U+270E><U+2763><U+2763><U+2712><U+2763><U+2730><U+270E><U+2763><U+2712><U+2763> <U+2763><U+270E><U+2763><U+2712><U+2712><U+2763><U+2712><U+2712><U+2763><U+2730> <U+2730><U+270E><U+2763><U+2763><U+2763><U+2763><U+2730><U+270E><U+2712><U+2730> <U+2712><U+2763><U+270E><U+2763><U+2712><U+2712><U+2712><U+2712><U+270E><U+2730>
              <U+2727><U+2721>
                                                 37

<removed-date>
              <U+270E><U+2730><U+2730><U+270E><U+2763><U+2730><U+2712><U+2712><U+2763><U+2763> <U+270E><U+270E><U+270E><U+2730><U+270E><U+2763><U+2763><U+2730><U+270E><U+2712> <U+2730><U+2763><U+270E><U+270E><U+270E><U+270E><U+270E><U+2712><U+2730><U+270E> <U+2712><U+2763><U+2730><U+270E><U+2712><U+2730><U+270E><U+2763><U+2763><U+2730> <U+270E><U+2763><U+2730><U+2712><U+2730><U+270E><U+2763><U+2763><U+2712><U+270E> <U+2730><U+2730><U+2763><U+2730><U+2730><U+2712><U+2763><U+2730><U+2730><U+2730>
              <U+2720><U+2714><U+2721>
              <U+2730><U+2730><U+2712><U+2763><U+2763><U+2763><U+2712><U+2712><U+2763><U+2763> <U+2763><U+2763><U+2730><U+270E><U+2763><U+2763><U+2712><U+2763><U+270E><U+2763> <U+2763><U+2712><U+270E><U+270E><U+2763><U+2763><U+270E><U+270E><U+2712><U+2730> <U+2712><U+270E><U+270E><U+2712><U+2712><U+270E><U+2730><U+2730><U+270E><U+2712> <U+2763><U+2763><U+2712><U+2712><U+270E><U+2763><U+2712><U+270E><U+270E><U+2712> <U+270E><U+2712><U+2730><U+270E><U+2763><U+2712><U+2763><U+270E><U+2712><U+2730>
              <U+2720><U+2726><U+2721>
              <U+2712><U+2712><U+270E><U+2730><U+2763><U+2763><U+2712><U+270E><U+270E><U+270E> <U+270E><U+2730><U+2712><U+2712><U+2763><U+2763><U+2763><U+2763><U+2712><U+2763> <U+2712><U+2763><U+270E><U+2730><U+2712><U+2730><U+2763><U+2712><U+270E><U+270E> <U+2712><U+2730><U+2730><U+2763><U+2730><U+2763><U+2763><U+2712><U+2730><U+2712> <U+2712><U+2712><U+270E><U+2730><U+2730><U+2712><U+2730><U+2763><U+2712><U+2763> <U+2730><U+2712><U+2730><U+2712><U+2763><U+2730><U+2730><U+270E><U+2712><U+2730>
              <U+2714><U+2722><U+2721>
<removed-apn>
              <U+2712><U+270E><U+2763><U+2763><U+2712><U+2763><U+2730><U+270E><U+2763><U+2712> <U+2763><U+2730><U+2712><U+2763><U+2730><U+2730><U+270E><U+2763><U+2712><U+2763> <U+2712><U+270E><U+2730><U+270E><U+2763><U+2712><U+2763><U+2763><U+2712><U+2730> <U+2712><U+2730><U+2763><U+2763><U+2730><U+2730><U+2763><U+270E><U+2763><U+270E> <U+2712><U+270E><U+270E><U+2712><U+2730><U+270E><U+2763><U+270E><U+2763><U+2730> <U+2763><U+2712><U+2763><U+2712><U+2712><U+2763><U+2763><U+2763><U+2763><U+2763>
              <U+271A><U+2721><U+2721>
              <U+2712><U+270E><U+270E><U+2712><U+2730><U+270E><U+2712><U+2730><U+2763><U+270E> <U+270E><U+2730><U+270E><U+2712><U+2730><U+270E><U+2763><U+2763><U+2763><U+2763> <U+2730><U+2730><U+2712><U+2763><U+2763><U+2763><U+2712>
              <U+271A><U+2714><U+271B>
              <U+2741><U+2714><U+2720><U+2721><U+261B>   <U+2722><U+2726>
              <U+2741><U+2714><U+2720><U+2720><U+261B>   <U+271A><U+2714><U+271B>
              <U+2741><U+2714><U+2720><U+2714><U+261B>   <U+2717><U+2704><U+2715>
              <U+2741><U+2714><U+2720><U+271A><U+261B>   <U+2715><U+270D><U+270E><U+272C><U+272F><U+272C><U+2730><U+272C><U+2712><U+2731> <U+2725><U+2605><U+2732><U+2733><U+2605><U+2729><U+2730><U+2605>
              <U+2741><U+2714><U+2714><U+2721><U+261B>
              <U+2741><U+2714><U+2714><U+271A><U+261B>   <U+2712><U+2729><U+270E><U+272C>
              <U+2741><U+2722><U+2721><U+2721><U+261B> <U+2722><U+2726>
              <U+2763><U+2712><U+2712><U+2763><U+270E><U+2763><U+2730><U+2712><U+2763><U+2730> <U+270E><U+2763><U+2763><U+270E><U+2763><U+2730><U+2712><U+2763><U+270E><U+2730> <U+270E><U+2763><U+2763><U+2712><U+2730><U+2730><U+2712><U+2763><U+2712><U+2712> <U+2763><U+270E><U+2763><U+2712><U+2712><U+2712><U+2712><U+2712><U+2763><U+2730> <U+2730><U+2730><U+2763><U+2763><U+2763><U+2763><U+2712><U+2763><U+270E><U+2730> <U+270E><U+2730><U+270E><U+2763><U+2712><U+2763><U+2763><U+2712><U+270E><U+2730>
              <U+2727><U+2721>
              <U+270E><U+2730><U+2730><U+270E><U+2763><U+270E><U+2712><U+2712><U+2763><U+2763> <U+2763><U+270E><U+270E><U+2730><U+270E><U+2763><U+2763><U+2730><U+270E><U+2712> <U+2730><U+2763><U+270E><U+270E><U+270E><U+270E><U+270E><U+2712><U+2730><U+270E> <U+2712><U+2763><U+2730><U+270E><U+2712><U+2730><U+270E><U+2763><U+2763><U+2730> <U+270E><U+2763><U+2730><U+2712><U+2730><U+270E><U+2763><U+2763><U+2763><U+270E> <U+2763><U+2730><U+2763><U+2712><U+2730><U+2712><U+2763><U+2763><U+2730><U+2730>
              <U+2720><U+2714><U+2721>
              <U+2730><U+2730><U+270E><U+2763><U+2763><U+2712><U+2730><U+2712><U+2712><U+2763> <U+2763><U+2763><U+2730><U+270E><U+270E><U+2763><U+2712><U+2763><U+270E><U+2763> <U+2763><U+2712><U+270E><U+2763><U+2763><U+2763><U+270E><U+270E><U+2712><U+2730> <U+2712><U+270E><U+270E><U+2712><U+2712><U+270E><U+2730><U+2730><U+270E><U+2712> <U+2763><U+2763><U+2712><U+2712><U+270E><U+2763><U+2712><U+270E><U+270E><U+2712> <U+270E><U+2712><U+2730><U+270E><U+2763><U+2712><U+2763><U+270E><U+2712><U+2730>
              <U+2720><U+2726><U+2721>
              <U+2712><U+2712><U+270E><U+2730><U+2763><U+2763><U+2712><U+270E><U+270E><U+270E> <U+270E><U+2730><U+2712><U+2712><U+2763><U+2763><U+2763><U+2763><U+2712><U+2763> <U+2712><U+2763><U+270E><U+2730><U+2712><U+2730><U+2730><U+2712><U+270E><U+2730> <U+270E><U+2730><U+2712><U+2763><U+2730><U+2730><U+2763><U+2712><U+2730><U+2712> <U+2712><U+2763><U+270E><U+2730><U+2730><U+2712><U+270E><U+2730><U+2712><U+2712> <U+2730><U+2712><U+2730><U+2730><U+2763><U+2730><U+2730><U+270E><U+2712><U+2730>
              <U+2714><U+2722><U+2721>
              <U+2730><U+270E><U+2763><U+2730><U+2712><U+2763><U+270E><U+2763><U+2763><U+2712> <U+2763><U+2730><U+2712><U+2763><U+2730><U+2730><U+270E><U+2763><U+2712><U+2712> <U+2763><U+2763><U+2730><U+2730><U+270E><U+2730><U+2763><U+2763><U+2712><U+2730> <U+2712><U+2730><U+2730><U+2763><U+2730><U+2730><U+2712><U+270E><U+2763><U+270E> <U+2712><U+270E><U+270E><U+2712><U+2730><U+270E><U+2763><U+270E><U+2763><U+2730> <U+2763><U+2712><U+2763><U+2712><U+2712><U+2763><U+2763><U+2763><U+2763><U+2763>
              <U+271A><U+2721><U+2721>
                                                 38

<removed-date>
              <U+2712><U+270E><U+270E><U+2712><U+2730><U+270E><U+2712><U+2730><U+2763><U+270E> <U+270E><U+2730><U+270E><U+2712><U+2730><U+270E><U+2763><U+2763><U+2763><U+2763> <U+2730><U+2730><U+2712><U+2763><U+2763><U+2763><U+2712>
              <U+271A><U+2714><U+271B>
              <U+2741><U+2714><U+2720><U+2721><U+261B>   <U+2722><U+2741>
              <U+2741><U+2714><U+2720><U+2720><U+261B>   <U+2720><U+2721><U+2741>
              <U+2741><U+2714><U+2720><U+2714><U+261B>   <U+2723><U+2741><U+271E>
              <U+2741><U+2714><U+2720><U+271A><U+261B>   <U+2715><U+270D><U+270E><U+272C><U+272F><U+272C><U+2730><U+272C><U+2712><U+2731> <U+2725><U+2605><U+2732><U+2733><U+2605><U+2729><U+2730><U+2605>
<removed-apn>
              <U+2741><U+2714><U+2714><U+2721><U+261B>
              <U+2741><U+2714><U+2714><U+271A><U+261B>   <U+2712><U+2729><U+270E><U+272C><U+2734><U+270C><U+2735><U+2713>
              <U+2741><U+2722><U+2721><U+2721><U+261B>   <U+2722><U+2741>
              <U+271F><U+2731><U+2729> <U+25CF><U+2712><U+2731> <U+271F><U+2731><U+2729> <U+2706><U+2605><U+2733> <U+25CF><U+2712><U+2731> <U+271F><U+2731><U+2729> <U+2725><U+2605><U+270D> <U+271F><U+2731><U+2713> <U+2715><U+2731><U+2712> <U+271F><U+2731><U+2733> <U+25CF><U+2712><U+2731> <U+2706><U+2713><U+272B> <U+2706><U+2713><U+272B> <U+2723><U+270D><U+270C> <U+271F><U+2731><U+2713> <U+2715><U+2731><U+2712>
              <U+2720>               <U+272E>                   <U+2720><U+2721>                  <U+2720><U+272E>
              <U+2725><U+2605><U+270D> <U+25CF><U+2712><U+2731> <U+2706><U+2713><U+272B> <U+25CF><U+2712><U+2731> <U+2725><U+2605><U+270D> <U+260E><U+2713><U+272B> <U+2706><U+2713><U+272B> <U+2715><U+2731><U+2712> <U+2725><U+2605><U+270D> <U+271F><U+2731><U+2713> <U+271E><U+2713><U+270D> <U+25CF><U+2712><U+2731> <U+2723><U+261E><U+2605> <U+271E><U+261E><U+270D> <U+2725><U+2605><U+270D> <U+271E><U+2713><U+270D>
                          <U+2714><U+2721>                  <U+2714><U+272E>                  <U+271A><U+2721>
              <U+271E><U+270D><U+2746> <U+2706><U+2605><U+2733> <U+275A><U+272C><U+272B> <U+271E><U+270D><U+2746> <U+271D><U+2731><U+2605> <U+2715><U+270D><U+2763> <U+271F><U+2731><U+2729> <U+2725><U+2605><U+270D> <U+2723><U+270D><U+270C> <U+2725><U+2605><U+270D> <U+2715><U+270D><U+2763> <U+271F><U+2731><U+2713> <U+2706><U+2605><U+2733> <U+271F><U+2731><U+2733> <U+271E><U+270D><U+2746> <U+2706><U+2605><U+2733>
                      <U+271A><U+272E>                  <U+2722><U+2721>                  <U+2722><U+272E>
              <U+271F><U+2731><U+2713> <U+271E><U+2713><U+270D> <U+271D><U+2731><U+2605> <U+2715><U+272B><U+2729> <U+2723><U+270D><U+270C> <U+2715><U+270D><U+2763> <U+2715><U+272B><U+2729> <U+2715><U+272B><U+2746> <U+271E><U+2713><U+270D> <U+271E><U+261E><U+270D> <U+271F><U+2731><U+2733> <U+271E><U+2713><U+270D> <U+2715><U+272B><U+2729> <U+2715><U+270D><U+2763> <U+271D><U+2731><U+2605> <U+2723><U+261E><U+2605>
                  <U+272E><U+2721>                  <U+272E><U+272E>                  <U+2727><U+2721>
              <U+2706><U+2713><U+272B> <U+271F><U+2731><U+2713> <U+2715><U+270D><U+2763> <U+2706><U+2605><U+2733> <U+271E><U+261E><U+270D> <U+271D><U+2731><U+2605> <U+2725><U+2605><U+270D> <U+2706><U+2713><U+272B> <U+2715><U+272B><U+2746> <U+271E><U+261E><U+270D> <U+2725><U+2605><U+270D> <U+2706><U+2713><U+272B> <U+2715><U+272B><U+2729> <U+271F><U+2731><U+2729> <U+25CF><U+2712><U+2731> <U+25CF><U+2712><U+2731>
              <U+2727><U+272E>                  <U+271B><U+2721>                  <U+271B><U+272E>                  <U+2726><U+2721>
              <U+2706><U+2605><U+2733> <U+271E><U+261E><U+270D> <U+2746><U+2605><U+270E> <U+271E><U+261E><U+270D> <U+2715><U+272B><U+2729> <U+2746><U+2605><U+270E> <U+2715><U+272B><U+2746> <U+2723><U+270D><U+270C> <U+25CF><U+2712><U+2731> <U+2715><U+272B><U+2746> <U+271E><U+261E><U+270D> <U+2715><U+2731><U+2712> <U+271E><U+261E><U+270D> <U+271E><U+2713><U+270D> <U+271E><U+2713><U+270D> <U+260E><U+2713><U+272B>
                              <U+2726><U+272E>                  <U+2741><U+2721>                  <U+2741><U+272E>
              <U+2715><U+2731><U+2712> <U+2715><U+270D><U+2763> <U+2715><U+270D><U+2763> <U+271F><U+2731><U+2713> <U+271D><U+2731><U+2605> <U+271E><U+261E><U+270D> <U+271E><U+261E><U+270D> <U+2723><U+261E><U+2605> <U+271E><U+2713><U+270D> <U+271E><U+270D><U+2746> <U+271F><U+2731><U+2713> <U+271F><U+2731><U+2729> <U+271F><U+2731><U+2713>
                                                 39

                           <U+2720><U+2721><U+2721>                <U+2720><U+2721><U+272E>
<removed-date>
              <U+2741><U+2714><U+2720><U+2721><U+261B>   <U+272E><U+2721>
              <U+2741><U+2714><U+2720><U+2720><U+261B>   <U+2720><U+2721><U+2741>
              <U+2741><U+2714><U+2720><U+2714><U+261B>   <U+2723><U+2741><U+271E>
              <U+2741><U+2714><U+2720><U+271A><U+261B>   <U+2715><U+270D><U+270E><U+272C><U+272F><U+272C><U+2730><U+272C><U+2712><U+2731> <U+2725><U+2605><U+2732><U+2733><U+2605><U+2729><U+2730><U+2605>
              <U+2741><U+2714><U+2714><U+2721><U+261B>
<removed-apn>
              <U+2741><U+2714><U+2714><U+271A><U+261B>   <U+2712><U+2729><U+270E><U+272C><U+2734><U+270C><U+2735><U+2713>
              <U+2741><U+2722><U+2721><U+2721><U+261B>   <U+272E><U+2721>
              <U+271F><U+2731><U+2729> <U+25CF><U+2712><U+2731> <U+271F><U+2731><U+2729> <U+2706><U+2605><U+2733> <U+25CF><U+2712><U+2731> <U+271F><U+2731><U+2729> <U+2725><U+2605><U+270D> <U+271F><U+2731><U+2713> <U+2715><U+2731><U+2712> <U+271F><U+2731><U+2733> <U+25CF><U+2712><U+2731> <U+2706><U+2713><U+272B> <U+2706><U+2713><U+272B> <U+2723><U+270D><U+270C> <U+271F><U+2731><U+2713> <U+2715><U+2731><U+2712>
              <U+2720>               <U+272E>                   <U+2720><U+2721>                  <U+2720><U+272E>
              <U+2725><U+2605><U+270D> <U+25CF><U+2712><U+2731> <U+2706><U+2713><U+272B> <U+25CF><U+2712><U+2731> <U+2725><U+2605><U+270D> <U+260E><U+2713><U+272B> <U+2706><U+2713><U+272B> <U+2715><U+2731><U+2712> <U+2725><U+2605><U+270D> <U+271F><U+2731><U+2713> <U+271E><U+2713><U+270D> <U+25CF><U+2712><U+2731> <U+2723><U+261E><U+2605> <U+271E><U+261E><U+270D> <U+2725><U+2605><U+270D> <U+271E><U+2713><U+270D>
                          <U+2714><U+2721>                  <U+2714><U+272E>                  <U+271A><U+2721>
              <U+271E><U+270D><U+2746> <U+2706><U+2605><U+2733> <U+275A><U+272C><U+272B> <U+271E><U+270D><U+2746> <U+271D><U+2731><U+2605> <U+2715><U+270D><U+2763> <U+271F><U+2731><U+2729> <U+2725><U+2605><U+270D> <U+2723><U+270D><U+270C> <U+2725><U+2605><U+270D> <U+2715><U+270D><U+2763> <U+271F><U+2731><U+2713> <U+2706><U+2605><U+2733> <U+271F><U+2731><U+2733> <U+271E><U+270D><U+2746> <U+2706><U+2605><U+2733>
                      <U+271A><U+272E>                  <U+2722><U+2721>                  <U+2722><U+272E>
              <U+271F><U+2731><U+2713> <U+271E><U+2713><U+270D> <U+271D><U+2731><U+2605> <U+2715><U+272B><U+2729> <U+2723><U+270D><U+270C> <U+2715><U+270D><U+2763> <U+2715><U+272B><U+2729> <U+2715><U+272B><U+2746> <U+271E><U+2713><U+270D> <U+271E><U+261E><U+270D> <U+271F><U+2731><U+2733> <U+271E><U+2713><U+270D> <U+2715><U+272B><U+2729> <U+2715><U+270D><U+2763> <U+271D><U+2731><U+2605> <U+2723><U+261E><U+2605>
                  <U+272E><U+2721>                  <U+272E><U+272E>                  <U+2727><U+2721>
              <U+2706><U+2713><U+272B> <U+271F><U+2731><U+2713> <U+2715><U+270D><U+2763> <U+2706><U+2605><U+2733> <U+271E><U+261E><U+270D> <U+271D><U+2731><U+2605> <U+2725><U+2605><U+270D> <U+2706><U+2713><U+272B> <U+2715><U+272B><U+2746> <U+271E><U+261E><U+270D> <U+2725><U+2605><U+270D> <U+2706><U+2713><U+272B> <U+2715><U+272B><U+2729> <U+271F><U+2731><U+2729> <U+25CF><U+2712><U+2731> <U+25CF><U+2712><U+2731>
              <U+2727><U+272E>                  <U+271B><U+2721>                  <U+271B><U+272E>                  <U+2726><U+2721>
              <U+2706><U+2605><U+2733> <U+271E><U+261E><U+270D> <U+2746><U+2605><U+270E> <U+271E><U+261E><U+270D> <U+2715><U+272B><U+2729> <U+2746><U+2605><U+270E> <U+2715><U+272B><U+2746> <U+2723><U+270D><U+270C> <U+25CF><U+2712><U+2731> <U+2715><U+272B><U+2746> <U+271E><U+261E><U+270D> <U+2715><U+2731><U+2712> <U+271E><U+261E><U+270D> <U+271E><U+2713><U+270D> <U+271E><U+2713><U+270D> <U+260E><U+2713><U+272B>
                              <U+2726><U+272E>                  <U+2741><U+2721>                  <U+2741><U+272E>
              <U+2715><U+2731><U+2712> <U+2715><U+270D><U+2763> <U+2715><U+270D><U+2763> <U+271F><U+2731><U+2713> <U+271D><U+2731><U+2605> <U+271E><U+261E><U+270D> <U+271E><U+261E><U+270D> <U+2723><U+261E><U+2605> <U+271E><U+2713><U+270D> <U+271E><U+270D><U+2746> <U+271F><U+2731><U+2713> <U+271F><U+2731><U+2729> <U+271F><U+2731><U+2713>
                          <U+2720><U+2721><U+2721>                 <U+2720><U+2721><U+272E>
                                                    40

<removed-date>
              <U+2741><U+2714><U+2720><U+2721><U+261B>   <U+272E><U+2720>
              <U+2741><U+2714><U+2720><U+2720><U+261B>   <U+2720><U+2721><U+2741>
              <U+2741><U+2714><U+2720><U+2714><U+261B>   <U+2723><U+2741><U+271E>
              <U+2741><U+2714><U+2720><U+271A><U+261B>   <U+2715><U+270D><U+270E><U+272C><U+272F><U+272C><U+2730><U+272C><U+2712><U+2731> <U+2725><U+2605><U+2732><U+2733><U+2605><U+2729><U+2730><U+2605>
              <U+2741><U+2714><U+2714><U+2721><U+261B>
              <U+2741><U+2714><U+2714><U+271A><U+261B>   <U+2712><U+2729><U+270E><U+272C><U+2734><U+270C><U+2735><U+2713>
<removed-apn>
              <U+2741><U+2722><U+2721><U+2721><U+261B>   <U+272E><U+2720>
              <U+271F><U+2731><U+2733> <U+25CF><U+2712><U+2731> <U+271F><U+2731><U+2729> <U+2706><U+2605><U+2733> <U+25CF><U+2712><U+2731> <U+271F><U+2731><U+2729> <U+2725><U+2605><U+270D> <U+271F><U+2731><U+2713> <U+2715><U+2731><U+2712> <U+271F><U+2731><U+2733> <U+25CF><U+2712><U+2731> <U+2706><U+2713><U+272B> <U+2706><U+2713><U+272B> <U+2723><U+270D><U+270C> <U+271F><U+2731><U+2713> <U+271F><U+2731><U+2733>
              <U+2720>               <U+272E>                   <U+2720><U+2721>                  <U+2720><U+272E>
              <U+2725><U+2605><U+270D> <U+2706><U+2605><U+2733> <U+2715><U+270D><U+2763> <U+271D><U+2731><U+2605> <U+2725><U+2605><U+270D> <U+260E><U+2713><U+272B> <U+2706><U+2713><U+272B> <U+271F><U+2731><U+2713> <U+2725><U+2605><U+270D> <U+271F><U+2731><U+2713> <U+271E><U+2713><U+270D> <U+25CF><U+2712><U+2731> <U+2723><U+261E><U+2605> <U+271E><U+261E><U+270D> <U+2725><U+2605><U+270D> <U+271E><U+2713><U+270D>
                          <U+2714><U+2721>                  <U+2714><U+272E>                  <U+271A><U+2721>
              <U+271E><U+270D><U+2746> <U+2706><U+2605><U+2733> <U+275A><U+272C><U+272B> <U+271E><U+270D><U+2746> <U+25CF><U+2712><U+2731> <U+2715><U+270D><U+2763> <U+271F><U+2731><U+2729> <U+2715><U+2731><U+2712> <U+2723><U+270D><U+270C> <U+271F><U+2731><U+2713> <U+271F><U+2731><U+2729> <U+271F><U+2731><U+2713> <U+2706><U+2605><U+2733> <U+271F><U+2731><U+2733> <U+271E><U+270D><U+2746> <U+2746><U+2605><U+270E>
                      <U+271A><U+272E>                  <U+2722><U+2721>                  <U+2722><U+272E>
              <U+271F><U+2731><U+2713> <U+271E><U+2713><U+270D> <U+271D><U+2731><U+2605> <U+2715><U+272B><U+2729> <U+2723><U+270D><U+270C> <U+2715><U+270D><U+2763> <U+2715><U+272B><U+2729> <U+2715><U+272B><U+2746> <U+271E><U+2713><U+270D> <U+271E><U+261E><U+270D> <U+271F><U+2731><U+2733> <U+271E><U+2713><U+270D> <U+2715><U+272B><U+2729> <U+2715><U+270D><U+2763> <U+271D><U+2731><U+2605> <U+2723><U+261E><U+2605>
                  <U+272E><U+2721>                  <U+272E><U+272E>                  <U+2727><U+2721>
              <U+2706><U+2713><U+272B> <U+271F><U+2731><U+2713> <U+2715><U+270D><U+2763> <U+25CF><U+2712><U+2731> <U+271E><U+261E><U+270D> <U+271D><U+2731><U+2605> <U+271E><U+261E><U+270D> <U+2715><U+2731><U+2712> <U+2715><U+272B><U+2746> <U+2706><U+2713><U+272B> <U+2725><U+2605><U+270D> <U+271E><U+261E><U+270D> <U+2725><U+2605><U+270D> <U+271E><U+261E><U+270D> <U+2715><U+2731><U+2712> <U+271E><U+2713><U+270D>
              <U+2727><U+272E>                  <U+271B><U+2721>                  <U+271B><U+272E>                  <U+2726><U+2721>
              <U+2746><U+2605><U+270E> <U+271F><U+2731><U+2733> <U+2706><U+2605><U+2733> <U+2725><U+2605><U+270D> <U+2725><U+2605><U+270D> <U+2706><U+2605><U+2733> <U+2715><U+270D><U+2763> <U+2725><U+2605><U+270D> <U+271F><U+2731><U+2733> <U+2715><U+272B><U+2746> <U+271E><U+261E><U+270D> <U+2715><U+2731><U+2712> <U+25CF><U+2712><U+2731> <U+271E><U+2713><U+270D> <U+271E><U+2713><U+270D> <U+260E><U+2713><U+272B>
                              <U+2726><U+272E>                  <U+2741><U+2721>                  <U+2741><U+272E>
              <U+2715><U+2731><U+2712> <U+2715><U+270D><U+2763> <U+2715><U+270D><U+2763> <U+271F><U+2731><U+2713> <U+271D><U+2731><U+2605> <U+271E><U+261E><U+270D> <U+271E><U+261E><U+270D> <U+2723><U+261E><U+2605> <U+271E><U+2713><U+270D> <U+271E><U+270D><U+2746> <U+271F><U+2731><U+2713> <U+271F><U+2731><U+2729> <U+271F><U+2731><U+2713>
                          <U+2720><U+2721><U+2721>                 <U+2720><U+2721><U+272E>
              <U+2741><U+2714><U+2720><U+2721><U+261B>   <U+272E><U+2714>
                                                 41

              <U+2741><U+2714><U+2720><U+2720><U+261B>   <U+2720><U+2721><U+2741>
<removed-date>
              <U+2741><U+2714><U+2720><U+2714><U+261B>   <U+2723><U+2741><U+271E>
              <U+2741><U+2714><U+2720><U+271A><U+261B>   <U+2715><U+270D><U+270E><U+272C><U+272F><U+272C><U+2730><U+272C><U+2712><U+2731> <U+2725><U+2605><U+2732><U+2733><U+2605><U+2729><U+2730><U+2605>
              <U+2741><U+2714><U+2714><U+2721><U+261B>
              <U+2741><U+2714><U+2714><U+271A><U+261B>   <U+2712><U+2729><U+270E><U+272C><U+2734><U+270C><U+2735><U+2713>
              <U+2741><U+2722><U+2721><U+2721><U+261B>   <U+272E><U+2714>
<removed-apn>
              <U+271F><U+2731><U+2733> <U+25CF><U+2712><U+2731> <U+271F><U+2731><U+2729> <U+2706><U+2605><U+2733> <U+25CF><U+2712><U+2731> <U+271F><U+2731><U+2729> <U+2725><U+2605><U+270D> <U+271F><U+2731><U+2713> <U+2715><U+2731><U+2712> <U+271F><U+2731><U+2733> <U+25CF><U+2712><U+2731> <U+2706><U+2713><U+272B> <U+2706><U+2713><U+272B> <U+2723><U+270D><U+270C> <U+271F><U+2731><U+2713> <U+2715><U+2731><U+2712>
              <U+2720>               <U+272E>                   <U+2720><U+2721>                  <U+2720><U+272E>
              <U+271E><U+261E><U+270D> <U+25CF><U+2712><U+2731> <U+2706><U+2713><U+272B> <U+271D><U+2731><U+2605> <U+2725><U+2605><U+270D> <U+260E><U+2713><U+272B> <U+2706><U+2713><U+272B> <U+25CF><U+2712><U+2731> <U+2725><U+2605><U+270D> <U+271F><U+2731><U+2713> <U+271E><U+2713><U+270D> <U+25CF><U+2712><U+2731> <U+2723><U+261E><U+2605> <U+271E><U+261E><U+270D> <U+2725><U+2605><U+270D> <U+271E><U+2713><U+270D>
                          <U+2714><U+2721>                  <U+2714><U+272E>                  <U+271A><U+2721>
              <U+271E><U+270D><U+2746> <U+2706><U+2605><U+2733> <U+275A><U+272C><U+272B> <U+271E><U+270D><U+2746> <U+271D><U+2731><U+2605> <U+2715><U+270D><U+2763> <U+271F><U+2731><U+2729> <U+2725><U+2605><U+270D> <U+2723><U+270D><U+270C> <U+2725><U+2605><U+270D> <U+2715><U+270D><U+2763> <U+271F><U+2731><U+2713> <U+2706><U+2605><U+2733> <U+271F><U+2731><U+2733> <U+271E><U+270D><U+2746> <U+2706><U+2605><U+2733>
                      <U+271A><U+272E>                  <U+2722><U+2721>                  <U+2722><U+272E>
              <U+271F><U+2731><U+2713> <U+271E><U+2713><U+270D> <U+271D><U+2731><U+2605> <U+2715><U+272B><U+2729> <U+2723><U+270D><U+270C> <U+2715><U+270D><U+2763> <U+2715><U+272B><U+2729> <U+2715><U+272B><U+2746> <U+271E><U+2713><U+270D> <U+271E><U+261E><U+270D> <U+271F><U+2731><U+2733> <U+271E><U+2713><U+270D> <U+2715><U+272B><U+2729> <U+2715><U+270D><U+2763> <U+271D><U+2731><U+2605> <U+2723><U+261E><U+2605>
                  <U+272E><U+2721>                  <U+272E><U+272E>                  <U+2727><U+2721>
              <U+2706><U+2713><U+272B> <U+271F><U+2731><U+2713> <U+2715><U+270D><U+2763> <U+2723><U+261E><U+2605> <U+25CF><U+2712><U+2731> <U+2723><U+261E><U+2605> <U+2725><U+2605><U+270D> <U+2706><U+2605><U+2733> <U+2715><U+272B><U+2746> <U+271E><U+261E><U+270D> <U+2725><U+2605><U+270D> <U+25CF><U+2712><U+2731> <U+2725><U+2605><U+270D> <U+271E><U+261E><U+270D> <U+2715><U+2731><U+2712> <U+271E><U+2713><U+270D>
              <U+2727><U+272E>                  <U+271B><U+2721>                  <U+271B><U+272E>                  <U+2726><U+2721>
              <U+2706><U+2605><U+2733> <U+271F><U+2731><U+2729> <U+271D><U+2731><U+2605> <U+260E><U+2713><U+272B> <U+2725><U+2605><U+270D> <U+2706><U+2605><U+2733> <U+2706><U+2713><U+272B> <U+2715><U+2731><U+2712> <U+271F><U+2731><U+2733> <U+2715><U+272B><U+2746> <U+271E><U+261E><U+270D> <U+2715><U+2731><U+2712> <U+25CF><U+2712><U+2731> <U+271E><U+2713><U+270D> <U+271E><U+2713><U+270D> <U+260E><U+2713><U+272B>
                              <U+2726><U+272E>                  <U+2741><U+2721>                  <U+2741><U+272E>
              <U+2715><U+2731><U+2712> <U+2715><U+270D><U+2763> <U+2715><U+270D><U+2763> <U+271F><U+2731><U+2713> <U+271D><U+2731><U+2605> <U+271E><U+261E><U+270D> <U+271E><U+261E><U+270D> <U+2723><U+261E><U+2605> <U+271E><U+2713><U+270D> <U+271E><U+270D><U+2746> <U+271F><U+2731><U+2713> <U+271F><U+2731><U+2729> <U+271F><U+2731><U+2713>
                          <U+2720><U+2721><U+2721>                 <U+2720><U+2721><U+272E>
              <U+2741><U+2714><U+2720><U+2721><U+261B>   <U+272E><U+271A>
              <U+2741><U+2714><U+2720><U+2720><U+261B>   <U+2720><U+2721><U+2741>
              <U+2741><U+2714><U+2720><U+2714><U+261B>   <U+2723><U+2741><U+271E>
                                                 42

              <U+2741><U+2714><U+2720><U+271A><U+261B>   <U+2715><U+270D><U+270E><U+272C><U+272F><U+272C><U+2730><U+272C><U+2712><U+2731> <U+2725><U+2605><U+2732><U+2733><U+2605><U+2729><U+2730><U+2605>
<removed-date>
              <U+2741><U+2714><U+2714><U+2721><U+261B>
              <U+2741><U+2714><U+2714><U+271A><U+261B>   <U+2712><U+2729><U+270E><U+272C><U+2734><U+270C><U+2735><U+2713>
              <U+2741><U+2722><U+2721><U+2721><U+261B>   <U+272E><U+271A>
              <U+271F><U+2731><U+2733> <U+25CF><U+2712><U+2731> <U+271F><U+2731><U+2729> <U+2706><U+2605><U+2733> <U+25CF><U+2712><U+2731> <U+271F><U+2731><U+2729> <U+2725><U+2605><U+270D> <U+271F><U+2731><U+2713> <U+2715><U+2731><U+2712> <U+271F><U+2731><U+2733> <U+25CF><U+2712><U+2731> <U+2706><U+2713><U+272B> <U+2706><U+2713><U+272B> <U+2723><U+270D><U+270C> <U+271F><U+2731><U+2713> <U+2715><U+2731><U+2712>
              <U+2720>               <U+272E>                   <U+2720><U+2721>                  <U+2720><U+272E>
<removed-apn>
              <U+271E><U+261E><U+270D> <U+25CF><U+2712><U+2731> <U+2706><U+2713><U+272B> <U+271D><U+2731><U+2605> <U+2725><U+2605><U+270D> <U+260E><U+2713><U+272B> <U+2706><U+2713><U+272B> <U+25CF><U+2712><U+2731> <U+2725><U+2605><U+270D> <U+271F><U+2731><U+2713> <U+271E><U+2713><U+270D> <U+25CF><U+2712><U+2731> <U+2723><U+261E><U+2605> <U+271E><U+261E><U+270D> <U+2725><U+2605><U+270D> <U+271E><U+2713><U+270D>
                          <U+2714><U+2721>                  <U+2714><U+272E>                  <U+271A><U+2721>
              <U+271E><U+270D><U+2746> <U+2706><U+2605><U+2733> <U+275A><U+272C><U+272B> <U+271E><U+270D><U+2746> <U+271D><U+2731><U+2605> <U+2715><U+270D><U+2763> <U+271F><U+2731><U+2729> <U+2725><U+2605><U+270D> <U+2723><U+270D><U+270C> <U+2725><U+2605><U+270D> <U+2715><U+270D><U+2763> <U+271F><U+2731><U+2713> <U+2706><U+2605><U+2733> <U+271F><U+2731><U+2733> <U+271E><U+270D><U+2746> <U+2706><U+2605><U+2733>
                      <U+271A><U+272E>                  <U+2722><U+2721>                  <U+2722><U+272E>
              <U+271F><U+2731><U+2713> <U+271E><U+2713><U+270D> <U+271D><U+2731><U+2605> <U+2715><U+272B><U+2729> <U+2723><U+270D><U+270C> <U+2715><U+270D><U+2763> <U+2715><U+272B><U+2729> <U+2715><U+272B><U+2746> <U+271E><U+2713><U+270D> <U+271E><U+261E><U+270D> <U+271F><U+2731><U+2733> <U+271E><U+2713><U+270D> <U+2715><U+272B><U+2729> <U+2715><U+270D><U+2763> <U+271D><U+2731><U+2605> <U+2723><U+261E><U+2605>
                  <U+272E><U+2721>                  <U+272E><U+272E>                  <U+2727><U+2721>
              <U+2706><U+2713><U+272B> <U+271F><U+2731><U+2713> <U+2715><U+270D><U+2763> <U+2723><U+261E><U+2605> <U+25CF><U+2712><U+2731> <U+2723><U+261E><U+2605> <U+2725><U+2605><U+270D> <U+2706><U+2605><U+2733> <U+2715><U+272B><U+2746> <U+271E><U+261E><U+270D> <U+2725><U+2605><U+270D> <U+25CF><U+2712><U+2731> <U+2725><U+2605><U+270D> <U+271E><U+261E><U+270D> <U+2715><U+2731><U+2712> <U+271E><U+2713><U+270D>
              <U+2727><U+272E>                  <U+271B><U+2721>                  <U+271B><U+272E>                  <U+2726><U+2721>
              <U+2706><U+2605><U+2733> <U+271F><U+2731><U+2729> <U+271D><U+2731><U+2605> <U+260E><U+2713><U+272B> <U+2725><U+2605><U+270D> <U+2706><U+2605><U+2733> <U+2706><U+2713><U+272B> <U+2715><U+2731><U+2712> <U+271F><U+2731><U+2733> <U+2715><U+272B><U+2746> <U+271E><U+261E><U+270D> <U+2715><U+2731><U+2712> <U+25CF><U+2712><U+2731> <U+271E><U+2713><U+270D> <U+271E><U+2713><U+270D> <U+260E><U+2713><U+272B>
                              <U+2726><U+272E>                  <U+2741><U+2721>                  <U+2741><U+272E>
              <U+2715><U+2731><U+2712> <U+2715><U+270D><U+2763> <U+2715><U+270D><U+2763> <U+271F><U+2731><U+2713> <U+271D><U+2731><U+2605> <U+271E><U+261E><U+270D> <U+271E><U+261E><U+270D> <U+2723><U+261E><U+2605> <U+271E><U+2713><U+270D> <U+271E><U+270D><U+2746> <U+271F><U+2731><U+2713> <U+271F><U+2731><U+2729> <U+271F><U+2731><U+2713>
                          <U+2720><U+2721><U+2721>                 <U+2720><U+2721><U+272E>
              <U+2741><U+2714><U+2720><U+2721><U+261B>   <U+272E><U+2722>
              <U+2741><U+2714><U+2720><U+2720><U+261B>   <U+2720><U+2721><U+2741>
              <U+2741><U+2714><U+2720><U+2714><U+261B>   <U+2723><U+2741><U+271E>
              <U+2741><U+2714><U+2720><U+271A><U+261B>   <U+2715><U+270D><U+270E><U+272C><U+272F><U+272C><U+2730><U+272C><U+2712><U+2731> <U+2725><U+2605><U+2732><U+2733><U+2605><U+2729><U+2730><U+2605>
                                                 43

              <U+2741><U+2714><U+2714><U+2721><U+261B>
<removed-date>
              <U+2741><U+2714><U+2714><U+271A><U+261B>   <U+2712><U+2729><U+270E><U+272C><U+2734><U+270C><U+2735><U+2713>
              <U+2741><U+2722><U+2721><U+2721><U+261B>   <U+272E><U+2722>
              <U+271F><U+2731><U+2733> <U+25CF><U+2712><U+2731> <U+271F><U+2731><U+2729> <U+2706><U+2605><U+2733> <U+25CF><U+2712><U+2731> <U+271F><U+2731><U+2729> <U+2725><U+2605><U+270D> <U+271F><U+2731><U+2713> <U+2715><U+2731><U+2712> <U+271F><U+2731><U+2733> <U+25CF><U+2712><U+2731> <U+2706><U+2713><U+272B> <U+2706><U+2713><U+272B> <U+2723><U+270D><U+270C> <U+271F><U+2731><U+2713> <U+2715><U+2731><U+2712>
              <U+2720>               <U+272E>                   <U+2720><U+2721>                  <U+2720><U+272E>
<removed-apn>
              <U+271E><U+261E><U+270D> <U+25CF><U+2712><U+2731> <U+2706><U+2713><U+272B> <U+271D><U+2731><U+2605> <U+2725><U+2605><U+270D> <U+260E><U+2713><U+272B> <U+2706><U+2713><U+272B> <U+25CF><U+2712><U+2731> <U+2725><U+2605><U+270D> <U+271F><U+2731><U+2713> <U+271E><U+2713><U+270D> <U+25CF><U+2712><U+2731> <U+2723><U+261E><U+2605> <U+271E><U+261E><U+270D> <U+2725><U+2605><U+270D> <U+271E><U+2713><U+270D>
                          <U+2714><U+2721>                  <U+2714><U+272E>                  <U+271A><U+2721>
              <U+271E><U+270D><U+2746> <U+2706><U+2605><U+2733> <U+275A><U+272C><U+272B> <U+271E><U+270D><U+2746> <U+271D><U+2731><U+2605> <U+2715><U+270D><U+2763> <U+271F><U+2731><U+2729> <U+2725><U+2605><U+270D> <U+2723><U+270D><U+270C> <U+2725><U+2605><U+270D> <U+2715><U+270D><U+2763> <U+271F><U+2731><U+2713> <U+2706><U+2605><U+2733> <U+271F><U+2731><U+2733> <U+271E><U+270D><U+2746> <U+2706><U+2605><U+2733>
                      <U+271A><U+272E>                  <U+2722><U+2721>                  <U+2722><U+272E>
              <U+271F><U+2731><U+2713> <U+271E><U+2713><U+270D> <U+271D><U+2731><U+2605> <U+2715><U+272B><U+2729> <U+2723><U+270D><U+270C> <U+2715><U+270D><U+2763> <U+2715><U+272B><U+2729> <U+2715><U+272B><U+2746> <U+271E><U+2713><U+270D> <U+271E><U+261E><U+270D> <U+271F><U+2731><U+2733> <U+271E><U+2713><U+270D> <U+2715><U+272B><U+2729> <U+2715><U+270D><U+2763> <U+271D><U+2731><U+2605> <U+2723><U+261E><U+2605>
                  <U+272E><U+2721>                  <U+272E><U+272E>                  <U+2727><U+2721>
              <U+2706><U+2713><U+272B> <U+271F><U+2731><U+2713> <U+2715><U+270D><U+2763> <U+2723><U+261E><U+2605> <U+25CF><U+2712><U+2731> <U+2723><U+261E><U+2605> <U+2725><U+2605><U+270D> <U+2706><U+2605><U+2733> <U+2715><U+272B><U+2746> <U+271E><U+261E><U+270D> <U+2725><U+2605><U+270D> <U+25CF><U+2712><U+2731> <U+2725><U+2605><U+270D> <U+271E><U+261E><U+270D> <U+2715><U+2731><U+2712> <U+271E><U+2713><U+270D>
              <U+2727><U+272E>                  <U+271B><U+2721>                  <U+271B><U+272E>                  <U+2726><U+2721>
              <U+2706><U+2605><U+2733> <U+271F><U+2731><U+2729> <U+271D><U+2731><U+2605> <U+260E><U+2713><U+272B> <U+2725><U+2605><U+270D> <U+2706><U+2605><U+2733> <U+2706><U+2713><U+272B> <U+2715><U+2731><U+2712> <U+271F><U+2731><U+2733> <U+2715><U+272B><U+2746> <U+271E><U+261E><U+270D> <U+2715><U+2731><U+2712> <U+25CF><U+2712><U+2731> <U+271E><U+2713><U+270D> <U+271E><U+2713><U+270D> <U+260E><U+2713><U+272B>
                              <U+2726><U+272E>                  <U+2741><U+2721>                  <U+2741><U+272E>
              <U+2715><U+2731><U+2712> <U+2715><U+270D><U+2763> <U+2715><U+270D><U+2763> <U+271F><U+2731><U+2713> <U+271D><U+2731><U+2605> <U+271E><U+261E><U+270D> <U+271E><U+261E><U+270D> <U+2723><U+261E><U+2605> <U+271E><U+2713><U+270D> <U+271E><U+270D><U+2746> <U+271F><U+2731><U+2713> <U+271F><U+2731><U+2729> <U+271F><U+2731><U+2713>
                          <U+2720><U+2721><U+2721>                 <U+2720><U+2721><U+272E>
              <U+2741><U+2714><U+2720><U+2721><U+261B>   <U+272E><U+272E>
              <U+2741><U+2714><U+2720><U+2720><U+261B>   <U+2720><U+2721><U+2741>
              <U+2741><U+2714><U+2720><U+2714><U+261B>   <U+2723><U+2741><U+271E>
              <U+2741><U+2714><U+2720><U+271A><U+261B>   <U+2715><U+270D><U+270E><U+272C><U+272F><U+272C><U+2730><U+272C><U+2712><U+2731> <U+2725><U+2605><U+2732><U+2733><U+2605><U+2729><U+2730><U+2605>
              <U+2741><U+2714><U+2714><U+2721><U+261B>
              <U+2741><U+2714><U+2714><U+271A><U+261B>   <U+2712><U+2729><U+270E><U+272C><U+2734><U+270C><U+2735><U+2713>
                                                 44

<removed-date>
              <U+2741><U+2722><U+2721><U+2721><U+261B>   <U+272E><U+272E>
              <U+271F><U+2731><U+2729> <U+25CF><U+2712><U+2731> <U+271F><U+2731><U+2729> <U+2706><U+2605><U+2733> <U+25CF><U+2712><U+2731> <U+271F><U+2731><U+2729> <U+2725><U+2605><U+270D> <U+271F><U+2731><U+2713> <U+2715><U+2731><U+2712> <U+271F><U+2731><U+2733> <U+25CF><U+2712><U+2731> <U+2706><U+2713><U+272B> <U+2706><U+2713><U+272B> <U+2723><U+270D><U+270C> <U+271F><U+2731><U+2713> <U+2715><U+2731><U+2712>
              <U+2720>               <U+272E>                   <U+2720><U+2721>                  <U+2720><U+272E>
              <U+2725><U+2605><U+270D> <U+25CF><U+2712><U+2731> <U+2706><U+2713><U+272B> <U+25CF><U+2712><U+2731> <U+2725><U+2605><U+270D> <U+260E><U+2713><U+272B> <U+2706><U+2713><U+272B> <U+2715><U+2731><U+2712> <U+2725><U+2605><U+270D> <U+271F><U+2731><U+2713> <U+271E><U+2713><U+270D> <U+25CF><U+2712><U+2731> <U+2723><U+261E><U+2605> <U+271E><U+261E><U+270D> <U+2725><U+2605><U+270D> <U+271E><U+2713><U+270D>
                          <U+2714><U+2721>                  <U+2714><U+272E>                  <U+271A><U+2721>
<removed-apn>
              <U+271E><U+270D><U+2746> <U+2706><U+2605><U+2733> <U+275A><U+272C><U+272B> <U+271E><U+270D><U+2746> <U+271D><U+2731><U+2605> <U+2715><U+270D><U+2763> <U+271F><U+2731><U+2729> <U+2725><U+2605><U+270D> <U+2723><U+270D><U+270C> <U+2725><U+2605><U+270D> <U+2715><U+270D><U+2763> <U+271F><U+2731><U+2713> <U+2706><U+2605><U+2733> <U+271F><U+2731><U+2733> <U+271E><U+270D><U+2746> <U+2706><U+2605><U+2733>
                      <U+271A><U+272E>                  <U+2722><U+2721>                  <U+2722><U+272E>
              <U+271F><U+2731><U+2713> <U+271E><U+2713><U+270D> <U+271D><U+2731><U+2605> <U+2715><U+272B><U+2729> <U+2723><U+270D><U+270C> <U+2715><U+270D><U+2763> <U+2715><U+272B><U+2729> <U+2715><U+272B><U+2746> <U+271E><U+2713><U+270D> <U+271E><U+261E><U+270D> <U+271F><U+2731><U+2733> <U+271E><U+2713><U+270D> <U+2715><U+272B><U+2729> <U+2715><U+270D><U+2763> <U+271D><U+2731><U+2605> <U+2723><U+261E><U+2605>
                  <U+272E><U+2721>                  <U+272E><U+272E>                  <U+2727><U+2721>
              <U+2706><U+2713><U+272B> <U+271F><U+2731><U+2713> <U+2715><U+270D><U+2763> <U+2723><U+261E><U+2605> <U+25CF><U+2712><U+2731> <U+2723><U+261E><U+2605> <U+2725><U+2605><U+270D> <U+2706><U+2605><U+2733> <U+2715><U+272B><U+2746> <U+271E><U+261E><U+270D> <U+2725><U+2605><U+270D> <U+25CF><U+2712><U+2731> <U+2725><U+2605><U+270D> <U+271E><U+261E><U+270D> <U+2715><U+2731><U+2712> <U+271E><U+2713><U+270D>
              <U+2727><U+272E>                  <U+271B><U+2721>                  <U+271B><U+272E>                  <U+2726><U+2721>
              <U+2706><U+2605><U+2733> <U+271F><U+2731><U+2729> <U+271D><U+2731><U+2605> <U+260E><U+2713><U+272B> <U+2725><U+2605><U+270D> <U+2706><U+2605><U+2733> <U+2706><U+2713><U+272B> <U+2715><U+2731><U+2712> <U+271F><U+2731><U+2733> <U+2715><U+272B><U+2746> <U+271E><U+261E><U+270D> <U+2715><U+2731><U+2712> <U+25CF><U+2712><U+2731> <U+271E><U+2713><U+270D> <U+271E><U+2713><U+270D> <U+260E><U+2713><U+272B>
                              <U+2726><U+272E>                  <U+2741><U+2721>                  <U+2741><U+272E>
              <U+2715><U+2731><U+2712> <U+2715><U+270D><U+2763> <U+2715><U+270D><U+2763> <U+271F><U+2731><U+2713> <U+271D><U+2731><U+2605> <U+271E><U+261E><U+270D> <U+271E><U+261E><U+270D> <U+2723><U+261E><U+2605> <U+271E><U+2713><U+270D> <U+271E><U+270D><U+2746> <U+271F><U+2731><U+2713> <U+271F><U+2731><U+2729> <U+271F><U+2731><U+2713>
                          <U+2720><U+2721><U+2721>                 <U+2720><U+2721><U+272E>
              <U+2741><U+2714><U+2720><U+2721><U+261B>   <U+272E><U+2727>
              <U+2741><U+2714><U+2720><U+2720><U+261B>   <U+2720><U+2721><U+2741>
              <U+2741><U+2714><U+2720><U+2714><U+261B>   <U+2723><U+2741><U+271E>
              <U+2741><U+2714><U+2720><U+271A><U+261B>   <U+2715><U+270D><U+270E><U+272C><U+272F><U+272C><U+2730><U+272C><U+2712><U+2731> <U+2725><U+2605><U+2732><U+2733><U+2605><U+2729><U+2730><U+2605>
              <U+2741><U+2714><U+2714><U+2721><U+261B>
              <U+2741><U+2714><U+2714><U+271A><U+261B>   <U+2712><U+2729><U+270E><U+272C><U+2734><U+270C><U+2735><U+2713>
              <U+2741><U+2722><U+2721><U+2721><U+261B>   <U+272E><U+2727>
                                                 45

<removed-date>
              <U+271F><U+2731><U+2729> <U+25CF><U+2712><U+2731> <U+271F><U+2731><U+2729> <U+2706><U+2605><U+2733> <U+25CF><U+2712><U+2731> <U+271F><U+2731><U+2729> <U+2725><U+2605><U+270D> <U+271F><U+2731><U+2713> <U+2715><U+2731><U+2712> <U+271F><U+2731><U+2733> <U+25CF><U+2712><U+2731> <U+2706><U+2713><U+272B> <U+2706><U+2713><U+272B> <U+2723><U+270D><U+270C> <U+271F><U+2731><U+2713> <U+2715><U+2731><U+2712>
              <U+2720>               <U+272E>                   <U+2720><U+2721>                  <U+2720><U+272E>
              <U+2725><U+2605><U+270D> <U+25CF><U+2712><U+2731> <U+2706><U+2713><U+272B> <U+25CF><U+2712><U+2731> <U+2725><U+2605><U+270D> <U+260E><U+2713><U+272B> <U+2706><U+2713><U+272B> <U+2715><U+2731><U+2712> <U+2725><U+2605><U+270D> <U+271F><U+2731><U+2713> <U+271E><U+2713><U+270D> <U+25CF><U+2712><U+2731> <U+2723><U+261E><U+2605> <U+271E><U+261E><U+270D> <U+2725><U+2605><U+270D> <U+271E><U+2713><U+270D>
                          <U+2714><U+2721>                  <U+2714><U+272E>                  <U+271A><U+2721>
<removed-apn>
              <U+271E><U+270D><U+2746> <U+2706><U+2605><U+2733> <U+275A><U+272C><U+272B> <U+271E><U+270D><U+2746> <U+25CF><U+2712><U+2731> <U+2715><U+270D><U+2763> <U+271F><U+2731><U+2729> <U+2715><U+2731><U+2712> <U+2715><U+270D><U+2763> <U+271F><U+2731><U+2713> <U+271F><U+2731><U+2729> <U+2715><U+270D><U+2763> <U+2706><U+2605><U+2733> <U+271F><U+2731><U+2733> <U+271E><U+270D><U+2746> <U+271D><U+2731><U+2605>
                      <U+271A><U+272E>                  <U+2722><U+2721>                  <U+2722><U+272E>
              <U+271F><U+2731><U+2713> <U+271E><U+2713><U+270D> <U+271D><U+2731><U+2605> <U+2715><U+272B><U+2729> <U+2723><U+270D><U+270C> <U+2715><U+270D><U+2763> <U+2715><U+272B><U+2729> <U+2715><U+272B><U+2746> <U+271E><U+2713><U+270D> <U+271E><U+261E><U+270D> <U+271F><U+2731><U+2733> <U+271E><U+2713><U+270D> <U+2715><U+272B><U+2729> <U+2715><U+270D><U+2763> <U+271D><U+2731><U+2605> <U+2723><U+261E><U+2605>
                  <U+272E><U+2721>                  <U+272E><U+272E>                  <U+2727><U+2721>
              <U+2706><U+2713><U+272B> <U+271F><U+2731><U+2713> <U+2715><U+270D><U+2763> <U+25CF><U+2712><U+2731> <U+271E><U+261E><U+270D> <U+271D><U+2731><U+2605> <U+271E><U+261E><U+270D> <U+2715><U+2731><U+2712> <U+2715><U+272B><U+2746> <U+2706><U+2713><U+272B> <U+2725><U+2605><U+270D> <U+271E><U+261E><U+270D> <U+2725><U+2605><U+270D> <U+271E><U+261E><U+270D> <U+2715><U+2731><U+2712> <U+271E><U+2713><U+270D>
              <U+2727><U+272E>                  <U+271B><U+2721>                  <U+271B><U+272E>                  <U+2726><U+2721>
              <U+2746><U+2605><U+270E> <U+271F><U+2731><U+2733> <U+2706><U+2605><U+2733> <U+2725><U+2605><U+270D> <U+2725><U+2605><U+270D> <U+2706><U+2605><U+2733> <U+2715><U+270D><U+2763> <U+2725><U+2605><U+270D> <U+271F><U+2731><U+2733> <U+2715><U+272B><U+2746> <U+271E><U+261E><U+270D> <U+2715><U+2731><U+2712> <U+25CF><U+2712><U+2731> <U+271E><U+2713><U+270D> <U+271E><U+2713><U+270D> <U+260E><U+2713><U+272B>
                              <U+2726><U+272E>                  <U+2741><U+2721>                  <U+2741><U+272E>
              <U+2715><U+2731><U+2712> <U+2715><U+270D><U+2763> <U+2715><U+270D><U+2763> <U+271F><U+2731><U+2713> <U+271D><U+2731><U+2605> <U+271E><U+261E><U+270D> <U+271E><U+261E><U+270D> <U+2723><U+261E><U+2605> <U+271E><U+2713><U+270D> <U+271E><U+270D><U+2746> <U+271F><U+2731><U+2713> <U+271F><U+2731><U+2729> <U+271F><U+2731><U+2713>
                          <U+2720><U+2721><U+2721>                 <U+2720><U+2721><U+272E>
              <U+2741><U+2714><U+2720><U+2721><U+261B>   <U+272E><U+271B>
              <U+2741><U+2714><U+2720><U+2720><U+261B>   <U+2720><U+2721><U+2741>
              <U+2741><U+2714><U+2720><U+2714><U+261B>   <U+2723><U+2741><U+271E>
              <U+2741><U+2714><U+2720><U+271A><U+261B>   <U+2715><U+270D><U+270E><U+272C><U+272F><U+272C><U+2730><U+272C><U+2712><U+2731> <U+2725><U+2605><U+2732><U+2733><U+2605><U+2729><U+2730><U+2605>
              <U+2741><U+2714><U+2714><U+2721><U+261B>
              <U+2741><U+2714><U+2714><U+271A><U+261B>   <U+2712><U+2729><U+270E><U+272C><U+2734><U+270C><U+2735><U+2713>
              <U+2741><U+2722><U+2721><U+2721><U+261B>   <U+272E><U+271B>
              <U+271F><U+2731><U+2729> <U+25CF><U+2712><U+2731> <U+271F><U+2731><U+2729> <U+2706><U+2605><U+2733> <U+25CF><U+2712><U+2731> <U+271F><U+2731><U+2729> <U+2725><U+2605><U+270D> <U+271F><U+2731><U+2713> <U+2715><U+2731><U+2712> <U+271F><U+2731><U+2733> <U+25CF><U+2712><U+2731> <U+2706><U+2713><U+272B> <U+2706><U+2713><U+272B> <U+2723><U+270D><U+270C> <U+271F><U+2731><U+2713> <U+2715><U+2731><U+2712>
                                                 46

              <U+2720>                  <U+272E>                <U+2720><U+2721>                  <U+2720><U+272E>
<removed-date>
              <U+2725><U+2605><U+270D> <U+25CF><U+2712><U+2731> <U+2706><U+2713><U+272B> <U+25CF><U+2712><U+2731> <U+2725><U+2605><U+270D> <U+260E><U+2713><U+272B> <U+2706><U+2713><U+272B> <U+2715><U+2731><U+2712> <U+2725><U+2605><U+270D> <U+271F><U+2731><U+2713> <U+271E><U+2713><U+270D> <U+25CF><U+2712><U+2731> <U+2723><U+261E><U+2605> <U+271E><U+261E><U+270D> <U+2725><U+2605><U+270D> <U+271E><U+2713><U+270D>
                          <U+2714><U+2721>                  <U+2714><U+272E>                  <U+271A><U+2721>
              <U+271E><U+270D><U+2746> <U+2706><U+2605><U+2733> <U+275A><U+272C><U+272B> <U+271E><U+270D><U+2746> <U+25CF><U+2712><U+2731> <U+2715><U+270D><U+2763> <U+271F><U+2731><U+2729> <U+2715><U+2731><U+2712> <U+2715><U+270D><U+2763> <U+271F><U+2731><U+2713> <U+271F><U+2731><U+2729> <U+2715><U+270D><U+2763> <U+2706><U+2605><U+2733> <U+271F><U+2731><U+2733> <U+271E><U+270D><U+2746> <U+271D><U+2731><U+2605>
                      <U+271A><U+272E>                  <U+2722><U+2721>                  <U+2722><U+272E>
<removed-apn>
              <U+271F><U+2731><U+2713> <U+271E><U+2713><U+270D> <U+271D><U+2731><U+2605> <U+2715><U+272B><U+2729> <U+2723><U+270D><U+270C> <U+2715><U+270D><U+2763> <U+2715><U+272B><U+2729> <U+2715><U+272B><U+2746> <U+271E><U+2713><U+270D> <U+271E><U+261E><U+270D> <U+271F><U+2731><U+2733> <U+271E><U+2713><U+270D> <U+2715><U+272B><U+2729> <U+2715><U+270D><U+2763> <U+271D><U+2731><U+2605> <U+2723><U+261E><U+2605>
                  <U+272E><U+2721>                  <U+272E><U+272E>                  <U+2727><U+2721>
              <U+2706><U+2713><U+272B> <U+271F><U+2731><U+2713> <U+2715><U+270D><U+2763> <U+25CF><U+2712><U+2731> <U+271E><U+261E><U+270D> <U+271D><U+2731><U+2605> <U+271E><U+261E><U+270D> <U+2715><U+2731><U+2712> <U+2715><U+272B><U+2746> <U+2706><U+2713><U+272B> <U+2725><U+2605><U+270D> <U+271E><U+261E><U+270D> <U+2725><U+2605><U+270D> <U+271E><U+261E><U+270D> <U+2715><U+2731><U+2712> <U+271E><U+2713><U+270D>
              <U+2727><U+272E>                  <U+271B><U+2721>                  <U+271B><U+272E>                  <U+2726><U+2721>
              <U+2746><U+2605><U+270E> <U+271F><U+2731><U+2733> <U+2706><U+2605><U+2733> <U+2725><U+2605><U+270D> <U+2725><U+2605><U+270D> <U+2706><U+2605><U+2733> <U+2715><U+270D><U+2763> <U+2725><U+2605><U+270D> <U+271F><U+2731><U+2733> <U+2715><U+272B><U+2746> <U+271E><U+261E><U+270D> <U+2715><U+2731><U+2712> <U+25CF><U+2712><U+2731> <U+271E><U+2713><U+270D> <U+271E><U+2713><U+270D> <U+260E><U+2713><U+272B>
                              <U+2726><U+272E>                  <U+2741><U+2721>                  <U+2741><U+272E>
              <U+2715><U+2731><U+2712> <U+2715><U+270D><U+2763> <U+2715><U+270D><U+2763> <U+271F><U+2731><U+2713> <U+271D><U+2731><U+2605> <U+271E><U+261E><U+270D> <U+271E><U+261E><U+270D> <U+2723><U+261E><U+2605> <U+271E><U+2713><U+270D> <U+271E><U+270D><U+2746> <U+271F><U+2731><U+2713> <U+271F><U+2731><U+2729> <U+271F><U+2731><U+2713>
                          <U+2720><U+2721><U+2721>                 <U+2720><U+2721><U+272E>
              <U+2741><U+2714><U+2720><U+2721><U+261B>   <U+272E><U+2726>
              <U+2741><U+2714><U+2720><U+2720><U+261B>   <U+2720><U+2721><U+2741>
              <U+2741><U+2714><U+2720><U+2714><U+261B>   <U+2723><U+2741><U+271E>
              <U+2741><U+2714><U+2720><U+271A><U+261B>   <U+2715><U+270D><U+270E><U+272C><U+272F><U+272C><U+2730><U+272C><U+2712><U+2731> <U+2725><U+2605><U+2732><U+2733><U+2605><U+2729><U+2730><U+2605>
              <U+2741><U+2714><U+2714><U+2721><U+261B>
              <U+2741><U+2714><U+2714><U+271A><U+261B>   <U+2712><U+2729><U+270E><U+272C><U+2734><U+270C><U+2735><U+2713>
              <U+2741><U+2722><U+2721><U+2721><U+261B>   <U+272E><U+2726>
              <U+271F><U+2731><U+2729> <U+25CF><U+2712><U+2731> <U+271F><U+2731><U+2729> <U+2706><U+2605><U+2733> <U+25CF><U+2712><U+2731> <U+271F><U+2731><U+2729> <U+2725><U+2605><U+270D> <U+271F><U+2731><U+2713> <U+2715><U+2731><U+2712> <U+271F><U+2731><U+2733> <U+25CF><U+2712><U+2731> <U+2706><U+2713><U+272B> <U+2706><U+2713><U+272B> <U+2723><U+270D><U+270C> <U+271F><U+2731><U+2713> <U+2715><U+2731><U+2712>
              <U+2720>               <U+272E>                   <U+2720><U+2721>                  <U+2720><U+272E>
                                                 47

<removed-date>
              <U+2725><U+2605><U+270D> <U+25CF><U+2712><U+2731> <U+2706><U+2713><U+272B> <U+25CF><U+2712><U+2731> <U+2725><U+2605><U+270D> <U+260E><U+2713><U+272B> <U+2706><U+2713><U+272B> <U+2715><U+2731><U+2712> <U+2725><U+2605><U+270D> <U+271F><U+2731><U+2713> <U+271E><U+2713><U+270D> <U+25CF><U+2712><U+2731> <U+2723><U+261E><U+2605> <U+271E><U+261E><U+270D> <U+2725><U+2605><U+270D> <U+271E><U+2713><U+270D>
                          <U+2714><U+2721>                  <U+2714><U+272E>                  <U+271A><U+2721>
              <U+271E><U+270D><U+2746> <U+2706><U+2605><U+2733> <U+275A><U+272C><U+272B> <U+271E><U+270D><U+2746> <U+271D><U+2731><U+2605> <U+2715><U+270D><U+2763> <U+271F><U+2731><U+2729> <U+2725><U+2605><U+270D> <U+2723><U+270D><U+270C> <U+2725><U+2605><U+270D> <U+2715><U+270D><U+2763> <U+271F><U+2731><U+2713> <U+2706><U+2605><U+2733> <U+271F><U+2731><U+2733> <U+271E><U+270D><U+2746> <U+2706><U+2605><U+2733>
                      <U+271A><U+272E>                  <U+2722><U+2721>                  <U+2722><U+272E>
<removed-apn>
              <U+271F><U+2731><U+2713> <U+271E><U+2713><U+270D> <U+271D><U+2731><U+2605> <U+2715><U+272B><U+2729> <U+2723><U+270D><U+270C> <U+2715><U+270D><U+2763> <U+2715><U+272B><U+2729> <U+2715><U+272B><U+2746> <U+271E><U+2713><U+270D> <U+271E><U+261E><U+270D> <U+271F><U+2731><U+2733> <U+271E><U+2713><U+270D> <U+2715><U+272B><U+2729> <U+2715><U+270D><U+2763> <U+271D><U+2731><U+2605> <U+2723><U+261E><U+2605>
                  <U+272E><U+2721>                  <U+272E><U+272E>                  <U+2727><U+2721>
              <U+2706><U+2713><U+272B> <U+271F><U+2731><U+2713> <U+2715><U+270D><U+2763> <U+2723><U+261E><U+2605> <U+25CF><U+2712><U+2731> <U+2723><U+261E><U+2605> <U+2725><U+2605><U+270D> <U+2706><U+2605><U+2733> <U+2715><U+272B><U+2746> <U+271E><U+261E><U+270D> <U+2725><U+2605><U+270D> <U+25CF><U+2712><U+2731> <U+2725><U+2605><U+270D> <U+271E><U+261E><U+270D> <U+2715><U+2731><U+2712> <U+271E><U+2713><U+270D>
              <U+2727><U+272E>                  <U+271B><U+2721>                  <U+271B><U+272E>                  <U+2726><U+2721>
              <U+2706><U+2605><U+2733> <U+271F><U+2731><U+2729> <U+271D><U+2731><U+2605> <U+260E><U+2713><U+272B> <U+2725><U+2605><U+270D> <U+2706><U+2605><U+2733> <U+2706><U+2713><U+272B> <U+2715><U+2731><U+2712> <U+271F><U+2731><U+2733> <U+2715><U+272B><U+2746> <U+271E><U+261E><U+270D> <U+2715><U+2731><U+2712> <U+25CF><U+2712><U+2731> <U+271E><U+2713><U+270D> <U+271E><U+2713><U+270D> <U+260E><U+2713><U+272B>
                              <U+2726><U+272E>                  <U+2741><U+2721>                  <U+2741><U+272E>
              <U+2715><U+2731><U+2712> <U+2715><U+270D><U+2763> <U+2715><U+270D><U+2763> <U+271F><U+2731><U+2713> <U+271D><U+2731><U+2605> <U+271E><U+261E><U+270D> <U+271E><U+261E><U+270D> <U+2723><U+261E><U+2605> <U+271E><U+2713><U+270D> <U+271E><U+270D><U+2746> <U+271F><U+2731><U+2713> <U+271F><U+2731><U+2729> <U+271F><U+2731><U+2713>
                          <U+2720><U+2721><U+2721>                 <U+2720><U+2721><U+272E>
              <U+2741><U+2714><U+2720><U+2721><U+261B>   <U+272E><U+2741>
              <U+2741><U+2714><U+2720><U+2720><U+261B>   <U+2720><U+2721><U+2741>
              <U+2741><U+2714><U+2720><U+2714><U+261B>   <U+2723><U+2741><U+271E>
              <U+2741><U+2714><U+2720><U+271A><U+261B>   <U+2715><U+270D><U+270E><U+272C><U+272F><U+272C><U+2730><U+272C><U+2712><U+2731> <U+2725><U+2605><U+2732><U+2733><U+2605><U+2729><U+2730><U+2605>
              <U+2741><U+2714><U+2714><U+2721><U+261B>
              <U+2741><U+2714><U+2714><U+271A><U+261B>   <U+2712><U+2729><U+270E><U+272C><U+2734><U+270C><U+2735><U+2713>
              <U+2741><U+2722><U+2721><U+2721><U+261B>   <U+272E><U+2741>
              <U+271F><U+2731><U+2733> <U+25CF><U+2712><U+2731> <U+271F><U+2731><U+2729> <U+2706><U+2605><U+2733> <U+25CF><U+2712><U+2731> <U+271F><U+2731><U+2729> <U+2725><U+2605><U+270D> <U+271F><U+2731><U+2713> <U+2715><U+2731><U+2712> <U+271F><U+2731><U+2733> <U+25CF><U+2712><U+2731> <U+2706><U+2713><U+272B> <U+2706><U+2713><U+272B> <U+2723><U+270D><U+270C> <U+271F><U+2731><U+2713> <U+271F><U+2731><U+2733>
              <U+2720>               <U+272E>                   <U+2720><U+2721>                  <U+2720><U+272E>
              <U+2725><U+2605><U+270D> <U+2706><U+2605><U+2733> <U+2715><U+270D><U+2763> <U+271D><U+2731><U+2605> <U+2725><U+2605><U+270D> <U+260E><U+2713><U+272B> <U+2706><U+2713><U+272B> <U+25CF><U+2712><U+2731> <U+2725><U+2605><U+270D> <U+271F><U+2731><U+2713> <U+271E><U+2713><U+270D> <U+25CF><U+2712><U+2731> <U+2723><U+261E><U+2605> <U+271E><U+261E><U+270D> <U+2725><U+2605><U+270D> <U+271E><U+2713><U+270D>
                                                 48

                           <U+2714><U+2721>                 <U+2714><U+272E>                    <U+271A><U+2721>
<removed-date>
              <U+271E><U+270D><U+2746> <U+2706><U+2605><U+2733> <U+275A><U+272C><U+272B> <U+271E><U+270D><U+2746> <U+271D><U+2731><U+2605> <U+2715><U+270D><U+2763> <U+271F><U+2731><U+2729> <U+2725><U+2605><U+270D> <U+2723><U+270D><U+270C> <U+2725><U+2605><U+270D> <U+2715><U+270D><U+2763> <U+271F><U+2731><U+2713> <U+2706><U+2605><U+2733> <U+271F><U+2731><U+2733> <U+271E><U+270D><U+2746> <U+2706><U+2605><U+2733>
                      <U+271A><U+272E>                  <U+2722><U+2721>                  <U+2722><U+272E>
              <U+271F><U+2731><U+2713> <U+271E><U+2713><U+270D> <U+271D><U+2731><U+2605> <U+2715><U+272B><U+2729> <U+2723><U+270D><U+270C> <U+2715><U+270D><U+2763> <U+2715><U+272B><U+2729> <U+2715><U+272B><U+2746> <U+271E><U+2713><U+270D> <U+271E><U+261E><U+270D> <U+271F><U+2731><U+2733> <U+271E><U+2713><U+270D> <U+2715><U+272B><U+2729> <U+2715><U+270D><U+2763> <U+271D><U+2731><U+2605> <U+2723><U+261E><U+2605>
                  <U+272E><U+2721>                  <U+272E><U+272E>                  <U+2727><U+2721>
<removed-apn>
              <U+2706><U+2713><U+272B> <U+271F><U+2731><U+2713> <U+2715><U+270D><U+2763> <U+2723><U+261E><U+2605> <U+271E><U+261E><U+270D> <U+271D><U+2731><U+2605> <U+2725><U+2605><U+270D> <U+2715><U+270D><U+2763> <U+2715><U+272B><U+2746> <U+2715><U+272B><U+2729> <U+2715><U+2731><U+2712> <U+2706><U+2713><U+272B> <U+2715><U+272B><U+2729> <U+2725><U+2605><U+270D> <U+2706><U+2605><U+2733> <U+271E><U+2713><U+270D>
              <U+2727><U+272E>                  <U+271B><U+2721>                  <U+271B><U+272E>                  <U+2726><U+2721>
              <U+2706><U+2605><U+2733> <U+271F><U+2731><U+2729> <U+2746><U+2605><U+270E> <U+2715><U+272B><U+2729> <U+2725><U+2605><U+270D> <U+2706><U+2605><U+2733> <U+2715><U+270D><U+2763> <U+2715><U+2731><U+2712> <U+271F><U+2731><U+2733> <U+2715><U+272B><U+2746> <U+271E><U+261E><U+270D> <U+2715><U+2731><U+2712> <U+25CF><U+2712><U+2731> <U+271E><U+2713><U+270D> <U+271E><U+2713><U+270D> <U+260E><U+2713><U+272B>
                              <U+2726><U+272E>                  <U+2741><U+2721>                  <U+2741><U+272E>
              <U+2715><U+2731><U+2712> <U+2715><U+270D><U+2763> <U+2715><U+270D><U+2763> <U+271F><U+2731><U+2713> <U+271D><U+2731><U+2605> <U+271E><U+261E><U+270D> <U+271E><U+261E><U+270D> <U+2723><U+261E><U+2605> <U+271E><U+2713><U+270D> <U+271E><U+270D><U+2746> <U+271F><U+2731><U+2713> <U+271F><U+2731><U+2729> <U+271F><U+2731><U+2713>
                          <U+2720><U+2721><U+2721>                 <U+2720><U+2721><U+272E>
              <U+2741><U+2714><U+2720><U+2721><U+261B>   <U+2727><U+2721>
              <U+2741><U+2714><U+2720><U+2720><U+261B>   <U+2720><U+2721><U+2741>
              <U+2741><U+2714><U+2720><U+2714><U+261B>   <U+2723><U+2741><U+271E>
              <U+2741><U+2714><U+2720><U+271A><U+261B>   <U+2715><U+270D><U+270E><U+272C><U+272F><U+272C><U+2730><U+272C><U+2712><U+2731> <U+2725><U+2605><U+2732><U+2733><U+2605><U+2729><U+2730><U+2605>
              <U+2741><U+2714><U+2714><U+2721><U+261B>
              <U+2741><U+2714><U+2714><U+271A><U+261B>   <U+2712><U+2729><U+270E><U+272C><U+2734><U+270C><U+2735><U+2713>
              <U+2741><U+2722><U+2721><U+2721><U+261B>   <U+2727><U+2721>
              <U+271F><U+2731><U+2729> <U+25CF><U+2712><U+2731> <U+271F><U+2731><U+2729> <U+2706><U+2605><U+2733> <U+271F><U+2731><U+2729> <U+271F><U+2731><U+2733> <U+2725><U+2605><U+270D> <U+271F><U+2731><U+2713> <U+2723><U+270D><U+270C> <U+271F><U+2731><U+2713> <U+2706><U+2605><U+2733> <U+25CF><U+2712><U+2731> <U+2706><U+2713><U+272B> <U+2723><U+270D><U+270C> <U+2725><U+2605><U+270D> <U+271F><U+2731><U+2729>
              <U+2720>               <U+272E>                   <U+2720><U+2721>                  <U+2720><U+272E>
              <U+271E><U+261E><U+270D> <U+2706><U+2605><U+2733> <U+2725><U+2605><U+270D> <U+2706><U+2605><U+2733> <U+271E><U+261E><U+270D> <U+260E><U+2713><U+272B> <U+271E><U+261E><U+270D> <U+25CF><U+2712><U+2731> <U+2725><U+2605><U+270D> <U+271F><U+2731><U+2713> <U+271E><U+2713><U+270D> <U+25CF><U+2712><U+2731> <U+2723><U+261E><U+2605> <U+271E><U+261E><U+270D> <U+2725><U+2605><U+270D> <U+271E><U+2713><U+270D>
                          <U+2714><U+2721>                  <U+2714><U+272E>                  <U+271A><U+2721>
                                                   49

<removed-date>
              <U+271E><U+270D><U+2746> <U+2706><U+2605><U+2733> <U+275A><U+272C><U+272B> <U+271E><U+270D><U+2746> <U+271D><U+2731><U+2605> <U+2715><U+270D><U+2763> <U+271F><U+2731><U+2729> <U+2723><U+270D><U+270C> <U+2723><U+270D><U+270C> <U+271F><U+2731><U+2713> <U+2706><U+2713><U+272B> <U+271F><U+2731><U+2713> <U+2706><U+2605><U+2733> <U+271F><U+2731><U+2733> <U+271E><U+270D><U+2746> <U+271D><U+2731><U+2605>
                      <U+271A><U+272E>                  <U+2722><U+2721>                  <U+2722><U+272E>
              <U+271F><U+2731><U+2713> <U+271E><U+2713><U+270D> <U+271D><U+2731><U+2605> <U+2715><U+272B><U+2729> <U+2723><U+270D><U+270C> <U+2715><U+270D><U+2763> <U+2715><U+272B><U+2729> <U+2715><U+272B><U+2746> <U+271E><U+2713><U+270D> <U+271E><U+261E><U+270D> <U+271F><U+2731><U+2733> <U+271E><U+2713><U+270D> <U+2715><U+272B><U+2729> <U+2715><U+270D><U+2763> <U+271D><U+2731><U+2605> <U+2723><U+261E><U+2605>
                  <U+272E><U+2721>                  <U+272E><U+272E>                  <U+2727><U+2721>
<removed-apn>
              <U+2706><U+2713><U+272B> <U+271F><U+2731><U+2713> <U+2715><U+270D><U+2763> <U+25CF><U+2712><U+2731> <U+271E><U+261E><U+270D> <U+271D><U+2731><U+2605> <U+271E><U+261E><U+270D> <U+2715><U+2731><U+2712> <U+2715><U+272B><U+2746> <U+2706><U+2713><U+272B> <U+2725><U+2605><U+270D> <U+271E><U+261E><U+270D> <U+2725><U+2605><U+270D> <U+271E><U+261E><U+270D> <U+2715><U+2731><U+2712> <U+271E><U+2713><U+270D>
              <U+2727><U+272E>                  <U+271B><U+2721>                  <U+271B><U+272E>                  <U+2726><U+2721>
              <U+2746><U+2605><U+270E> <U+271F><U+2731><U+2733> <U+2706><U+2605><U+2733> <U+2725><U+2605><U+270D> <U+2725><U+2605><U+270D> <U+2706><U+2605><U+2733> <U+2715><U+270D><U+2763> <U+2725><U+2605><U+270D> <U+271F><U+2731><U+2733> <U+2715><U+272B><U+2746> <U+271E><U+261E><U+270D> <U+2715><U+2731><U+2712> <U+25CF><U+2712><U+2731> <U+271E><U+2713><U+270D> <U+271E><U+2713><U+270D> <U+260E><U+2713><U+272B>
                              <U+2726><U+272E>                  <U+2741><U+2721>                  <U+2741><U+272E>
              <U+2715><U+2731><U+2712> <U+2715><U+270D><U+2763> <U+2715><U+270D><U+2763> <U+271F><U+2731><U+2713> <U+271D><U+2731><U+2605> <U+271E><U+261E><U+270D> <U+271E><U+261E><U+270D> <U+2723><U+261E><U+2605> <U+271E><U+2713><U+270D> <U+271E><U+270D><U+2746> <U+271F><U+2731><U+2713> <U+271F><U+2731><U+2729> <U+271F><U+2731><U+2713>
                          <U+2720><U+2721><U+2721>                 <U+2720><U+2721><U+272E>
              <U+2741><U+2714><U+2720><U+2721><U+261B>   <U+2727><U+2720>
              <U+2741><U+2714><U+2720><U+2720><U+261B>   <U+2720><U+2721><U+2741>
              <U+2741><U+2714><U+2720><U+2714><U+261B>   <U+2723><U+2741><U+271E>
              <U+2741><U+2714><U+2720><U+271A><U+261B>   <U+2715><U+270D><U+270E><U+272C><U+272F><U+272C><U+2730><U+272C><U+2712><U+2731> <U+2725><U+2605><U+2732><U+2733><U+2605><U+2729><U+2730><U+2605>
              <U+2741><U+2714><U+2714><U+2721><U+261B>
              <U+2741><U+2714><U+2714><U+271A><U+261B>   <U+2712><U+2729><U+270E><U+272C><U+2734><U+270C><U+2735><U+2713>
              <U+2741><U+2722><U+2721><U+2721><U+261B>   <U+2727><U+2720>
              <U+271F><U+2731><U+2729> <U+25CF><U+2712><U+2731> <U+271F><U+2731><U+2729> <U+2706><U+2605><U+2733> <U+25CF><U+2712><U+2731> <U+271F><U+2731><U+2729> <U+2725><U+2605><U+270D> <U+271F><U+2731><U+2713> <U+2715><U+2731><U+2712> <U+271F><U+2731><U+2733> <U+25CF><U+2712><U+2731> <U+2706><U+2713><U+272B> <U+2706><U+2713><U+272B> <U+2723><U+270D><U+270C> <U+271F><U+2731><U+2713> <U+2715><U+2731><U+2712>
              <U+2720>               <U+272E>                   <U+2720><U+2721>                  <U+2720><U+272E>
              <U+2725><U+2605><U+270D> <U+25CF><U+2712><U+2731> <U+2706><U+2713><U+272B> <U+25CF><U+2712><U+2731> <U+2725><U+2605><U+270D> <U+260E><U+2713><U+272B> <U+2706><U+2713><U+272B> <U+2715><U+2731><U+2712> <U+2725><U+2605><U+270D> <U+271F><U+2731><U+2713> <U+271E><U+2713><U+270D> <U+25CF><U+2712><U+2731> <U+2723><U+261E><U+2605> <U+271E><U+261E><U+270D> <U+2725><U+2605><U+270D> <U+271E><U+2713><U+270D>
                          <U+2714><U+2721>                  <U+2714><U+272E>                  <U+271A><U+2721>
              <U+271E><U+270D><U+2746> <U+2706><U+2605><U+2733> <U+275A><U+272C><U+272B> <U+271E><U+270D><U+2746> <U+25CF><U+2712><U+2731> <U+2715><U+270D><U+2763> <U+271F><U+2731><U+2729> <U+2715><U+2731><U+2712> <U+2723><U+270D><U+270C> <U+271F><U+2731><U+2713> <U+271F><U+2731><U+2729> <U+271F><U+2731><U+2713> <U+2706><U+2605><U+2733> <U+271F><U+2731><U+2733> <U+271E><U+270D><U+2746> <U+2746><U+2605><U+270E>
                                                 50

                      <U+271A><U+272E>                    <U+2722><U+2721>               <U+2722><U+272E>
<removed-date>
              <U+271F><U+2731><U+2713> <U+271E><U+2713><U+270D> <U+271D><U+2731><U+2605> <U+2715><U+272B><U+2729> <U+2723><U+270D><U+270C> <U+2715><U+270D><U+2763> <U+2715><U+272B><U+2729> <U+2715><U+272B><U+2746> <U+271E><U+2713><U+270D> <U+271E><U+261E><U+270D> <U+271F><U+2731><U+2733> <U+271E><U+2713><U+270D> <U+2715><U+272B><U+2729> <U+2715><U+270D><U+2763> <U+271D><U+2731><U+2605> <U+2723><U+261E><U+2605>
                  <U+272E><U+2721>                  <U+272E><U+272E>                  <U+2727><U+2721>
              <U+2706><U+2713><U+272B> <U+271F><U+2731><U+2713> <U+2715><U+270D><U+2763> <U+2723><U+261E><U+2605> <U+271E><U+261E><U+270D> <U+271D><U+2731><U+2605> <U+2725><U+2605><U+270D> <U+2715><U+270D><U+2763> <U+2715><U+272B><U+2746> <U+2715><U+272B><U+2729> <U+2715><U+2731><U+2712> <U+2706><U+2713><U+272B> <U+2715><U+272B><U+2729> <U+2725><U+2605><U+270D> <U+2706><U+2605><U+2733> <U+271E><U+2713><U+270D>
              <U+2727><U+272E>                  <U+271B><U+2721>                  <U+271B><U+272E>                  <U+2726><U+2721>
<removed-apn>
              <U+2706><U+2605><U+2733> <U+271F><U+2731><U+2729> <U+2746><U+2605><U+270E> <U+2715><U+272B><U+2729> <U+2725><U+2605><U+270D> <U+2706><U+2605><U+2733> <U+2715><U+270D><U+2763> <U+2715><U+2731><U+2712> <U+271F><U+2731><U+2733> <U+2715><U+272B><U+2746> <U+271E><U+261E><U+270D> <U+2715><U+2731><U+2712> <U+25CF><U+2712><U+2731> <U+271E><U+2713><U+270D> <U+271E><U+2713><U+270D> <U+260E><U+2713><U+272B>
                              <U+2726><U+272E>                  <U+2741><U+2721>                  <U+2741><U+272E>
              <U+2715><U+2731><U+2712> <U+2715><U+270D><U+2763> <U+2715><U+270D><U+2763> <U+271F><U+2731><U+2713> <U+271D><U+2731><U+2605> <U+271E><U+261E><U+270D> <U+271E><U+261E><U+270D> <U+2723><U+261E><U+2605> <U+271E><U+2713><U+270D> <U+271E><U+270D><U+2746> <U+271F><U+2731><U+2713> <U+271F><U+2731><U+2729> <U+271F><U+2731><U+2713>
                          <U+2720><U+2721><U+2721>                 <U+2720><U+2721><U+272E>
              <U+2741><U+2714><U+2720><U+2721><U+261B>   <U+2727><U+2714>
              <U+2741><U+2714><U+2720><U+2720><U+261B>   <U+2720><U+2721><U+2741>
              <U+2741><U+2714><U+2720><U+2714><U+261B>   <U+2723><U+2741><U+271E>
              <U+2741><U+2714><U+2720><U+271A><U+261B>   <U+2715><U+270D><U+270E><U+272C><U+272F><U+272C><U+2730><U+272C><U+2712><U+2731> <U+2725><U+2605><U+2732><U+2733><U+2605><U+2729><U+2730><U+2605>
              <U+2741><U+2714><U+2714><U+2721><U+261B>
              <U+2741><U+2714><U+2714><U+271A><U+261B>   <U+2712><U+2729><U+270E><U+272C><U+2734><U+270C><U+2735><U+2713>
              <U+2741><U+2722><U+2721><U+2721><U+261B>   <U+2727><U+2714>
              <U+271F><U+2731><U+2729> <U+25CF><U+2712><U+2731> <U+271F><U+2731><U+2729> <U+2706><U+2605><U+2733> <U+271F><U+2731><U+2729> <U+271F><U+2731><U+2733> <U+2725><U+2605><U+270D> <U+271F><U+2731><U+2713> <U+2723><U+270D><U+270C> <U+271F><U+2731><U+2713> <U+2706><U+2605><U+2733> <U+25CF><U+2712><U+2731> <U+2706><U+2713><U+272B> <U+2723><U+270D><U+270C> <U+2725><U+2605><U+270D> <U+271F><U+2731><U+2729>
              <U+2720>               <U+272E>                   <U+2720><U+2721>                  <U+2720><U+272E>
              <U+271E><U+261E><U+270D> <U+2706><U+2605><U+2733> <U+2725><U+2605><U+270D> <U+2706><U+2605><U+2733> <U+271E><U+261E><U+270D> <U+260E><U+2713><U+272B> <U+271E><U+261E><U+270D> <U+25CF><U+2712><U+2731> <U+2725><U+2605><U+270D> <U+271F><U+2731><U+2713> <U+271E><U+2713><U+270D> <U+25CF><U+2712><U+2731> <U+2723><U+261E><U+2605> <U+271E><U+261E><U+270D> <U+2725><U+2605><U+270D> <U+271E><U+2713><U+270D>
                          <U+2714><U+2721>                  <U+2714><U+272E>                  <U+271A><U+2721>
              <U+271E><U+270D><U+2746> <U+2706><U+2605><U+2733> <U+275A><U+272C><U+272B> <U+271E><U+270D><U+2746> <U+271D><U+2731><U+2605> <U+2715><U+270D><U+2763> <U+271F><U+2731><U+2729> <U+2723><U+270D><U+270C> <U+2723><U+270D><U+270C> <U+271F><U+2731><U+2713> <U+2706><U+2713><U+272B> <U+271F><U+2731><U+2713> <U+2706><U+2605><U+2733> <U+271F><U+2731><U+2733> <U+271E><U+270D><U+2746> <U+271D><U+2731><U+2605>
                      <U+271A><U+272E>                  <U+2722><U+2721>                  <U+2722><U+272E>
                                                 51

<removed-date>
              <U+271F><U+2731><U+2713> <U+271E><U+2713><U+270D> <U+271D><U+2731><U+2605> <U+2715><U+272B><U+2729> <U+2723><U+270D><U+270C> <U+2715><U+270D><U+2763> <U+2715><U+272B><U+2729> <U+2715><U+272B><U+2746> <U+271E><U+2713><U+270D> <U+271E><U+261E><U+270D> <U+271F><U+2731><U+2733> <U+271E><U+2713><U+270D> <U+2715><U+272B><U+2729> <U+2715><U+270D><U+2763> <U+271D><U+2731><U+2605> <U+2723><U+261E><U+2605>
                  <U+272E><U+2721>                  <U+272E><U+272E>                  <U+2727><U+2721>
              <U+2706><U+2713><U+272B> <U+271F><U+2731><U+2713> <U+2715><U+270D><U+2763> <U+2723><U+261E><U+2605> <U+271E><U+261E><U+270D> <U+271D><U+2731><U+2605> <U+2725><U+2605><U+270D> <U+2715><U+270D><U+2763> <U+2715><U+272B><U+2746> <U+2715><U+272B><U+2729> <U+2715><U+2731><U+2712> <U+2706><U+2713><U+272B> <U+2715><U+272B><U+2729> <U+2725><U+2605><U+270D> <U+2706><U+2605><U+2733> <U+271E><U+2713><U+270D>
              <U+2727><U+272E>                  <U+271B><U+2721>                  <U+271B><U+272E>                  <U+2726><U+2721>
<removed-apn>
              <U+2706><U+2605><U+2733> <U+271F><U+2731><U+2729> <U+2746><U+2605><U+270E> <U+2715><U+272B><U+2729> <U+2725><U+2605><U+270D> <U+2706><U+2605><U+2733> <U+2715><U+270D><U+2763> <U+2715><U+2731><U+2712> <U+271F><U+2731><U+2733> <U+2715><U+272B><U+2746> <U+271E><U+261E><U+270D> <U+2715><U+2731><U+2712> <U+25CF><U+2712><U+2731> <U+271E><U+2713><U+270D> <U+271E><U+2713><U+270D> <U+260E><U+2713><U+272B>
                              <U+2726><U+272E>                  <U+2741><U+2721>                  <U+2741><U+272E>
              <U+2715><U+2731><U+2712> <U+2715><U+270D><U+2763> <U+2715><U+270D><U+2763> <U+271F><U+2731><U+2713> <U+271D><U+2731><U+2605> <U+271E><U+261E><U+270D> <U+271E><U+261E><U+270D> <U+2723><U+261E><U+2605> <U+271E><U+2713><U+270D> <U+271E><U+270D><U+2746> <U+271F><U+2731><U+2713> <U+271F><U+2731><U+2729> <U+271F><U+2731><U+2713>
                          <U+2720><U+2721><U+2721>                 <U+2720><U+2721><U+272E>
              <U+2741><U+2714><U+2720><U+2721><U+261B>   <U+2727><U+271A>
              <U+2741><U+2714><U+2720><U+2720><U+261B>   <U+2720><U+2721><U+2741>
              <U+2741><U+2714><U+2720><U+2714><U+261B>   <U+2723><U+2741><U+271E>
              <U+2741><U+2714><U+2720><U+271A><U+261B>   <U+2715><U+270D><U+270E><U+272C><U+272F><U+272C><U+2730><U+272C><U+2712><U+2731> <U+2725><U+2605><U+2732><U+2733><U+2605><U+2729><U+2730><U+2605>
              <U+2741><U+2714><U+2714><U+2721><U+261B>
              <U+2741><U+2714><U+2714><U+271A><U+261B>   <U+2712><U+2729><U+270E><U+272C><U+2734><U+270C><U+2735><U+2713>
              <U+2741><U+2722><U+2721><U+2721><U+261B>   <U+2727><U+271A>
              <U+271F><U+2731><U+2729> <U+25CF><U+2712><U+2731> <U+271F><U+2731><U+2729> <U+2706><U+2605><U+2733> <U+25CF><U+2712><U+2731> <U+271F><U+2731><U+2729> <U+2725><U+2605><U+270D> <U+271F><U+2731><U+2713> <U+2715><U+2731><U+2712> <U+271F><U+2731><U+2733> <U+25CF><U+2712><U+2731> <U+2706><U+2713><U+272B> <U+2706><U+2713><U+272B> <U+2723><U+270D><U+270C> <U+271F><U+2731><U+2713> <U+2715><U+2731><U+2712>
              <U+2720>               <U+272E>                   <U+2720><U+2721>                  <U+2720><U+272E>
              <U+271E><U+261E><U+270D> <U+25CF><U+2712><U+2731> <U+2706><U+2713><U+272B> <U+271D><U+2731><U+2605> <U+2725><U+2605><U+270D> <U+260E><U+2713><U+272B> <U+2706><U+2713><U+272B> <U+25CF><U+2712><U+2731> <U+2725><U+2605><U+270D> <U+271F><U+2731><U+2713> <U+271E><U+2713><U+270D> <U+25CF><U+2712><U+2731> <U+2723><U+261E><U+2605> <U+271E><U+261E><U+270D> <U+2725><U+2605><U+270D> <U+271E><U+2713><U+270D>
                          <U+2714><U+2721>                  <U+2714><U+272E>                  <U+271A><U+2721>
              <U+271E><U+270D><U+2746> <U+2706><U+2605><U+2733> <U+275A><U+272C><U+272B> <U+271E><U+270D><U+2746> <U+271D><U+2731><U+2605> <U+2715><U+270D><U+2763> <U+271F><U+2731><U+2729> <U+2723><U+270D><U+270C> <U+2723><U+270D><U+270C> <U+271F><U+2731><U+2713> <U+2706><U+2713><U+272B> <U+271F><U+2731><U+2713> <U+2706><U+2605><U+2733> <U+271F><U+2731><U+2733> <U+271E><U+270D><U+2746> <U+271D><U+2731><U+2605>
                      <U+271A><U+272E>                  <U+2722><U+2721>                  <U+2722><U+272E>
              <U+271F><U+2731><U+2713> <U+271E><U+2713><U+270D> <U+271D><U+2731><U+2605> <U+2715><U+272B><U+2729> <U+2723><U+270D><U+270C> <U+2715><U+270D><U+2763> <U+2715><U+272B><U+2729> <U+2715><U+272B><U+2746> <U+271E><U+2713><U+270D> <U+271E><U+261E><U+270D> <U+271F><U+2731><U+2733> <U+271E><U+2713><U+270D> <U+2715><U+272B><U+2729> <U+2715><U+270D><U+2763> <U+271D><U+2731><U+2605> <U+2723><U+261E><U+2605>
                                                 52

                  <U+272E><U+2721>                    <U+272E><U+272E>                <U+2727><U+2721>
<removed-date>
              <U+2706><U+2713><U+272B> <U+271F><U+2731><U+2713> <U+2715><U+270D><U+2763> <U+25CF><U+2712><U+2731> <U+271E><U+261E><U+270D> <U+271D><U+2731><U+2605> <U+271E><U+261E><U+270D> <U+2715><U+2731><U+2712> <U+2715><U+272B><U+2746> <U+2706><U+2713><U+272B> <U+2725><U+2605><U+270D> <U+271E><U+261E><U+270D> <U+2725><U+2605><U+270D> <U+271E><U+261E><U+270D> <U+2715><U+2731><U+2712> <U+271E><U+2713><U+270D>
              <U+2727><U+272E>                  <U+271B><U+2721>                  <U+271B><U+272E>                  <U+2726><U+2721>
              <U+2746><U+2605><U+270E> <U+271F><U+2731><U+2733> <U+2706><U+2605><U+2733> <U+2725><U+2605><U+270D> <U+2725><U+2605><U+270D> <U+2706><U+2605><U+2733> <U+2715><U+270D><U+2763> <U+2725><U+2605><U+270D> <U+271F><U+2731><U+2733> <U+2715><U+272B><U+2746> <U+271E><U+261E><U+270D> <U+2715><U+2731><U+2712> <U+25CF><U+2712><U+2731> <U+271E><U+2713><U+270D> <U+271E><U+2713><U+270D> <U+260E><U+2713><U+272B>
                              <U+2726><U+272E>                  <U+2741><U+2721>                  <U+2741><U+272E>
<removed-apn>
              <U+2715><U+2731><U+2712> <U+2715><U+270D><U+2763> <U+2715><U+270D><U+2763> <U+271F><U+2731><U+2713> <U+271D><U+2731><U+2605> <U+271E><U+261E><U+270D> <U+271E><U+261E><U+270D> <U+2723><U+261E><U+2605> <U+271E><U+2713><U+270D> <U+271E><U+270D><U+2746> <U+271F><U+2731><U+2713> <U+271F><U+2731><U+2729> <U+271F><U+2731><U+2713>
                          <U+2720><U+2721><U+2721>                 <U+2720><U+2721><U+272E>
              <U+2741><U+2714><U+2720><U+2721><U+261B>    <U+2727><U+2722>
              <U+2741><U+2714><U+2720><U+2720><U+261B>    <U+2720><U+2721><U+2741>
              <U+2741><U+2714><U+2720><U+2714><U+261B>    <U+2723><U+2741><U+271E>
              <U+2741><U+2714><U+2720><U+271A><U+261B>    <U+2715><U+270D><U+270E><U+272C><U+272F><U+272C><U+2730><U+272C><U+2712><U+2731> <U+2725><U+2605><U+2732><U+2733><U+2605><U+2729><U+2730><U+2605>
              <U+2741><U+2714><U+2714><U+2721><U+261B>
              <U+2741><U+2714><U+2714><U+271A><U+261B>    <U+2712><U+2729><U+270E><U+272C><U+2734><U+270C><U+2735><U+2713>
              <U+2741><U+2722><U+2721><U+2721><U+261B>    <U+2727><U+2722>
              <U+271F><U+2731><U+2733> <U+25CF><U+2712><U+2731> <U+271F><U+2731><U+2729> <U+2706><U+2605><U+2733> <U+25CF><U+2712><U+2731> <U+271F><U+2731><U+2729> <U+2725><U+2605><U+270D> <U+271F><U+2731><U+2713> <U+2723><U+270D><U+270C> <U+271F><U+2731><U+2733> <U+25CF><U+2712><U+2731> <U+2706><U+2713><U+272B> <U+2706><U+2713><U+272B> <U+2723><U+270D><U+270C> <U+271F><U+2731><U+2713> <U+271F><U+2731><U+2733>
              <U+2720>               <U+272E>                   <U+2720><U+2721>                  <U+2720><U+272E>
              <U+2725><U+2605><U+270D> <U+2706><U+2605><U+2733> <U+2715><U+270D><U+2763> <U+271D><U+2731><U+2605> <U+2725><U+2605><U+270D> <U+260E><U+2713><U+272B> <U+2706><U+2713><U+272B> <U+271F><U+2731><U+2713> <U+2725><U+2605><U+270D> <U+271F><U+2731><U+2713> <U+271E><U+2713><U+270D> <U+25CF><U+2712><U+2731> <U+2723><U+261E><U+2605> <U+271E><U+261E><U+270D> <U+2725><U+2605><U+270D> <U+271E><U+2713><U+270D>
                          <U+2714><U+2721>                  <U+2714><U+272E>                  <U+271A><U+2721>
              <U+271E><U+270D><U+2746> <U+2706><U+2605><U+2733> <U+275A><U+272C><U+272B> <U+271E><U+270D><U+2746> <U+25CF><U+2712><U+2731> <U+2715><U+270D><U+2763> <U+271F><U+2731><U+2729> <U+2715><U+2731><U+2712> <U+2723><U+270D><U+270C> <U+271F><U+2731><U+2713> <U+271F><U+2731><U+2729> <U+271F><U+2731><U+2713> <U+2706><U+2605><U+2733> <U+271F><U+2731><U+2733> <U+271E><U+270D><U+2746> <U+2746><U+2605><U+270E>
                      <U+271A><U+272E>                  <U+2722><U+2721>                  <U+2722><U+272E>
              <U+271F><U+2731><U+2713> <U+271E><U+2713><U+270D> <U+271D><U+2731><U+2605> <U+2715><U+272B><U+2729> <U+2723><U+270D><U+270C> <U+2715><U+270D><U+2763> <U+2715><U+272B><U+2729> <U+2715><U+272B><U+2746> <U+271E><U+2713><U+270D> <U+271E><U+261E><U+270D> <U+271F><U+2731><U+2733> <U+271E><U+2713><U+270D> <U+2715><U+272B><U+2729> <U+2715><U+270D><U+2763> <U+271D><U+2731><U+2605> <U+2723><U+261E><U+2605>
                  <U+272E><U+2721>                  <U+272E><U+272E>                  <U+2727><U+2721>
                                                 53

<removed-date>
              <U+2706><U+2713><U+272B> <U+271F><U+2731><U+2713> <U+2715><U+270D><U+2763> <U+25CF><U+2712><U+2731> <U+271E><U+261E><U+270D> <U+271D><U+2731><U+2605> <U+2725><U+2605><U+270D> <U+2715><U+2731><U+2712> <U+2715><U+272B><U+2746> <U+2706><U+2713><U+272B> <U+2725><U+2605><U+270D> <U+271D><U+2731><U+2605> <U+2715><U+272B><U+2729> <U+271E><U+261E><U+270D> <U+2715><U+2731><U+2712> <U+271E><U+2713><U+270D>
              <U+2727><U+272E>                  <U+271B><U+2721>                  <U+271B><U+272E>                  <U+2726><U+2721>
              <U+2706><U+2605><U+2733> <U+271F><U+2731><U+2729> <U+271E><U+270D><U+2746> <U+2725><U+2605><U+270D> <U+2725><U+2605><U+270D> <U+2706><U+2605><U+2733> <U+2706><U+2713><U+272B> <U+2715><U+2731><U+2712> <U+2725><U+2605><U+270D> <U+2715><U+272B><U+2746> <U+271E><U+261E><U+270D> <U+2715><U+2731><U+2712> <U+2746><U+2605><U+270E> <U+271E><U+2713><U+270D> <U+271E><U+2713><U+270D> <U+260E><U+2713><U+272B>
                              <U+2726><U+272E>                  <U+2741><U+2721>                  <U+2741><U+272E>
<removed-apn>
              <U+2715><U+2731><U+2712> <U+2715><U+270D><U+2763> <U+2715><U+270D><U+2763> <U+271F><U+2731><U+2713> <U+271D><U+2731><U+2605> <U+271E><U+261E><U+270D> <U+271E><U+261E><U+270D> <U+2723><U+261E><U+2605> <U+271E><U+2713><U+270D> <U+271E><U+270D><U+2746> <U+271F><U+2731><U+2713> <U+271F><U+2731><U+2729> <U+271F><U+2731><U+2713>
                          <U+2720><U+2721><U+2721>                 <U+2720><U+2721><U+272E>
                                                 54

